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STATUS OFAWP LITIGATION 
\$rmm^^fc*w-[ALABAMA 
tU0^l%EBE8iafq^ 
Abbott Laboratories, Inc. 
(Agouron Pharmaceuticals, Inc. 
|Afcon Laboratories, Inc 
lAIIergan Inc. 
Alpharma, Inc 
j ALZA Corporation 
(Amgen, Inc. 
(Andrx Corporation (Dismissed) 
|Andrx Phannaceuticals, Inc. 
lAstraZeneca Pharmaceuticals LP 
|AstraZeneca LP 
Aventis Pharmaceuticals, Inc 
[Aventis Behring, L.LC. 
Baxter Healthcare Corporation 
Baxter International, Inc. 
'Bayer Corporation 
Bayer Pharmaceuticals Corporation 
Bayer Healthcare, LLC 
Biovai! Pharmaceuticals, Ina 
Boehnnger Ingelheim Corporation 
Boehringer Ingelheim Pharmaceuticals, Inc. 
Bristol-Myers Squibb Company 
DEY L P 
Bsai, Inc. 
Eli Lilly & Company (Dismissed) 1 
Endo Pharmaceuticals, Inc | 
Ethex Corporation | 
Forest Laboratories, Inc | 
Forest Pharmaceuticals, Inc. | 
Fujisawa Healthcare, Inc. | 
Fujisawa USA, Inc. 
G.D. Searle, L.LC. 
Genzyme Corporation" | 
Gilead Sciences, Inc. (dismissed) 
GlaxoSmrthKHne P.LC. 
Glaxo Wellcome, Inc. (dismissed) | 
Hoffmann-LaRoche Inc | 
Immunex Corporation j 
IVAX Conporation 
I VAX Pharmaceuticals, Inc. J 
(Circuit Court of Montgomery County, AL 
CV-2005-219 
l u ^ r ^ r 
fiig^f^5^MJeip>^^^EDj 
1/26/2005 
1 
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STATUS OF AWP LITIGATION 
ImimzMmmmM [ALASKA I 
\J 
(Janssen Pharmaceutica Products, LP 
jjohnson & Johnson 
}K-V Pharmaceutical Company (Dismissed) 
(King Pharmaceuticals, Inc. 
[McNeiJ-PPC, Inc. 
(Medlmruine, Inc. 
Merck & Co., Inc. 
(Monarci Pharmaceuticals, Inc. 
JMylan Laboratories, Inc. 
JMylan Pharmaceuticals, fnc. 
JNovartis Pharmaceuticals Corporation 
(Novo Nardisk Pharmaceuticals, Inc. 
|Organoi Pharmaceuticals USA, Inc. 
[Ortho Biotech Products, LP 
1 Ortho-McNeil Pharmaceutical, Inc. 
Par Pharmaceutical, Inc. 
Pfizer, Inc. 
Pharmacia Corporation 
Pharmacia & Upjohn Company Corporation 
Purdue Pharma, L.P. 
Purepac Pharmaceutical Co. 
Roche Laboratories, Inc. 
Roxane Laboratories, Inc. 
Sandoz, Inc. 
Sanofi-Synthefabo, Inc. 
Schering-Plough Corporation 
SmithKline Beecham Corporation 
Takeda Pharmaceuticals North America, Inc. j 
TAP Pharmaceutical Products, inc. 1 
Teva Pharmaceuticals USA, Inc. I 
UDL Laboratories, fnc. j 
Warrick Pharmaceuticals Corporation | 
Watson Laboratories, Inc. | 
Watson Pharma, Inc. j 
Watson Pharmaceuticals, Inc. I 
Wyeth, Inc. j 
Wyeth Pharmaceuticals, Inc. | 
ZLB Behring, L.L.C. j 
N M ^ i l S ^ ^ 
^Jpharma Branded Products Division, Inc. .. 1 
QJpharma USPD, Inc. 
Amgen, Inc. 1 
mimmtimimtiM^BMma&i Superior Court, Anchorage Alaska f 
3AN-06-12026CI | 
^mmzmmmmmmmd 
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STATUS OF AWP LITIGATION 
1 — 
JAstraZeneca Pharmaceuticals LP 
(AstraZeneca LP 
Aventis Pharmaceuticals, Inc. 
Aventis Behring, L.L.C. n/k/a ZLB Behring 
JBarr Laboratories, Inc. 
1 Baxter Healthcare Corporation 
(Ben Venue Laboratories, Inc. 
iBoehringer Ingelheim Pharmaceuticals. Inc. 
Bristol-Myers Squibb Company 
(Centocor, Inc. 
[Duramed Pharmaceuticals, Inc. 
[Forest Laboratories, Inc. 
(Immunex Corporation 
[ivax Corporation 
fVAX Pharmaceuticafs, inc. 
Janssen Pharmaceutica Products, LP 
Johnson & Johnson 
|McNeil-PPC, Inc. 
Merck & Co., inc. 
Mylan Laboratories, Inc. 
Mylan Pharmaceuticals, inc. 
Novartis Pharmaceuticals Corporation 
Ortho Biotech Products, LP 
Ortho-McNeil Pharmaceutical, Inc. 
Par Pharmaceutical, Inc-
Pfizer, Inc. 
Pharmacia Corporation 1 
Purepac Pharmaceutical Co. 1 
Roxane Laboratories, Inc. n/k/a Boehringer Ingelheim Roxane, Inc. | 
Sandoz, Inc. 
frk/a Geneva Pharmaceuticals, INC. | 
Schering Corporations 1 
Schering-Plough Corporation | 
Sicor, INC. 
f/k/a Sicor Pharmaceuticals, INC. J 
f/k/a Gensia Sicor 
SmithKline Beecham Corporation | 
d/b/a Glaxosmithkline | 
Teva Pharmaceuticals USA, Inc. | 
Warrick Pharmaceuticals Corporation j 
Watson Pharma, Inc. | 
| f/k/a Schein Pharmaceuticals, INC. J. | | 
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STATUS OF AWP LITIGATION 
vsffiszm&B&m, 
ARIZONA 
1 I 
1 . 
(Watson Pharmaceuticals, INC. 
• M M O E t e M i y ^ ^ 
(Abbott Laboratories 
(Amgen, Inc. 
(Apothecon, Inc. 
(AstraZeneca, PLC 
AstraZeneca US 
f AstraZeneca Pharmaceuticals LP 
(Aventis Pharmaceuticals, inc. 
lAventis Behring, L.L.C. 
|B. Braun Medical, Inc. 
(Baxter Healthcare Corporation 
(Baxter Internationa! Inc. 
| Bayer Corporation 
[Bedforc Laboratories 
|Ben Venue Laboratories, Inc. 
JBoehringer Ingelheim Pharmaceuticals, inc. 
^ iogen IDEC U.S. 
Bristol-Myers Squibb Co. 
Centocor, Inc. 
Deylnc. 
Fujisawa Healthcare, Inc. 
Fujfsawa USA, Inc. 
Gensra Inc. 
Gensia Sicor Pharmaceuticals, Inc. 
GlaxoSmithKline P.L.C. | 
Glaxo Wellcome, Inc. 
Hoechst Marion RousseJ, Inc. | 
Immunex Corporation | 
Janssen Pharmaceutica Products, LP | 
Johnson & Johnson | 
McNeil-PPC, Inc. 
Merck & Co., Inc. ( 
Oncology Therapeutics Network Corp. j 
Ortho Biotech j 
Pharmacia Corporation 1 
Pharmacia & Upjohn, Inc. | 
Rhone-Poulenc Rorer, SJ\. j 
Roxane Laboratories, Inc. ( 
Schering-Plough Corporation, j 
Sicor Pharmaceuticals, Inc. | 
SmithKUne Beecham Corporation j 
(Superior Court of Maricopa County, AZ j 12/6/20051 
A0027 
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STATUS OF AWP LITIGATION 
mm&m$mm& 
ARKANSAS 
mmmMM&i^ 
CALIFORNIA 
: L 
(TAP Pharmaceutical Products, Inc. 
jwarrick Pharmaceuticals Corporation 
Iwatson Pharmaceuticals, Inc. 
|Zeneca, Inc. 
ussHaaii^ |Dey, Inc. 
[Schering-Plough Corporation 
|Schering Corporation 
| Warrick Pharmaceuticals Corporation 
1 Schering-Plough Corporation 
[Schering Corporation 
M E l ^ (circuit Court of Pulaski County, AR 
CV-04-634 
M g ^ ^ M ^ ^ ^ [Abbott Laboratories, Inc. 
Wyeth, Inc. 
[Wyeth Pharmaceuticals, inc. 
Arngen, Inc. 
Armour Pharmaceutical Co. 
jAventis Behring, L.L.C 
Aventis Pharmaceuticals, Inc. 
B. Braun Medical, Ina 
B. Braun of America, Inc. 
Baxter Healthcare Corp. 
Bedford Laboratories 
Ben Venue Laboratories, Inc. 
Boehringer Ingelheim Corporation 
Boehringer Ingelheim Pharmaceuticals, Inc. 
CM. Boehrfnger Sohn Grundstucksverwaltung , 
Bristol-Myers Squibb Company ! 
Dey, Inc. 
Dey L P . | 
EMD, Inc. 
Geneva Pharmaceuticals Inc. | 
Sicor, Inc. f/k/a Gensia Pharmaceuticals, Inc. 
Gensia Inc. | 
Gensia Sicor, Inc j 
Glaxo Wellcome, Inc., f//k/a Burroughs Wellcome Co. 
GlaxoSmithKline PLC | 
Hoechst Marion Roussel, Inc. j 
Immunex Corp. j 
Upha, S.A. 
McGaw, Inc. | 
Merck KgaA | 
1 Superior Court of Los Angeles County, CA 
BSA09342 
I 
b^is^^ 1/20/2004 
^ J © a ^ ^ 
[ 01/20/2004 (Abbott) 
04/15/2003 (Dey) 
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STATUS OF AWP LITIGATION 
\mmmmm& CONNECTICUT 
mmmms^M^B^ 
FLORIDA 
ImmmmmzmiA HAWAII 
j | I 
r 
r 
[ \J 
\ \J 
JMylan Laboratories, Inc. 
(Mylan Pharmaceuticals, Inc. 
JNovartis AG 
Pharma Investment, LTD. 
[Roxane Laboratories, Inc. 
[Sandoz, inc. 
1 Schering-Plough Corp. 
ISmithKline Beecham Corporation d/b/a GlaxoSmiihKIine 
JTeva Pharmaceutical Industries, LTD. 
[Warrick Pharmaceuticals Corp. 
2LB Behring, L.L.C. 
tefei^gE^^ 
[Aventis Pharmaceuticals, Inc. 
|Dey, Inc. 
Roxane Laboratories, Jna 
! Warrick Pharmaceuticals Corporation Schering-Plough Corporation 
Schering Corporation 
GlaxoSmithKline P.LC. d/b/a GlaxoSmithKline 
Glaxo Weflcome, Inc. d/b/a GlaxoSmithKline 
SmithKline Beecham Corporation, d/b/a GlaxoSmfthKline 
Pharmacia Corporation 
# ^ p l p f E £ £ N l ^ $ ^ ^ 
Boehringer Ingelheim Corporation 
EMD Pharmaceuticals, Inc. 
LIpha, S-A. 
Merck & Company, Inc. 
Merck LIpha, SJK. j 
KGaA 
Dey, Inc. ] 
Warrick Pharmaceuticals Corp. | 
Roxane Laboratories, Inc. j 
Schering-Plough Corporation j 
Schering Corporation | 
M ^ f s ^ E g g M g ^ ^ 
Abbott Laboratories, Inc. | 
Alpharma USPD, Inc. 
ftpothecon, Inc. | 
^straZeneca LP | 
^traZeneca Pharmaceuticals, LP | 
Mentis Pharmaceuticals, Inc. | 
\ventis Behring LLC n/k/a ZLB Behring | 
\ [Sarr Laboratories, Inc. | 
M B ? ^ ^ 
| Four separate lawsuits filed in 
Superior Court of Hartford, CT 
? ! » 1 5 ^ ^ ^ 
Circuit Court of Leon County, FL 
98-3032A 
mmm^m^mmmmM^^^M\ Circuit Court of the first Circuit, State of Hawaii 
Q6-[!-072Q~04 EEH 
k:::%lB?»^SS;^^^sd 3/12/2003 
I (all filed same date) | 
^ m j s ' i ^ ^ 
S ^ i i i f e ^ ^ 
4/27/2006) 
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STATUS OF AWP LITIGATION 
^ * P ^ 
IDAHO 
(Baxter Healthcare Corporation 
jBayer Corporation - DISMISSED 
(Ben Venue Laboratories, Inc. 
1 Boehringer Ingelheim Pharmaceuticals, Inc. 
Boehringer Ingelheim Roxane, Inc. f/k/a Roxane Labs, Inc. 
| Bristol-Myers Squibb Co. 
|Centocor, Inc. 
|Dey, Inc. 
E.R. Squibb Co. - DISMISSED 
Forest Pharmaceuticals, Inc. 
I GlaxoSmithKIine Pharmaceuticals 
Hoffmann-LaRoche Inc. 
|Hosprra, Inc. 
1VAX Corporation 
n / A v n i t' - i i 
Janssen Pharmaceutica Products, LP 
Johnson & Johnson, Inc. 
'McNeif-PPC, Inc. 
Merck & Company, Inc. 
Mylan Laboratories, inc. 
MyJan Pharmaceuticals, Inc. 
Novartis Pharmaceuticals Corporation ' 
Ortho Biotech Products, LP 
Par Pharmaceutical Cos., Inc. 
Pfizer, Inc. 
Pharmacia Corporation 
Purepac Pharmaceutical Co. 
Roche Laboratories, Inc. | 
Sandoz, Inc. | 
Schering-Plough Corporation | 
Sicor Pharmaceuticals, Jnc. f/k/a Gensra Sicor Pharm | 
TAP Pharmaceutical Products, Inc. | 
Teva Pharmaceuticals USA, Inc. | 
Warrick Pharmaceuticals Corporation J 
Watson Pharmaceuticals. Inc. | 
Watson Pharma, Inc, | 
Watson Laboratories, Inc. I 
^ M E & g l r l l N t f ^ ^ 
Alphanma USPD, Inc. | 
AstraZeneca LP " | 
AstraZeneca Pharmaceuticals LP | 
3arr Laboratories, Inc. 1 
Fourth Judicial Circuit of Ada County, ID 1 
1 
» K « « B ^ a ^ ^ 
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STATUS OF AWP LITIGATION 
\m$wm&mm£M 
ILLINOIS 
| j 
| Cento cor, Inc. 
11 vax Corporation 
IVAX Pharmaceuticals, Inc. 
panssen Pharmaceutica Products, LP 
(Johnson & Johnson 
[McNeil-3PC, Inc. 
Merck & Co., Inc. 
Ortho Biotech Products, LP 
Ortho-McNeil Pharmaceutical, Inc. 
|Par Pharmaceuticals 
Purepac Pharmaceutical Co. 
|$andoz Inc. 
iTeva Pharmaceuticals USA, Inc. 
(Watson Pharmacueticals, fnc. 
IWatson Pharma, inc. 
ymm^mmmM^km^^Mm-mm^MMm^mm^^ 
Abbott Laboratories, Inc. 
Alpharma, Inc. 
Alpha Therapeutic Corp. 
Amgen, inc. 
AstraZeneca Pharmaceuticals LP 
AstraZeneca LP 
Aventis Pharmaceuticals, Inc. ; 
Aventis Behring, LL.C. n/k/a ZLB Behring, LL .C. I 
B. Braun of America, Inc. 
Barr Pharmaceuticals, Inc. 
Baxter International, Inc. 1 
Bayer Corporation j 
Ben Venue Laboratories, fnc. | 
Boehringer Ingelheim Corporation | 
Boehringer Ingelheim Pharmaceuticals, Inc. 1 
Bristol-Myers Squibb Company 1 
Chiron Corporation J 
Dey, Inc. | 
Bkins-Sinn, Inc. 1 
Forest Laboratories, Inc. j 
Immunex Corporation 1 
VAX Corporation | 
IVAX Pharmaceuticals, Inc. | 
Janssen Pharmaceutical Products, LP j 
Johnson & Johnson | 
mmmrnm^mmim^^^m^m Circuit Court of Cook County, IL 
051CH2474 
1 
\mmmmm?mmmmm 2/27/2005 
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STATUS OF AWP LITIGATION 
b l ^ i ^ i ^ l ^ i i ^ 
KENTUCKY 
[McGaw, Inc. 
iMcNeiLPPC, Inc. 
Merck & Co., Inc. 
JMylan Laboratories, Inc. 
[Mytan Pharmaceuticals, Inc. 
jNovartis Pharmaceuticals Corporation 
NovoPharm USA, Inc. 
Ortho Biotech Products, LP 
Ortho-McNeil Pharmaceutical, Inc. 
(Par Pharmaceutical, Cos. 
| Pfizer, Inc. 
(Pharmacia Corporation 
[Purepac Pharmaceutical Co. 
[Roxane Laboratories, Inc. 
jSchering-Plough Corporation 
Sicor Pharmaceuticals Inc., f/k/a Gensra Sicor 
SmithKfine Beecham Corporation d/b/a GlaxoSmithKiine 
TAP Pharmaceutical Products, Inc. 
Teva Pharmaceutical Products Inc. 
Warrick Pharmaceutical Industries, LTD 
Watson Pharma, Inc. f/k/a Schein Pharmaceuticals, Inc. 
Watson Pharmaceuticals, Inc. 
I ^ E & S i ^ 
Abbott Laboratories, Inc. 
Alpharma, Inc. 
Amgen, Inc. 
AstraZeneca Pharmaceuticals, LP 
AstraZeneca, LP | 
Aventis Pharmaceuticals, Inc. | 
Aventis Behering. LLC | 
B. Braun of America, Inc. | 
B. Braun McGaw 
Ban Pharmaceuticals, Inc. | 
Baxter International, Inc. | 
Bayer Corporation j 
Ben Venue Laboratories, Inc. | 
Boehringer Ingelheim Corporation 
Boehringer Ingelheim Pharmaceuticals, Inc, | 
Bristol-Myers Squibb Company j 
Dey, Inc. j 
|
 : [Forest Laboratories, inc. [_ 
^mmmmmmm^mm^mmis Circuit Court of Franklin County, KY 
03-C1-1135 
iMm-wmmmffijm?m 11/4/2004 
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STATUS OF AWP LITIGATION 
fe^6.^*^;?K^^®id 
MASSACHUSETTS 
[ | 
[ | 
I 
! § ^ ^ ; - ^ ^ S ^ l 
MINNESOTA j 
(imunex Corporation 
| Ivax Corporation 
I Ivax Pharmaceuticals, Inc. 
| Janssen Pharmaceutical Products, LP 
| Johnson & Johnson, Inc. 
j McNeil- PPC, Inc, 
j Merck & Company, Inc. 
|Mylan Laboratories, Inc. 
[Mylan Pharmaceuticals, Inc. 
| Novartis Pharmaceuticals Corporation 
iNovopharm USA, Inc. 
Ortho Biotech Products, LP 
1 Ortho-McNeil Pharmaceutical, Inc. 
j Par Pharmaceutical Companies, Inc. 
1 Pfizer, Inc. 
Pharmacia 
Purepac Pharmaceutical Co. 
Roxane Laboratories, Inc. 
Sandoz, Inc. f/k/a Geneva Pharmaceuticals, Inc. 
Sicor Pharmaceuticals, (nc. 
SmithKIine Beecham Corporation d/b/a 
GlaxoSmithKHne 
Tap Pharmaceutical Products, Inc. 
Teva Pharmaceutical Industries, Ltd. 
Watson Pharma, Inc. 
Watson Pharmaceuticals, Inc. 
&«ai$$g&gro3&^^ 
Mylan Laboratories, Inc. | 
Barr Labatories, Inc. | 
Duramed Pharmaceuticals, Inc. | 
Ivax Corporation | 
Warrick Pharmaceuticals Corporation | 
Watson Pharmaceuticals, Inc. 
Schein Pharmaceutical, Inc. - | 
Teva Pharmaceuticals USA, Inc. | 
Par Pharmaceutical, Inc. | 
Dey, Inc. ( 
Ethex Corporation | 
Purepac Pharmaceutical Co. | 
Roxane Labatories, Inc. j 
^m^pmmMmm3mtm:--s&^mimm^,rmmmmimik Dharmacia Corporation r 
United States District Court, MA 1 
03-CV-11865-PBS 
'smmmmmmm ^ wm 9/25/2003 
« ^ « « a i ^ ^ Two lawsuits tiled District Court | 06/18/2002 (Pharmacia)! 
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STATUS OF AWP LITIGATION 
vsmmmtimims 
MISSISSIPPI 
(Warrick Pharmaceutical Corporation 
|Dey, Inc. 
| of Hennepin County, MN 
(05-1395 
I 08/2003 (Warrick)j 
} | l A M £ ^ ^ 
Abbott Laboratories, Inc. 
j Abbott Pharmaceuticals - DISMISSED 
(Aicon Laboratories, Inc. -DISWIISSED 
[Allergan, Inc. -DISMISSED 
Alphanma, Inc. 
[Alpha Therapecutic Corp. -DISMISSED 
[Alza Corporation 
[Amgen, Inc. 
|Andrx Pharmaceuticals, Inc. -DISMISSED 
|AstraZeneca Pharmaceuticals LP 
[AstraZeneca LP 
|Aventis Pharmaceuticals, Inc. 
Aventis Behring, L.L.C. 
B. Braun of America, Inc. -DISMISSED 
!Barr Laboratories, inc. 
Barr Pharmaceuticals. Inc. -DISMISSED 
Baxter Healthcare Corporation 
Baxter International, Inc. -DISMISSED 
Bayer Corporation - DISMISSED 
( j Bayer Pharmaceuticals Corporation - DISWIISSED 
I 
Bayer Healthcare, LLC - DISMISSED 
Ben Venue Laboratories, Inc. 
Biovail Pharmaceuticals, Inc. -DISMISSED j 
Boehringer Ingelheim Corporation -DISMISSED 
Boehringer Ingelheim Pharmaceuticals, lnc. 
Bristol-Myers Squibb Company 1 
Chiron Corp. -DISMISSED j 
Dermik Laboratories, Inc. -DISMISSED j 
DEY, Inc. 
Eisai, Inc. 1 
Eli Lilly & Company | 
Elkins-Sinn, Inc. -DISMISSED 
Endo Pharmaceuticals, Inc. -DISMISSED j 
Ethex Corporation -DISMISSED | 
Forest Laboratories, Inc. -DISMISSED | 
Forest Pharmaceuticals, Inc. | 
Fujisawa Healthcare, Inc. -DISMISSED j 
Fujisawa USA, inc. -DISMISSED | 
| Chancery Court of Hinds County, MS 
G2005-2021 
Genzyme Corporation -DISMISSED | | 
I 10/20/2005] 
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V 
|Gilead Sciences, Inc. -DISMISSED 
GlaxoSrnrthKiine P.LC. 
)Glaxo Wellcome, Inc. 
(Hoffmann-LaRoche Inc. 
| Immunex Corporation 
IVAX Corporation -DISMISSED 
| IVAX Pharmaceuticals, Inc. 
j janssen Pharmaceutical Products, LP 
(Johnson & Johnson 
|K-V Pharmaceutical Company -DISMISSED 
(King Pharmaceuticals. Inc. -DISMISSED 
McGaw, Inc.-DISMISSED 
|McNeiI-PPC, Inc. 
|Medlmmune, Inc. 
|Merck&Co., Inc. 
[Monarch Pharmaceuticals, Inc. -DISMISSED 
Mylan Laboratories, Inc. 
|Myfan Pharmaceuticals, Inc. 
Novartis Pharmaceuticals Corporation 
Novo Nordisk Pharmaceuticals, Inc. -DISMISSED 
Novopharm USA, Inc. 
Oncology Therapeutics Network Corp. -DISMISSED 
Organon Pharmaceuticals USA, Inc. -DISMISSED 
Orthc^BiotecfTProducts, LP 
Ortho-McNeil Pharmaceutical, Inc. 
Par Pharmaceutical, Inc. 
Purdue Pharma, L P . -DISMISSED | 
Purepac Pharmaceutical Co. -DISMISSED 
Roche Laboratories, Inc. -DISMISSED 
Roxane Laboratories, Inc. | 
Sandoz, Inc. | 
Sanofi-Synthelabo, Inc. | 
Schering-Plough Corporation j 
Serono, Inc. -DISMISSED 
Sicor Pharmaceuticals. Inc. 
SmithKline Beecham Corporation 
Takeda Pharmaceuticals North America, Inc. j 
TAP Pharmaceutical Products, inc. | 
Teva Pharmaceuticals USA, Inc. | 
UDL Laboratories, Inc. -DISMISSED 
Warrick Pharmaceuticals Corporation j 
[Watson Laboratories, Inc. j 
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Ises^^g^^iSf^l 
MISSOURI 
M g | ^ ? ^ , M I 
1 MONTANA 
^iSl?'fe^S^^Si->l 
NEVADA J 
|Watson Pharma, Inc. 
Watson Pharmaceuticals, Inc. 
Wyeth, Inc. 
IWyeth Pharmaceuticals, Inc. 
ZLB Behring, L.L.C. 
N i i p & t m ^ 
Dey, Inc. 
Dey, L P . 
MerckKgaA 
EMD, Inc. 
| Warrick Pharmaceuticals Corporation 
Schering-Plough Corporation 
|Schering Corporation 
iMylan Laboratories, Inc. 
|Mylan Pharmaceuticals, Inc. 
[NovoPharrn, Ltd. 
Schein Pharmaceutical, Inc. 
Teva Pharmaceutical Industries, Ltd. 
Teva Pharmaceutical USA 
Watson Pharmaceuticals, Inc. 
mi^msmmi&m^m^msmmsmm^s^s^s^ Abbott Laboratories, Inc. 
American Home Products Corporation 
AmGen, Inc. 
AstraZeneca 
Aventis Pharma ' 
Chiron | 
Baxter Pharmaceutical Products, Inc. | 
BristoJ-Myers Squibb Company 1 
Dey, Inc. | 
SmrthKIine Beecham Corporation d/b/a GlaxoSmithKline | 
Pharmacia Corporation 
Hoecbst Marion Roussel, Inc. 
Immunex Corporation 
EH Lilly and Company, Inc. | 
Schering-Plough Corp. | 
Pharmacia & Upjohn Company | 
Smith Kline Beecham Corporation | 
Warrick Pharmaceuticals Corporation J 
N ^ $ E B i ^ ^ 
Abbott Laboratories, Inc. | 
3axter Pharmaceutical Products, Inc. 1 
immmmmjikmMM&wm'W Circuit Court of the City of S t Louis, MO 
054-1216 
immBmmmmsi&mm%m District Court of Lewis and Clark County, MT 
p^-s^a^imf^sim'S 
.:l?^inm»-MS%-2f*«i^:j 
«i891SJBK«B8E?^^ 
District Court of Washoe County, NV 1 
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^Biffi£^S!Rtt-S& 
NEW YORK 
(state) 
mM^m^^m^s. NEW YORK 
((cities & counties) 
J 
j 
| Bayer Corporation 
Bristol-Myers Squibb Company 
|GiaxoSmithKiine Corporation 
J GJaxo Wellcome, inc. 
j Pharmacia Corporation 
(Pharmacia & Upjohn Company 
(Smith Kline Beecham Corporation 
Tap Holdings, Inc. 
[Warrick Pharmaceuticals Corporation 
[ S S N O ^ E ^ 
(Aventis Pharmaceuticals, Inc. 
| Pharmacia Corporation 
GiaxoSmithKline, PLC 
Gfaxo Wellcome, Jna 
jSmithKlineBeecham Corporation 
l ^ r E & ' g E ^ 
Amgen, Inc. 
Immunex Corporation 
Andrx Corporation 
Astrazeneca Pharmaceuticals LP 
Astrazeneca LP 
Zeneca Holdings, Inc. 
Aventis Pharmaceuticals Inc. 
Aventis Behring, LLC 
Dermik Laboratories, Inc. 1 
Hoechst Marion Roussel j 
Sanofi-Synthelabo, Inc. 1 
ZLB Behring, LLC j 
Barr Laboratories, Inc. | 
Baxter Healthcare Corporation j 
Baxter International, Inc. 
Bayer Corporation 
Biogen Idee, inc. | 
Bristol-Myers Squibb Co. j 
Oncology Therapeutics Network, Corp. | 
Ben Venue Laboratories, inc. | 
Boehringer Jngelheim Pharmaceuticals, Inc. 1 
Boehringer Ingelheim Corporation | 
Roxane Laboratories, inc. j 
Chiron Corp. 1 
\mm£?mwmmmmmm<m&. 
1 Supreme Court of Albany County, NY 
mmmmm&?m%mmMmmmg-
U. S. District Court of Massachusetts 
fr^^ii^iiS»ae%ii^:^ 
2/13/2003 
!^^i ; ' '«M^ifc«^f^Jf«d 
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1 
|Dey, Inc. 
E.M.D., Inc. 
Eli Lilly and Company 
)Endo Pharmaceuticals, inc. 
(Ethex Corporation 
Forest Pharmaceuticals, Inc. 
(Forest Laboratories, Inc. 
JFujIsawa Healthcare, Inc. 
iFujisawa USA Inc. 
GlaxoSmithKiine, Inc. 
GlaxoS nithKIine, P.LC. 
| Glaxo Weitcome inc. f/k/a Burroughs Weficome Co. 
|SmithKlineBeecham d/b/a GlaxoSmithKiine 
Hoffman-LaRoche, Inc. 
Roche Laboratories, Inc. 
IvaxCorp. 
Ivax Pharmaceuticals, Inc. 
lAlza Corporation 
Centocor, Jna 
Ethicon, fnc. 
Janssen Pharmaceutical Products LP 
Johnson & Johnson 
McNeil-PPC, Inc. 
Ortho Biotech Products, LP 
Ortho-McNeil Pharmaceutical, Inc. i 
King Pharmaceuticals, Inc. 1 
King Research and Development | 
Monarch Pharmaceuticals, Inc. j 
Medimmune, Inc. 1 
Merck & Co., Inc. 1 
Mylan Laboratories, Inc. 1 
Mylan Pharmaceuticals, Inc. 1 
UDL Laboratories, Inc. 1 
Geneva Pharmaceuticals 1 
Novartis Pharmaceuticals Corp- 1 
Sandoz, inc., f/k/a Geneva Pharmaceuticals, Inc. j 
Novo Nordisk Pharmaceuticals, Inc. 1 
Organon Pharmaceuticals USA, Inc. I 
Par Pharmaceutical Cos., Inc. 
Par Pharmaceutical, Inc. | 
Agouron Pharmaceuticals, Inc. 
Greenstone, LTD [ 
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?jAYEwm;^_4 
OHIO 
smuErjsfet^^ :r (PENNSYLVANIA ] 
| ) 
| 1 
| J 
[ I 
1 Pfizer Inc 
(Pharmacia Corp 
|Purdue Frederick Company 
(Purdue Pharma, L P 
1 Purdue Pharma Company 
Schenng Corporation 
(Schenng-Pfough Corp 
[Warnck Pharmaceuticals Corporation 
(Serono Inc 
[TAP Pharmaceutical Products Inc 
[Novopharm USA Fnc 
[Sicor, Inc 
[TEVA Pharmaceutical industnes Ltd 
|TEVA Pharmaceuticals USA, Jnc 
[Watson Pharma, Inc f/k/a Schein Pharmaceuticals, Inc 
Watson Pharmaceuticals Inc 
Wyeth Inc 
| M A M E b D E F E t o A N T § r ^ 
Oey, Inc 
Warnck Pharmaceuticals Corp 
Schenng Plough Corp ~^ 
Schenng Corp 
Abbott Laboratories Inc 
Pharmacia Corp 
Roxane Laboratones, Inc 
Boehnnger Ingelheim Pharmaceuticals, Inc 
Ben Venue Laboratones, Inc 
NAMEKPEgENDANTS'Sr ^ $* ^ l ^ V T ^ % « % S f t 
Tap Pharmaceutical Products, Inc | 
Abbott Laboratories, Inc j 
AstraZeneca PLC 1 
Zeneca Holdings, Inc | 
AstraZeneca Pharmaceuticals LP | 
AstraZeneca LP | 
Bayer AG 
Bayer Corporation | 
SmithKIme Beecham Corporation d/b/a j 
GlaxoSmithKline | 
Slaxo Wellcome, Inc J 
Dfl2:erf Inc | 
Dharmacia Corporation j 
(vaieE^^nv^^ >\ -v 
'Court of Common Pleas Hamilton, OH 
A0402047 
Smuq&ftj^b,. *g£ ftk^, W*P»?fl 
Commonwealth Court of PA ] 
212 M D 2004 
i # -* : ?<% «** s Z2~ >im * 1 
11/17/2004 
£^*&.*s w^tn-M m m 
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$MieSSSrSSE3IS 
(South Carolina | 
14 Separate complaints 
[for Medicaid and SHP j 
total of 28 lawsuits 
{Johnson & Johnson 
Alza Corporation 
(Centocor, inc. 
|Ethicon, Inc. 
| Janssen Pharmaceutical Products, LP 
McNeif-PPC, Inc. 
lOrtho Biotech, inc. 
Ortho E lotech Products, LP 
j Ortho-McNeil Pharmaceutical, Inc. 
Amgen Inc. 
|lmmunex Corporation 
Bristol-Myers Squibb Company 
[Baxter ntemational, Inc. 
[Baxter Healthcare Corporation 
[luirnuno-US, Inc. 
lAventis Pharmaceuticals, Inc. 
Aventis Behring, LLC 
Hoechst Marion Roussel, Inc, 
Boehringer Ingelheim Corporation 
Boehringer Ingelheim Pharmaceuticals, Inc. 
Ben Venue Laboratories, Inc. 
Bedford Laboratories 
Roxane Laboratories 
Schering-Plough Corporation 
Warrick Pharmaceuticals Corporation i 
Schering Sales Corporation ! 
Dey, inc. I 
Takeda Chemical industries, Ltd. | 
N A - t V t g d ^ f e E ; ^ 
Abbott Laboratories, Inc. | 
Baxter Internationa!, Inc. I 
Baxter Healthcare Corporation J 
Dey, LP, f/k/a Dey laboratories I 
Boehringer Ingelheim Roxane, Inc. j 
Roxane Laboratories, Inc. | 
Ben Venue Laboratories, Inc. ) 
Warrick Pharmaceuticals Corporation | 
Schering-Plough Corporation j 
Schering Corporation ) 
AJpharma, Inc. | 
Court of Common Pleas, County of Richland | igkMWf :^mmm^^mm4 0803/2006 
0803/2006 
0803/20061 
0803/2006 
0803/2006) 
0803/2006 
0803/2006 
0803/2006 
0803/2006 
0803/2006 
12/1/2006) 
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s ^ ^ r E ^ r ^ ^ ^ ^ l 
TEXAS 
^ S T ^ ^ S S S B S ^ 
Utah 
1 [ 
1gK^;c^^feli^ili! 
[Par Pharmaceuticals Companies, Inc. 
Teva P larmaceutfcais USA. Inc. 
Ivax Corporation 
(Watson Pharmaceuticals, Inc. 
jBarr Pharmaceuticals, Inc. 
| Bristol-;Vlyers Squibb Company 
| Mylan Laboratories, Inc. 
ISandoz, Inc. 
[Novartis Pharmaceuticals Corporation 
N$l/iHS£EEENp^ 
[Abbott Laboratories, Inc. 
| Abbott Laboratories 
[Hospira, Inc. 
B. Braun Medical, Inc. 
[Baxter Healthcare Corporation 
[Dey, Inc. 
Warrfck Pharmaceutical Corporation 
Schering-Plough Corporation 
Schering Corporation 
Roxane Laboratories, Inc. 
Boehringer ingelheim Corporation 
Boehringer Ingelheim Pharmaceuticals, Inc. 
Ben Venue Laboratories, inc. 
K M » l E ^ 
Actavis US. Inc. 
Bar Laboratories, Inc. 
Endo Pharmaceuticals, Inc. 
Ethex Corporation | 
Mylan Laboratories, Inc. ] 
Dey, Inc. | 
Mylan Pharmaceuticals, Inc. | 
UDL Laboratories. Inc. 1 
Par Pharmaceuticals, Inc. | 
Ranbaxy, Inc. | 
Sandoz, Inc. | 
Teva Pharmaceuticals USA, inc. | 
Watson Pharmaceuticals, Inc. 
Watson Laboratories, Inc. | 
Watson Pharma, Inc. | 
JThree lawsuits filed in Travis County, TX 
GV401286 (Abbott) 
GV002327 (Dey, Roxane. Warrick) 
GV3-03079 (Roxane, Boehringer) 
^ ! # § S « ^ 
Third Judicial District, Salt Lake County, Utah 
Civil No. 70913719 , 
j 12/1/2006 
J 12/1/2006i 
12/1/2006 
12/1/2006] 
j 1/16/20071 
1/16/2007] 
1/16/2007] 
1/16/2007 
I 1/16/2007 
% i&ffitffimM&2^^\ 
n _j 
((^W^e^MSSif^m^SM 
9/21/20071 
« 6 ! « ^ N I & r t ^ 1 ^ ^ 
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(WEST VIRGINIA 
mm^sms^iam WISCONSIN 
1 Warrick Pharmaceuticals Corporation 
Schering-Plough Corporation 
|Dey, Inc. 
(Abbott Laboratories 
(Abbott Laboratories, Inc. 
te/HU=W^^^ 
[Abbott Laboratories 
[Arngen, Inc. 
(AstraZeneca Pharmaceuticals, LP 
1 AstraZeneca, LP 
JAventis Pharmaceuticals, inc. 
lAventis Behring, LLC 
| Baxter International, Inc. 
Bayer Corporation 
|Ben venue Laboratories, Inc. 
Boehringer Ingelheim Corporation 
Beohringer ingelheim Pharmaceuticals, Inc. 
Boehringer Ingelheim Roxane, Inc. 
Bristol-Myers Squibb Co. 
Dey, Inc. 
Fujisawa Healthcare - DISMISSED 
Gensia SIcor Pharmaceuticals - DISMISSED 
GlaxoSmithKline, Inc. - DISMISSED 
Immunex Corporation 
Ivax Corporation 
Ivax Pharmaceuticals, Inc. 
Janssen Pharmacuetical Products, LP 
Johnson & Johnson, Inc. 
McNeil-PPC, Inc. | 
Merck & Company, Inc. | 
Mylan Laboratories, Inc. | 
Mylan Pharmaceuticals. Inc. 1 
Novartis Pharmacetuclals Corporation | 
Ortho Biotech Products, LP 
Ortho-McNeil Pharmaceutical, Inc. | 
Pfizer, fnc. 
Pharmacia | 
Sandoz, Inc. f/k/a Geneva Pharmaceuticals, Inc. | 
Schering-Plough Corporation J 
Sicor Pharmaceuticals, Inc. f/k/a Gensia Secor Pharms, Inc. | 
SmithKline Beecham Corporation p7b/a GlaxoSmithKline . | 
Tap Pharmaceutical Products, Inc. | 
(Circuit Court of Kanawha County, WV 
I01-C-3011 
kaii^^M^ I Circuit Court of Dane County, Wl 
04-CV-1709 
I 10/11/2001 
mmmm^:^:mmmimd J 6/3/2004 
I 
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Teva Pharmaceuticals Industries, LTD 
Warrick Pharmaceuticals Corporation 
Watson Pharma, inc. 
Watson Pharmaceuticals, Inc. 
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Utah Medicaid Provider Manual 
Division of Medicaid and Health Financing 
Pharmacy Services 
Updated July 2010 
Products mailed directly to a patient from the manufacturer using a single designated distributor are not covered by 
Medicaid. Manufacturers are increasingly shipping products, developed to target specific diseases, directly to 
patients via a Pharmacy Benefit Management service. 
Medicaid will not enter into agreements or utilize distribution programs that violate patient confidentially or prohibit 
free trade of a product. When products are available through usual and customary channels to all pharmacies, the 
products will become Medicaid benefits. 
Medicaid restricts hemophilia blood factors to a single provider. The purpose is to provide a uniform hemophilia 
case management support program to the patient and patient's physician and to achieve economies in the purchase 
of blood factor through a sole source contract. Medicaid will reimburse only the sole source provider for hemophilia 
case management, blood factors VII, VIII and IX. No other provider will be paid for blood factors VII, VIII or IX. 
Medicaid clients who choose not to participate in the Medicaid Hemophilia!) 
arrangements for procurement and payment of the blood factor. 
program must make their own 
The contract affects only the procurement and management of the prescribed blood factor. The patient's physician 
continues to be responsible to develop a plan of care and to prescribe the blood factor. The contract with the sole 
source provider specifies the provider must work closely with the patient's primary Care Provider physician or 
managed care plan. 
Managed care plans which contract with Medicaid continue to be responsible for hemophilia-related services such as 
physical therapy, lab work, unrelated nursing care, and physician services. 
As of October 2000, the sole source provider is University Hospital Home 
concerning hemophilia case management and blood factors VII, VIII and Df 
Infusion Services. Please direct questions 
to this provider: (801) 213-9600. 
Medicaid utilizes Centers for Disease Control (CDC) pricing information arid Estimated Acquisition Cost (EAC), 
which is calculated as AWP -15%, in determining the reimbursement rates for immunizations paid by fee-for-
service Medicaid. Medicaid will continue to use lesser logic and reimburse t)he lower of CDC and EAC. 
CDC pricing information can be found at http://www.cdc.gov/vaccines/proglrams/vfc/cdc-vac-price-list.htm . 
6 REIMBURSEMENT POLICIES 
Effective April 1, 2000, Medicaid requires all pharmacy claims to be submitted electronically through the Point of 
Sale system. Medicaid will only accept a claim submitted on paper when (1) a client becomes eligible for Medicaid 
after receiving services (retroactive Medicaid) AND (2) the provider's software cannot support a claim with a 
previous date of service. 
Beginning April 1, 2000, Medicaid will return all Universal Pharmacy Claim's (NCPDP) submitted on a paper form 
to the provider with a cover letter requiring the claim be submitted electronically. 
Point of Sale System 
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Utah Medicaid Provider Manual 
Division of Medicaid and Health Financing 
Pharmacy Services 
Updated July 2010 
The Point of Sale (POS) system provides pharmacists with the capability to submit pharmacy claims electronically. 
It enables pharmacies to immediately determine Medicaid client eligibility, verify drug coverage, and have "real 
time" claim processing. Federal law has mandated the use of NCPDP 5.1 effective October 17, 2003. NCPDP5.1 is 
the national claim format developed by the National Council for prescription drugs. All pharmacies routinely billing 
Utah Medicaid must use NCPDP 5.1 when billing Medicaid through Point-of-Sale, 
Pharmacy claims are routed electronically through network companies (switches). The network companies currently 
participating in this process are RelayHealth and Emdeon. Other interested and qualified networks may also 
participate. 
For information about submitting claims through RelayHealth or Emdeon, please call RelayHealth Customer 
Support at 1-800-388-2316 or Emdeon Customer Service at 1-800-333-6869. 
Included with this manual are instructions, and a Resolution List to assist in resolving denials. 
PRODUR, Prospective Drug Utilization Review Program, is an adjunct to the Point Of Sale (POS) system used for 
pharmacy claims. It is a system to monitor the client's complete Medicaid drug history, including any pharmacy or 
physician. It identifies on the computer screen, as the prescription is being filled, any potential adverse drug events 
(ADE) of severity level 1, drug duplicates as well as therapeutic class drug duplicates. PRODUR contains modules 
to review drug interactions and responds with a message to the pharmacist. Modules include: Minimum - Maximum 
Dose, Dose range (cumulative dose), Duplication, Drug - Drug Interaction, Drug - Disease Interaction, 
Minimum/Maximum Pediatric Daily Dose, Minimum/Maximum Geriatric Daily Dose and Side Effects Module. 
Criteria for the Side Effects Module are listed in this chapter. 
If you would like more information on PRODUR, please contact Medicaid Information. 
Criteria for Side Effects Module 
For the Side Effects Module, First DataBank© has established the following editorial criteria: 
a. Frequency: A side effect is defined as 'common or more frequent' when the incidence is greater than or 
equal to 10%. A side effect is defined as 'rare or less frequent' when the incidence is less than 10%, 
b. Severity: A side effect is defined as 'less severe' if it is nonthreatening (e.g., constipation). A side effect is 
defined as 'severe' if it may be life-threatening (e.g., agranulocytosis). 
c. Visibility: A side effect id defined as 'visible* if it is definitely detectable (e.g., rash). This includes detection 
by the patient or by someone other than the patient. A side effect is defined as 'may be visible' if the 
detectability is less clear cut. For example, a headache is not exactly visible, per se. However, the patient may 
be able to convey that he has a headache. In these cases, it is assumed that the patient is responsive or 
communicative. Also, assessment is based on a physical examination which may include use of a blood 
pressure cuff, thermometer, stethoscope, weight measurement, and fluid input/output measurement. Finally, a 
side effect is defined as ' not visible' if it is definitely not visible (e.g., neutropenia), or if it is not detectable 
by routine physical exam. 
d. Lab tests: The intent of this indicator is not to establish which lab tests should be ordered for a given drug as 
baseline or for monitoring. Rather, it is intended to indicate whether or not lab tests are necessary as follow-
up for a given drug/side effect pair. 
Page 26 of 32 SECTION 2 
Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU. 
Machine-generated OCR, may contain errors.
ADDENDUM C 
Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU. 
Machine-generated OCR, may contain errors.
Actions Known To The State Involving Named Defendants or Their Corporate 
Partners or Subsidiaries 
Defendant Baxter International: 
• Alabama v. Abbott Labs, et al9 Circuit Court of Montgomery County, CV-2005-
219; 
• Alaska v. Alpharma Branded Products Division, Superior Court, Anchorage, 3 
AN-06-12026 CI; 
• Arizona v. Abbott Labs, et al.9 Superior Court of Maricopa County, 
2:2006cv00045; 
• California v. Abbott Labs, et al9 Superior Court of Los Angeles County, 
BS109342; 
• Hawaii v. Abbott Labs, et al9 Circuit Court of the First Circuit, State of Hawaii, 
06-1-0720-04 EEH; 
• Illinois v. Abbott Labs, et al9 Circuit Court of Cook County, 05 CH 2474; 
• Kentuclcy v. Abbott Labs, et al, Circuit Court of Fifanklin County, 03-CI-1135; 
• Mississippi v, Abbott Labs, et al9 Chancery Court bf Hinds County, G2005-2021; 
• Montana v. Abbott Labs, et al9 Federal District Court of Massachusetts, 02-CV-
12084-PBS; 
• Pennsylvania v. Abbot Labs, et aL9 Commonwealth Court of Pennsylvania, 212 
M.D. 2004; 
• Wisconsin v. Abbott Labs, et al9 Circuit Court of Dane County, 04-CV-1709; 
Defendant Boehringer Ingelheim Corporation: 
• Alabama v. Abbott Labs, et al9 Circuit Court of Montgomery County, AL CV-
2005-219; 
• Alaska v. Alpharma Branded Products Division, Superior Court, Anchorage, 3 
AN-06-12026 CI; 
• Arizona v. Abbott Labs, et al, Superior Court of Maricopa County, 
2:2006cv00045; 
• California v. Abbott Labs, et al9 Superior Court of Los Angeles County, 
BS109342; 
• Florida v. Boehringer Ingelheim, et aL9 Circuit Court of Leon County, 98-3032A; 
• Hawaii v. Abbott Labs, et al9 Circuit Court of the F|irst Circuit, State of Hawaii, 
06-1-0720-04 EEH; 
• Illinois v. Abbott Labs, et al9 Circuit Court of Cook County, 05 CH 2474; 
• Kentuclcy v. Abbott Labs, et al., Circuit Court of Franklin County, 03-CI-1135; 
• Massachusetts v. Mylan Labs, et al.9 United States District Court of 
Massachusetts, 03-CV-11865-PBS; 
• Mississippi v. Abbott Labs, et al9 Chancery Court of Hinds County, G2005-2021; 
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• Ohio v. Dey, Inc., et al, Court of Common Please, Hamilton, Ohio, A0402047; 
• Pennsylvania v. Abbot Labs, et al, Commonwealth Court of Pennsylvania, 212 
MX). 2004; 
• Texas v. Warrick Pharmaceuticals, et al, District Court of Travis County, 
GV002327; 
• Wisconsin v. Abbott Labs, et al, Circuit Court of Dane County, 04-CV-1709; 
Defendant Forest Labs: 
• Alabama v. Abbott Labs, et al, Circuit Court of Montgomery County, AL CV-
2005-219; 
• Alaska v. Alpharma Branded Products Division, Superior Court, Anchorage, 3 
AN-06-12026 CI; 
• Hawaii v. Abbott Labs, et al, Circuit Court of the First Circuit, State of Hawaii, 
06-1-0720-04 EEH; 
• Illinois v. Abbott Labs, et al, Circuit Court of Cook County, 05 CH 2474; 
• Kentucky v. Abbott Labs, et al, Circuit Court of Franklin County, 03 -CI-113 5; 
• Mississippi v. Abbott Labs, et al, Chancery Court of Hinds County, G2005-2021; 
Defendant Novartis: 
• Alabama v. Abbott Labs, et al, Circuit Court of Montgomery County, AL CV-
2005-219; 
• Alaska v. Alpharma Branded Products Division, Superior Court, Anchorage, 3 
AN-06-12026 CI; 
• California v. Abbott Labs, et al, Superior Court of Los Angeles County, 
BS109342; 
• Hawaii v. Abbott Labs, et al, Circuit Court of the First Circuit, State of Hawaii, 
06-1-0720-04 EEH; 
• Illinois v. Abbott Labs, et al, Circuit Court of Cook County, 05 CH 2474; 
• Kentucky v. Abbott Labs, et al, Circuit Court of Franklin County, 03-CI-l 135; 
• Mississippi v. Abbott Labs, et al, Chancery Court of Hinds County, G2005-2021; 
• Wisconsin v. Abbott Labs, et al, Circuit Court of Dane County, 04-CV-1709; 
Defendant Pfizer: 
• Alabama v. Abbott Labs, et al, Circuit Court of Montgomery County, AL CV-
2005-219: 
• Alaska v. Alpharma Branded Products Division, Superior Court, Anchorage, 3 
AN-06-12026 CI; 
• Hawaii v. Abbott Labs, et al, Circuit Court of the First Circuit, State of Hawaii, 
06-1-0720-04 EEH; 
• Illinois v. Abbott Labs, et al, Circuit Court of Cook County, 05 CH 2474; 
• Kentucky v. Abbott Labs, et al, Circuit Court of Franklin County, 03-CI-l 135; 
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• Pennsylvania v. Abbot Labs, et ah, Commonweatth Court of Pennsylvania, 212 
M.D. 2004; 
• Wisconsin v. Abbott Labs, et al9 Circuit Court oflDane County, 04-CV-1709; 
Defendant Schering-Plough: 
• Alabama v. Abbott Labs, et al9 Circuit Court of Montgomery County, AL CV-
2005-219; 
• Alaska v. Alpharma Branded Products Division, Superior Court, Anchorage, 3 
AN-06-12026 CI; 
• Arizona v. Abbott Labs, et al9 Superior Court of Maricopa County, 
2:2006cv00045; 
• Arkansas v. Dey, Inc., et al9 Circuit Court of Pulalski County, CV-04-634; 
• California v. Abbott Labs, et al9 Superior Court of Los Angeles County, 
BS109342; 
• Florida v. Boehringer Ingelheim, et al.9 Circuit Court of Leon County, 98-3032A; 
• Hawaii v. Abbott Labs, et al, Circuit Court of the First Circuit, State of Hawaii, 
064-0720-04 EEH; 
• Illinois v. Abbott Labs, et al9 Circuit Court of Codk County, 05 CH 2474; 
• Mississippi v. Abbott Labs, et al9 Chancery Court of Hinds County, G2005-2021; 
• Missouri v. Dey, Inc., et al9 Circuit Court of the City of St. Louis, 054-1216; 
• Montana v. Abbott Labs, et al, Federal District Court of Massachusetts, 02-CV-
12084-PBS; 
• Ohio v. Dey, Inc., et al9 Court of Common Please,, Hamilton, Ohio, A0402047; 
• Pennsylvania v. Abbot Labs, et al.9 Commonwealtli Court of Pennsylvania, 212 
M.D. 2004; 
• Texas v. Warrick Pharmaceuticals, et aL9 District (tourt of Travis County, 
GV002327; 
• Wisconsin v. Abbott Labs, et al9 Circuit Court of Qane County, 04-CV-1709; 
Defendant Wyeth: 
• Alabama v. Abbott Labs, et al9 Circuit Court of Montgomery County, AL CV-
2005-219; 
• California v. Abbott Labs, et al9 Superior Court of Los Angeles County, 
BS109342; 
• Mississippi v. Abbott Labs, et al9 Chancery Court c^ f Hinds County, G2005-2021; 
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IN THE CIRCUIT COURT OF 
MONTGOMERY COUNTY, ALABAMA 
STATE OF ALABAMA, 
Plaintiff, 
ABBOTT LABORATORIES, INC.; AGOURON 
PHARMACEUTICALS, INC.; ALCON 
LABORATORIES, INC; ALLERGAN, INC.; 
ALPHARMA, INC.; ALZA CORPORATION; 
AMGEN, INC.; ANDRX PHARMACEUTI-
CALS, INC.; ASTRAZENECA PHARMACEU-
TICALS LP; ASTRAZENECA LP; AVENTIS 
PHARMACEUTICALS, INC.; AVENTIS 
BEHRING, LX.C; BARR LABORATORIES, 
INC.; BAXTER HEALTHCARE CORPORA-
TION; BAXTER INTERNATIONAL, INC.; 
BAYER CORPORATION; BAYER PHARMA-
CEUTICALS CORPORATION; BAYER 
HEALTHCARE, LLC; BIOVAIL PHARMA-
CEUTICALS, INC.; BOEHRINGERINGEL 
HEIM CORPORATION; BOEHRINGER 
INGELHEIM PHARMACEUTICALS, INC.; 
BRISTOL-MYERS SQUIBB COMPANY; DEY, 
L.P.; EISAI, INC.; ENDO PHARMACEUTI-
CALS, INC.; ETHEX CORPORATION; 
FOREST LABORATORIES, INC.; FOREST 
PHARMACEUTICALS, INC.; FUJISAWA 
HEALTHCARE, INC.; FUJISAWA USA, INC.; 
G.D. SEARLE,L.L.C; GENZYME CORPOR-
ATION; GILEAD SCIENCES, INC.; 
HOFFMANN-LAROCHE, INC.; IMMUNEX 
CORPORATION; IVAX CORPORATION; 
IVAX PHARMACEUTICALS, INC.; JANSSEN 
PHARMACEUTICA PRODUCTS, LP; 
JOHNSON & JOHNSON; ICING PHARMA-
CEUTICALS, INC.; MCNEIL-PPC, INC.; 
MEDIMMUNE, INC.; MERCK & CO., INC.; 
MONARCH PHARMACEUTICALS, INC.; 
MYLAN LABORATORIES, INC.; MYLAN 
PHARMACEUTICALS, INC.; NOVARTIS 
PHARMACEUTICALS CORPORATION; 
CV-105-219 
JURY TRIAL DEMANDED 
S2 
en 
3 
CO 
CO 
en 
Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU. 
Machine-generated OCR, may contain errors.
NOVO NORILSK PHARMACEUTICALS, 
INC.; ORGANON PHARMACEUTICALS USA, 
INC.; ORTHO BIOTECH PRODUCTS, LP; 
ORTHO-MCNEIL PHARMACEUTICAL, 
INC.; PAR PHARMACEUTICAL, INC.; 
PFIZER, INC.; PHARMACIA CORPORA-
TION; PHARMACIA & UPJOHN COMPANY 
CORPORATION; PURDUE PHARMA, L.P.; 
PUREPAC PHARMACEUTICAL CO.; 
ROCHE LABORATORIES, INC.; ROXANE 
LABORATORIES, INC.; SANDOZ, INC.; 
SANOFI-SYNTHELABO, INC.; SCHERING-
PLOUGH CORPORATION; SMITHKLINE 
BEECHAM CORPORATION D/B/A GLAXO-
SMTIHKLINE; TAKEDA PHARMACEUTI-
CALS NORTH AMERICA, INC.; TAP 
PHARMACEUTICAL PRODUCTS, INC.; 
TEVA PHARMACEUTICALS USA, INC.; UDL 
LABORATORIES, INC.; WARRICK 
PHARMACEUTICALS CORPORATION; 
WATSON LABORATORIES, INC.; WATSON 
PHARMA, INC.; WATSON PHARMACEUTI-
CALS, INC.; WYETH, INC.; WYETH 
PHARMACEUTICALS, INC.; ZLB BEHRING, 
L.L.C., and FICTITIOUS DEFENDANTS 1 
through 200, whose true names are not presently 
known, but who are manufacturers, distributors, 
marketers, and/or sellers of prescription drugs 
who reported or caused to be reported false and 
inflated pricing information to industry 
publishers upon which information the Alabama 
Medicaid Agency relied in reimbursing 
providers for the dispensing of such drugs, and 
whose true names will be added upon discovery, 
Defendants. 
2 
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SECOND AMENDED COMPLAjQ^T 
The State of Alabama, by and through its Attorney Genejral (hereinafter "the State"), files 
this second amended complaint against the above-named Defendants and alleges, on information 
and belief, the following: 
INTRODUCTION 
L The Defendants have engaged in false, misleading wanton, unfair, and deceptive 
acts and practices in the pricing and marketing of their prescription drug products The 
Defendants' fraudulent pricing and marketing of their prescription drugs have impacted elderly, 
disabled, and poor Alabama citizens covered by the State's Medicaid program ("Alabama 
Medicaid") by causing the Alabama Medicaid Agency to pay grossly excessive prices for the 
Defendants' prescription drugs, 
2, Fair and honest drug pricing is a matter of great (importance to the State and its 
citizens. Expenditures by the State and its agencies for prescription drug reimbursement have 
increased dramatically in the past several years as a result, in part, of Defendants' fraudulent 
pricing scheme. Each year Alabama spends hundreds of millions of dollars on prescription drugs 
under the Alabama Medicaid program. In 2004 alone, Alabama Medicaid spent almost $600 
million on prescription drugs. Since 1990, Alabama Medicaid [prescription drug expenditures 
have increased tenfold. This exponential increase in prescription idrug costs in recent years has 
contributed to a health care funding crisis within the State that (requires action to ensure fair 
dealing between the Defendants and the State and its agencies. 
3. The State is accountable to its citizens and taxpayers for how it spends limited 
State resources, and it is obligated to pursue any party whose unlawful conduct has led to the 
overspending of State funds, Consequently, the State, by and through its Attorney General, 
3 
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brings this action to recover amounts overpaid for prescription drugs by Alabama Medicaid, 
including pharmacy dispensed drugs and co-payments for drugs covered by Medicare, as a result 
of the fraudulent and wanton conduct'of Defendants, The State further seeks to prohibit and 
permanently enjoin Defendants from continuing to perpetrate their drug-pricing scheme, to 
require Defendants to publicly disclose true drug prices, and to require Defendants to account for 
and disgorge all profits obtained by Defendants as a result of their improper and unlawful 
actions, 
4* This lawsuit seeks legal and equitable redress for the fraudulent and wanton 
marketing and pricing conduct of Defendants, who have profited from their wrongful acts and 
practices at the expense of the State, 
PARTIES 
5. Plaintiff is the State of Alabama. The State brings this action in its capacity as 
sovereign and on behalf of the Alabama Medicaid Agency, 
6. The Attorney General, as chief law officer of the State of Alabama pursuant to 
Alabama Code § 36-15-12, is statutorily authorized to initiate and maintain this action. 
Defendant Abbott 
7. Defendant Abbott Laboratories, Inc. ("Abbott") is a Delaware corporation with its 
principal place of business located at 100 Abbott Park Road, Abbott Park, 11* 60064. Ross 
Products is a division of Abbott. Abbott is engaged in the business of manufacturing, 
distributing, marketing, and/or selling prescription drugs that are reimbursed by state Medicaid 
agencies nationwide, Pharmaceuticals that are manufactured, distributed, marketed, and/or sold 
by Abbott and reimbursed by Alabama Medicaid for which a claim is made in this litigation are 
identified in Exhibit A, attached. 
4 
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Defendant Alcon 
8. Defendant \ Icoi i 1 laboratories, Inc.. ("Alcon") is la Delaware corporation with its 
principal place of business located at 6201 S, Freeway (Tl~3)} Fort Worth, TX 76134-2099. 
Alcon is engaged in the business of manufacturing, distributing, marketing, and/or selling 
prescription drugs that are reimbursed by state Medicaid agencies nationwide. Pharmaceuticals 
that are manufactured, distributed, marketed, and/or sold by Alton and reimbursed by Alabama 
Medicaid for which a claim is made in this litigation are identified in Exhibit A, attached. 
Defendant Allergan 
9. Defendant Allergan, Inc. ("Allergan") is a Delawajre corporation with its principal 
place of business located at 2525 Dupont Drive. Irvine, CA 92612,, Allergan is engaged in the 
business of manufacturing, distributing, marketing, and/or selling prescription drugs that are 
reimbursed by state Medicaid agencies nationwide. Pharmaceuticals that are manufactured, 
distributed, marketed, and/or sold by - " * »••*! H'-T^I:::-^; jy Alabama Medicaid for which a 
claim is made in this litigation are identified in Exhibit A, attache ,^, 
The Alpharma Defendants 
10. Defendant Abharmii. In; r1 'Wpikinricj'1) ir a Delaware corporation with its 
principal place of business located at One Executive Drive, Fort Lfee, "NJ 07024-1399. 
11. Defendant Purepac Pharmaceutical Co. ("Purepac'*)J a wholly-owned subsidiary of 
Alpharma, is a Delaware corporation with its principal place of business located at 14 Commerce 
Drive, Suite 301, Cranford, N.T 07016, 
12. Alpharma and Purepac (collectively, the "Alpharmi Defendants") are diversified 
healthcare companies that individually, and/or in combination with one another, engage in the 
business of manufacturing, distributing, marketing, and/or selling prescription drugs that are 
5 
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reimbursed by state Medicaid agencies nationwide. Pharmaceuticals that are manufactured, 
distributed, marketed, and/or sold by the Alpharma Defendants and reimbursed by Alabama 
Medicaid for which a claim is made in this litigation are identified in Exhibit A, attached, 
The Amgen Defendants 
13. Defendant Amgen, Inc. ("Amgen") is a Delaware corporation with its principal 
place of business located at One Amgen Center Drive, Thousand Oaks, CA 91320-1799, 
14, Defendant Immunex Corporation ("Immunex"), a Washington corporation with its 
principal place of business located at 51 University Street, Seattle, WA 98101, was acquired by 
Amgen in 2002. 
15. Amgen and Immunex (collectively, the "Amgen Defendants**) are diversified 
healthcare companies that individually, and/or in combination with one another, engage in the 
business of manufacturing, distributing, marketing, and/or selling prescription drugs that are 
reimbursed by state Medicaid agencies nationwide. Pharmaceuticals that are manufactured, 
distributed, marketed, and/or sold by the Amgen Defendants and reimbursed by Alabama 
Medicaid for which a claim is made in this litigation are identified in Exhibit A, attached. 
Defendant Andrx 
16, Defendant Andrx Pharmaceuticals, Inc., ("Andrx Pharm") is a Florida corporation 
with its principal place of business located a 4955 Orange Drive, Davie, FL 33314. Andrx 
Pharm is engaged in the business of manufacturing, distributing, marketing, and/or selling 
prescription drugs that are reimbursed by state Medicaid agencies nationwide. Pharmaceuticals 
that are manufactured, distributed, marketed, and/or sold by Andrx Pharm and reimbursed by 
Alabama Medicaid for which a claim is made in this litigation are identified in Exhibit A, 
attached. 
6 
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The- AstraZeneca Defendants] 
17, Defendant AstraZeneca Pharmaceuticals LP ("AstraZeneca Pharm") is a Delaware 
limited partnership with its principal place of business located! at 1800 Concord Pike, PXX Box 
15437, Wilmington, DE 19850-5437. 
18 Defendant AstraZeneca LP ("AstraZeneca'5), formerly Astra Pharmaceuticals LP, 
is a Delaware limited partnership with its principal place of business located at 725 Chesterbrool: 
Boulevard, Wayne, PA 19087. 
AstraZeneca Pharm and AstraZeneca (collectively, the "AstraZeneca Defendants") 
are diversified healthcare companies that individually, and/or i|n combination with one another; 
engage in the business of manufacturing distributing, marketing and/or selling prescription 
drugs that are reimbursed by state Medicaid agencies nationwide. Pharmaceuticals that are 
manufactured, distributed, marketed, and/or sold by the AstraZeneca Defendants and reimbursed 
by Alabama Medicaid W M\\0^ r\ ub'im i nmde in this litigation are identified in ExlVibit A, 
attached. 
The Aventis Defendants 
20, Defendant Aveiiths Phaunaceuticals, Inc.. ("Aventis") is a Delaware corporation 
with its principal place of business located at 300 Somerset Corporate Boulevard, Bridgewater, 
NJ 08807-2854. 
21. Defendant Aventis Behring, L.L.C. ("Aventis Behring") is a Delaware limited 
liability company with its principal place of business located tit 1020 First Avenue, King of 
Prussia, PA 19406-1310, Aventis Behring was formerly k^own as Centeon I 1 >' ami 
currently operates as ZLB Behring. 
7 
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22. Defendant ZLB Behring, L,L.C. ("ZLB Behring"), formerly known as Aventis 
Behring, is a Delaware limited liability company and a subsidiary of CSL Limited of Melbourne 
Australia, with its principal place of business located at 1020 First Avenue, P.O.. Box 61501, 
King of Prussia, PA 19406-0901. 
23. Aventis, Aventis Behring, and ZLB Behring (collectively, the "Aventis 
Defendants") are diversified healthcare companies that individually, and/or in combination with 
one another, e;ngage in the business of manufacturing, distributing, marketing, and/or selling 
prescription drugs that are reimbursed by state Medicaid agencies nationwide. Pharmaceuticals 
that are manufactured, distributed, marketed, and/or sold by the Aventis Defendants and 
reimbursed by Alabama Medicaid for which a claim is made in this litigation are identified in 
Exhibit A, attached. 
Defendant Barr 
24. Defendant Barr Laboratories, Inc. ("Barr"), a subsidiary of Barr Pharmaceuticals, 
Inc., is a Delaware corporation with its principal place of business located at 2 Quaker Road, 
P.O. Box 2900, Pomona, NY 10970-0519, Barr is engaged in the business of manufacturing, 
distributing, marketing, and/or selling prescription drugs that are reimbursed by state Medicaid 
agencies nationwide. Pharmaceuticals that are manufactured, distributed, marketed, and/or sold 
by Barr and reimbursed by Alabama Medicaid for which a claim is made in this litigation are 
identified in Exhibit A, attached.. 
The Baxter Defendants 
25. Defendant Baxter International, Inc. ("Baxter International") is a Delaware 
corporation with its principal place of business located at One Baxter Parkway, Deerfield, IL 
60015-4633. 
8 
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26. Defendant Baxter Healthcare Corporation ("Baxter Healthcare"), a wholly-owned 
subsidiary of Baxter International, Inc , is a Delaware corporation, with its pi incipal place of 
business located at One Baxter Parkway, Deerfield, IL 60015. 
27. Baxter International and Baxter Healthcare (collectively, the "Baxter Defendants") 
ar e diversified healthcare con lpanies that ii idividually, and/oi ii i combination with one anothei , 
engage in the business of manufacturing, distributing, marketing, and/or selling prescription 
drugs that are reimbursed by state Medicaid agencies nationwide. Pharmaceuticals that are 
manufactured, distributed, marketed, and/or sold by the Baxter Defendants and reimbursed by 
Alabama Medicaid for which a claim is made in this litigation are identified in Exhibit A, 
attached. 
The Bayer Defendants 
28. Defendant Bayer Corporation ("Bayer"), formerly Miles, Inc, is an Indiana 
corporatioi :i with its prii icipal place of business located at 100 Bayei Road, Pittsburgh, PA 
15205-9707. Bayer Corporation is a wholly-owned United States subsidiary of Bayer AG, a 
German corporation with its principal place of business located t^ 51368 Leverkusen, Germany. 
29. Defendant Bayei Pharmaceuticals Corporation ("Bayer Pharm") is a Delaware 
corporation with its principal place of business located at 4001 Morgan Lane, West Haven, CT 
06516, 
30. Defendant Bayer Healthcare, LLC ("Bayer Healthcare") is a legally it idependent 
company with six divisions operating under the Bayer AG Umbrella, Bayer Healthcare is a 
Delaware limited liability company with its principal place of|business located at 511 Benedict 
Avenue, Tanytown, NY 10591. 
9 
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31. Bayer, Bayer Pharm, and Bayer Healthcare (collectively, the "Bayer Defendants") 
are diversified healthcare companies that individually, and/or in combination with one another, 
engage in the business of manufacturing, distributing, marketing, and/or selling prescription 
drugs and biological products that are reimbursed by state Medicaid agencies nationwide-
Pharmaceuticals and biological products that are manufactured, distributed, marketed, and/or 
sold by the Bayer Defendants and reimbursed by Alabama Medicaid for which a claim is made 
in this litigation are identified in Exhibit A, attached. 
Defendant Biovail 
32. Defendant Biovail Pharmaceuticals, Inc. ("Biovail") is a Delaware corporation 
with its principal place of business located at 700 Route 202/206, North Bridgewater, NJ 08807. 
Biovail is engaged in the business of manufacturing, distributing, marketing, and/or selling 
prescription drugs that are reimbursed by state Medicaid agencies nationwide., Pharmaceuticals 
that are manufactured, distributed, marketed, and/or sold by Biovail and reimbursed by Alabama 
Medicaid for which a claim is made in this litigation are identified in Exhibit A, attached. 
The Boehringer Defendants 
33. Defendant Boehringer Ingelheim Corporation ("Boehringer") is a Nevada 
corporation with its principal place of business located at 900 Ridgebury Road, Ridgefield, CT 
06877. Boehringer includes a number of subsidiary companies that manufacture, distribute, 
market, and/or sell prescription drugs, including, but not limited to, the following: 
a, Defendant Boehringer Ingelheim Pharmaceuticals, Inc., 
("Boehringer Pharm") is a Delaware corporation with its principal 
place of business located at 900 Ridgebury Road, Ridgefield, CT 
06877;and 
10 
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b* Defendant Roxane Laboratories, Inc., ('fRoxane"), a Delaware 
coi poration with its principal place of b|usiness located at 1809 
Wilson Road, Columbus, OH 43228-9579|-
34, Boehringer, Boehringer Pharm, and Roxane (collectively "the Boehringer 
Defendants") are diversified healthcare companies that individually, and/oi in combination with 
one another, engage in the business of manufacturing, distributing, marketing, and/or selling 
prescription drugs that are reimbursed by state Medicaid agencies nationwide* Pharmaceuticals 
thai are manufactured, distributed, marketed, ;vr.i-.. . / , • :]•»- Bc^h:::,L_- Defen/:i:::. :.:•' 
reimbursed by Alabama Medicaid for which a claim is made ih this litigation are identified in 
Exhibit A, attached. 
Defendant Bristol-Myers Squibtf 
35, Defendant Bristol-Myers Squibb Company ("Bilistol-Myers Squibb"), formerly 
Bristol-Myers Company, is a Delaware corporation with its principal place of business located at 
345 Park Avenue, New York, NY 10154-0037. Bristol-Myers $quibb, which includes a number 
of divisions and/or subsidiary companies, is engaged in tjhe business of manufacturing, 
distributing, marketings and/or selling pi escription drugs that are reimbursed by state Medicaid 
agencies nationwide.. Pharmaceuticals that are manufactured, distributed, marketed, and/or sold 
by Bristol-Myers Squibb, and/or its subsidiaries and divisions, and reimbursed by Alabama 
Medicaid for which a claim is made in this litigatioi i are identified in E> i- *" ' .•".•yr.h-- \ 
Defendant DEY 
36, Defendant DEY, LJP. ("DEY"), formerly DEY Laboratories, is a Delaware limited 
pai tnership with its principal place of business located at 2751 Napa Valley Corporate Drive, 
Napa, CA 94558.. DEY is an indirect subsidiary of Merck &GaA, a German pharmaceutical 
11 
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conglomerate, and is an affiliate of EMD, Inc.. DEY is engaged in the business of 
manufacturing, distributing, marketing, and/or selling prescription drugs that are reimbursed by 
state Medicaid agencies nationwide. Pharmaceuticals that are manufactured, distributed, 
marketed, and/or sold by DEY and reimbursed by Alabama Medicaid for which a claim is made 
in this litigation are identified in Exhibit A, attached. 
Defendant Eisai 
37, Defendant Eisai, Inc. ("Eisai"), the U.S. pharmaceutical subsidiary of Tokyo-based 
Eisai Co., Ltd,, is a Delaware corporation with its principal place of business located at 500 
Frank W, Burr Boulevard, Teaneck, NJ 07666. Eisai is engaged in the business of 
manufacturing, distributing, marketing, and/or selling prescription drugs that are reimbursed by 
state Medicaid agencies nationwide. Pharmaceuticals that are manufactured, distributed, 
marketed, and/or sold by Eisai and reimbursed by Alabama Medicaid for which a claim is made 
in this litigation are identified in Exhibit A, attached. 
Defendant Endo 
38. Defendant Endo Pharmaceuticals, Inc. ("Endo"), formerly Endo Laboratories, 
L L C , and a subsidiary of Endo Pharmaceuticals Holdings, Inc., is a Delaware corporation with 
its principal place of business located at 100 Painters Drive, Chadds Ford, PA 19317.. Endo is 
engaged in the business of manufacturing, distributing, marketing, and/or selling prescription 
drngs that are reimbursed by state Medicaid agencies nationwide- Pharmaceuticals that are 
manufactured, distributed, marketed, and/or sold by Endo and reimbursed by Alabama Medicaid 
for which a claim is made in this litigation are identified in Exhibit A, attached. 
12 
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Defendant ETHEX 
39, Defendant ETHEX Corporation ("ETHEX"), a wholly-owned subsidiary of K- v 
Pharmaceutical Company, is a Missouri corporation with its principal place of business at 10888 
Metro Court, St. Louis, MO 63043-2413., ETHEX is engaged id the business of manufacturing, 
distributing, marketing, and/or" selling pi escription di xigs that are reimbursed by state Medicaid 
agencies nationwide. Pharmaceuticals that are sold by ETHE^ C and reimbursed by Alabama 
Medicaid for which a claim is made in this litigation are identified! in Exhibit A, attached.. 
The Forest Defendants 
40, Defendant Forest Laboratories, Inc.. ("Forest") is 3 Delaware corporation with its 
principal place of business located at 909 Third Avenue, New York, NY 10022. 
41., Defendant Forest Pharmaceuticals,, Inc. ("Forest Pharm"), a wholly-owned 
subsidiary of Forest, is a Delaware corporation with its principal place of business located at 
13600 Shoreline Drive, St Louis, MO 63045, 
42, Forest and Forest Pharni (collectively, the "Forest Defendants") are diversified 
healthcare companies that individually, and/or in combination With one another, engage in the 
business of manufacturing, marketing, distributing, and/or selling prescription drugs that are 
reimbursed by State Medicaid agencies nationwide. Pharmaceuticals that are manufactured, 
distributed, marketed, and/or sold by the Forest Defendants and reimbursed by Alabama 
Medicaid for which a claim is made in this litigation are identified in Exhibit A, attached. 
The Fujisawa Defendants 
43. Defendant Fujisawa Healthcare, Inc. ("Fujisawa") it a Delaware corporation and a 
wholly-owned subsidiary of Fujisawa Pharmaceutical Company. Ltd., of Osaka, Japan. 
Fujisawa1* principal place i>f business is located at Three Parkwajf North, Deerfield, IL 60015, 
13 
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44. Defendant Fujisawa USA, Inc. ("Fujisawa USA") is or was a Delaware corporation 
with its principal place of business located at Three Parkway North* Deerfield, IL 60015. 
45. Fujisawa and Fujisawa USA (collectively, the "Fujisawa Defendants") are or were 
engaged in the business of manufacturing, distributing, marketing, and/or selling prescription 
drugs that are reimbursed by state Medicaid agencies nationwide, Pharmaceuticals that are or 
were manufactured, distributed, marketed, and/or sold by the Fujisawa Defendants and 
reimbursed by Alabama Medicaid for which a claim is made in this litigation are identified in 
Exhibit A, attached. 
Defendant Genzvme 
46. Defendant Genzyme Corporation ("Genzyme"), formerly Genzyme Massachusetts 
Corporation, is a Massachusetts corporation with its principal place of business located at 500 
Kendall Street, Cambridge, MA 02139.. Genzyme is engaged in the business of manufacturing, 
distributing, marketing, and/or selling prescription drugs that are reimbursed by state Medicaid 
agencies nationwide. Pharmaceuticals that are manufactured, distributed, marketed, and/or sold 
by Genzyme and reimbursed by Alabama Medicaid for which a claim is made in this litigation 
are identified in Exhibit A, attached. 
Defendant Gilead 
47. Defendant Gilead Sciences, Inc. ("Gilead") is a Delaware corporation with its 
principal place of business located at 333 Lalceside Drive, Foster City, CA 94404. Gilead is 
engaged in the business of manufacturing, distributing, marketing, and/or selling prescription 
drugs that are reimbursed by state Medicaid agencies nationwide, Pharmaceuticals that are 
manufactured, distributed, marketed, and/or sold by Gilead and reimbursed by Alabama 
Medicaid for which a claim is made in this litigation are identified in Exhibit A, attached. 
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Defendant GlaxoSmithKline 
48. DefendruV SniithKJine Beecham i -•» - ,•- • . ; . \^M:, . u Jine 
("GlaxoSmithKline"), is a Pennsylvania corporation with its principal place of business located 
at One Franklin Plaza, 200 North 16lh Street, Philadelphia, PA| 19102, GlaxoSmithKIine is 
engaged in the business of r'-r.vffc. v :':r. \ -V \n\*:.\r _ -. - j : \ v, ^ anJ - ..*. „-. mg prescription 
drugs that are reimbursed by state Medicaid agencies nationwide- Pharmaceuticals that are 
manufactured, distributed, marketed, and/or sold by GlaxoSihithKIine and reimbursed by 
Alabama Medicaid for which a claim, is made in this litigatioh are identified in Exhibit A, 
attached. 
The Hoffmann-LaRoche Defendant^ 
49 Defei idai il Hoffmann-LaRoche, Inc.. ("Hoffmam^LaRoche") is a New Jersey 
corporation with its principal place of business located at 340|Kingsland Street, Nutley, NJ 
07110-1199 Hoffrnann-LaRoche is the U.S. prescription drug unit of the Roche Group. 
50,. Defendant Roche Laboratories, Inc.. ("Roche Labs") lis a Delaware corporation with 
its principal place of business located at 340 Kingsland Street, Ntitley, NJ 07110-1199. Roche 
Labs is a marketing and sales subsidiary of Hoffrnann-LaRoche* 
5L HoffmamvLaRoclie and Roche Labs (collectively, the "Hoffrnann-LaRoche 
Defendants") are diversified healthcare companies that individually, and/or in combination with 
one another, engage in the business of manufacturing, distributing, marketing, and/or selling 
prescription drugs that am reimbursed by state Medicaid agencies nationwide. Pharmaceuticals 
that are manufactured, distributed, marketed, and/or sold by the Hoffrnann-LaRoche Defendants 
and reimbursed by Alabama Medicaid for which a claim is made|in this litigai; > ''i^tifir.i 
in Exhibit A,, attached 
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The IVAX Defendants 
52, Defendant I VAX Corporation ("IV AX") is a Florida corporation with its principal 
place of business located at 4400 Biscayne Blvd., Miami, FL 33137-3227* 
53.. Defendant I VAX Pharmaceuticals, Inc., ("IV AX Pharm"), a wholly-owned 
subsidiary of IVAX, is a Florida corporation with its principal place of business located at 4400 
Biscayne Blvd., Miami, FL 33137. 
54. IVAX and IVAX Pharm (collectively, the "IVAX Defendants") are diversified 
healthcare companies that individually, and/or in combination with one another, engage in the 
business of manufacturing, distributing, marketing, and/or selling prescription drugs that are 
reimbursed by state Medicaid agencies nationwide. Pharmaceuticals that are manufactured, 
distributed, marketed, and/or sold by the IVAX Defendants and reimbursed by Alabama 
Medicaid for which a claim is made in this litigation are identified in Exhibit A, attached. 
The J&J Defendants 
55. Defendant Johnson & Johnson ("J&J") is a New Jersey corporation with its 
principal place of business located at One Johnson & Johnson Plaza, New Brunswick, NJ 08933. 
J&J includes a number of subsidiary or affiliate companies including, but not limited to, the 
following: 
a. Defendant ALZA Corporation ("ALZA"), is a Delaware corporation with 
its principal place of business located at 1900 Charleston Road, Mountain 
View, CA 94039, and was acquired by J&J from Defendant Abbott in 
2000; 
b. Defendant Janssen Pharmaceutica Products, LP ("Janssen"), a wholly-
owned subsidiary of J&J, is a New Jersey limited partnership with its 
principal place of business located at 1125 Trenton-Harbourton Road, 
Titusville,NJ 08560; 
c Defendant McNeil-PPC, lnc, ("McNeil"), a wholly-owned subsidiary of 
J&J, is a New Jersey corporation with its principal place of business 
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located at 7050 Camp Hill Road, Fort Washington, PA 19034, McNeil 
Consumer & Specialty Pharmaceuticals ('JMcNeil Cons") is a division of 
McNeii-PPC, Inc.; 
d. Defendant Ortho Biotech Products, LP ("Ortho Biotech"), a wholly-owned 
subsidiary of J&J, is a New Jersey limited partnership with its principal 
place of business located at 430 Rt 22 feast, Bridgewater, NJ 08807-
0914;and 
e. Defendant Ortho-McNeil Pharmaceutical, Inc. ("Ortho-McNeil"), a 
wholly-owned subsidiary of J&J, is a Delaware corporation with its 
principal place of business located at lOOQ'tLS. Route 202 South, Raritan, 
NJ 08869.. 
56 J&J, ALZA, Janssen, McNeil, Ortho Biotech, and Ortho-McNeil (collectively "the 
J&J Defendants") are diversified healthcare companies that individually, and/or in combination 
with one another, engage in the business of manufacturing, distributing, marketing, and/or selling 
prescription drugs that are reimbursed by state Medicaid agencie|s nationwide. Pharmaceuticals 
that are manufactured, distributed, marketed, and/or sold by the Jl&J Defendants and reimbursed 
by Alabama Medicaid for which a claim is made in this litigatibn are identified in Exhibit A, 
attached 
The King Defendants 
57, Defendant King Pharmaceuticals, Inc. ("King") isi a Tcnnc^e. .... :y-.~.c.. -
its principal place of business located at 501 Fifth Street, Bristol, TN 37620. 
58, Defendant Monarch Pharmaceuticals, Inc, ("l^Ionarch"), a wholly-owned 
subsidiary of King, is a Tennessee corporation with its principal place of business located at 501 
Fifth Street, Bristol, TN 37620. 
59, King and Monarch (collectively, the "King Defendants") are diversified healthcare 
companies that individually, andAv in combination villi o\v: another, engage in the business of 
manufacturing, distributing, marketing, and/or selling prescriptiorl drugs that are reimbursed by 
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state Medicaid agencies nationwide, Pharmaceuticals that are manufactured, distributed, 
marketed, and/or sold by the King Defendants and reimbursed by Alabama Medicaid for which a 
claim is made in this litigation are identified in Exhibit A, attached. 
Defendant Medlmmune 
60, Defendant Medlmmune, Inc.. ("Medlmmune") is a Delaware corporation with its 
principal place of business located at One Medlmmune Way, Gaithersburg, MD 20878, 
Medlmmune is engaged in the business of manufacturing, distributing, marketing, and/or selling 
prescription drugs that are reimbursed by state Medicaid agencies nationwide. Pharmaceuticals 
that are manufactured, distributed, marketed, and/or sold by Medlmmune and reimbursed by 
Alabama Medicaid for which a claim is made in this litigation are identified in Exhibit A, 
attached. 
Defendant Merck 
6L Defendant Merck & Co., Inc. ("Merck") is a New Jersey corporation with its 
principal place of business located at One Merck Drive, PX), Box 100, Whitehouse Station, NJ 
08889-0100. Merck is engaged in the business of manufacturing, distributing, marketing, and/or 
selling prescription drugs that are reimbursed by state Medicaid agencies nationwide-
Pharmaceuticals that are manufactured, distributed, marketed, and/or sold by Merck and 
reimbursed by Alabama Medicaid for which a claim is made in this litigation are identified in 
Exhibit A, attached. 
The Mvlan Defendants 
62, Defendant Mylan Laboratories, Inc. ("MyIan") is a Pennsylvania corporation with 
its principal place of business located at 1500 Corporate Drive, Suite 400, Canonsburg, PA 
15317, 
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63., Defendant Mylan Pharmaceuticals, Inc. ("My{an Pharm")5 a wholly-owned 
subsidiary of Mylan, is a West Viiginia corporation with its pi iucipa! place of business located at 
1500 Corporate Drive, Suite 400, Canonsburg, PA 15317.. 
64. Defendant UDL Laboratories, Inc. ("DDL"), a wholly-owned subsidiary of Mylan, 
is an Illinois corporation with its principal place of business lolcated at 1718 Northrock Court, 
RockforcUL 61103. 
65- Mylan, Mylan Phann, and UDL (collectively, the "Mylan Ddciidaiii'-H ar: 
diversified healthcare companies that individually, and/or in Combination with one another, 
engage in the business of manufacturing, distributing, marketing, and/or selling prescription 
drugs that are reimbursed by state Medicaid agencies nationwide. Pharmaceuticals that are 
manufactured, distributed, marketed, and/or sold by the Mylan [Defendants and reimbursed by 
Alabama Medicaid for which a claim is made in this Iitigatiqn are identified in Exhibit A, 
attached. 
The Novartis Defendants 
66. Defendant Novartis Pharmaceuticals Corporation! ('Novartis") is a Delaware 
coiporation with its principal place of business located at Grit* Health Plaza, East Hanover, NJ 
07936-1080. 
67, Defendant Sandoz, Inc. ("Sandoz"), formerly know|n as Geneva Pharmaceuticals, 
Inc., and a member of the Novartis group of companies, is a belaware coiporation with its 
principal place of business located at 506 Carnegie Center, Suit|e 400, Princeton, NJ 08540-
6243, 
68.. Novartis and Sandoz (collectively, the "Novartis Defendants") are diversified 
healthcare companies that individually, and/or in combination wi|th one another, engage in the 
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business of manufacturing) distributing, marketing, and/or selling prescription drugs that are 
reimbursed by state Medicaid agencies nationwide, Pharmaceuticals that are manufactured, 
distributed, marketed, and/or sold by the Novartis Defendants and reimbursed by Alabama 
Medicaid for which a claim is made in this litigation are identified in Exhibit A, attached. 
Defendant Novo Nordisk 
69. Defendant Novo Nordisk Pharmaceuticals, Inc. ("Novo Nordisk") is a Delaware 
corporation with its principal place of business located at 100 College Road West, Princeton, NJ 
08540-7814, Novo Nordisk is the U.S. health care affiliate of Novo Nordisk A/S, Novo Nordisk 
is engaged in the business of manufacturing, distributing, marketing, and/or selling 
pharmaceuticals that are reimbursed by state Medicaid agencies nationwide. Pharmaceuticals 
that are manufactured, distributed, marketed, and/or sold by Novo Nordisk and reimbursed by 
Alabama Medicaid for which a claim is made in this litigation are identified in Exhibit A, 
attached. 
Defendant Organon 
70. Defendant Organon Pharmaceuticals USA, Inc. ("Organon"), a subsidiary of Akzo 
Nobel NV, is a Delaware corporation with its principal place of business located at 56 Livingston 
Avenue, Roseland, NJ 07068, Organon is engaged in the business of manufacturing, 
distributing, marketing, and/or selling prescription drugs that are reimbursed by state Medicaid 
agencies nationwide. Pharmaceuticals that are manufactured, distributed, marketed, and/or sold 
by Organon and reimbursed by Alabama Medicaid for which a claim is made in this litigation are 
identified in Exhibit A, attached. 
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Defendant Par 
7 L J >•:-?''i'M\r\' P: i'^irrnv.;-.-.^... hi. .'" . :••• ' v. - New Jersey corporation with its 
principal place of business located at One Ram Ridge Road, Spring Valley, NY 10977. Par is 
engaged in the business of manufacturing, distributing, marketing, •.- ' •*• '.:;,._ :>:-'-:W.\ 
drugs that are reimbursed by state Medicaid agencies nationwide. Pharmaceuticals that are 
manufactured, distributed, marketed, and/or sold by Par and reimbursed by Alabama Medicaid 
for which a claim is made in this litigation are identified in Exhibit A, attached 
The Pfizer Defendants 
72, Defendant Pfizer, Inc. ("Pfizer") is a Delaware corporation with its principal place 
of business located at 235 East 42nd Street, New York, NY 10017- With the merger of Pfizer 
and Pharmacia Corporation in 2003, Pfizer became the largest dru^ company in the world today. 
73, Defendant Pharmacia Corporation ("Pharmacia") \$ a Delaware corporation with 
its principal place of business located at 235 East 42nd Street, New York, N y 10017-5755. 
74, Defendant Pharmacia & Upjohn Company Corporalion (ctP & IT), a subsidiary of 
Pharmacia Corporation, is a Delaware corporation with its principal place of business located at 
235 E. 42nd Street, New York, NY 10017-5703. 
75, Defendant G.D. Searle, LX,C« ("Searle"), a subsidikry of Pharmacia Corporation, 
is a Delaware limited liability company with its principal plac^ of business located u 490! 
Searle Parkway, Skokie, II , 60077-2919. 
76 Defendant Agouron Pharmaceuticals, Inc. ("Agouroti") is a California corporation 
with its principal place of business located at 10777 Science Oentei Drive; ci;n Diego, CA 
92121, 
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77, Pfizer, Pharmacia, P & U, Searle and Agouron (collectively, the "Pfizer 
Defendants") are diversified healthcare companies that individually, and/or in combination with 
one another, engage in the business of manufacturing, distributing, marketing, and/or selling 
prescription drugs that are reimbursed by state Medicaid agencies nationwide- Pharmaceuticals 
that are manufactured, distributed, marketed, and/or sold by the Pfizer Defendants and 
reimbursed by Alabama Medicaid for which a claim is made in this litigation are identified in 
Exhibit A, attached. 
Defendant Purdue 
78. Defendant Purdue Pharma, LJP. ("Purdue") is a Delaware limited partnership with 
its principal place of business located at One Stamford Forum, 201 Tr^ssor Boulevard, Stamford, 
CT 06901-3431 Purdue is engaged in the business of manufacturing, distributing, marketing, 
and/or selling prescription drugs that are reimbursed by state Medicaid agencies nationwide-
Pharmaceuticals that are manufactured, distributed, marketed, and/or sold by Purdue and 
reimbursed by Alabama Medicaid for which a claim is made in this litigation are identified in 
Exhibit A, attached. 
Defendant Sanofi 
79.. Defendant Sanofi-Synthelabo, Inc. ("Sanofi"), the U.S. affiliate of the global 
pharmaceutical company Sanofi-Aventis, is a Delaware corporation with its principal place of 
business located at 90 Park Avenue, New York, NY 10016. Sanofi is engaged in the business of 
manufacturing, distributing, marketing, and/or selling prescription drugs that are reimbursed by 
state Medicaid agencies nationwide. Pharmaceuticals that are manufactured, distributed, 
marketed, and/or sold by Sanofi and reimbursed by Alabama Medicaid for which a claim is made 
in this litigation are identified in Exhibit A, attached, 
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The Schering Defendants 
80, Defendant Schering-Plough Corporation ("Schering-Plough") is a New Jersey 
corporation with its principal place of business located at 2000 Galloping Hill Road, Kenilworth, 
NJ 07033, 
81., Defendant Waniek Pharmaceuticals Corporation ("Warrick"), a wholly-owned 
subsidiary of Schering-Plough, is a Delaware corporation with its principal place of business 
located at 12125 Moya Blvd., Reno, NV 89506-2600. 
82. Schering-Plough aii«l WKIIICL (collectively, the "Schering Defendants") are 
diversified healthcare companies that individually, and/or in combination with one another, 
engage in the business of manufacturing, distributing, marketing, and/or selling prescription 
drugs that are reimbursed by state Medicaid agencies nationwide. Pharmaceuticals that are 
manufactured, distributed, marketed, and/or sold by the Schering (Defendants and reimbursed by 
Alabama Medicaid for which a claim is made in tins litigation are identified in Exhibit A, 
attached. 
Defendant TAP Pharmaceutical 
83., Defendant TAP Pharmaceutical Products, Inc. ("TAP"), a joint venture between 
Abbott Laboratories and Takeda Chemical Industries, Ltd-, of Qsaka, Japan, is a Delaware 
corporation with its principal place of business located at 675 Nortn Field Drive, Lake Forest, IL 
60045., TAP is engaged in the business of mailufacturing, distributing, marketing, and/or selling 
prescription drugs that are reimbursed by state Medicaid agencies nationwide. Pharmaceuticals 
that are manufactured, distributed, marketed, and/or sold by TAP I and i einibursed by Alabama 
Medicaid for which a claim is made in this litigation are identified ih Exhibit A, attached. 
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Defendant Takeda Pharmaceuticals 
84. Defendant Takeda Pharmaceuticals North America, Inc. ("Takeda Pharm"), a 
wholly-owned subsidiary of Takeda Phannaceutical Company Limited, is a Delaware 
corporation with its principal place of business located at 475 Half Day Road, Suite 500, 
Lincolnshire, IL 60069, Takeda Pharm is engaged in the business of manufacturing, 
distributing, marketing, and/or selling prescription drugs that are reimbursed by state Medicaid 
agencies nationwide. Pharmaceuticals that are manufactured, distributed, marketed, and/or sold 
by Takeda Pharm and reimbursed by Alabama Medicaid for which a claim is made in this 
litigation are identified in Exhibit A, attached. 
Defendant Teva 
85> Defendant Teva Pharmaceuticals USA, Inc. ("Teva"), a wholly-owned American 
subsidiary of Teva Pharmaceutical Industries, Ltd., and formerly Lemmon Pharmaceutical 
Company, is a Delaware corporation with its principal place of business located at 1090 
Horsham Road, P.O. Box 1090, North Wales, PA 19454-1090, Teva is engaged in the business 
of manufacturing, distributing, marketing, and/or selling prescription drugs that are reimbursed 
by state Medicaid agencies nationwide. Pharmaceuticals that are manufactured, distributed, 
marketed, and/or sold by Teva and reimbursed by Alabama Medicaid for which a claim is made 
in this litigation are identified in Exhibit A, attached.. 
The Watson Defendants 
86., Defendant Watson Pharmaceuticals, Inc., {"Watson") is a Nevada corporation with 
its principal place of business located at 311 Bonnie Circle, Corona, CA 92880, 
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87. Defendant Watson Laboratories, Inc. ("Watson Labk"), a wholly-owned subsidiary 
of Watson, is a Nevada corporation with its principal place of business located at 311 Bonnie 
Circle, Corona, CA 92880, 
88. Defendant Watson Pharma, Inc. ("Watson Pharma")), a wholly-owned subsidiary of 
Watson since 2000, is a Delaware corporation with its principal place of business located at 311 
Bonnie Circle, Corona, CA 92880. 
89. Watson, Watson Labs, and Watson Pharma (collectively, the "Watson 
Defendants") are diversified healthcare companies that individually, and/or in combination with 
one another, engage in the business of manufacturing, distributing, marketing, and/or selling 
prescription drugs that are reimbursed by state Medicaid agenciesi nationwide. Pharmaceuticals 
that are manufactured, distributed, marketed, and/or sold by Ithe Watson Defendants and 
reimbursed by Alabama Medicaid for which a claim is made in this litigation are identified in 
Exhibit A, attached. 
The Wvetli Defendants 
90. Defendant Wyeth, Inc. ("Wyeth"), formerly American Home Products Corp., is a 
Delaware corporation with its principal place of business located at Five Giralda Farms, 
Madison, NJ 07940, 
91. Defendant Wyeth Pharmaceuticals, Inc, ("Wyeth Phatm"), a division of Wyeth, is 
a Delaware corporation with its principal place of business located at 500 Areola Road, 
Collegeville, PA 19426.. 
92. Wyeth and Wyeth Pharm (collectively, the "Wyeth Defendants") are diversified 
healthcare companies that individually, and/or in combination witli one another, engage in the 
business of manufacturing, distributing, marketing, and/or sellingl prescription drugs that are 
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reimbursed by state Medicaid agencies nationwide. Pharmaceuticals that are manufactured, 
distributed, marketed, and/or sold by the Wyeth Defendants and reimbursed by Alabama 
Medicaid for which a claim is made in this litigation are identified in Exhibit A, attached. 
Fictitious Defendants 
93. Fictitious Defendants 1 through 200, whose true names are presently unknown, 
are manufacturers, distributors, marketers, and/or sellers of prescription drugs who reported or 
caused to be reported false and inflated pricing information to industry publishers upon which 
information the Alabama Medicaid Agency relied in reimbursing providers for the dispensing of 
such drugs, and whose true names will be added upon discovery, 
94. Upon information and belief, the drugs identified for each Defendant are involved 
in the fraudulent or wanton pricing scheme outlined in this complaint. In addition to those drugs, 
there may be other drugs which are or have been manufactured, distributed, marketed, and/or 
sold by Defendants and which are subject to the fraudulent pricing scheme, but the names of 
those drugs are unavailable to Alabama Medicaid at the present time. For example, some of the 
Defendants manufacture, distribute, market, and/or sell multiple source brand name and generic 
drugs not listed in Exhibit A which are also manufactured by other companies, Alabama 
Medicaid is unable to determine without additional investigation and information which 
Defendants sold these multiple source brand name drugs and/or generic drugs as part of the 
scheme (and, if so, to what extent) for which Alabama Medicaid paid reimbursement to the 
provider. Likewise, Alabama Medicaid is unable to determine without additional information 
which Defendants sold physician-dispensed (Medicare Part B) drugs as part of the scheme for 
which Alabama Medicaid paid reimbursement to the provider. The State intends for this 
complaint to cover all drugs manufactured, distributed, marketed, and/or sold by Defendants 
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(induing Fictitious Defendants 1-200) which are subject to tHe fiaudulent c>r wanton pricing 
scheme described herein, even though the names of some of) those drugs are not identified 
because the information is not currently available to the State. 
JURISDICTION AM) VENUE 
95. This Court has jurisdiction over the State's claims as they involve claims arising 
exclusively under Alabama law. 
96, This Court has personal jurisdiction over each befendant either because the 
Defendant resides in Alabama, does business in Alabama, purposefully directs or directed its 
actions toward Alabama, and/or has the requisite minimum contacts with Alabama necessary to 
constitutionally permit the Court to exercise jurisdiction. 
97» Venue is proper in Montgomery County, Alabama pursuant to Alabama Code § 6-
3-7, because the State pays reimbursement through Alabama Medicaid for prescription drugs 
dispensed in this County and throughout the State. The events giving rise to the claims herein 
wfcw, fo ^ teSMSsi $3stf*, va ttus GQuaty > tte State9 * $m<%*l atSM sod <^^ttoo& are. heated w. 
this County, and the State regularly and systematically conducts busliness in this County, 
FACTUAL BACKGROUND 
The Alabama Medicaid Program 
98. The Alabama Medicaid program is a state-adminiitered program with federal 
matching funds which pays for medical care, including prescription drug benefits, for Alabama's 
low-income and disabled citizens. Alabama Medicaid currently colvers approximately 900,000 
individuals. Prescription drug benefits represent over 15% of Alabama Medicaid's annual 
budget* Since 1990, the total annual cost of pharmacy-dispensed prescription drugs to Alabama 
27 
Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU. 
Machine-generated OCR, may contain errors.
Medicaid has increased tenfold, from total annual costs of approximately $60 million in 1990 to 
approximately $600 million in 2004.. 
99, Alabama Medicaid reimburses medical providers, including physicians and 
pharmacists, for drugs prescribed for, and dispensed to, Alabama Medicaid recipients pursuant to 
statutory and administrative formulas. Alabama Medicaid also pays up to the 20% co-payment 
for physician administered prescription drugs for Alabama Medicare beneficiaries who are 
qualified to receive Medicaid benefits. 
100, Reimbursement for pharmacy-dispensed prescription drugs under the Alabama 
Medicaid program is based on information supplied by Defendants to industry reporting services. 
This information includes the following price indices: (i) Average Wholesale Price ("AWP")> 
which is commonly understood as the average price charged by wholesalers to retailers, such as 
hospitals, doctors and pharmacies, for prescription drugs, (ii) Wholesale Acquisition Cost 
("WAC")3 which is commonly understood as the average price paid by wholesalers to the 
manufacturers for prescription drugs, and (iii) on occasion (but prior to 2003), Direct Price, 
which is commonly understood as the price charged by drug manufacturers to non-wholesaler 
customers for prescription drugs. At all times relevant to this action, Defendants were aware of 
Alabama Medicaid's drug reimbursement formulas and procedures for pharmacy-dispensed 
drugs. 
101, Medicare is a health insurance program created by the federal government for the 
elderly, disabled, and other eligible persons, Individuals become eligible for Medicare health 
insurance benefits when they turn 65 years of age or earlier if they are certified as disabled. 
There are two major components of the Medicare Program, Part A and Part B. Medicare Part B 
is an optional program that provides coverage for some healthcare services for Alabama's 
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participating elderly, disabled and other eligible citizens not covered by Part A. Medicare Part B 
pays for a portion of the cost of prescription drugs, generally thoie drugs which are administered 
by a physician provider or used with certain medical equipment. 
102. For prescription drugs covered by Part B, Medicare pays eighty percent (80%) of 
the allowable amount under federal regulations. (Until recently, the allowable amount was 95% 
of the national AWP for the drug.) The remaining 20% is paid by the Medicare beneficiary as a 
co-payment For Alabama Medicare beneficiaries who are alsol qualified to receive Medicaid 
benefits, Alabama Medicaid pays the 20% co-payment up to the amount Alabama Medicaid 
would have paid if it were the only payor. At all relevant times tb this action, Defendants were 
aware of the Alabama Medicaid's drug reimbursement formulasl and procedures for Medicare 
Part B drugs. 
The Defendants* Reporting of Inflated Pricing Information 
103. Defendants knowingly, willfully, wantonly, and/br intentionally provided or 
caused to be provided false and inflated AWP, WAC, and/or Direct Price information for their 
drugs to various nationally known drug industry reporting services, including First DataBank 
(a/k/a Blue Book), Medical Economics, Inc. (a/k/a Red Book), an<p Medispan. These reporting 
services published the pricing information to various reimbursers,i such as Alabama Medicaid, 
who have contracted to receive the information (either in electronic 0r hard copy form) as a basis 
to provide reimbursement to the medical or pharmacy providers who provide the drugs to 
patients. 
104. Alabama Medicaid purchased and utilized the Defendants' published AWP, 
WAC, and Direct Price information from First DataBank (Blue Boole), and Medical Economics, 
Inc. (Red Book). The information from Blue Book was and is usedlby Alabama Medicaid with 
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respect to reimbursement for pharmacy-dispensed drugs.. As a general matter, the information 
from Red Book was and is used with respect to reimbursement for Medicare Part B drug co-
payments. At all relevant times to this action, Alabama Medicaid relied upon the AWP, WAC, 
and/or Direct Price provided by Defendants to the industry reporting services in determining the 
amount Alabama Medicaid reimburses providers. 
105. Defendants knew that the false and deceptive inflation of AWP, WAC, and/or 
Direct Price for their drugs would cause Alabama Medicaid to pay excessive amounts for these 
drugs. Defendants' inflated A WPs, WACs, and Direct Prices greatly exceeded the actual prices 
at which they sold their drugs to retailers (physicians, hospitals, and pharmacies) and 
wholesalers, Defendants' reported AWPs, WACs, and/or Direct Prices were false and 
misleading and bore no relation to any price, much less a wholesale or actual sales price. 
106, Defendants knowingly, willfully, wantonly, and/or intentionally concealed the 
true AWP, WAC, and/or Direct Price information for their respective drugs from Alabama 
Medicaid. Each Defendant knows its own AWP, WAC, and Direct Price which it reports to the 
industry reporting services for use by Medicare and the state Medicaid agencies. Each 
Defendant also knows whether the prices it reports to the reporting services accurately and 
truthfully represent the actual prices as reflected by market experience and conditions. Unless 
governmental or industry surveys, lawsuits, or criminal or regulatory investigations publicly 
reveal the true AWP, WAC, or Direct Price for a particular drug at issue, Alabama Medicaid, 
like other state Medicaid agencies, is not privy to the actual market prices which it can then 
compare against the reported prices. Defendants have concealed true market pricing information 
from the State for the purpose of avoiding detection of the fraudulent scheme described herein. 
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107. Defendants used undisclosed discounts, rebates aitjd other inducements which had 
the effect of lowering the actual wholesale or sales prices charged to their customers as 
compared to the reported prices. In addition. Defendants employed secret agreements to conceal 
the lowest prices charged for their pharmaceutical products. As a result of these concealed 
inducements, Defendants have prevented third parties, including Alabama Medicaid, from 
determining the true prices it charges its customers. 
Defendants* Marketing of the "Spread" 
108. Defendants refer to the difference between the reported AWP and WAC, on the 
one hand, and the actual price of a drug, on the other, as the "spread" or, alternatively, "return to 
practice" or "return on investment." Defendants knowingly and ihtentionally created a "spread" 
on their drugs and used the "spread" to increase their sales and| market share of these drugs, 
thereby increasing their profits. Defendants induced physician ,^ pharmacies, and pharmacy 
chain stores to purchase their drugs, rather than competitors' drugs, by persuading them that the 
larger "spread" on Defendants' drugs would allow the physicians and pharmacies to receive 
more money, and make more of a profit, through reimbursement at the expense of Alabama 
Medicaid. 
109. Defendants manipulated and controlled the size of tfte "spread" on their drugs by 
both increasing their reported AWPs, WACs, and Direct Prices and (decreasing their actual prices 
to wholesalers and providers over time. 
110. In addition to manipulating the reported AWP, tWAC, and/or Direct Price, 
Defendants used free goods, educational grants and other incentlives to induce providers to 
purchase their drugs, all of which lowered the actual prices of the Defendants* drugs, resulting in 
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increased profits foi providers, as well as increased market share and profits of the Defendants, 
at the expense of Alabama Medicaid, 
111. The unfair, fraudulent, wanton, and deceptive practices engaged in by the 
Defendants in creating and reporting, or causing to be reported, false and inflated AWP, WACS 
and/or Direct Price information for their drugs, or otherwise concealing actual pricing 
information, and marketing the "spread" on their drugs as an inducement to providers to utilize 
Defendants' drugs, has resulted in the State paying millions of dollars in excess Medicaid 
payments, while at the same time enriching Defendants with excessive, unjust and illegal profits. 
Other Lawsuits, Settlements, Government Investigations, and Criminal Proceedings 
132* The State's complaint was not drafted in a vacuum. Each family of Defendants in 
this case has been sued for the same or similar Medicaid drug pricing fraud scheme in one or 
more of at least twenty-one other states-1 A number of the Defendants have also been sued for 
related conduct in one or more of numerous pending federal actions.2 
113,. Published opinions and other public record documents generated during the 
course of the parallel state and federal litigation reveal that these Defendants reported fraudulent 
AWPs or other pricing information for selected drugs that bore no relationship whatsoever to the 
price at which those drugs were actually being sold to pharmacies and providers. For example, a 
majority of the Defendants named herein have been made the subject of an action in New York 
alleging a fraudulent AWP pricing scheme.3 In that suit, New York City (which pays 25% of 
' Lawsuits have been filed in the States of Arizona, Arkansas, California, Connecticut, Florida, Illinois, Kentucky, 
Massachusetts., Minnesota, Mississippi, Missouri, Montana, Nevada, New Jersey, New York, North Carolina, Ohio, 
Pennsylvania, Texas, West Virginia, and Wisconsin, the City of New York, and multiple New York counties.. 
2
 Most of the lawsuits that assert claims for violations of federal law have been consolidated for pretrial purposes in 
multi-district federal litigation in Boston, Massachusetts. However, no federal claims are being asserted in this case, 
?
 The City of New York v Abbott Laboratories, Inc., D4-CV-06054, in the United States District Court for flic 
Southern District of New York (August 4,2004), 
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Medicaid costs for its residents) sets forth for each of the manufacturers and drugs at issue the 
inflated AWP reported to industry reporting services by the Defendants and the estimated true 
AWP which should have been reported. Depending on the drt^ g in question, New York City 
alleges that, in some instances, the reported price is over 8 times the true price. New York City's 
reimbursement methodology, similar to Alabama Medicaid's, is based upon AWP reported by 
the manufacturers to the same reporting services upon which Alabama Medicaid relies. Because 
the reported AWFs and, correspondingly, the true AWFs are national (not regional) in scope, 
New York City's experience likely parallels Alabama's and lendsl obvious support to the State's. 
allegations herein. The other' state lawsuits, dealing with many of the same defendants and drugs 
at issue in Alabama, also lend corroborative support. 
114. Federal criminal actions have been instituted against various of the named 
Defendants,4 As part of those criminal proceedings, a number of (the drug companies named in 
this lawsuit pled guilty to and/or agreed to settle criminal charges df having engaged in unlawful 
marketing and sales practices with respect to certain of their prescription drugs reimbursed under 
federal programs, such as Medicare, and state programs, such as |vfedicaid. These Defendants 
paid record fines and civil penalties for this admittedly wrongful conduct 
115. The guilty pleas, settlements, and admissions of fault by the criminal defendants 
implicate some of the Defendants herein in what is becoming to bellcnown as a far-reaching and 
widespread scheme in the pharmaceutical industry to unlawfully! increase market share and 
profits for their products. For example, in early 2001, Bayer agreedlto settle the federal criminal 
investigation into Bayer's marketing and sales practices with respect to KOaTE® and 
Kogenate®, and Bayer paid SI4 million to the federal and state governments. The Government 
4
 The criminal actions include: USA v TAP Pharmaceutical Products, Inc , I ;OKcrj-30354-WGY (D. Mass); USA v, 
AstraZeneca Pharmaceuticals, LP, 1:03-cr-00055 (D. Del); and USA v. Bayer Corp., l:03-cr-10118-RGS (D. 
Mass..). 
33 
Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU. 
Machine-generated OCR, may contain errors.
had alleged that Bayer set and reported AWPs for the drugs at levels far higher than the actual 
acquisition costs of the products. Then, in 2003, Bayer agreed to plead guilty to federal criminal 
charges and paid fines and civil penalties totaling over $257 million for, among other things, 
illegally relabeling its drugs Cipro© and Adalat CC© in order to circumvent the Medicaid 
Rebate Program, thus defrauding the state Medicaid programs of millions of dollars in rebate 
payments. 
116. In October 2001, Defendant TAP, in order to resolve federal criminal charges, 
agreed to plead guilty to federal criminal and civil fraud charges for, among other things, 
conspiring to violate the Prescription Drug Marketing Act ("PDMA") by providing free samples 
of Lupron® to medical providers "blowing and expecting" that these medical providers would 
charge patients for such free samples.. TAP agreed to pay over $875 million in fines and civil 
penalties to the federal government and the fifty (50) states. 
117, In June 2003, certain of the AstraZeneca Defendants agreed to plead guilty to 
criminal charges similar to those brought against TAP, In particular, the AstraZeneca 
Defendants pled guilty to federal criminal and civil fraud charges for, among other things, 
conspiring to violate the PDMA by providing free samples of Zoladex® to medical providers 
"knowing and expecting" that those medical providers would charge patients for such free 
samples and illegally bill those free samples to state Medicaid programs. The AstraZeneca 
Defendants were also charged with knowingly and willfully offering and paying illegal 
remuneration to physicians by marketing a "Return-to~Practice" program to induce orders to 
purchase Zoladex®, The Return-to-Practice program consisted of inflating the AWP used by 
Medicaid for reimbursement of the drug, deeply discounting the price paid by physicians for the 
drug, and marketing the spread between the AWP and the discounted price to physicians. The 
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AWP was set at levels far higher than the majority of its physibian customers actually paid for 
the drug. In resolution of these charges, the AstraZeneca Defendants paid almost $355 million in 
damages and fines to the federal and state governments, 
118, In April 2003, GlaxoSmithKline PLC agreed to resolve a federal criminal 
investigation and to pay fines and civil penalties to the federal | and state governments totaling 
more than $87 million to resolve claims against the GSK Defendants similar to those made 
against the Bayer Defendants. 
119- In October 2002, Pfizer agreed to resolve a federdl criminal investigation into its 
marketing and sales practices. Pfizer admitted providing unre$tricted "educational grants" to 
customers designed to hide the true best price of Lipitor®. Whil$ this case does not involve any 
"best price" claims, the wrongdoing admitted by Pfizer that led tol liability under federal law also 
provides evidence of liability under state law - Le., evidence ct?f Pfizer's participation in the 
unfair and deceptive scheme in this case, including, but not liinited to, evidence that Pfizer 
provided improper incentives and inducements to encourage salles of its products at inflated 
prices. 
120, In 2004, Schering-Plough Corporation agreed to sdttle criminal and civil charges 
relating to the best price reporting of Claritin®. The Schering jPlough Defendants paid $293 
million to the federal and state governments to resolve its civil and ladministrative liabilities. 
121, While a portion of the federal settlement proceeds fifom the above-described cases 
has been returned to the states, including Alabama, the State has n^t been compensated fiilly for 
its losses from the wrongful conduct that these guilty pleas or civil Settlements evidence.5 
122, Government investigations by Congress, the General Accounting Office 
("GAO"), Health and Human Services, and the Department oi Justice ("DOJ") have also 
5
 None of the settlements described herein operate as a bar to any of the claims rn^de in this complaint. 
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revealed fraudulent drug pricing schemes by various Defendants. For example, according to 
Representative Pete Staik of the U.S, House Ways and Means Committer Abbott has engaged in 
a price manipulation scheme through inflated representations regarding AWP and direct prices. 
Representative Stark has stated that: "Abbott has intentionally reported inflated prices and has 
engaged in other improper business practices in order to cause its customers to receive windfall 
profits from . «, Medicaid , . . for the express purpose of expanding sales and increasing market 
share ., . . This was achieved by arranging financial benefits or inducements that influenced the 
decisions of health care providers submitting . . . Medicaid claims" The TJ..S, Department of 
Justice has documented at least 81 instances in which Abbott's reported AWPs were 
substantially higher than the actual wholesale prices paid by wholesalers,, Indeed, the federal 
government's investigation revealed that Abbott created spreads of more than 20,000 percent 
through the reporting of false and misleading average wholesale prices, 
123, Generic or multi-source drug manufacturers are aware of the AWPs reported by 
their competitors and of the actual sales price of their generic competitors' products* Generic 
drug manufacturers manipulate their own AWPs in order to gain or maintain a competitive 
advantage in the market for their generic products. The natural and expected result is that multi-
source drugs have some of the highest spreads of any drugs, sometimes resulting in an AWP 
exceeding actual costs by over 50,000%. A few examples collected by the DOJ are set forth 
below: 
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IDIfendantiS^ 
! Baxter* 
\ Baxter'1' 
Boehringer* 
B. Braun 
Bristol-Myers 
Group* 
Dey* 
Immunex* 
| Pharmacia* 
J Sicor Group 
1 Watson* 
Dextrose 
Sodium Chloride 
Leucovorin Calcium 
Sodium Chloride 
Etoposide (Vepesid) 
Albuterol Sulfate 
Leucovorin Calcium 
Etoposide 
Tobramycin Sulfate 
Vancomycin HCL 
$ 928.5] 
$ 928.51 
$ 184.40 
$ 11.33 
$ 136.49 
$ 30.25 
$ 137.94 
$ 157.65 
$ 342.19 
$ 70.00 
$ 2.23 
S 1.71 
$ 2.76: 
$ 1.49 
$ 34.3J 
$ 9.17 
$ 14.5$ 
. $ 9.47 
$ 6.98 
$ 3.84 
%T®if iSei^reMl 
41,167% 
54,399% 
6,581% 
660% 
298% 
230% 
846% 
1,565% 
4,802% 
1,567% 
* Defendants herein. 
124. Some of the conduct described herein goes back o^er 10 years prior to the filing 
of the original complaint in this action, As explained above, however, the nature and extent of 
the fraudulent scheme were not known to the State because information concerning the true 
prices which should have been reported to the reporting services was concealed and not publicly 
available. It has only been through recent regulatory investigations, criminal actions, and civil 
actions that the impact of the fraudulent scheme on the State has| been indicated or revealed. 
Even today, the true market prices for many of the drugs in questioh for the entire time period at 
issue are not known by the State. 
125, Additionally, it would be impractical, if not impossible, to list in this Complaint, 
for the entire time period that the inflated pricing scheme has been in| effect, the true market price 
as compared to the reported price for each drug in question* It is not unusual for a drug 
manufacturer to report fluctuating prices for a particular drug on multiple occasions within a 
particular year, month, week, or even day. To display pricing reports for all of the Defendants 
and all of the drugs in question over a ten-year-plus period would be $ massive undertaking, and 
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limitations of time and space do not permit that information, even if it were available, to be s^t 
forth in this pleading. 
126. For purposes of specificity of pleading (particularly with respect to the fraud 
allegations), suffice it to say that Defendants are and have been on notice of the claims asserted 
herein as a result of the many investigations and actions undertaken around the country on this 
same subject Indeed, each Defendant should know without further allegation from the State 
exactly how its reported prices compare to its true prices and whether it has engaged in an 
inflated pricing scheme regarding prescription drugs., 
CLAIMS 
COUNT ONE - FRAUDULENT MISREPRESENTATION 
127. The State hereby repeats, incorporates by reference and realleges each and every 
allegation set forth above in this Complaint. 
128. Defendants committed fraud against the State and its agency, Alabama Medicaid. 
Defendants reported or caused to be reported AWP, WAC, and Direct Price for their products on 
a periodic and continuing basis for publication and dissemination to state Medicaid agencies 
such as Alabama Medicaid., Defendants knew that the AWP, WAC, and Direct Price 
information which they provided and caused to be reported was false. Defendants mis-
represented the pricing information with the intent of inducing Alabama Medicaid to rely on the 
false information in setting prescription drug reimbursement rates. Alabama Medicaid 
reasonably relied on the false pricing data in setting prescription drug reimbursement rates and 
making payment based on said rates- Defendants' misrepresentations are continuing, as they 
regularly and periodically continue to issue false and inflated AWP, WAC, and Direct Price 
information for publication by the industry reporting services. As a result of Defendants* 
38 
Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU. 
Machine-generated OCR, may contain errors.
fraudulent conduct, the State has been damaged by paying grossly excessive amounts for 
Defendants' prescription drugs, 
129. By engaging in the acts and practices described above, the Defendants have 
engaged and continue to engage in repeated fraudulent acts and practices in violation of Alabama 
common law and Section 6-5401 of the Alabama Code. 
130. Defendants* conduct was and is knowing, intentional, gross, oppressive, 
malicious, wanton, and/or committed with the intention to cause injury. 
COUNT TWO - FRAUDULENT SUPPRESSION 
131. The State hereby repeats, incorporates by reference] and re-alleges each and every 
allegation set forth above in this Complaint. 
140.. Defendants committed fraud against the State and itfe agency, Alabama Medicaid. 
Defendants voluntarily undertook to report or cause to be reported ^WP, WAC, and Direct Price 
for their products on a periodic and continuing basis for publication and dissemination to state 
Medicaid agencies including Alabama Medicaids Defendants knew that the AWP, WAC, and 
Direct Price information which they provided and/or caused to be reported was false, incomplete 
and/or outdated and Defendants suppressed and concealed facts within their knowledge which 
would have materially qualified the reported prices, Defendants ha{l a duty under the particular 
circumstances to provide accurate and complete AWP, WAC, and Qtrect Price information. By 
controlling the AWP, WAC, and Direct Price information for covered drugs which is reported to 
and through the publishers, Defendants concealed and suppressed th^ir fraudulent conduct from 
Alabama Medicaid, Defendants knew that the AWP, WAC, and Direct Price information which 
they concealed or failed to disclose and/or update would induce Alabama Medicaid to rely on 
false pricing information in setting prescription drug reimbursement! rates. Alabama Medicaid 
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was in fact induced to rely on the false pricing data in setting prescription drug reimbursement 
rates and made payments based on said rates.. Alabama Medicaid could not have reasonably 
discovered the fraudulent nature of the published AWP, WAC, and Direct Price information, as 
Defendants took active steps to conceal true market pricing information and to avoid detection of 
the fraudulent pricing scheme. Defendants* suppression and concealment of information was 
continuing, as they regularly and periodically continued to conceal material information 
regarding inflated AWP, WAC, and Direct Price information submitted by Defendants for 
publication by the industry reporting services. As a result of Defendants' fraudulent conduct, the 
State has been damaged by paying grossly excessive amounts for Defendants' prescription drugs. 
141. By engaging in the acts and practices described above, the Defendants have 
engaged and continue to engage in repeated fraudulent suppression and concealment in violation 
of Alabama common law and Section 6-5-102 of the Alabama Code. 
142. Defendants' conduct was and is knowing, intentional, gross, oppressive, 
malicious, wanton, and/or committed with the intention to cause injury. 
COUNT THREE - WANTONNESS 
143. The State hereby repeats* incorporates by reference and realleges each and every 
allegation set forth above in this Complaint 
144. With reckless indifference to the consequences, Defendants consciously reported 
false and inflated pricing information, including AWP, WAC, and Direct Price, while knowing 
of the falsities and being conscious that, from reporting such false and inflated pricing 
information, injury would likely or probably result 
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145. Defendants' actions did, in fact> injure the Sltate, and specifically Alabama 
Medicaid, by causing Alabama Medicaid to pay grossly excessive amounts for Defendants* 
prescription drugs,. 
146« By engaging in such actions and practices, the Defendants have engaged and 
continue to engage in repeated wanton acts and practices in violation of Alabama common law. 
147. Defendants' conduct was and is knowing, intentional, gross, oppressive, 
malicious, fraudulent, and/or committed with the intention to causfc injury. 
COUNT FOUR - UNJUST ENRICED^EENT 
148. The State hereby repeats, incorporates by reference and realleges each and every 
allegation set forth above in this Complaints 
149. As a result of the false and misleading statements land representations regarding 
drug prices contained in each Defendant's reporting of AWP? WAC, and Direct Price, Alabama 
Medicaid has paid excessive amounts in connection with purcihases or reimbursements of 
purchases of Defendants' prescription drugs. 
150. . Defendants knew that medical providers, including pharmacies and physicians, 
who obtained Medicaid reimbursement for Defendants' drug prbducts were not entitled to 
improperly inflated reimbursement rates that were based on Defendants* false AWPs, WACs, 
and Direct Prices, 
151. As a result of the excessive payments to providers by I Alabama Medicaid of all or 
part of the "spread," Defendants obtained increased sales and market share for their products, 
and, therefore, increased profits, and were unjustly enriched at thfc expense of the State and 
Alabama Medicaid, 
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152. Defendants knew they were not entitled to the profits that resulted from the sales 
obtained through the use of the spreads they created, and Defendants should be required to 
account for and make restitution to the State of all such amounts obtained through the use of 
such spreads. 
PRAYER FOR RELIEF 
Wherefore, Plaintiff prays for relief as follows: 
(1) an order enjoining each and every Defendant from continuing the fraudulent, 
wanton, deceptive and/or unfair acts or practices complained of herein, and requiring corrective 
measures; 
(2) an award of compensatory damages to the State in such amount as is proved at 
trial; 
(3) an award of punitive damages; 
(4) an accounting of all profits or gains derived in whole or in part by each Defendant 
through the fraudulent, wanton, unfair and/or deceptive acts or practices complained of herein; 
(5) an order imposing a constructive trust on and/or requiring disgorgement by each 
Defendant of all profits and gains earned in whole or in part through the fraudulent, wanton, 
unfair and/or deceptive acts or practices complained of herein; 
(6) an award of costs and prejudgment interest; and 
(7) such other and further relief as the Court may deem appropriate and just.. 
JURY DEMAND 
Plaintiff hereby requests a trial by jury on all claims so triable. 
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Mobile, AL 36601 
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W. Daniel "Dee" Miles, III (MIL060) 
Clinton C.Carter (CAR 112) 
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CERTIFICATE OF SERVICE 
I hereby certify that I have on this 11 day of January, 2006, electronically served a true 
and correct copy of the foregoing pleading on counsel of record by transmission to LNFS> 
pursuant to Case Management Order No. 2. 
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EXHIBIT A 
Through the following list, the State of Alabama inijends to capture not only 
the drug names listed, but also all variations of the drug names which incorporate 
prefixes, suffixes, modifiers, supplements, application nomenclatures, and/or drug 
delivery methods, to the extent not already specified. 
1 Defendant Group 1 
1 Abbott I 
Drug Name "1 
Aminosyn 
Aminosyn tl 
Anzemet© 
Biaxin® 
Biaxin® XL 
Clindamycin Phosphate 
Coliagenase Santyl® 
Cylert® 
Depakene® 
Depakote® 
Depakote© ER 
Depakote® Sprinkle 
Dextrose in Water 
Dextrose w/Sodium Chloride 
Dipyridamole 
EES.®400 
Ery-tab® 
Erythromycin 
Erythromycin Ethylsuccinate 
GabitriJ® 
Gengraf® 
Humira® 
Hytrin® 
Isoptin® SR 
Kaletra® 
Ketorolac Tromethamine 
K-Lor® 
K-Tab® 
Leucovorin Calcium 
Liposyn® II 
Liposyn® III 
Mavik® 
Norvirts) 
Omnicef® 
OxyContln® 
Paclitaxel 
PCE® 
PediaSure® 
Pediazole® 
Potassium Chloride 
Promethazine HCi 
Rondec® 
Rythmo!® 
Sodium Chloride 
SSD 1 
Synagis® 
1 Synthroid® 
Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU. 
Machine-generated OCR, may contain errors.
Defendant Group 1 
Alcon 
Allergan 
Alpharma 
Drug Name 1 
Tarka® 
TriCor® 
Vancomycin HCI 
VicodinES® 
Vicoprofen® 
Zemplar® 
Azopt® 
Betoptic S® 
Betoptic® 
Ciloxan® 
Cipro® HC OTIC 
Ciprodex® 
lopidine® 
Neomycin/Polymyxin/HC 
Nutren® 
Patanol® 
Peptamen Junior® 
Prednisolone Acetate 
Timolol Maleate 
TobraDex® 
Travatan® 
Vigamox™ 
Acular® 
Alocrii® 
Alphagan® 
Alphagan® P 
Betagan® 
Blephamide® 
Elimite® 
Lumigan® 
Ocuflox® 
Poiytrim® 
Pred Forte® 
Proplne® 
Restasis® 
Tazorac® 
Acetaminophen w/Codeine 
Acyclovir 
Albuterol Sulfate 
Amantadine HCI 
Bleomycin Sulfate 
Carbamazepine 
Carbidopa/Levodopa 
Carboplatin 
Cimeditlne HCI 
Clonazepam 
Clonidlne HCI 
Cyproheptadine HCI 
Diazepam 
Diclofenac Sodium 
Diltiazem HCI 
Enulose 
Erythromycin Estolate 
1 Erythromycin Ethylsucdnate 
- 2 -
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Defendant Group j 
Amgen 
Andrx 
Drug Name 1 
Etodolac 
Fluvoxamine Maleate 
Gabapentin 
Hydrochlorothiazide 
Ibuprofen 
Ipratropium Bromide 
Isosorblde Mononitrate 
Leucovorin Calcium 
lindane 
Lorazepam 
Lovastatin 
Metformin HCI 
Metoclopramide HCI 
Naproxen 
Nifedipine 
Nystatin 
Nystatin w/Triamcinoione 
Oxazepam 
Paclltaxel 
Pentoxifylline 
Phenobarbital 
Phenytoin 
Potassium Chloride 
Promethazine 
Propoxyphene Napsylate w/APAF^  
Spironolactone 
Sulfatrim® 
Tizanadine HCI 
Tramadol HCI 
Aranesp® 
Enbrel© 
1 Epogen® 
Hydrea® 
Kineret® 
1
 Leucovorin Calcium 
1 Leukine® 
Methotrexate 
Methotrexate Sodium 
Neulasta® 
Neulasta® 
Neupogen® 
Neupogen® 
Novantrone 
Albuterol 
Altocor™ 
Garila XT® 
Diitia XT® 
Embrex®600 
Famotidine 
Glipizide ER 
Histex® 
Metformin HCI 
Potassium Chloride 
Taztia XT® j 
J — - H 
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Defendant Group 1 
AstraZeneca 
Aventis 
Drug "Name"'"''"' ll'J'u" 1 
Accolate® 
Arimidex® 
Atacand® 
Atacand HCT® 
Casodex® 
Crestorts) 
Emia® 
Entocort® EC 
Faslodex® 
Foscavlr® 
Iressa® 
Merrem® 
Nexium® 
Nolvadex® 
Plendil® 
Prilosec® 
Pulmicort® 
Rhlnocort® 
Rhinocort Aqua® 
Seroquel® 
Sular® 
Tenoretic® 
Tenormin® 
Toprol-XL® 
Zestoretic® 
Zestril® 
Zomig® 
Zomig® ZMT 
Actonel® 
Aliegra® 
Ailegra-D® 
Altace® 
Amaryl® 
Anzemet® 
Anzemet® 
Arava® 
Azmacort® 
BenzaClin® 
Benzamycin® 
1 Biociate™ 
Calcimar 
Carafate® 
Cardizem® 
Cardizem® CD 
Cardizem® SR 
Carimune NF 
Ctaforan® 
Copaxone® 
Cromolyn Sodium 
DDAVP® 
Desmopressin Acetate 
DiaBeta® 
DiiacorXR® 
Gammar-P 1V 
Helixate® j 
1 Helixate® FS 
-4-
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Defendant Group 1 
Barr 
Baxter 
Drug Name-" 1 
Humate-P® 
indapamlde 
total® 
Lantus® 
Lasix® 
Lovenox® 
Lozol® 
Monoclate-P® 
Nasacort® 
Nasacori® AQ 
Penlac® 
Psorcon® 
Psorcon® E™ 
Rhophylac® 
Rifadin® 
RiluteK® 
Seldane® 
Seldane-D® 
Slo-Bid 
Taxotere® 
Theophylline Anhydrous 
Topicort® 
Trental® 
Zaroxolyn 
Acetaminophen w/Codeine 
Amphetamine Salt Combinations! 
Aviane® 
Cenestin® 
Cephalexin 
Ciprofloxacin HCI 
Danazol 
Dextroamphetamine Sulfate 
Diazepam 
Digoxin 
Erythromycin w/Sulfisoxazole 
Fluoxetine HCI 
Hydroxyurea 
Hydroxyzine Pamoate 
Megestrol Acetate 
Methotrexate 
Methylprednisolone 
l\/letociopramide HCI 
Mirtazapine 
Naltrexone HCI 
Oxycodone w/Acetaminophen 
Tamoxifen Citrate 
Trazodone HCI 
Warfarin Sodium 
Advate™ 
Bebuiin®VH 
Blociate™ 
Cisplatin 
Decadron® 
Dextrose 
1 Dextrose w/Sodium Chloride 
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Defendant Group 1 
Bayer 
Biovail 
Boehringer 
Drug Name 1 
Dipyridamole 
Doxorubicin HCI 
Etoposide 
Feiba®VH Immuno 
Gammagard® SID 
Hemofil™ M 
intralipid 
Iveegam™ EN 
Leucovorin Calcium 
Mesna 
Peptamen Junior® 
Promethazine 
Promethazine HCI 
Recombinate™ 
Sodium Chloride 
Toradol® 
Travasol® 
Vancomycin HCI 
Adalat® 
Adalat® CC 
Avelox® 
Baycol® 
Cipro® 
Cipro® 1..V. 
Cipro® XR 
Gamimune® N 
Gamunex® 
Koate®-DVI 
Koate-HP 
Kogenate® 
Kogenate® FS 
Mycelex 
Precose® 
Prolastin® 
Cardizem® LA 
Cedax® 
Rondec® 
Rondec® DM 
Vasotec® 
Zovirax® 
Aggrenox® 
Alupent® 
Atrovent® 
Azathioprlne 
Butorphanot Tartrate 
Catapres® 
Catapres*TTS® 
Comblvent® 
Dexamethasone 
Diclofenac Sodium 
Dlgoxin 
Duraclon® 
Flomax® 
1 Furosemide 
-6-
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Defendant Group 1 Drug Name 
Bristol-Myers Squibb 
natupenaoi 
Hydroxyurea 
ipratropium Bromide 
Lactulose 
Leucovorin Calcium 
Lithium Carbonate 
Marinol® 
Megestrol Acetate 
Methadone HCi 
Methotrexate 
Metoclopramide HCI 
Mexitii® 
Micardis HCT® 
Micardis® 
Mirapex® 
Mirtazapine 
Mobic® 
Morphine Sulfate 
Naproxen 
Oramorph®SR 
Oxycodone w/Acetaminoph^n 
Prednisone 
Roxicet® 
Roxicodone® 
Sodium Polystyrene Sulfonate 
Viramune® 
Ability® ' 
Albuterol 
Amantadine HCI 
Avalide® 
Avapro® 
, BiCNU® 
Blenoxane NovaPlus 
Blenoxane® 
BuSpar® 
Capoten® 
Capozide© 
Captopril 
Carboplatin 
Cefaclor 
Cefadroxil 
Cefell® 
Cephalexin 
Clonazepam 
Corgard® 
Coumadin® 
Cytoxan® 
Dovonex® 
Duricef® 
Etodolac 
Etopophos® j 
Florinef® Acetate j 
Glucophage® j 
Glucophage® XR 
Glucovance® 
1 1 Hydrea 
- 7 -
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o 
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o 
o 
Defendant Group 1 
jDEY 
L _ 
Endo 
Drug Name "1 
Hydroxychloroquine Sulfate 
Ifex® 
Lac-Hydrln® 
Megace® 
Mesnex® 
Methylphenidate HCI 
Monopril® 
Monopril©-HCT 
Nadolol 
Paraplatin® 
Paraplatin® Novaplus 
Percocet® 
Platinol® 
Plavix® 
Potassium Chloride 
Pravachol® 
Prochlorperazine Maleate 
Prolixin® 
Prolixin® Decanoate 
Questran® 
Reyataz® 
Rubex® 
Serzone® 
Sinemet® 
Sinemet® CR 
Stadol 
Stadol NS® 
Sustiva® 
Taxol® 
Tequin® 
Trazodone HCI 
Trimox® 
Ultracai® 
Ultravate® 
VePesid® 
Videx® 
Videx® EC 
Warfarin Sodium 
| Westcort® 
Zerit® 
j AccuNeb® 
Albuterol 
Albuterol Sulfate 
Cromolyn Sodium 
DuoNeb® 
EpiPen® 
EpIPen® Jr 
ipratropium Bromide 
Sodium Chloride 
AcipHex® 
Aricept® 
Zonegran® 
Carbidopa/Levodopa 
1 CimetSdine 
- 8 -
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Defendant Group j 
iETHEX 
Forest 
Fujisawa 
Genzyme 
Gllead 
Drug Name 1 
Endocei® 
Hydrocodone w/Acetaminophen 
Lidoderm® 
Moban® 
Morphine Sulfate 
Percocet® 
Anemagen™ 
Benazepril HCl 
Bromfenex™ PD 
Buspirone HCl 
Disopyramide Phosphate 
Doxazosin Mesylate 
Histinex® HC 
Hydro-Tussin™ HC 
Hyoscyamlne Sulfate 
Isosorbide Mononitrate 
Ketorolac Tromethamine 
Naproxen 
NatalCare® 
NitroQuick® 
Oxycodone HCl 
Potassium Chloride 
Prednisolone 
Aerobrd® 
Aerobid®-M 
AeroChamber® 
Benzonatate 
Celexa® 
Diltiazem HCl 
i Esgic-Plus 
s Flumadine® 
Hydrocodone w/Acetaminophen 
Isosorbide Dinitrate 
Levothroid® 
i Lexapro® 
Lorcet Plus® 
i Lorcet® 
Namenda® 
Theophylline Anhydrous 
Tiazac® 
AmBisome® 
Cyclocort® 
Fluphenazine Decanoate 
Haloperidoi Decanoate 
Prograf® 
Protoplc® 
Ceredase® i 
Cerezyme® 1 
Fabrazyme® j 
Renagel® i 
Truvada® 
Viread® 
• " " ' - • " • • " — - • 1 j 
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Defendant Group f 
1 ^ 
GlaxoSmithKline | 
Drug Name 1 
Advair DIskus® 
Agenerase® 
Amerge® 
Amoxil® 
AugmentJn ES-600® 
Augmentin XR® 
Augmenting 
Avandamet® 
Avandia® 
Bactroban© 
Beclovent 
Beconase AQ® 
Beconase® 
Ceftin® 
Combivir® 
Compazine 
Coreg® 
Cortisporin 
Cutivate® 
Dexedrine® 
Dibenzyline® 
Dyazide 
Eplvir® 
Eskalith GR® 
Famvir® 
Flolan® 
Flonase® 
Flovent® 
Fortaz® 
Granisetron HCI 
Hycamtin® 
Imltrex® 
! Imuran™ 
Kytrll® 
Larnlctal® 
Lanoxin® 
Lotronex® 
Mepron® 
Naveibine® 
Oxistat® 
Paxil CR® 
Paxil® 
Purinethol® 
Relafen® 
Requip® 
Retrovir® 
Serevent® 
Serevent® Diskus® 
Tagamet® 
Tazicef® 
Trandate® 
Trizivir® 1 
Urispas® j 
Valtrex® 
1 Ventolin® 
- 1 0 -
Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU. 
Machine-generated OCR, may contain errors.
Defendant Group 1 
Hoffman-LaRoche 
IVAX 
Drug Name 1 
Wellbutrin SR® 
Wellbutrin XL® 
Wellbutrin® 
Zantac® 
Zlagen® 
Zofran ODT€> 
Zofran® 
Zovirax® 
Accutane® 
Anaprox® 
Anaprox® DS 
Bumex® 
Cardene® 
Cardene® SR 
CellCept® 
Copegus® 
Cytovene® 
Demadex® 
EC-Naprosyn® 
Fortovase® 
Fuzeon® 
Granlsetron HCI 
Intron® A 
Invirase® 
Klonopin® 
Kytril® 
Naprosyn® 
Naproxen 
Naproxen Sodium 
Pegasys® 
Rocaltrol® 
Rocephin® 
Roferon® A 
Soriatane® 
Tamiflu® 
Ticlid® 
Toradol® 
Vaicyte™ 
Xeloda® 
Xenical® 
Acetaminophen w/Codeine 
Albuterol 
Albuterol Sulfate 
Amantadine HCI 
Amltriptyline HCI 
Amltriptyline w/Perphenazine 
Amox Tr-Potasslum Clavuianate 
Amoxicillin 
Aspirin 
Baclofen | 
Benztropine Mesylate 
Biohist LA® 
Bumetanide 
Carbamazepine 
1 Cefaclor 
-11-
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Defendant Group T Drug Name 1 
Cefadroxil 
Cephalexin 
Chemdal HD 
Cimetidine 
Clozapine 
Cyclobenzaprine HCI 
Cyproheptadine HCI 
Diazepam 
Doxazosin Mesylate 
Doxepin HCI 
Enalaprii Maleate 
Etodolac 
Famotidine 
Ferrous Sulfate 
Fluphenazine HCI 
Fluvoxamine Maleate 
Furosemide 
Gabapentin 
Giyburide w/Metformln HCI 
Hydrochlorothiazide 
Hydrocodone w/Acetaminophen 
Hydroxyzine HCI 
Hydroxyzine Pamoate 
ibuprofen 
Indomethacin 
Ipratropium Bromide 
Labetaiol HCI 
Lactulose 
Levothyroxlne Sodium 
Lisinopril 
Lorazepam 
i Loxapine Succinate 
Meclizine HCI 
Megestrol Acetate 
Metformin HCI 
Metformin HCI ER 
Methyldopa 
Methylphenidate HCI 
! Metociopramide HCI 
Misoprostol 
Nifedipine 
Nitrofurantoin Macrocrystal 
Nov-Onxoi 
Nystatin 
Onxol™ 
Oxazepam 
Oxybutynin Chloride 
Oxycodone w/Acetaminophen 
Paclitaxel Novaplus 
Perphenazine 
Phenobarbital 
Potassium Chloride 
Primidone 
Proglycem® 
Propoxyphene Napsylate w/Acetaminophen 
Propranolol HCI 
1 Quinine Sulfate 
- 1 2 -
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Defendant Group 1 
| 7 _ J 
King 
Drug Name ~ 1 
_ _ 
Sulfamethoxazole/Trimethoprim 
Sulindac 
Theophylline Anhydrous 
Tramadol HC! 
Trazodone HCI 
Valproic Acid 
Verapamil HC! 
AcipHex® | 
Concerta® 
Doxii® 
Ditropan XL® 
Duragesic® 
Elmiron® 
Ethyol® 
Flexeril® 
Floxin© 
Grifulvin V® 
Haldol© 
Haldol® Decanoate 
Hismanal® 
Levaquin® 
Motrin® 
Mycelex® 
Nizoral® 
Ortho Evra® 
OrthoTri-Cyclen® 
Ortho-Cyclen® 
Ortho-Novum® 
Pancrease® 
Pancrease® MT 
Pepcid® AC 
Procrit® 
Propulsid® 
Regranex® 
Remicade® 
i Reminyl® 
Risperdal® 
Risperdal® Consta™ 
Spectazole® 
! Sporanox® 
Terazol® 3 
Terazoi®7 
Tolectin® 
Topamax® 
Tylox® 
j Uftracei® \ 
Ultram® | 
Urispas® 1 
Altace® 
Cortisporin® 
Levoxyl® 
Lorabid® 
Skelaxin® 
' • i - 1 
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Defendant Group 1 
Medlmmune 
| Merck 
Myian 
Drug Name I 
Ethyol® 
Synagis® 
Cancidas® 
Cosopt® 
Cozaar® 
Crixivan® 
Decadron® 
Dolobid® 
Fiexeril® 
Fosamax® 
Hyzaar® 
Maxalt® 
Maxalt-MLT® 
Mevacor® 
Noroxin® 
Pepcid® 
Piendil® 
Prilosec® 
Primaxin® 
Prinivil® 
Prinzide® 
Proscar® 
Sinemet® CR 
Singulair® 
Timoptic® 
Timoptic-XE® 
Trusopt® 
Vaseretic® 
Vasotec® 
Vioxx® 
Zetia® 
Zocor® 
Acebutoiol HCI 
Acticin® 
Albuterol Sulfate 
Allopurinol 
Amitriptyline Chlordlazepoxide 
Amitriptyline HCI 
Amitriptyline w/Perphenazine 
Atenolol 
Benazepril HCI 
Bisoprolol Fumarate/HCTZ 
Bumetanlde 
Buspirone HCI 
Butorphanol Tartrate 
Captopril 
Carbidopa/Levodopa 
Cefaclor 
Cimetidine 
Clonazepam 
Clonidine HCI 
Clorazepate Dipotassium 
j Clozapine 
- 1 4 -
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Defendant Group 1 Drug Name H 
Cyciobenzaprine HCI 
Diazepam 
Digitek® 
Diltiazem HCI 
Diphenoxylate w/Atropine 
Doxepin HCI 
Enalapril Maleate 
Enalaprll Maleate w/HCTZ 
Estradiol 
Etodolac 
Famotidine 
Fluphenazine HCI 
Flurbiprofen 
Fluvoxamine Maleate 
Furosemide 
Glipizide 
Glyburide Micronized 
Granulex® 
Guanfacine HCI 
Haloperidol 
Hydrochlorothiazide 
Hydroxychloroquine Sulfate 
Ketoprofen 
Kristaiose 
Leucovorin Calcium 
Llslnoprll 
Llsinopril w/HCTZ 
Loperamide HCI 
Lorazepam 
Lovastatin 
Meclofenamate Sodium 
Mentax 
Metformin HCI 
Methotrexate 
Methyldopa 
Methyldopa/Hydrochlorothiazilde 
Metoprolol Tartrate 
Mlrtazapine 
Nadolol 
Naproxen 
Naproxen Sodium 
Nifedipine Extended-release 
Nitrek 
Nitrofurantoin 
Nitroglycerin 
Nizatidine 
Nortriptyline HCI 
Omeprazole 
Orphenadrine Citrate 
Paciitaxel 
Pentoxifylline 
Phenytek 
Phenytoin Sodium Extended 
Piroxicam | 
Propoxyphene HCI w/APAP 
Propoxyphene Napsylate w/APAP 
1 Propranolol HCI 
- 1 5 -
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Defendant Group 1 
Novartis 
Drug Name 1 
Ranitidine HOI 
Spironolactone 
Sulindac 
Tamoxifen Citrate 
Temazepam 
Terazosin HCI 
Thioridazine HCI 
Thiothixene 
Tramadol HCI 
Triamterene w/HCTZ 
Verapamil HCI 
Acetaminophen w/Codeine 
Actigati® 
Amiodarone HCI 
Amltrfptyline HCI 
Amox Tr/Potassium Clavulanate 
Amphetamine Salt Combinations 
Anafranll® 
Aredia® 
Aspirin 
Atenolol 
Azathioprine 
Bisoproloi Fumarate 
Bisoproloi Fumarate with HCTZ 
Brethine 
Bromocriptine Mesylate 
Bumetanide 
Bupropion HCI 
Carisoprodol 
Cataflam® 
Chlorpromazine HCI 
I Cimetldine 
1 Clemastine Fumarate 
Clomipramine HCI 
Clonazepam 
Clozaril® 
COMTan® 
Desferal® 
Desferal® Mesylate 
Desipramine HCI 
Diclofenac Sodium 
Diovan HCT® 
Diovan© 
DynaCirc CR® 
DynaCirc® 
Eildel© 
Enalapril Maleate 
Enalapril Maleate/HCTZ 
Estraderm® 
Etodoiac 
Exelon® 
Famotidine 
Famvir® 
Femara® 
Ferrous Sulfate 
1 Fiorinal® w/Codeine #3 
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Defendant Group f Drug Name ~j 
Fluoxetine HCI 
Fluphenazine HCI 
Fluvoxamine Maleate 
Focalin™ 
Foradll® 
Fosinopril Sodium 
Furosemtde 
Gleevec™ 
Giyburide 
Haloperidol 
Hydergine LC 
Hydergine® 
Hydrochlorothiazide 
Hydrocodone w/Acetaminoph&n 
Hydroxychloroquine Sulfate 
Hydroxyzine Pamoate 
Ibuprofen 
Imlpramine HCI 
Isosorbide Dinitrate 
Labetalol HCI 
Lamisii® 
Lescol® 
Lescol® XL 
Levothyroxine Sodium 
Lindane 
Llslnoprii 
Lisinopril-HCTZ 
Uvostin® 
Lonox® 
Lopressor HOT® 
Lopressor® 
Loratadine 
Lorazepam 
Lotensin HOT® 
Lotensin® 
Lotrel® 
Lovastatin 
Loxapine Succinate 
MelJeril® 
Mellerit-S 
Metformin HCI 
Methocarbamol 
Methyldopa 
Metbylphenidate HCI 
Metoproiol Tartrate 
Miacaicin® 
Mirtazapine 
! Nabumetone 
Naproxen I 
Neoral® 
Nitrofurantoin Macrocrystal 
Nizatidine 
Nortriptyline HCI 
! Omeprazole 
I Oxaprozin 
Oxazepam 
Pamelor® 
'• — " • i — — - « » - i . . i 
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Defendant Group [ 
Novo Nordisk 
Organon 
Par 
Drug Name 1 
Parlodel® 
Perphenazine 
Potassium Chloride 
Promethazine HCI 
Propoxyphene Napsylate w/APAP 
Propranolol HCI 
Ranitidine HCI 
Ritalin LA® 
Ritalin® 
Ritalin® SR 
Sandimmune® 
Sandoglobulin® 
Sandostatln LAR® 
Sandostatin LAR® Depot 
Sandostatln® 
Sotalol 
Spironolactone 
Starllx® 
Tegretol® 
Tegretol®-XR 
Terazosin HCI 
Theophylline Anhydrous 
Thioridazine HCL 
Thiothixene 
Tizanldine HCI 
Tramadol HC! 
Transderm-Nitro® 
Trazodone HCI 
Triamterene w/HCTZ 
Trifluoperazine HCI 
Trileptal® 
Valproic Acid 
Vivelle® 
Voltaren® 
; Warfarin Sodium 
; Zaditor™ 
Zelnorm® 
Zometa® 
PNovoFine® 30 
Novolin® 70/30 
Novoiin® N 
Novolin® R 
Novolog® 
NovoLog® Mix 70/30 
NovoSeven© 
Prandin® 
I Remeron® 
Benztropine Mesylate 
Buspirone HCI 
Doxepin HCI 
Enalapril Maleate 
Famotidine 
Flecalnide Acetate ! 
1 Fluoxetine HCI 
Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU. 
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Defendant Group j 
Pfizer 
Drug Name 1 
Glyburide w/Metformin HCI 
ibuprofen 
Imipramine HCI 
Lovastatln 
Meclizine HCI 
Megestrol Acetate 
Metformin HCL ER 
Minoxidil 
Oxaprozln 
Paroxetine HCI 
Ranitidine HCI 
Sotaiol 
SSD® 
Tizanidine HCI 
Torsemide 
Accupril® ' 
Activella® 
Adriamycin 
Aidactone® 
Ambien® 
Ansaid® 
Aromasin® 
Arthrotec® 
Atgam® 
Axert® 
Azuifidine® 
Bextra® 
Bleomycin Sulfate 
Calan® SR 
Camptosar® 
Cardura® 
Caverject® 
Celebrex® 
Cleocin HCI® 
Cleocin Pediatric® 
Cleocin T© 
Cleocin® 
Clindamycin HCI 
Clindamycin Phosphate 
Cognex® 
Colestid® 
Cortef® 
Covera-HS® 
Cytotec® 
Daypro® 
Depo®-Testoterone 
Depo-Medrol® 
Depo-Provera© 
Detrol® 
Detrol®LA 
Diflucan® 
Dilantin® 
Dliantin-125® 
Dostinex® 
EDence® 
I Estring® ^ 
- 1 9 -
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Defendant Group | 
1 Purdue 
Drug Name 1 
Estrostep® Fe 
Etoposide 
Feidene® 
FemHRT® 
Flagyl® 
Fragmin® 
Gabapentin 
Genotropin® 
Geodon® 
Glucotrol XL® 
Glucotrol® 
Glyburide 
Glyburide MIcronized 
Glynase® 
Glyset® 
Ibuprofen 
Kerlone® 
Lipitor® 
Loestrin® Fe 
Lopid® 
Lunelle™ 
Methytprednisolone 
Micronase® 
Mirapex® 
Mycobutin® 
Navane® 
Neurontin® 
Nitrodisc 
Nitrostat® 
Norpace®CR 
Norvasc® 
Omnicef® 
Piroxlcam 
Procardia XL® 
Procardia® 
Provera® 
Relpax® 
Rescriptor® 
Rezulin® 
Spironolactone 
Toposar® 
Trovan® 
Vagifem® 
Vantin® 
Vfend® 
Vlracept® 
Vistaril® 
Xalatan® 
Zarontin® 
Zithromax® 
Zithromax® Tri-Pak 
Zoloft® ] 
Zyrtec® 
Zyrtec-D® 
Zyvox® i 
1 Cerumenex® " 
- 2 0 -
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Deleridant'Group'T 
Sanofi 
Schering 
TAP 
Takeda 
TEVA 
Drug Name ' 1 
MS Contin® 
OxyOontin® 
Trilisate® 
Unlphyl® 
Ambien® 
Eligard® 
Eioxatin® 
Hyalgan® 
Plaquenll® 
Talacen® 
Albuterol 
Albuterol Sulfate 
Cedax® 
Cetestone SoJuspan 
Clarinex® 
Claritln® 
Claritln-D® 
Clotrimazole 
Diprolene® 
Diprolene® AF 
Elocon® 
Eulexin® 
Foradil® 
imdur® 
i lntron®A 
I Isosorbide Mononitrate 
K-Dur® 
i Labetalol HCl 
Lotrimln® 
Lotrisone® 
Nasonex® 
Nitro-Dur® 
Normodyne® 
Peg-lntron® 
Potassium Chloride 
i Proventi)® 
Proventil® HFA 
Rebetol® 
Rebetron® 
Temodar® 
Theo-Dur® 
Theophylline Anhydrous 
TrtnaVin® 
Vancenase® 
Vancenase® AQ 
Vancerll® 
Zetia® 
Prevacid® 
Prevpac® 
Actos® 
Acetaminophen w/Codeine j 
1 Acyclovir j 
-21-
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Defendant Group 1 Drug Name 1 
Albuterol 
Albuterol Sulfate 
Amiodarone HCI 
Amox Tr/Potassium Clavulanate 
Amoxicillin 
Amoxicillin Trlhydrate 
Benzonatate 
Budeprion SR 
Bupropion HCI 
Calcitriol 
Carbamazepine 
Carbidopa/Levodopa 
Cephalexin 
Chlorzoxazone 
Cimetidine 
Clemastine Fumarate 
Clindamycin HCI 
Clonazepam 
Diclofenac Sodium 
Diflunisal 
Diltiazem HCI 
Doxazosin Mesylate 
Enalapril Maleate 
Etodoiac 
Famotidine 
Fluocinonide 
Fluoxetine HCI 
Fluphenazine Decanoate 
Fosinopril Sodium 
Gabapentin 
Gemfibrozil 
Glyburide 
Glyburide Micronized 
Haloperidol Decanoate 
; Hydrocodine Bitartrate and Ibuprofen 
Hydroxychloroquine Sulfate 
Ketoconazole 
Ketoprofen 
i Loperamide HCI 
j Lovasfcatin 
Mebendazole 
Methylphenidate HCI 
Metoclopramide HCI 
Metoprolo! Tartrate 
Minocycline HCI 
Mirtazaplne 
Moban 
Moexipril HCI 
Mupirocin 
Nabumetone 
Naproxen 
Naproxen Sodium 
Nifediac®CC 
Nlfedical© XL | 
Nifedipine 
Nortriptyline HCI 
1 Nystatin 
- 2 2 -
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Defendant Group 1 
Watson 
L . 
Drua Name I 
Oxycodone HCI 
Penicillin V Potassium 
Pentoxifylline 
Potassium Chloride 
Prednisolone 
Propoxyphene Napsylate and Acetaminophen 
Propranolol HCI 
Ranitidine HCI 
Sotaloi 
Sucralfate 
Sulfamethoxazole/Trimethoprim 
Ticlopidine HCI 
Tizanidine HCI 
Torsemide 
Tramadol HCI 
Trazodone HCI 
Ursodtart 
Valproic Acid 
Acyclovir 
Amoxapine 
Aspirin 
Baclofen 
Bisoprolol Fumarate with HCTJ2 
Bupropion HCI 1 
Buspirone HC! 
Butalbltal Compound w/Codeiifie 
Carlsoprodol 
Cimetidine 
Clindamycin HCI 
Clonazepam 
Clorazepate Dlpotassium 
Cyclobenzaprlne HCI 
Diazepam 
Diclofenac Sodium 
Dicyclomine HCI 
Diltiazem HCI 
Diltiazem XR 
Doxepin HCI 
Enalapril Maleate 
Famotidine 
Ferrleclt© 
Ferrous Sulfate 
Furosemide 
Glipizide 
Glipizide ER 
GuanfacineHCI 
Hydrochlorothiazide 
Hydrocodone w/Acetaminophpn i 
Hydroxychloroquine Sulfate 
Hydroxyzine HCI 
Hydroxyzine Pamoate 
Ibuprofen 
INFeD(S) | 
Ketoprofen ! 
Labetalol HCI 
1 Lactulose _ 
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Defendant Group T 
Wyeth 
Drucj Name ""] 
Lisinapril 
Lorazepam 
Low-Ogestre!® 
Loxapine Succinate 
Meclizine HCI 
Meprobamate 
Metformin HCI 
Methocarbamol 
Methylphenldate HCI 
Minocycline HCI 
Minoxidil 
Mirtazapine 
Naproxen 
Naproxen Sodium 
Necon® 
Neomycin/Poiymyxin/HC 
Nephn>Vite(a> RX 
Nifedipine 
Nifurantoin Monohyd Macro 
Norco® 
Nortriptyline HCI 
Oxybutynin Chloride 
Oxycodone/APAP 
Pentazocine/Naloxone 
Prednisone 
Primidone 
Promethazine HCI 
Propranolol HCI 
Quinine Sulfate 
Ranitidine HCI 
Sucralfate 
Suiindac 
Thioridazine HCI 
i Thiothixene 
Trazodone HCI 
Triamterene w/HCTZ 
Trihexyphenidyl HCI 
TriNessa™ 
Trivora® 
Valproic Acid 
Vancomycin HCI 
Verapamil HCI 
Alesse® j 
Atenolol 
Ativan® 
BeneFIX® 
Cefaclor 
Cimetidine 
Cordarone® 
Deciomycin® 
Diamox® Sequels® 
Diazepam 
Diltiazem HCI 
EffexorXR® ! 
Effexoi® 
1 Erythromycin w/Sulfisoxazole 
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Defendant Group [ Drug Name 1 
Etodolac 
Furosemide 
Hydrochlorothiazide 
Inderal® 
Inderal® LA 
Ismo® 
Ketoprofen 
Lo/Ovral® 
Lodtne® 
Lorazepam 
Maxzide® 
Methotrexate 
Micro«K 
Mysoline® 
Naproxen 
Neptazane® 
Norplant 
Novantrone 
Orudis® 
Oruvail® 
Pentoxifylline 
Phenergan® 
Premarin® 
Premphase® 
Prempro™ 
Promethazine HCI 
1
 Propranolol HCI 
Protonix® 
Qumidex Extentabs® 
Rapamune® 
ReFacto® 
Sectral® 
Sonata® 
Sulindac 
Suprax® 
Tenex® 
Triphasil® 
Vancomycin HCI | 
Verelan® i 
Zlac® 
Zosyn® 
i - .J...,..,.., . ; 
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PO Box 4160 
Montgomery AL 36103-4160 
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14 West Erie Street OCT 17 2006 
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JAMES E. FOSLER 
FOSLERLAW GROUP, INC. 
737 West Fifth Avenue; Suite 205 
Anchorage AS 99501 
(907) 277-1557/(907) 277-1657 (fax) 
Attorneys for Plaintiff 
IN THE SUPERIOR COURT FOR THE STATE OF ALASKA 
THIRD JUDICIAL DISTRICT AT ANCHORAGE 
STATE OF ALASKA, 
Plaintiff, 
vs. 
ALPHARMA BRANDED PRODUCTS 
DIVISION INC.; ALPHARMA USPD INC.; 
AMGEN INC.; ASTRAZENECA 
PHARMACEUTICALS LP; ASTRAZENECA 
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LP; AVENTIS PHARMACEUTICALS INC.; 
AVENTIS BEHRING, LLC, n/k/a ZLB 
BEHRING; BARR LABORATORIES, INC.; 
BAXTER HEALTHCARE CORP.; BEN 
VENUE LABORATORIES, INC.; 
BOEHRINGER INGELHEIM 
PHARMACEUTICALS, INC.; BRISTOL-
MYERS SQUIBB CO.; CENTOCOR, INC.; 
DURAMED PHARMACEUTICALS, INC.; 
FOREST LABORATORIES, INC.; 
IMMUNEX CORP.; IVAX CORP.; IVAX 
PHARMACEUTICALS, INC.; JANSSEN 
PHARMACEUTICAL PRODUCTS, LP; 
JOHNSON & JOHNSON; McNEIL-PPC, INC.; 
MERCK & CO., INC.; MYLAN 
LABORATORIES, INC.; MYLAN 
PHARMACEUTICALS, INC.; NOVARTIS 
PHARMACEUTICALS CORP.; ORTHO 
BIOTECH PRODUCTS, LP; ORTHO-McNEIL 
PHARMACEUTICAL, INC.; PAR 
PHARMACEUTICAL COS., INC.; PFIZER 
INC.; PHARMACIA CORP.; PUREPAC 
PHARMACEUTICAL CO.; ROXANE, INC., 
n/k/a BOEHRINGER INGELHEIM, ROXANE, 
INC.; SANDOZ, INC., ffk/a GENEVA 
PHARMACEUTICALS, INC.; SCHERTNG 
CORPORATION; SCHERING-PLOUGH 
CORP.; SICOR, INC., f/k/a SICOR 
PHARMACEUTICALS, INC., Vk/a GENSIA 
SICOR; SMITHKLINE BEECHAM CORP., 
d/b/a GLAXOSMITHKLINE; TEVA 
PHARMACEUTICALS USA, INC.; 
WARRICK PHARMACEUTICALS 
CORPORATION; WATSON PHARMA, INC., 
flk/a SCHEIN PHARMACEUTICALS, INC.; 
and WATSON PHARMACEUTICALS, INC., 
Defendants. 
CaseNo:3AN-06-12026CI 
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AMENDED COMPLAINT 
Plaintiff, the State of Alaska ("the State" or "Alaska'*), alleges for its Complaint 
against the above-captioned defendants as follows: 
NATURE OF THE ACTION 
1, This lawsuit is brought pursuant to Alaska's Unfair Trade Practices and 
Consumer Protection Act, AS 45.50.471, et seq, ("the Act"). 
2. Alaska brings this lawsuit to recover damagesl and obtain injunctive relief from 
defendants, who are manufacturers of prescription drugs, As described in this Complaint, 
defendants have taken advantage of the enormously complicated and non-transparent market 
for prescription drugs to engage in an unlawful scheme to cause Alaska to pay inflated prices 
for prescription drugs. The scheme involves the publication by defendants of phony "average 
wholesale prices" ("AWPs"), which then become the basis for calculating the cost at which 
"providers" - the physicians and pharmacies who provide these prescription drugs to patients 
- are reimbursed by Alaska. Defendants reinforce this basid tactic with other deceptive 
practices described in this complaint, including the use of secret discounts and rebates to 
providers, and the use of various devices to keep secret the prices of their drugs currently 
available in the marketplace to other purchasers. By engaging in this unlawful scheme, 
defendants have succeeded in having Alaska finance windfall profits to these providers. 
Defendants attempt to profit from their scheme by using the llure of these windfall profits 
competitively to encourage providers to buy more of their diftigs instead of competing in the 
AMENDED COMPLAINT 
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marketplace solely on the basis of legitimate factors such as price and the medicinal value of 
their drugs* 
PARTIES AND JURISDICTION 
3. The State is authorized to bring this lawsuit by AS 44,23.020,45,50.501 and 
45.50.551. As described in this Complaint, defendants1 unlawful scheme has resulted in 
higher prices for prescription drugs being paid by Alaska's Medicaid program, The 
defendants have used and continue to use the methods, acts, and practices set forth in this 
Complaint that, among other violations, are illegal under the Act. 
4. Defendants are pharmaceutical companies whose fraudulent schemes, including 
the publication of excessive and inflated prices for prescription drugs as described in this 
Complaint, have caused to be presented to officers and/or employees of Alaska false or 
fraudulent claims for payment or approval of certain drugs to get these false or fraudulent 
claims paid or approved by the Alaska Medicaid program, and have resulted in Alaska paying 
for drugs at inflated prices, as detailed below. 
5. At all times material to this civil action, each defendant has transacted business 
in Alaska by, including, but not limited to, selling directly or tlirough wholesalers its drugs, 
including those identified in this Complaint, to purchasers within the State of Alaska. 
6. The following three defendants are hereinafter referred to as the Alpharma 
group: 
(i) defendant Alpharma Branded Products Division, Inc. is a Delaware 
corporation with its principal place of business located at 1 New England 
Avenue, Piscataway, NJ 08854. Alpharma Branded Products Division Inc. 
AMENDED COMPLAINT 
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manufactures and markets pharmaceutical products, including Kadian, 
Alpharma Branded Products Division Inc. is i wholly-owned subsidiary of 
Alpharma, Inc.; 
(ii) defendant Alpharma USPD, Inc. ("Alpfoarma USPD") is a Maryland 
corporation with its principal place of business located in Baltimore, Maryland. 
Alpharma USPD, Inc. manufactures and markets pharmaceutical products under 
its own name under Labeler Code 00472; and| 
(iii) defendant Purepac Pharmaceutical Co., ("Purepac") is a Delaware 
corporation in the business of manufacturing and selling pharmaceuticals. 
Purepac's principal place of business is 14 Cojnmerce Dr., Suite 301, Cranford, 
NJ 07016. 
Until December 19,2005, defendants Alpharma USPD, Inc|. and Purepac were wholly-owned 
subsidiaries of Alpharma, Inc. On that date, Alpharma USIfD and Purepac were purchased by 
Actavis Group HF and became wholly-owned subsidiaries 0f Actavis, Inc., a wholly-owned 
subsidiary of Actavis Group HF. 
7. The following two defendants are hereinafter referred to as the Amgen group: 
(i) defendant Amgen, Inc. ("Amgen") is a|Delaware corporation with its 
principal place of business at One Amgen Dr.> Thousand Oaks, CA 91320-
1799; and 
(ii) defendant Immunex Corp. ("Immunexl), a wholly-owned subsidiary of 
Amgen since July, 2002, is a Washington statp corporation engaged in the 
business of manufacturing and selling pharmaceuticals. Immunex1 s principal 
place of business is located at 5-1 University SL, Seattle, WA 98101. Immunex 
is also being sued for the conduct of its subsidiaries and/or divisions, including 
but not limited to Lederle Oncology Corp. 
8. Defendants AstraZeneca Pharmaceuticals LP knd AstraZeneca LP 
("AstraZeneca") are related Delaware corporations with their principal place of business at. 
1800 Concord Pike, Wilmington, DE 19850. 
AMENDED COMPLAINT 
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9. The following two defendants are hereinafter referred to as the Aventis group: 
(i) defendant Aventis Pharmaceuticals/ Inc. is a Delaware corporation with 
its principal place of business located at 300-400 Somerset Corporate Blvd., 
Bridgewater, NJ 08807-2854; and 
(ii) defendant Aventis Behring, LLC, n/k/a ZLB Behring, is headquartered at 
1020 First Ave., King of Prussia, PA 19406-090 L 
10. The following two defendants are hereinafter referred to as the Barr group: 
(i) defendant Barr Laboratories, Inc. (nBLP) is a Delaware corporation 
engaged in the business of manufacturing and selling pharmaceuticals. BLI's 
principal place of business is located at 400 Chestnut Ridge Road, Woodcliff 
Lake, NJ 07677. BLI is a subsidiary of Barr Pharmaceuticals, Inc. (,rBPP); and 
(ii) defendant Duramed Pharmaceuticals, Inc. ("Duramed") is a Delaware 
corporation engaged in the business of manufacturing and selling 
pharmaceuticals. Duramed's principal place of business is located at 5040 
Duramed Circle, Cincinnati, OH 45213. Duramed is a subsidiary of BPL 
11. Defendant Baxter Healthcare Corp. ("Baxter") is a Delaware corporation in the 
business of manufacturing and selling pharmaceuticals with its principal place of business 
located at One Baxter Pkwy,, Deerfield, IL 60015.. Baxter is a subsidiary of Baxter 
International, Inc. 
12. The following three defendants are hereinafter referred to as the Boehringer 
group: 
(i) defendant Boehringer Ingelheim Pharmaceuticals, Inc. ("Boehringer 
Pharm"), a wholly-owned subsidiary of Boehringer Ingelheim Corp., is a 
Connecticut corporation engaged in the business of manufacturing and selling 
pharmaceuticals. Boehringer Pharm!s principal place of business is located at 
900 Ridgebury R&, Ridgefield, CT 06877; 
AMENDED COMPLAINT 
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(ii) defendant Roxane, Inc., n/k/a Boehringter Ingelheim Roxane, Inc. 
("Roxane"), a wholly-owned subsidiary of Boehringer Ingelheim Corp., is a 
Delaware corporation engaged in the business of manufacturing and selling 
pharmaceuticals. Roxane's principal place of pusiness is located at 1809 Wilson 
Rd., Columbus, OH 43216-6532; and 
(Hi) defendant Ben Venuo Laboratories, Incl 
subsidiary of Boehringer Ingelheim Corp,, is a 
the business of manufacturing and selling phamaceuticals 
principal place of business is located at 300 Nc|)rthfield 
Beti Venue is also being sued for the conduct 
divisions, including but not limited to Bedfordl 
("Ben Venue"), a wholly-owned 
Delaware corporation engaged in 
., Ben Venue's 
Rd„ Bedford, OH 44146. 
its subsidiaries and/or 
Laboratories. 
Of 
13. Defendant Bristol-Myers Squibb Co. ("BristoWMyers") is a Delaware 
corporation engaged in the business of manufacturing and sellling pharmaceuticals. Bristol-
Myers' principal place of business is located at 345 Park Av#., New York, NY 10154-0037. 
Westwood-Squibb ("Westwood") is a division of Bristol-Myers, Bristol-Myers is also being 
sued for the conduct of its subsidiaries and/or divisions, including but not limited to 
Apothecon, Inc. 
14. Defendant Forest Laboratories, Inc. ("Forest") ^ s a Delaware corporation 
engaged in the business of manufacturing and selling pharmaceuticals. Forests principal 
place of business is located at 909 Third Ave,, New York, NV 10022. 
15. The following six defendants are hereinafter referred to as the Johnson & 
Johnson group; 
(i) defendant Johnson & Johnson ("J&J") ii a New Jersey corporation 
engaged in the business of manufacturing and selling pharmaceuticals. J&J's 
principal place of business is located at One Jolinson & Johnson Plaza, New 
Brunswick, NJ 08933; 
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(ii) defendant Janssen Pharmaceutical Products, LP ("Janssen"), a wholly-
owned subsidiary of J&J, is a New Jersey limited partnership engaged in the 
business of manufacturing and selling pharmaceuticals, Janssen's principal 
place of business is located at 1125 Trenton-Harbourton Rd., Titusville, NJ 
08560; 
(iii) defendant Ortho Biotech Products, LP ("Ortho Biotech") , a wholly-
owned subsidiary of J&J, is a New Jersey limited partnership engaged in the 
business of manufacturing and selling pharmaceuticals. Ortho Biotech's 
principal place of business is located at 700 U.S. Hwy. 202, Raritan, NJ 08869; 
(iv) defendant Ortho-McNeil Pharmaceutical, Inc. ("Ortho-McNeil11), a 
wholly-owned subsidiary of J&J, is a Delaware corporation engaged in the 
business of manufacturing and selling pharmaceuticals, Ortho-McNeil's 
principal place of business is located at 1000 U.S. Rte. 202 S«, Raritan, NJ 
08869; and 
(v) defendant McNeil-PPC, Inc. ("McNeil"), a wholly-owned subsidiary of 
J&J, is a New Jersey corporation engaged in the business of manufacturing and 
selling pharmaceuticals. McNeil's principal place of business is located at 7050 
Camp Hill Rd.5 Ft Washington, PA 19034, McNeil Consumer & Specialty 
Pharmaceuticals ("McNeil Cons") is a division of McNeil 
(vi) defendant Centocor, Inc. is a wholly owned subsidiary of Defendant 
Johnson & Johnson with its principal place of business at 800/850 Ridgeview 
Dr,, Horsham, PA 19044. The principal drug it markets is Remicade for 
autoimmune conditions. 
16. Defendant Merck & Co., Inc. ("Merck") is a New Jersey corporation engaged in 
the business of manufacturing and selling pharmaceuticals. Merck's principal place of 
business is located at One Merck Dr., Whitehouse Station, NJ 08889-0100, 
17. The following two defendants are hereinafter referred to as the My Ian group: 
(i) defendant Mylan Laboratories, Inc. ("Mylan") is a Pennsylvania 
corporation engaged in the business of manufacturing and selling 
pharmaceuticals, mainly through its subsidiaries, Mylan's principal place of 
business is located at 1500 Corporate Dr., Ste. 400, Canonsburg, PA 15317; and 
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(ii) defendant Mylan Pharmaceuticals, Inc. 
owned subsidiary of Mylan, is a West Virginia corporation engaged in the 
business of manufacturing and selling pharmaceuticals. Mylan Pharm's 
principal place of business is located at 1500| 
Canonsburg, PA 15317. 
("Mylan PharmM), a wholly-
i
i mi 
Corporate Dr., Ste. 400, 
18. The following two defendants are hereinafter!referred to as the Novartis group: 
(i) defendant Novartis Pharmaceuticals Cbrp. ("Novartis") is a New Jersey 
corporation engaged in the business tif manufacturing and selling 
pharmaceuticals, Novartisr principal place oflbusiness is located at One Health 
Plaza, East Hanover, NJ 07936; and 
(ii) defendant Sandoz, Inc. ("Sandoz"), foitmerly known as Geneva 
Pharmaceuticals, Inc., is a Delaware corporation engaged in the business of 
manufacturing and selling pharmaceuticals, Sandoz's principal place of 
business is located at 506 Carnegie Ctr,, Princeton, NJ 08540. 
19. Defendant Par Pharmaceutical Cos., Inc. ("Pat") is a Delaware corporation with 
its principal place of business located at One Ram Ridge RcjL* Spring Valley, NY 10977. Par 
is also being sued for the conduct of its subsidiaries and/or divisions, including but not 
limited to Par Pharmaceutical, Inc. 
20. The following two defendants are hereinafter referred to as the Pfizer group: 
(i) defendant Pfizer Inc. ("Pfizer") is a Delaware corporation with its 
New York, NY 10017. In April, 
is also being sued for the conduct 
principal place of business at 235 E, 42nd St., 
2003, Pfizer acquired Pharmacia Corp. Pfizeij 
of its subsidiaries and/or divisions, including but not limited to Warner-
Lambert, Pfizer-Warner-Lambert Division, P^rke-Davis Group, and 
Greenstone, Ltd.; and 
(ii) defendant Pharmacia Corp. (Tharmacik") is a Delaware corporation with 
its principal place of business located at 100 Rte. 206 N., Peapack, NJ 07977. 
Pharmacia was created through the merger of Pharmacia and Upjohn, Inc., and 
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Monsanto Co. on March 31,2000. Pharmacia was acquired by defendant Pfizer 
in 2003, 
21. The following three defendants are hereinafter referred to as the Schering 
group: 
(i) defendant Schering Corporation ("Schering") is a corporation organized 
under the laws of New Jersey with its principle place of business located at 1 
Giralda Farms, P.O. Box 1000, Madison, NJ 07940. Schering-Plough Corp. and 
Schering are the actual manufacturers, marketers, sellers, and/or suppliers of the 
products involved in this litigation and are Warrick Pharmaceuticals 
Corporation's actual parent(s) or shareholder(s). 
(ii) defendant Schering-Plough Corp, ("Schering-Plough") is a New Jersey 
corporation with its principal place of business located at 2000 Galloping Hill 
Rd.? Kenilworth, NJ 07033-0530. Schering-Plough has engaged in the practices 
described in this complaint under its own name and through its wholly-owned 
subsidiary, Warrick Pharmaceuticals Corporation; and 
(ii) defendant Warrick Pharmaceuticals Corporation ("Warrick"), is a 
Delaware corporation with its principal place of business at 12125 Moya Blvd., 
Reno, NV, Warrick is a wholly-owned subsidiary of defendant Schering-
Plough and has been since its formation in 1993. Warrick manufactures generic 
pharmaceuticals. 
22. Defendant SmithKline Beecham Corp., d/b/a GlaxoSmithKline 
("GlaxoSmithKline"), is a Delaware corporation with its principal place of business at One 
Franklin Plaza, Philadelphia, PA 19102. 
23. The following four defendants are hereinafter referred to as the Teva group: 
(i) defendant Teva Pharmaceuticals USA, Inc. ("Teva USA") is a Delaware 
corporation engaged in the business of manufacturing and selling 
pharmaceuticals. Teva US As principal place of business is located at 650 
Cathill Rd., Sellersville, PA 18960. Teva USA is a subsidiary of an Israeli 
corporation, Teva Pharmaceutical Industries, Ltd. ("Teva Ltd.")- Teva USA is 
also being sued for the conduct of Novopharm USA, Inc., a subsidiary of 
Novopharm Ltd. Novopharm Ltd. was acquired by Teva Pharmaceutical 
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Industries Ltd. and Novopharm USA, Inc. w^s subsequently merged into Teva 
USA; 
(ii) defendant Ivax Corp. ("Ivax")> which 
of Teva Ltd, on January 26,2006, is a Florida! 
engaged in the business of manufacturing anq 
principal place of business is located at 4400 
became a wholly-owned subsidiary 
(formerly Delaware) corporation 
selling pharmaceuticals. Ivax's 
Biscayne Blvd., Miami, FL 33137; 
(iii) defendant Ivax Pharmaceuticals inc. ("Ivax Pharm"), a wholly-owned 
subsidiary of Ivax, is a Florida corporation engaged in the business of 
manufacturing and selling pharmaceuticals. Ivax Pharm's principal place of 
business is located at 4400 Biscayne Blvd., Miami, FL 33137; and 
(iv) defendant Sicor, Inc., f/k/a Sicor Pharmaceutical Inc., f/k/a Gensia 
Sicor Pharmaceuticals, Inc., is a Delaware corporation with its principal place of 
business located at 19 Hughes, Irvine, California. In January, 2004, Sicor, Inc. 
was acquired by Teva Ltd. and is now a wholly-owned subsidiary of that entity. 
24. The following two defendants are hereinafter referred to as the Watson group: 
(i) defendant Watson Pharma, Inc., f/k/a Sichein Pharmaceuticals, Inc. 
("Watson Pharma"), a wholly-owned subsidiary of Watson Pharmaceuticals, 
Inc. since 2000, is a Delaware corporation engaged in the business of 
manufacturing and selling pharmaceuticals, Watson Pharmaes principal place of 
business is located at 311 Bonnie Cir,, Corona), CA 92880; and 
(ii) defendant Watson Pharmaceuticals, Inc. ("Watson") is a Nevada 
corporation engaged in the business of manufacturing and selling 
pharmaceuticals. Watson's principal place of ousiness is located at 311 Bonnie 
Cir., Corona, CA 92880. 
25. Jurisdiction over the subject matter of this actibn is based on AS 44.23.020, 
45.50,501 and 45.50.551, which grant the State authority to file suit against the defendants. 
26. Personal jurisdiction over each of the defendants is proper under Alaska's Long 
Arm Statute, as codified in AS 09,05.015, 
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27, Venue is proper in the Third Judicial District at Anchorage pursuant to Rule 3 
of the Alaska Rules of Civil Procedure because defendants committed unlawful acts and/or 
practices in Anchorage. 
FACTUAL BACKGROUND 
A, The market for prescription drugs. 
28. The market for prescription drugs is enormously complex and non-transparent. 
It is composed of over 65,000 separate national drug codes ("NDCs") (there is a separate 
NDC number for each quantity of each drug manufactured by each defendant). The essential 
structure of the market is as follows. The drugs are manufactured by enormous and hugely-
profitable companies such as defendants. Defendants sell the drugs (usually with 
intermediaries and agents involved in the process) to physicians, hospitals, and pharmacies. 
These physicians, hospitals, and pharmacies are commonly referred to as "providers/1 The 
providers then, in essence, resell the drugs to their patients when the drugs are prescribed for, 
administered by, or dispensed to those patients. Most patients have private or public health 
insurance coverage. Where a patient has such insurance, the payment that is made for the 
patient's prescribed drug ultimately will be made, in whole or in large part, by a private 
insurance company, a self-insured entity, or a government entity (in the case of the Medicare 
and Medicaid programs). These private insurance companies, self-insured entities, and 
government entities are commonly known as "payers," More often than not, the payer makes 
the reimbursement payment directly to the provider, not to the patient. 
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29. This market structure means that the market i|br prescription drugs differs in 
two crucial respects from most markets. 
30. First, in most markets, the ultimate consumer* of a product determine the 
demand for the product. This is not the case for prescription drugs. In the prescription drug 
market, the decision to use a prescription drug is overwhelniingly made not by the consumer 
of the drug - the patient - but by physicians, hospitals in which the patient is treated, home 
health-care agencies, long-term care facilities, or (with respfect to the decision to use generic 
drugs versus brand-name drugs) pharmacies. Because prescription drugs are dispensed only 
on a physician's order, the physician has the principal say as| to what drug will be chosen for 
the patient. However, hospitals, particularly teaching hospitals, also have considerable 
influence over this choice. If a hospital decides to put one dhig as opposed to a competing 
drug on its "formulary" (the list of drugs that the hospital stdcks), physicians (particularly 
residents and attending physicians who are employed by the (hospital) likely will choose the 
drug on the formulary rather than a competing drug, Likewise, although pharmacies do not 
prescribe drugs, pharmacies can exert important influence oyer the choice of which drug the 
patient will purchase if there is a choice between a generic version or brand-name version of 
the drug the physician has prescribed. 
31. A second difference between the prescription dlrug market and ordinary markets 
is that in ordinary markets, the ultimate consumer of the product pays for it directly. In the 
prescription drug market, however, most payments for drugs are made by "payers" through 
private or public insurance programs. 
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32. This structure of the prescription drug market produces the following 
fundamental fact that underlies defendants' unlawful scheme. If a defendant drug 
manufacturer can cause a "payer" to reimburse the provider for defendant's drug at a higher 
price than the price the provider paid to buy the drug from the defendant, there will be a 
"spread" between the two prices, and that "spread" is retained by the provider as additional 
profit. The larger the "spread" that can be created for a particular drug, the greater the 
incentive the provider has to choose, or influence the choice of, that drug rather than a drug of 
a competing manufacturer. 
B* The purpose of the Medicaid program and how it responds to 
the complexity of the drug market. 
33. Alaska provides medical assistance to its neediest citizens through the Alaska 
Medicaid program. 
34. The Alaska Medicaid program is an enormous purchaser of drugs, purchasing 
over $124.9 million annually (covering the period July 1, 2004 to June 30, 2005), and 
purchasing over $686.8 million between 1993 and 2005. Although defendants' participation 
in the Alaska Medicaid program is purely voluntary, all defendants have chosen to participate 
and sell drugs to Alaska Medicaid participants because of the size of the Alaska Medicaid 
program. Thus, Alaska may at any given time have to reimburse a provider for any of the 
drugs of any of the defendants - a universe of many thousands of drugs. 
35. Alaska's task is further complicated in that federal law places limits on what 
Alaska may pay providers for any particular drug. Specifically, Alaska cannot reimburse 
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providers more than "the lower of the - (1) estimated acquisition costs plus reasonable 
dispensing fees established by the agency; or (2) providers' usual and customary charges to 
the general public," 42 C.FJR. §447.331. "Estimated acquisition cost" is defined as "the 
agency's best estimate of the price generally and currently paid by providers for a drug 
marketed or sold by a particular manufacturer or labeler in Ihe package size of drug most 
frequently purchased by providers." 42 C.F.R. §447301. Thus, pursuant to federal law, the 
highest price Alaska can pay for a drug is the provider's cost to acquire that drug, 
36, Because defendants have hidden both the prices at which they sell their drugs to 
wholesalers, and their knowledge about the prices at which wholesalers sell their drugs to 
providers (as described in more detail herein), Alaska has nq> access to the pricing information 
it needs to estimate accurately the providers1 acquisition cost of defendants' drugs. Because 
neither Alaska nor any other state has sufficient personnel ox knowledge required to compile 
complete and accurate lists of defendants' drug prices, entire businesses have grown up to 
provide pricing information to the states and others. Three of these are of particular 
importance in this case. They are First DataBank, the Red Book, and Medispan, These 
compendia purport to supply accurate price information on defendants1 drugs through surveys 
of wholesalers and information obtained from defendants themselves. 
37. Alaska, like most other states, has chosen First DataBank as its primary cost 
source. First DataBank purports to supply the states with accurate information about the 
AWP of all drugs, information it receives from the drug manufacturers themselves. As First 
DataBank explained AWP to its customers in September, 1991: 
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Average Wholesale Price (AWP) is perhaps the most misunderstood concept in 
the pharmaceutical industry. The purpose of this article is to describe what is 
meant by AWP and to explain some of the underlying concepts involved in the 
acquisition, determination and maintenance of First DataBanks AWP. 
AWP represents an average price which a wholesaler would charge a pharmacy 
for a particular product. The operative word is average. AWP never means that 
every purchase of that product will be exactly at that price. There are many 
factors involved in pricing at the wholesale level which can modify the prices 
charged even among a group of customers from the same wholesaler. AWP 
was developed because there had to be some price which all parties could agree 
upon if machine processing was to be possible. 
At First DataBank, all pricing information is received in hard copy from the 
manufacturers. Catalogs, price updates, and other information reach us by fax, 
Federal Express, or U.S. mail. In the past two years, fax transmission has, 
streamlined the acquisition of data to a large extent, 
See Exh. A. 
38. For virtually the entire time period relevant hereto, First DataBank and the 
other medical compendia have represented that their published AWPs reflect actual average 
wholesale prices. 
39. Because Alaska, like most other states, has no source of comprehensive 
information about providers' acquisition cost for defendants' drugs, Alaska has relied on the 
prices defendants reported to the medical compendia. Consistent with First DataBank's 
suggestion that some providers were paying less than AWP, Alaska agreed to pay providers 
an amount consisting of AWP minus 5%. Alaska has continued to pay a separate dispensing 
fee to providers to reimburse them for the service provided in dispensing drugs to customers. 
At no time did Alaska intend systematically to reimburse providers, on the average, at prices 
higher than the providers1 average acquisition costs. Like most other states, Alaska did not 
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appreciate until recently that defendants were reporting AW|Ps that were not only higher than 
actual acquisition costs, but higher than any discount percentage that Alaska or any other 
state was using to estimate providers1 acquisition costs. 
40. As a practical matter, Alaska, like most other states, is dependent on the 
medical compendia for the maintenance of its Medicaid claibs processing system. When a 
pharmacy fills a prescription and dispenses a drug to a Medicaid patient, information 
regarding that prescription is communicated electronically tQ Alaska through the Point-of-
Sales claim processing system. On a weekly basis, First DatlaBank electronically sends its 
updated AWPs for the thousands of NDC-numbered drugs listed in its database to First 
Health to update Alaska's Medicaid file. These prices become the basis for Alaska's 
reimbursements to providers. There is no other electronic source for this information. 
Accordingly, Alaska is functionally dependent on the accuracy of the data defendants supply 
to First DataBank in meeting its obligation to pay providers uo more than their actual 
acquisition cost of defendants'drugs. 
C Defendants' corruption of the government Medicaid assistance programs* 
41, Defendants have defeated the intent of the Medicaid program to pay providers 
no more than their acquisition cost by reporting false and inflated AWPs to the medical 
compendia and/or by reporting prices that they knew, because of the manner of the medical 
compendia's operations, would misrepresent defendants' true| wholesale prices. One purpose 
of this scheme was and is to create the spread between a drugfs true wholesale price and the 
false and inflated AWP published by the medical compendia tod thereby increase the 
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incentive for providers to choose the drug for their patients, or, at a minimum, to counteract 
the same tactic used by a competitor. 
42. The higher the spread between the AWP and the true wholesale price, the more 
profit a provider can make. Defendants often market their products by pointing out 
(explicitly and implicitly) that their drug's spread is larger than the spread of a competing 
drug. 
43. All of the defendants have inflated their drugs* reported AWPs to levels far 
beyond any real average wholesale price for their drugs. One high-ranking industiy executive 
has described it as the industry practice to do so. 
44. In 2004, high-ranking executives of defendants Roxane, Aventis, and Barr 
testified before Congress that their AWPs do not reflect the actual selling prices of their 
drugs. 
45. Attached as Exhibit B to this Complaint is a list of drugs manufactured by the 
defendants and/or their subsidiaries that the U.S. Department of Justice, after an extensive 
investigation, found to have inflated AWPs. The U.S. Department of Health and Human 
Services concluded, with respect to all drugs utilized in the Medicare program that ft[a] 
general conclusion reached in reviewing GAO [General Accounting Office] and OIG [Office 
of Inspector General] data is that there is a level of overstatement in the listed AWP for all 
drugs ., „H Payment Reform for Part B Drugs, 68 Fed. Reg. 50,430 (August 20, 2003) 
(emphasis added). 
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46, Alaska has obtained the false prices defendants caused to be published by 
FirstData Bank, Alaska has also obtained data showing theltrue AWPs of defendants' drugs 
from two of the largest national drug wholesalers: Cardinal land AmerisourceBergen-
Attached as Exhibit C to this Complaint is a chart containing additional examples of 
defendants' drugs that have false and inflated AWPs. For e$ch defendant, Exhibit C 
identifies: (a) the NDC; (b) the name of the drug; (c) the fal$e AWP published by First 
DataBank as of the end of each year from 2001 to 2003; (d)lthe average AWP published by 
First DataBank for each year from 2001 to 2003; (e) a market price for the NDC for each year 
from 2001 to 2003; and (f) the spread between the market pijice and the AWP. The AWPs 
and market prices are unit prices. The source of the market prices is AmerisourceBergen, one 
of the three largest drug wholesalers. The market price is th<fe average price at which 
AmerisourceBergen sold the NDC numbered drug to the classes of trade that are reimbursed 
by the Alaska Medicaid program, Le., retail pharmacies, chain pharmacies, and long-term 
care facilities. The spread is calculated as average AWP minus the market price, expressed as 
a percentage of the market price. The NDC numbered drugg on Exhibit C are those for 
which the Alaska Medicaid program purchased in significant! amounts. Plaintiff has similar 
data for years prior to 2001 and after 20035 which data will b0 produced to defendants upon 
request during discovery. The NDC numbered drugs identified in Exhibit C constitute many 
of the NDC numbered drugs upon which the state is seeking damages. 
47. As they have done with their AWPs, defendants have illegally and deceptively 
misrepresented and inflated the wholesale acquisition cost (,rWAC!r) of their drugs. WAC is 
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the price at which defendants sell their drags to wholesalers. Defendants have made it appear 
that any reduction in the purchase price below the listed WAC would result in a loss to the 
wholesaler and was3 hence, unachievable, when in fact defendants secretly discounted the 
WAC to purchasers other than the Medicaid program through an elaborate charge back 
system (as described in more detail below). 
DEFENDANTS1 EXACERBATION OF THE COMPLEXITIES OF THE 
MARKET AND AFFIRMATIVE CONCEALMENT OF THEIR WRONGDOING 
48. Defendants have been able to succeed in their drug pricing scheme for more 
than a decade by exacerbating the complexities of the huge and complex drug market, and by 
purposely concealing their pricing scheme from Alaska and other payers, as set forth below. 
49. The published wholesale price of any of the thousands of NDC numbered drugs 
might, and often does, change at any time. As a consequence, to track the current published 
prices of drugs utilized by a state's citizens requires resources and expertise that most states 
do not have. 
50. Defendants have further exacerbated the inherent complexities of the drug 
market by utilizing marketing schemes that conceal the true price of their drugs in the 
following different ways. 
5L First, defendants sell their drugs in a unique manner that hides the true prices. 
This scheme works as follows. Upon agreeing on a quantity and price of a drug with a 
provider or group of providers, a defendant purports to sell the agreed-upon drugs at the 
WAC price to a wholesaler with whom the defendant has a contractual arrangement. The 
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wholesaler then ships the product to the provider, charging) the provider the price originally 
agreed upon by (he drug manufacturer and the provider, wHich price is lower than the WAC. 
When the wholesaler receives payment from the provider, it sends a bill to the defendant, 
called a "charge back," for the difference between the WAC and the lower price actually paid 
by the provider. These charge backs (or "shelf adjustments!" or economic inducements with 
varying names) are kept secret from the payers, including Alaska, so that it appears that the 
wholesaler actually purchased the drug at the higher WAC price. The effect of this practice is 
to create the impression of a higher than actual wholesale price paid by the wholesaler and 
passed on to the provider. Defendants hide other actual pricte reductions by directly paying 
providers market share rebates and other off-invoice rebates and discounts that are calculated 
long after the actual purchase date of the drugs. 
52. Second, defendants further inhibit the ability d>f Alaska and other payers and 
ultimate purchasers to learn the true cost of their drugs by trapping the sales agreements they 
negotiate with providers in absolute secrecy, terming them ttade secrets and proprietary, to 
preclude providers from telling others the actual price they jj>aid. 
53. Third, defendants further obscure the true prices for their drugs through their 
policy of treating so-called classes of trade differently. Thu$, for the same drug, pharmacies 
are given one price, hospitals another, and doctors yet another. 
54. Fourth, some defendants have hidden their real drug prices by providing free 
drugs and phony grants to providers as a further means of discounting the overall price of 
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their drugs. For example, defendant AstraZeneca paid $355 million to settle federal fraud 
charges that it induced doctors to falsely bill Medicare and Medicaid. 
55. Defendants have hidden from the public their motives for utilizing an inflated 
AWP. Indeed, one official, a high-ranking employee of Dey, even went so far as to lie under 
oath about Dey's marketing of their spreads. Only with the disclosure of materials secured by 
litigants in recent discovery has it become apparent that one reason defendants have 
intentionally manipulated the nation's drug reimbursement system is to compete for market 
share on the basis of a phony price spread, instead of the true selling price or the medicinal 
efficacy of their drugs. 
56. Defendants have farther concealed their conduct by making sure that all of the 
entities that purchase drugs directly from the defendants (and thus know the true price of their 
drugs) have had an incentive to keep defendants1 scheme secret. Defendants' scheme permits 
all providers - pharmacies, physicians, and hospitals/clinics - to make some profit off 
defendants' inflated spread, because all of them are reimbursed in some manner on the basis 
of the AWP for at least some of the drugs they sell or administer. For providers, therefore, 
the greater the difference between the actual price and the published AWP, the more money 
they make, Thus, providers willingly sign drug sales contracts requiring them to keep secret 
the prices they pay for drugs. 
57. Defendants themselves have continuously concealed the true price of their 
drugs and have continued to report and cause to be published false and inflated AWPs and 
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WACs as if they were real, representative prices. Indeed, iri the 2000 edition of Novartis' 
Pharmacy Benefit Report, an industry trade publication, the (glossary defines AWP as follows: 
Average wholesale price (AWP) - A published suggested wholesale price for a 
drug, based on the average cost of the drug to a pharmacy from representative 
sample of drug wholesalers. There are many AWPs available within the 
industry, AWP is often used by pharmacies to price prescriptions. Health plans 
also use AWP ~ usually discounted - as the basis for Reimbursement of covered 
medications, 
Novartis Pharmacy Benefit Report: Facts and Figures, 2000 edition, East Hanover, NJ, 
Novartis Pharmaceuticals Corporation, p. 43. 
58. Defendants' unlawful scheme has completely corrupted the market for 
prescription drugs. Instead of competing on price and medicinal value alone, defendants have 
deliberately sought to create a powerful financial incentive fqr providers to prescribe drugs 
based primarily on the spread between the true price of a drug and its published AWP or 
WAC. Creating incentives for providers to prescribe drugs based on such a spread is 
inconsistent with Alaska law and public policy. Large price spreads on higher priced drugs 
encourage providers to prescribe more expensive drugs instead of their lower priced 
substitutes, thereby increasing the cost of healthcare. Competition on the basis of such 
spreads also has the potential to influence providers (consciously or unconsciously) to 
prescribe less efficacious drugs over ones with greater medicinal value. Because of 
defendants' concealment of their scheme, Alaska has unknowingly underwritten this 
perversion of competition in the drug market. In sum, defendants have been, and continue to 
be, engaged in an insidious, deceptive scheme that is causing Alaska to pay scores of millions 
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of dollars a year more than it should for its prescription drugs, and may well be inducing 
some providers to prescribe less efficacious drugs. 
THE GOVERNMENTAL INVESTIGATIONS OF DEFENDANTS' CONDUCT 
59. The first governmental investigation of defendants1 conduct began in 1995 
when a small infusion pharmacy, Ven-a-Care of the Florida Keys, filed a sealed qui tarn 
action with the Federal Government alleging that certain of the defendants were intentionally 
inflating the reported AWPs of certain drugs, primarily physician administered drugs. 
60. In 1997, in response to the Ven-a~Care lawsuit, the Federal Government issued 
subpoenas to certain of the defendants, including Dey, Abbott, and Warrick, seeking pricing 
information from them. 
61. In 2000, Congress began its investigation of the pricing practices of some of the 
defendants in connection with the Medicare Part B program based on the materials it received 
through its subpoenas. On September 28,2000, as part of this investigation, U.S. 
Representative Pete Stark wrote to the president of the Pharmaceutical Research and 
Manufacturers of America (the main pharmaceutical trade association of which most of the 
defendants are members) as follows: 
Drug company deception costs federal and state governments, private insurers 
and others billions of dollars per year in excessive drug costs • This corruptive 
scheme is perverting the financial integrity of the Medicare program and 
harming beneficiaries who are required to pay 20% of Medicare's current 
limited drug benefit. Furthermore, these deceptive, unlawful practices have a 
devastating financial impact upon the states' Medicaid Program.... 
The evidence I have obtained indicates that at least some of your members have 
knowingly and deliberately falsely inflated their representations of the average 
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wholesale price ("AWP"), wholesaler acquisition coit ("WAC") and direct price 
("DP") which are utilized by the Medicare and Medicaid programs in 
establishing drug reimbursements to providers. The evidence clearly 
establishes and exposes the drug maaufacturers themselves that were the direct 
and sometimes indirect sources of the fraudulent misrepresentation of prices. 
Moreover, this unscrupulous "carter of companies has gone to extreme lengths 
to "mask" their drugs' true prices and their fraudulent conduct from federal and 
state authorities. I have learned that the difference between the falsely inflated 
representations of AWP and WAC versus the true pripes providers are paying is 
regularly referred to in your industry as "the spread55 +... 
The evidence is overwhelming that this "spread" did hot occur accidentally but 
is the product of conscious and folly informed business decisions by certain 
PhRMA members . . . . . 
146 Cong. Rec. El 622 (daily ed., September 28, 2000) (September 28,2000 letter from 
House Committee on Ways and Means, Subcommittee on Health, to Alan F. Holmer, 
President, Pharmaceutical Research and Manufacturers of America, Washington, D.C). 
62. On December 21, 2000, Congress passed the Medicare, Medicaid and SCHIP 
Benefits Improvement and Protection Act of 2000 ("BIPA"),| Pub. L. No. 106-554, § 429(c) 
(2000), which required a comprehensive study of drug pricing. 
63. Continuing Congress' investigation of Medicare Part B pricing in 2001, 
Congressman Stark wrote to defendant Bristol-Myers on Febtruary 22, 2001 outlining 
numerous apparently illegal pricing practices: 
The evidence clearly shows that Bristol has intentionally reported inflated 
prices and has engaged in other improper business practices in order to cause its 
customers to receive windfall profits from Medicare and Medicaid when 
submitting claims for certain drugs. The evidence further reveals that Bristol 
manipulated prices for the express purpose of expanding sales and increasing 
market share of certain drugs where the arranging of a financial benefit or 
inducement would influence the decisions of healthcare providers submitting 
the Medicare and Medicaid claims, 
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147 Cong. Rec. E244-45 (daily ed.5 February 28, 2001). 
64. In 2003, the House Committee on Energy and Commerce expanded Congress' 
Medicare investigation into pricing practices in the state Medicaid program. On June 26, 
2003, Chairman Billy Tauzin (R,-La.) and Oversight and Investigations Subcommittee 
Chairman James Greenwood (R,-Pa.) wrote as follows to 26 drug companies, including many 
of the defendants here: 
The Committee on Energy and Commerce is conducting an investigation into 
pharmaceutical reimbursements and rebates under Medicaid. This inquiry 
builds upon the earlier work by this Committee on the relationship between the 
drug pricing practices of certain pharmaceutical companies and reimbursements 
rates under the Medicare program. In that investigation, the Committee 
uncovered significant discrepancies between what some pharmaceutical 
companies charged providers for certain drugs and what Medicare then 
reimbursed those providers for dispensing those drugs. This price difference 
resulted in profit incentives for providers to use the drugs of specific companies 
as well as higher costs to the Medicare system and the patients it serves. For 
example, we learned that one manufacturer sold a chemotherapy drug to a 
health care provider for $7.50, when the reported price for Medicare was $740. 
The taxpayer therefore reimbursed the doctor almost $600 for dispensing the 
drug and the cancer patient had a $148 co-payment Such practices are 
unacceptable in the view of the Committee, which is why we are in the process 
of moving legislation to address these abuses. 
The Committee has similar concerns regarding drug prices in Medicaid, which 
has a substantially larger pharmaceutical benefit than Medicare. 
House Committee on Energy and Commerce Press Release, Tauzin, Greenwood Expand 
Medicaid Fraud Investigation (June 26, 2003), available at http://energycommerce. 
house.gov/108/News/06262003_1003.htm. 
65. On December 7, 2004, the House Subcommittee of Oversight and Investigation 
of the Commerce and Energy Committee conducted a hearing on "Medicaid Prescription 
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Drug Reimbursement; Why the Government Pays Too Muih." In his opening remarks, 
Chairman Joe Barton (R.-TX) stated: 
Data obtained by the committee from five of the largest retail pharmacy chains 
reveals that during the period of July 1, 2002 to June 20, 2003, the average 
acquisition costs for seven widely prescribed generic drugs was 22 cents, while 
the average Medicaid reimbursement just for those drtugs alone was 56 cents, 
more than double the cost 
"Medicaid Prescription Drug Reimbursement: Why the Government Pays Too Much," 
Hearing Before the House Subcommittee on Oversight and ibvestigations, No, 108-126, at 5 
(2004), available at http://frwebgate.access.gpo.gov/cgi-bin/iliseftpxgi?IPaddress== 
162 J40.64.52&filename=97275.pdf&d^ 
66. The importance to Alaska and the other states of the information being sought 
by this investigation was explained by Henry Waxman during the December 2004 House 
Committee on Energy and Commerce hearings on Medicaid pricing practices. Congressman 
Waxman explained that even though the federal government had access to the manufacturers' 
actual average manufacturers prices ("AMPs"), the states did hot: 
the drug industry was powerful, and they succeeded in (securing a provision in 
the basic legislation that kept the Best Price and the AMP information a secret. 
Can you imagine that? The federal government knew this information, but we 
kept it a secret from the states. This has proved to be a costly error. Without 
this crucial piece of information, states who were, after all, responsible for 
establishing the reimbursement rate for prescription drugs could not set their 
reimbursement rates appropriately, As a result, [the states] continued to rely on 
the average wholesale price minus the arbitrary amount, because they did not 
have the information needed to set a more appropriate reimbursement rate. 
Id at 23 (emphasis added). 
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67. As a result of all these investigations, many states began to investigate 
defendants1 drug pricing practices on their own, leading to lawsuits in some 20 separate 
states, including Alaska. Notwithstanding these investigations and lawsuits, defendants 
continue to publish, or participate in the publication of, inflated wholesale prices, and 
continue to hide the true prices of their drugs, including opposing in litigation discovery of 
the actual prices of these drugs. 
THE INJURY TO THE MEDICAID PROGRAM 
CAUSED BY DEFENDANTS' FALSE WHOLESALE PRICES 
68. Medicaid is a joint federal and state health-care entitlement program authorized 
by federal lav/, with mandatory and optional provisions for eligibility and benefits covered, 
including pharmacy. The Alaska Medicaid program is administered by the Alaska 
Department of Health and Social Services, 
69. Alaska Medicaid's drug expenditures have increased dramatically. In fiscal 
year 1999 (covering the period July 1,1998 to June 30,1999), Alaska Medicaid had drug 
expenditures totaling approximately $38.8 million. In fiscal year 2005 (covering the period 
July 1,2004 to June 30, 2005), Alaska Medicaid drug expenditures totaled $124,9 million, 
which constitutes approximately 12.8% of Alaska's overall Medicaid budget. As of 
December, 2004, the number of Alaska citizens enrolled in Medicaid was approximately 
116,500, which represented approximately 17.6% of the State's population. 
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70. During the relevant time period, with some exceptions, reimbursement to 
pharmacies, physicians, and hospitals for drugs covered by| the Alaska Medicaid program has 
been made at defendants' published AWP minus 5%, plus & dispensing fee. 
71. For a minority of the drugs purchased by Alajska, the state sets its 
reimbursement rate at either the federal upper limit ("FULfj) or at a rate established by the 
state maximum allowable cost ("MAC") program, For multi-source drugs that have at least 
three suppliers, the Center for Medicaid Services ("CMS") (generally establishes FULs, 
defined as 150% of the least costly therapeutic equivalent fusing all national compendia) that 
can be purchased by pharmacies in quantities of 100 tablets or capsules or, in the case of 
liquids, the commonly listed size. 42 C.F,R> § 447332* As a practical matter, CMS has 
relied on the defendants' inflated prices to set most of its FtJLs. The states also may set 
reimbursement rates for these drugs at rates lower than thelFUL pursuant to the state MAC 
program and Alaska has done so in a number of imtmQQS. Had defendants reported truthful 
prices, the FULs and state MACs would have been lower. In addition, had defendants 
reported truthful prices, the State would not have paid basdd on FULs or MACs, but rather 
based on truthful AWPs. 
72. At all relevant times, each defendant was aware of the reimbursement formula 
used by the Alaska Medicaid program and the dependencelof the Medicaid program on 
defendants' reported AWPs. 
73. By reporting false and inflated wholesale pribes, and by keeping their true 
wholesale prices secret, defendants have knowingly enabled providers of drugs to Medicaid 
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recipients to charge Alaska false and inflated prices for these drugs, and interfered with 
Alaska's ability to set reasonable reimbursement rates for these drugs. 
74. As a consequence, the Alaska Medicaid program has paid more for prescription 
drugs than it would have if defendants had reported their true wholesale prices, 
DEFENDANTS1 CONDUCT WAS INTENTIONALLY 
IN DISREGARD OF ESTABLISHED LAW 
75. Defendants had a duly to deal truthfully and honestly with Alaska and they 
knew so. 
76. Moreover, it has uniformly been the law for over 60 years that it is unlawful for 
a seller to cause to be circulated a price at which no, or few, sales are actually expected, 
whether it is called a list price, suggested price, or benchmark price. E.g., FTC v. Colgate-
Palmolive Co., 380 U.S. 372 (1965); FTC v. The Crescent Publishing Group, Inc., 129 
F.Supp.2d. 311 (SJD.N.Y. 2001). Defendants either knew of this law or acted in reckless and 
willful disregard of it, 
77. Congress has, in its hearings on the subject, excoriated the pharmaceutical 
industry for causing untrue AWPs to be published. 
78. Defendants have willfully ignored, and continue to ignore: (a) their duty to 
Alaska to behave with scrupulous honesty; (b) case law uniformly holding that their pricing 
practices are unlawful; and (c) the reprimands of Congress. 
79. As a result, penalties and forfeitures, consistent with Alaska1s statutory scheme, 
are mandated in this case. 
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HARM TO ALASKA 
80. Defendants' unlawful activities have significantly and adversely impacted 
Alaska. Alaska has paid more for the drugs it purchases through its Medicaid program than it 
would have if defendants had reported the true wholesale prices of their drugs. 
COUNT I 
(Violation of the Alaska Unfair Trade Practices 
and Consumer Protection Act) 
81. Plaintiff hereby realleges all previous paragraphs. 
82. AS 45.50.471 (a) prohibits unfair methods of competition and unfair or 
deceptive acts or practices in the conduct of trade or commerce. Defendants' conduct as 
alleged above violated and continues to violate this statute^ 
83. In addition, AS 45.50.471(b)(ll) expressly prohibits "engaging in any other 
conduct creating a likelihood of confusion or of misunderstanding and which misleads 
deceives or damages a buyer or a competitor in connectioni with the sale or advertisement of 
goods and services*" Defendants5 conduct as alleged abov^ violated and continues to violate 
this statute. 
84. In addition, AS 45.50.471(a)(12) expressly prohibits "using or employing 
deception, fraud, false pretense, false promise, misrepresentation, or knowingly concealing, 
suppressing, or omitting a material fact with intent that others rely upon the concealment, 
suppression or omission in connection with the sale or advertisement of goods or services 
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whether or not a person has in fact been misled, deceived or damaged.'5 Defendants' conduct 
as alleged above violated and continues to violate this statute. 
85. By committing the acts alleged above, defendants have violated AS 45.50.471. 
$6, Alaska has been harmed by defendants' unfair and deceptive conduct in that it 
has paid far more for defendants' drugs than it would have paid had defendants truthfully 
reported the AWPs of their drugs. 
COUNTH 
(Unjust Enrichment) 
87. Plaintiff hereby realleges all previous paragraphs. 
88. As a result of defendants' misleading pricing information, Alaska purchased 
drugs at prices greater than they would have had defendants not engaged in unlawful conduct. 
89. Each defendant knew that Alaska was being overcharged by pharmacy 
providers and physicians as a direct result of defendants' misleading pricing information. 
90. Each defendant knew that it was not entitled to the profits it realized from the 
increased sales and market share that resulted from the excessive payments made by Alaska. 
91. As a result of defendants' unlawful conduct, defendants obtained increased 
sales, market share and profits at the expense of Alaska. 
PRAYER FOR RELIEF 
WHEREFORE, Alaska prays for judgment as follows: 
1. For an award of damages in excess of the $100,000 jurisdictional limit of this 
Court; 
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2. For a declaration that defendants1 conduct as ^scribed above constitutes unfair 
and/or deceptive acts or practices within the ntieaning of AS 45.50.471; 
3. For a permanent injunction that defendants arid their employees, "officers, 
directors, agents, successors, assigns, affiliates merged or acquired 
predecessors, parent or controlling entities, subsidiaries, and any and all persons 
acting in concert or participation with defendants, from continuing the unlawful 
conduct, acts, and practices described above; 
4. For compensatory, restitution and/or disgorgement damages against each 
defendant for all excessive prescription-drug payments paid as a result of their 
unlawful conduct; 
5. For civil penalties in the amount of $25,000 f<j>r each separate violation of the 
Act; 
6. For punitive damages; 
7. For costs, Ml reasonable attorneys' fees, and prejudgment interest; and 
8. For other relief deemed just and equitable by the Court. 
DATED; October 17, 2006. 
Respectfully submitted, 
FOSLERLAW GROUP, INC 
JAMES E. POSLER 
Isj/aBarNo.: 9711055 
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Undeistandlnj[AW 
Average Wholes-ste Price (AW) ts 
perhaps the most misunderstood concept 
In the phanaaceudca! Industry, The 
purpose of this article 1$ Id describe whtf 
b meant by AWP and to explain some of 
the unde^yiag concept* Involved to the 
acqul$Ittov d e t e n t i o n and 
maintenance of F N DataBankfc AWP, 
AWP represents an average price 
whleh a whole&ter would charge & 
pharmacy (or a pariicuJar product The 
operative word is aterogt AWP never 
m«^thatev^pun*a»crff tatprodu^ 
will be exactly at that price There are. 
many /actors invdhred In pricing at the 
wholesale level wh$ch can modify the 
prices charged even among a group of 
customers from the same wholesaler, 
AWP was developed because there had to 
be some pries which all parties could agree 
upon If machine processing was to be 
possible, 
At first DaUBank, ail pricing 
toforinatlcn is received In hard copy from 
the manufacturers, Catalogs, price 
updates, and other Information reach u$ 
by fax Federal Expraa, or U.S> m*& In the 
past two years, fax transmission has 
stfeamtaed the acquisition o! data to a 
large extent 
Hr$t DataBank has fcstoblishd 
$p$$lc contact people within each m^or 
drug rtanu^hwryiibeJert organisation. 
When pricing or other questions arise, we 
knew who W ask (or reliable lnfonns3on> 
Knowing who to talk to prevent* 
misinformation and kaeps problems to a 
irtnimum, Usually It Is our contact people 
who 5<rtd WormaSon to u5 when there are 
price changes or oiher product chan|& 
We mate sure that we are placed cm ft* 
priority matting list BO that we receive the 
Wonattloft before the trade. Becaw 
personnel movraent wtthln a corporation 
1$ the mm, wj cofftlntuaDy w&rk to laep 
our contact list current 
Once the information Is received, v/e 
often have to Interpret what the daia 
represents. There can be confusing or 
cortfracSctory fecto*, not to mention hard 
to read fax's a d typographical w o n , Our 
data entry experts have experience as 
phannacy technician* or In related folds. 
With th»ir tawWgi and proficiency, 
potfcntl&J txtou are detected before they 
become part of the database. As an 
example, occuionelly a manufacturer 
which nomurtiy sends us wholesale m 
pricing will Inadvertently send direct or 
suggested l($t price*, It 1$ up to the M to 
recognhs the error and ask the 
manufacturer to send the correct 
Information, 
The pricing Information which we 
receive can fc-e to the form of wholesale n&t* 
direct, or s u i t e d wholesale prfc# (>« 
Figure 1> it \t cur task to convert thm 
prices into AWP, There «re severe! wy$ in 
which AWPIB are derived* Large 
manufacturers such as Merck have a one 
price pol'cy tor all jwrcha&tf whether 
H'hoteala or dW& They supply their 
Dubbhed direct prtc&s to which we must 
de*ennirrt a markup factor and arrive at M 
AWR Others supply wfotesate net pi\m 
H o w Drugs arc Purchased 
mmmm**m9+mm*. 
$W> 
swp, 
4 / v 
^ ! "PHarmacy 
Flgurel 
otty In order to determine an appropriate 
markup, it Is necessary to smvey 
wholesalers, TheaccomfAnyi^&klebsr 
(see next page) describes this process in 
deull Wholesaler survey ere» 
Important part ol what First ItoBank do« 
to establish realistic A W pricing, 
Some ttitoutourers do not sell 
products through wholesaler but supply a 
suggested wholesale price, which 1$ 
fcp^ftfwjgffi !) 
T h e Monthly Interest 
Editor, r.„ ,....„» JtoWil$on 
P«WlsheUm..M,« Joe Hiwchmann 
EdtiorJai AwUUnW—•-Amy Ream 
Contributor*; Ed £detaeto,Vl$nte 
Hakcy, fccnel* CWlhfc Jerry totals, 
Uada$aHi>o,8dhRwJer 
PubliiW moathty by first F^ ?aBesnk 
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mmm 
regarded as the AWP. Others apply 
different markup factor? to each 
product or type of product and supply 
suggested wholesale prices which 
v/hoies&Iers use a* their AWP» Many 
generic supplier* fall into th^eategary 
Csee Figure 2). 
Ma!ntenan« of pricing is perhaps 
ths most challenging task d aft It Is 
m o I e s a l t t S m e y s 
FJrtt OataBank recognise* thai the 
phirmtwttfct! tedurtiy Is constantly 
evoWng. New compiles and new product*' 
are Introduced aJmott dsity, Wt wleriuiKJ, 
that uthtti product distribution change* wlt^j 
^<jrbetw«njmmufdCtUrtK^ofe«ddr '" 
pricing fttmctorwmty change. Theat'tate^ 
try changes have mwfe the wh&Jejalwturyey'' 
fundamental in malntftlnlfl£ current pribtng" 
data. 
At First D*tt£ftift, whole**Jar turvq* 
we doa* for two m i o t w to establiah at 
AverseWfro!e*afof^oe{AWP) markup toft 
a new company that does nd) provide a, 
Suggested Wholesale Met (SWP), or-to . 
•confafli that tht martup thai First DttaSftrik, 
uUllzta for AWP t* representative of the 
'vrhdttrier Induitty Awvtyrt&yke 
performed on it tin jle NDC mn&er br lorh^ 
mamtfacturtrt enure line of produqMnt&I] 
either ci^tkftwh&lewilerti surveyed off*
 ( 
number of product* within each nutoUfaetii^j 
The number of survey* performed !t 
tocf&ulity. Jlr« DataBaM fMvuj* at mtof* 
mum live drug whotwleri that repteititt' 
l o w two-Wrd* of the touJ dollar volum^i 
idmj wbotaa!*;*/
 t Thtmaricup fliit Rrif* * 
toataBank utilize* is rtpi&wttlY* of 'V*' 
Iwhatet&Ier* on is nationa! level S&ttuae 
jindlvidvsl whole* afe;* rwty wart up each : 
taaauf acturer dHfswittyj a weighted average, 
top i cotmrvwt wm&i tt ^isolated That.' 
n$r th$ market *hir* bdd i>y the \^te«}eri'. . 
liurveyed affectaihe « « r k u p p w p o ^ o i « l ^ 
Wholesaler* with higher dru? dotto^ujpfc $ 
'have more wdght fc (he tf eterrnlntiiOQ a/t& ,'j 
'final Buriwp. Tiiw, * high*? degree W 
J In mo$t earn, the result* km turvtyf: 
WtchivhitRrikD»taStokimlnA fo$n\£ 
ItnitineH that they do not, it ii policy ftit**f 
hrtt Dai&ftnk wlD change tht rrur&p orcftle" 
Ito tfyt>n marten) ace reality* 
First DataBanH HAWP* Calculation P r o o f s 
figure 2 
necemty to con&tantly remind 
manufacturer* that their pricing datai 
.mutt fce tupplied on time, With tta 
Advent of on-line claims processing, 
pricing jnust be there when the update 
occurs Some manufacturer* do not 
release their price updates until the 
effective date to that purchasers 
cannot take the opportunity of 
[purchasing at the old price Just before 
the Increase, We have made an alky 
jeffok 1o apprise the numutecturarc of 
our deadlines so that the^ do not mm 
jthe monthly schedule. We are 
beginning to uee results to thf$ e l ta t 
Data eoqut?!tion \$ a difficult, 
[exacting task which require* constant 
[vigilance, Reporting AWP is an 
toportant {unction of First Databank 
knd we take this reaponsibfflty 
pwlowly. 
in 
fries Mines And Balance 
meets 
Although the expected movement 
p AWPt 15 upwtrd, there is an 
pcc&donftl d#dl»e without a 
po:rejponding diange In wholeaUe net 
pr direct prices. 5nch An occur/snc* 
usually resultt wh&\ two companies 
merge Into a alftgie entity. Seeking to 
rnerga two pricing methods Into a 
unified tfhole, some products exhibit 
an AWP drop, 
Pharmacies holding inventories of 
these product* had expected to sell 
their Inventory based on current or 
future AWP, Consequently, when 
biiitog Hiftd parties at AWP, the stock 
on hand will produce \t$t profit than 
expected* 
The accounting method most 
commonly used \t to carry inventory at 
the lower of coat or market value. The 
telling price does not enter into the 
picture until the product U actually 
$ofd« U the selling price decrease* 
Wow actual co&tt than the carrying 
value drops correspondingly, 
Cotjveraetyt if the selling price does not 
decrease below actual cost, then the 
carrying value doe* not drop, but the 
effects are felt in future cash flow and 
profitability. 
At femg as merger* and 
acquisitions continue In the 
pharmaceutical lncmstryk we can 
expect occasional AWP decre&te*. 
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R1-019294 
MonthlyInttwst/Septtmbtr 19$ J 
Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU. 
Machine-generated OCR, may contain errors.
Reality and AWP 
If you were ever confused by the 
AWP lor the product Corgerd you m 
not alonk AWP pricing is an 
. increasingly confosinftosiMw,a n d 
• U^wpedkBywwhfttiapafBcular 
product's AWP does not behave as 
expected* Unfortunately, nonstandard 
pricing In the pharmaceutical Industry 
is becoming the norm. The following 
examples will clarify' some of thes& 
'issue?, 
7h< ccnteion often originate 
from the current atmosphere ol 
frequent merger* and acquisitions in 
the pharmaceutical Industry. When 
two compares nwge, the pricing 
philosophy of the larger becomes 
dominant. Product swapping and 
habitual changes in marketing 
strategies -what has beencaUed the 
pending1 of the Industry * further 
complicate the situation, . 
Let's go back to tte t&mple of 
Coward which tM& article .opened ' 
wf& Ustyear grfstoMjeyer* acquired 
$$ulbb> which manufactures Corg&rd* 
The new entity, Bristol-Meyere 5qu!b& 
moved Corgard (along with Corcide) to 
the Bristol Lab* fine of products, fltet 
DataSanV responded by revising the 
AWP's to reflect th* accepted Bristol 
Labs' markup, (Sea page one for a 
discussion of markups.) 
However, Corgard still has an 
fflJC number recognizable In the 
industry as a Squibb product. I.e. rt has 
a labeler code 0/00003, Aftftough the 
distributor changed, and thus the 
AWP,.(he NOC number remained the 
same, Since any particular iabeler 
code is no longer strictly associated 
with only one distributor two 
products with the s^me Iabeler may 
hav* AWPks calculated /rem totally 
different markups, 
Although ^occasional . 
wholesaler may still be treating these 
drug* AS Squibb products, thi* fc the 
exception. Brat DataBmk always 
publishes the surveyed AWP, 
Capoten, Prolixin and Rauzlde, 
among other product* in the VS. 
$qylbb Croup, recently wcampttiled 
another type of pricing change This 
division of Squibb Introduced price* to 
the wholesalers where previously only 
direct pricing was available, After 
thoroughly r « earchto t whotewterf 
responses, we uwtltuted e new markup 
procedure, V/e were careful to include 
every product affected in order to 
minimise the occurrences of pricing 
changes, 
in some C&SCB the reason behind 
such a change may be invisible to 
someone who see* only the rwuto. in 
other caies a new Manufacturer Name 
or a ehwge to the Labeler Identifier 
field provide? the key, Regardless 
there !$ much consideration to ensure 
ItatfteAWPreltoctsmHty/ 
sasssssm syaegyggg! 
Bob Matutat Promoted to 
Manager of Professional 
Servicer 
I iJ"iliilillWPWHlHtt 
Bob Malutait has been promoted to 
Manager of the Professional Servicc5 
Department His new responsibilities 
include overseeing the creation and 
maintenance ol all NDDF™, MDF, 
clinical, OUR and Canadian products. 
He will also continue hi* Involvement 
in the implementation and modification 
ol ill product* In order to ensure that 
the customers requirements are being 
matatthedintcaHeveL 
Bob graduated Irom the University 
of California Berkeley with a BA in • 
Political Science, received his 
D o c t o r a l the UCSFSchocfo/ 
Pharmacy and completed a ho$pital 
pharmacy residency at the University 
of Iillnol$ Medical Center, Chicago. 
kaddition, Bob has lOytmot 
hospital experience al w o major' 
medical centers including three y^rs 
In drug information and (our years in a 
clinical pharmacy position, He joined 
Rrst DataBank in Kr vpn , nf 1987 U 
Stall Phantacisi./iofessiv 
We eongratalatf V b -*-
advancement and fit hi* • *n *-, and 
look forward to watching w-:nrure 
successes. 
Arkansas Medicaid 
Arkansas Prior Authortotlon 
(AR'PA)l$ now agitable , W 
Oaftoltions are u follow* 
0 e Prior author!, ^m \h not required 
1 - Prior authorization 1$ required 
Colorado Medicaid 
Colorado Prtor Authorization will be 
changed from 0-2 definition* to M 
definitions, The new PA coot v 
3 « Prior authorization Is required If 
drug Is dispensed through an 
outpatient pharmacy. 
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Intermediaries/Carriers BSSSSSBg 
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Trananithl AB-00-S6 Date; SEPTEMBER 8,2ftfl0 
•W^WIMWIW*^l l i^«W'MaHM>MtMWW W ^^ i Nil) I II 
CHANGE REQUEST 1232 
SUBJECT* An Adffidos&t Sftwce of Average VHtoksalc JPrte 0*te ta Mcfeg Brags w& 
Biologic*!? Covered fcf ttie Medicare IVograra 
Tftepaipo&ofthisPto^^ 
q%ofe$afc£Bi#<i^(attac^^ T& 
albwaa»sfi>ryoiiarJaftu»iy2001 <pi^yupdfl& Ifaesecc^atfadffl^ 
tfe^paymmt allowance ibr drugs andbfolqgioals <&v^bylhe Medici ptogram is desoibcd iiiPM 
A&-99-63. TTiatPM state that to 
paid based cc the tower of fee bilfed rihaige or 95 percent of the average whotesate pnce refected ia 
sources such as tfafrRed Book fflto Bot& or Mexfoggt E x a l t e tf^ 
«eiK>tipduc|editttltt<&d5^ White the Bfoe Book is DO logger 
avmlabfe, anc^1torpui?lkalian, Mce Alert; is available. Aku, there ate electronic versions oftbe same data* 
•Itic.&ta ia &e attachments haw corns from the United States fepartiaeni of Justice (DOJ) and the 
Naikmal AssociaflaB of Medicaid Fraud Control Units (NMCFCU), Tfcey are an aJtenjative source of 
&m$0uasi&> Itese dak aie Iran x ^ ^ 
Mii&mote, tiicDOJ has iodfcated^ because j p ^ ^ 
advertised wholesale fc^ogpn<^,eiai^6oma wholesalersS^ actual 
acquis&esa costs may be lower. The DOJ indicates Itei same physidana and ^cppliess obtain dtogs at 
prk^ tow^ to tte w h o l e s For 
em®pte> &e BGJ data fiom wholesale caislogs fadfcates an averts wtefesSe price of $22 for one 
albatooi sulfate NDC whkh is s^samitia^ 
canp^to$15ftjroaGPO< These dataategsaendly conskfctfttwth findjees ^ ^ 010 3neporta 
Tfc^hasb^nt taresp^^ ttader separate cover, 
ofpridi&dri^ covered 
DOJ md NAMFCU have piwi&d tbse darfa to First Date Baak; * c^upsn^ tot compiles average 
wholesale prices for most Stele Medicaid program On May 1,20005 First Data Bank provided these 
mx average witalesale prices to State 'Medicaid programs, SOT^ States have &tody k^fcijoented these 
aew avKage wholesale prices while otters havs tiofc 
HCFA-P«6v«AB 
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Ymasetocoaskterfte^ 
<juait$riy update &r the 32 drugs (Aitachtnest I), as jper PM AB*9?-63J These mtgs account for 75 
percent of M&$mv spending and 70 parceat of sarags (based o& DOJ data) for the drugs cm ths 
am^e^DOJJfel Howwa; we have some <#acffiraabq^aecesfocare^ 
prices for 14 <&«notherapy drugs aad 3 do«iftg&UHS{Atfe^ 
poB^assoriai^wi&i&pro^ TteteftHfc, 
youaisiKtftocofl»d(^a£tf&te 
Medical altowaiK^wMtewft^^ Forthe 
<lrcg3 shows. & AJk&mejtfZ u&yourusiiaJ sou^ctfavtsags Hiotesa^ptiesfc y^ariifiscl quarterly 
Tbedstaintheseatia^^ 
pricing n i l e sdesa i^mHt f^^ 
date as tfe socttiefi of a v « ^ 
drugs ID Attachment 1-
Yo« are to ^ r t by October 1 5 , 2 ^ 
Jmimy2O0lvp(k^ AJ^ywaretoptovide&listofw 
identify as usual and fiw & r n ^ 2 Q 0 1 * ^ 
& Attachment I aM 2 ( & ^ ^ You an?fc submit those 
jaaabcK isDOJAWF^icfeigov* 
For die dmg£ m AtMxmeaf i > w s . ^ j p v i & a d ^ *fcteh coaid 
^ectyoifffeiaaiy200i\^tes. We w&p^vido guidance m ^ ^ 
y«OT figure dtagiJ^^ 
eoxwsyhowweplaBtoafiust^^ 
are both subject to the AWP rales and j>aidcH}aj^sto>i^bask 
The enclosed data show a price for each NDC that iseam^geofi tewM^^ 
ftfcvsdotKufcies^ ThsIXMindfca^tpt 
fite trumt>«^ (^toded fe 
ia^oepmy. Ifyoudeckietoiisefi^ 
'one of Ib^pnxfacts for fee wraigc? %k)lesafc ppce in. this new ^ t i ^ , y p i ^ ^ J a b to the j^ymcim 
^ s ^ y f i ^ d a ^ You mygm 6$ f 
fitiettamferaf fee wholesale^)* You taay also give the'nams and te& 
of fhednag (available b ite Red Book) ssDOJks fexficated that i 
directly. So^oft l^nmrfaciur^ 
members of a GPO roight aiso dbiaia these drugs tfoough that organ? 
whdfeaJeprices. Howevrc,yoasJ&tttd^ 
change their procedure for obtaining drugs, Further, you should iacficatejl 
use of thesGSQwx&Mid do not sssoxnz arry HabiBty for ths choice of son 
i tn^Ser of &e ma*mfi$urar 
soften supply the drugs 
hyaeians or supplier who are 
I at or below these average 
crian or supplier is reqjmcd to 
a you are not advocating the 
s by the physician or supplier. 
Sections 1£42(o) mid 1833{aXiXS) of fte Social Security Act (the Act] rehire && Medicate pnogcam 
lo set paytaeail allowances for drugs md biologfaikaiifcekw^ 
of .tite average wfaolcsaje price, the attached data ieprsseflt.a&othsr souk« of aveiage wholesale prices 
ibr&epJW^yfcotf t h e a i ^ T&srefia^ useof thismvsoun^of^er^ 
of the Act 
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t t e procedure fcrptocessiHg intermediary claims has ao ic toga l As described in PM AB-97-25, all 
carrier will cas tes to & n m See of d i a ^ <todnigpayBK33{ ^lowaftceiqxfeiss ibr all cfc^ gs and 
bioiogicafe directly &> the fiscal iatemiaSanes in tteir jurisdk&oa Confers should soniact ibs fiscal 
&fen^iariestt»deta^^ C#ri«sfir& to send this t i ^ ^ 
E&1 fiscal iiaisniiatKar^ T To&rtter claiify, fiscal tenBedkfesmu^ use each 
carrier's drug paytneat afiawaaccs for claims submitted uad&r feat earner's jurisdiction. 
Attachments (3) 
The effective date for tfcfs (PM) fe Sqpiemtw 8,2S0& 
:i3*e imp! lamentation date for fins PM is September 8,200ft, 
Tk e$e insirmctioBS should be tmptameatei wfthm yoor current a p*ntf&g budget 
T&fc PM m*y be discarded September J> 20&t 
If yaw fcavfc any questions contact Robert Niemann at 41&-7$$-453:L 
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Aftachm&nt 1 - }f you decide to use these data, use solely! these date to 
update the HCPCS biffing codes that coffespond to the drugs on this list. 
. 
* 
L 
| ftMfftftfty 
| Acetytcy&Qtot 
| AesiyJeyxtefcii 
j Acefylcy^^e 
j Ac»fyk:ysfe&* 
I Ac^fcVsNfcft* 
| Aefctyfcystefoe 
} Ace^/c^eta* 
j Ac*fr/cnte/n* 
| Ac*^fcysfe&* 
t Ace*yfeytfa&** 
| Acety^tefre 
j ActfMcytfe&e 
J Ae*frte)$feiite 
1 AcyclovirSotfkntt 
AcyctovfrScdtom 
i Acydby^Soc£fm 
A«K*^vfr Jfltfwn 
Acycto VITJOI&WTJ 
Acj^vfrSodtom 
Affidavit todfym 
•" Aey$fovfr&dtom 
A^ctovfr&d&mj 
Acrero^&tfwnl 
AeycfovfrSodSt/wl 
A^yetovfrSodrt/ml 
Afiyetewfr Sodteml 
AcyctovSrSotfktfnl 
Aeydov*rSacHcm j 
AcydovkSodfuml 
A^&al$v1fa}*\ 
AIM&olto)tote\ 
A^er<rfStJlfofeM 
AttHrf^Sutfafe 
Albuterol $vtfat*\ 
Afctteraj&^te 
A/i^^&itfotej 
AttHitwo^^eJ 
Arolkodft^ateji 
Amikacin $uMate\{ 
i\ fto*tm 
A tAbbt&Hvsp.'ifSOUlH 
>| (Abbott Hosp.ys6l,rH 
{o*¥)/$OUH 
j t&e>r)/SQMH 
(fo^/SOUR 
{freyVSOUft 
(PwysoiAu 
(&*yJ/$OUB 
(Dey)/sairw 
^uktb9i)^MH(VlALJ 
fFd«klfrig)/SOU?H[WAJL> 
{l^ifkllngV50tJH{ylAL} 
{FcmW^gyspUlHiVIAL) 
(AW>^Hosp.)/(Vfol, Rfpiop) 
fAfr&ott Bosp.)#Yfci rtlpk>p) 
I (App)/lhU,W(VJalJ 
fAw}/tN^U(VtafJ 
{App)/J*DJ 
(ftpri/N» 
(B^arcO/n>lUC^D.V.) 
i f l«^rt}) /mjja&M} 
fFaukrm3)/WJLU 
(Fauk*tao}/K>l,U j 
(fujfeowa/AWVPDt U 
.MAD. I 
(fti|«rv««5/APF)/PDIfM j 
rv»AD 
(F«|$awia/AP?}/r£iIJJ j 
fVIALl 
(FMjl^iwa/AP^/PDLU | 
{Gen$la}/^U(VIAL} 
fQ^$kj}/JP1>LU(VIAl) 
{D*y)7SOtm 
(DeyVSOLm 
(Dey)/$Ot,,ffl "... 1 
'GteWSQivin 
{Seh^ln^OL^M 
(WarrfckJ/SOLIH 
fWarrrck)/50UH 
(Warrfcfc^WMH 
Afcbotf Hosp-)/(VN*> R*p*op) 
Abbdt Ko$pj/(W fflplop) j 
1 ^ e o w f m i ^ 
4 , 
j >0&3Dnnt3s .. 
20^4mf.30mt35 
10%, 4tr£ *2s 
J 10%»)'0mtait 
I0&&frfc3$ 
20%. I00ml/feo 
j 20&4mU& 
" m ^ n l 3 s ^ 
?O&30mC3s 
jOMirt t , ?0$ 
?O&3OmL10s 
JOSMmLtt* 
J !0^30rnUOs 
j 500 mg, TOs 
IOQpmgr ids 
1 tfOmg/roUOmJ 
[. 50mg/jfnt2fl^ 
15s,500rr^|,aci 
fSs, 1000 rng,e«* 
SQOmg, 10s 
looo m&. 10s 
sbom&ios j 
iOOQnig,.tat .... 1 
J500ing, 10s 1 
lOQOmSrlQs 1 
" ' SBOmjg, 10s j 
iOO&mg.tOs 
j | 
5D0mg, Kfc J 
lOOOmg.lC* | 
0.5%. 50 mi | 
0.083%r3mL2Ss,l^| 
^OS3^,-3ml,30srUrt 
a083%»aml,.<ft:,-UD(i. 
0.5ft »m* 
MM^3mi rtfjs. j 
0,063%, 3mt25s,Ul>" j , 
asstsami I i, 
J»mB/«rt.2nrtt »oJ ]c 
2$Omg/mi2mU3M* 
] " HB£ 
1^074^3307^ 
0P074-33O6WK 
N ^ - O t " 8 1 ^ 
J 4 ? $ o ^ M ^ 
#502^?81-30 
U9502^»a2ife 
-»5Q2HDT^-04 
j*sbi4>V8a*tb 
j ^ 502-0182*30 
U1703^32GW4 
kl703-Oi«)3-3I 
^1703^4*04 
£}70iQ2O4-31 
0074-442?-$! 
to074-44Sa-6Y, 
[|63%23-0%25H1O-
1^23-032^-^0 
\63$^\o$~\o 
1^23^105-20 
(55390*06} a-io 
553W>-0^3-20j 
A|7aV03i'l-2D 
6f7iDM3rt-43 
<&323OIQ5-10 
63323h0ii0^2D| 
#3»032MD| 
<S3S^3£5^20 
(»/03^l04H^ 
00703^ 8105-03 
4?502-O^^D 
49502-0^7^03 
49502-0^97-33 
49$(&4697-60\ 
m&25^$$\ 
S^ispCHDij 
5793O-J50CM38 
59?3D-I515^4| 
T 1 " " ^ ! ^ ^ ^ 
J) W< 
*J MC&fl 
{ w<. 
j MJJ 
{ " MK 
{ ^K 
j MK 
j *A^ 
1 M* j M1C6S 
J BB 
j MK,ee "~ 
MK 
1 &a,MK 
|JI BB.MK. 
[• ' MK 
MK 
MK 
MK 
fee.ASO.H 
$&.AS&,FtO& 
n i 
n "i 
BB, MJC 
fiB.MK . 
BB '"""} 
ee, MK [ 
8S j 
68 j 
5B,MtC . j 
&&rMK ( 
&B, MK " ' j 
m,MK J 
0ft, WK j 
8a,M?CikHt> j 
S3,M^AN(> j 
fefi,MK "J 
30Q74-19S54M j &B j 
iOQ7f 195^ -01 j **'*** [ 
j Av«mq^ 
Iwhofesole 
f wiBi 
I «UTO 
j $18 JS 
$^5,80 
$15.27 "" 
W * ^ 
f ?WS0": 
$31.08 
1 $?B.57 
L J 5 0 ^ 
5»3;s6.... 
$?L00 
1 $ ! ^ 
^ ^ l ^ 
&49.0S 
$700 JO 
j $*&0O 
['''^28^)6. 
! W»15 
$7SA5 
mrm 
$4017$ 
$e ,^oo 
$179.SO 
|37|;50 
f/5LSO 
J.150.00 
$230,00 
$J00.00 
5186.00 
•$5,?$ 
$^.17 
$H01 
$22,01 
$7/,2 
$&\M 
59Ji5 
» « . 
$125:00 
$i5a«L 
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j 
j 
[ 
[ 
f Am&^Stff^[{Abb^^ ?0s 
j Amikacin SuXote j (Apothecon) Amtfctn/IK J, li 
... .: 1 CW«J) 
f Amtkach$vitek 
j Air$x&k$dtek 
| A^<H^Su^ 
j ArototfoSuJfote 
1 Amipeoeto &$pte 
] Amftc^ywflate 
| AmffcaonSoftote 
I Amikacin SvXate 
Amltet&a&tfate 
An&ttk\5rttote 
| Awpbafcrcto B 
Ampfcotercfa ft 
Antphaiercin & 
C^cttriol 
Cafctfrio/ 
CBrnkmydn] 
l •> «,iwi •?„*,->... — •• MI. i f 
(Vksl) 
»{{»e«ofd}/IN^ U{lD>Vr M J 
4^edtorf)/lHJ, U (5,'iLv* f.lv) 
fVlAl) 
fVIAl) 
fatotoyiNlUfrMJ 
l$t^ymJU$:M.} 
ft^rota)/MJ,tt(Vlal) 
|(Apolhwcon} ft>ngteone/M>i 
U 
(Gem!a)/PPI,|l{$.DtV*) 
(Pbotmo^a/Upjohft) 
• Ampfr6<*vTI>l,U 
(Afcbptt Hasp)<McJ)ex/IH 4, 
UfAMtt 
(Afabott Hasp)Cafcfleaq/iNJ, 
(AbbQitHespWHlV 
(tobfcii HospJAHl, 14 (ADD-: 
VANTAGE) j 
(Abfooit Ho&J/MJ,»(VAIL, 
(Abbc*Ho$|>,J/IKi, U(VAiL, 
{Abb^Ho*p.)/(v&al Fflpfc^) 
(At>fck*Ho^3/(V^ Rfriep) 
(Pharmotia/ttpjoho) 
(Httflfmoda/Upjohti) 
C\*odn/\M,U 
fAdd-Vemtag*) 
tAdd-Vcurtasge) j 
{Add-Vcmfc?0s) 
{Add-Vafttas*} j 
P>ey)/50U1H j 
j 250mg/ct^2iT^ 
25&mg/rnt4mt j 
|250mg/iiri2irt,!05 
J250mQ/n^4i^Kfc 
50rttg/frt,2mUO$ 
250mg/mt4rol. I& 
J25Qnr^/ml2.ml, JOs 
J250mg/ni3mUO& 
1.50 n&/ro{, 2 ml, 105 
^j t ig /ml ,2ml f 10s 
250> ma/nit, 4 M 10$ 
S&!tv0rea 
5a ros,Go 
50mg,ea 
Imcg/mUniUtXfc 
2raQ/mi,!mLt00$ 
3O0rn§A5Ornt$0rnJ, 
4&.
 f j 
150mg/mL2ml25s 
150rog/nU2mg/roU 
2ml 10s 
ISOmg/rnlSml 10$ j 
t60m9/nf)J;2mL255j 
t50mg/ml4ml,25s J 
lSOm^ml 2rrrt» 25s | 
ISOmg/^UmUS* 
]5Qmo/mJf4ml2Ss 
150rr>g/roUmL2&| 
150 nig/m^ ml, 25s [ 
I5&mg/ml4ml25sn 
}0ro§/mUml&& j 
"jisWW 9574i f { i»'.iMK""' 
00015^02^20 j R.MK" """ 
j'abdi^3023-» 
1^35^22^02 
'$5390^£-04 
617034*20507 
41703-0^2^04 
p 570^0202-07 
W03-C202-0& 
W#s^22HD3 
0O703-PD32-O3 
OD7D3^04MX5 
00003^437^30 
\(kff(&97B5*oi 
00013-1405-44 
O0O74-T2OCKH 
00074*1210-0! 
0QO74-7447-H; 
00074*744<H)2 
0Q074-7444-0I 
00074*7445-01 
00074^4050-0* 1 
00074^4051-^11 
ODCK#-087CH& 
000t#-0775<& 
00009-3124*031 
D0db^-D^62^Si 
000(^447-03 j 
0OCW^>728^ 
i^W^^L 
Ij "'RM1C"""~ 
( ' ^ M X V F P 
1 BS.MK,?} 
J MK 
ft*. MK 
I $&. Mfc 
J Bfc'OS'" 
j 3D. MK 
&B 
R 
| M 8B 
A5B 
1 R 
ft- ."1 
/yiK " | 
MtW" 
ASD,B6,W^05 I 
H j 
BB J 
r 
BB,M^ 
R&. WK j 
&3, MK 
et, Mt 
•0Br;MlC j 
&B.MK | 
1 i3S8.0&' 
^17.31 
j J34.49 
$65-53 
$125.33 
r
^s,oo 
[$8^.00 
j iASO.00. 
$^00,00 
' £72.68 
j $7o.oa 
j$140,00 
^.20 
j #\80 
1" j-waw " 
'itjm.m 
»,W-35 
$120.00 
$35.00 
$H,72 
$30.00 
$75,35 
$174.00 
$41.20 
$124,CX) 
^126.00 
SU2.0D 
« 42.00 
$Z5W 
tg.MK | $23.(K 
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j 
j 
i C&Biofynia&vti 
J AtxtteH 
[ &*8uro J^»pxphcrf* 
1 Sootftim Fftcttphate 
j StnSvm Pte«pfc*&* 
} £oc#t/m fto*phate 
| to#xam*ttio$Qne 
Sodium ftftospfcttfe 
Paxfiwe 
ftfcKfro** 
&£Xit6lG 
D&xiratff 
&sxtros«| 
Psxtowe 
Jtexfrw* 
Dexttcw] 
ttexirtft? 
i>exJr#iel 
Pexfirosef 
DfcXJmset 
itexirayg) 
Oexhttffc 
O&xfrwel 
Ctextrosej 
j Itexlro**! 
*j (&»y>/SOMB 
- \ 
(ft#sawa/APP}/(&Ui 
1 {Mfcawa/A^)/miJ 
1 (Mto^APP)/»44,U 
mm..... 
(VUH 
.fVIMIv 
[ < ^ ^ y w , s j { M J & ^ 
< Abbott Hosp,)/(ADD-
: VANTAGE UFECARE) 
(Abbotftfo*p,)/{AD&» 
VANTAGE) 
_VAKtAOEU?E0A^ ! 
(Abbott Hosp,)/(UFECA|)iO ! 
(/^b^HKiipr)/pM(^m) 
i Abbott Hasp^/fflfiiCA^ 
(Abbome^i/i^cAftia "j 
(AbboHHwp.) 
/{UFECARE/PLAStIC) 
(AbboHHosp,) 
/fUR5CA«£/PiASTIC) 
(AlsboHHosp,) 
/(urecAws/ptAsnc) 
(Abbfcfifck&p.) I 
/(Ul^AI^JASflS) 
fAbbe^Hwp.) ~ 1 
(AbbotfHosp,) 
(Abbott Hasp.) 
/(UP^CARS/PIASTIC) 
(AbboftHosp,) 
/fUFSCAR^PtASflC) 
1 UD 
I 5m§/mlSml 
J lOmg/fTil, IGmi 
| 4rhg/mt * mTea 
•4rn&//ri5m! 
30ml 
j 4mg/cpL$ml 
30mi 
SOW 
1 4mg/mJ;5mre<i 
5%.50*rtf 
$&2$Grfii 
5^)00 JD} 
250roi ! 
rwi5&"&ii 1 
S5i$0mi 
i|» > HI" t •' HUHMM—M—« 
J4?sce*«»-i2| »»*MK 
j 00364-665 -^53 j i 
0(^4^227741 
f ^ * ^ ) * & 0 G 
|o(J4^1^2D 
C^£lgfr5Q 
|id323^>?45-05 
^2&OI6$-30 
^ ^ ' t i t ^ f ? 
\om64-6m£i 
00074-7100-13 
00074^00*02 
0pO74-7J0O^ 
00074-152H& 
<m^7?22-dt. 
f^^7«aSi] 
. 5%. iOOrnf j ^ ? * ^ P ? M 7 | 
.{IQDOmlcontainer), 1 
1000 mf 
(lOoOmlcbntatvert* j 
1000 ml 
5%, 500 ml j 
(tOOOm^contofnart, f 
(lOOOrnlcontaineri, f 
50ft. 60S) ml. j 
(.1000 mi can*a&?erj', J 
7G&50Omt: 
[Buktoctage).7C&, 
2000m) 
(?(K)Om]confeirier), |4 
SQOmt 
5^250^1 < 
(Abi^Htap.) l 5%. 500 mi ' |( 
6lX>74*)51fra$} 
toto74-.M94$\ 
to7^"i«K^3 
pQa7^l$^03 
3007*5645^2$ j 
<^4£«M?^5.j. 
00074-7120*07 
30074*7?l^? 
X&7*7922^2 
)0074-7922^3 
,fcl , IN.IWW^IH'*1 'nil ' ' I 
j ao$ 
• { SB 
j »' 
" • S& 
j OT* 
1 * 
j B$ 
j 8* 
tttiw 
j ' m 
m 
m f i 
6&,M i 
mm 
ASB ' j 
3^;a otN.m | 
03 j 
"ASD.OS,R7O«R1I 
tKI j 
w 1 
as j 
BB.AW 
&^OS,fi 
BB j 
85 
&ii 
«.t« ! 
j $45.7] 
f *H.50" 
$2.6$^ 
5 0 , ^ ~ 
5K(S7^ 
'{'"^ojbo"" 
I io.Vo " 
sioxwcT'" 
w^"""" 
*li»'"" 
1 " $ 3 ^ "" 
$4.12 
$3.2S 
$3i& 
:
 $i»45 
. $K4S '" 
$1,45 
£/4,S4 
$J5.7T 
$3.87 
$9J? 
$3,69 
$4.2<i 
$13,^ 0 
$8,81 
$5,54 
$1.61 
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[ 
L 
J DtxtoH 
f Jtex&aw 
I ftexfmt 
1 6*xlr<ttfi 
J £exfa»i 
T _ a*»to*$ 
r _.&***«*? 
j fc^XfrlMe 
J 2texft*«# 
I fcixfrckss-
[ itex/rose 
[ f>ftX3tt** 
[ &*X*rt>*& 
Vexkosa 
gexfronr 
Dextows 
Itexfra*e| 
Jtexfroso 1 
itoxfrose] 
&axfrctfg| 
jtexfrroej 
"^ Jtextowtj 
"" itexfroi*! 
/to(0a$*j 
^texftwej 
bexfrosel 
bttxtrosel 
" " XteXjratej 
teXtatfO1 
•i (Abbott Bos*} 
/{imcM&tuisnc} 
> fAbboHHosp.) " 
/{UFSCARS/PUVSIIC} 
4 (AW>o»Hofp,)/WJ,U, 
M*NHBA$)_ 
(EaK^r)/(*UIIC PACKAGE 
{Boxfc*)#EULK FAOCAGS) 
(Bart*J/{OiAS$ FBI* Ffltl) 
{ftax^f)/(GU5SUKOElFEl) 
(B^fe$VWHi*BAO *tU5) 
*AOV 
._.., _»AG)
 u r 
[{fcatferJ/(QtfAl> fACK M I & 
*AG) 
{&Qxlef)/{aUAt> fACK, MINI* 
fcAG) 
(a0***r)/(51N«HSPAat 
($oxferK$ftTGtePACi: 
MIHJ-BAG] 
tlMoaery^IHGlgPACK j 
{eaxief]/{$INGLSFACfC 
{&axief)/(SfNGLEI»ACK 
MfNl-IMM?) 
{*axliirM$iNGlEfACJC 
M!M~MG) 
<Mc^«wl/(!000 ML GUSS 
(MeCJw>/(BXCa) 
(McGo^O^CH) 1 
(McrOawJ/ffiXCEt) 
l M c G w ) / { e x ( ^ y 
(Mc&ow)/fGtAS5 
CONTAINS 1O00MI) 
(McGtrw)/(GtA$S 
1 S i^obbni 
|{2000mJcontct^fir 
SQ&lOOOttl 
jnOOOfrt contained 
j 5&50m) 
| 5& leomf 
5O .^?06O.mt 
7og&.2j6ami 
7O&lQO0rrtf 
7Cfo,mm 
$&.mrd 
j sscLfiaTnw 
j 6%, JOSroi" 
1 5&2Srrt 
SSW&irt 
250 ml 
Writ 
25Qmf 1 
500ml 1 
1000m) 
WrlOOrrii" 1 
J0%,250*W j 
5%,50rnf 
£0&,50Gml 
5&,1000ml j 
SODml " \ 
"" $&,m25Drri"' 
K>£, ?000mr 
500ml 
?0&>5COrti 1 
100074-7922^ 
DOO'74-793^1? 
J00074-79364S 
J000W52M1 
G 0 3 3 8 - O O W B 
JJODJ38^03}^& 
00338-07^-06 
00338^348-04 
J0033&OQ32-13 
jO033^O5SVli 
\o033a-DQ174\ 
CK&3&-0017*38 
!0033flrOai7^0 
D033frOQtWi 
CKm&*ooi<$-G2 
00338-0017-Oj; 
00338-00*7*02 
0033*-00!7>03j 
oo^^i7»tt 
005^0017^48 
00358^023-02 
00338-00 i 7*4X1 
0026iH28CK55 
002(U-75)CuOO 
owiwsio-iol 
002&-7510-20 
DQ2^752dTO] 
&0264-I29O-50 
&2*4-52?2-$5 
' I",,. 1 •! .11 • 1 .llitl.ll I n 
H u»'ift 
OS 
j OS 
5R tRt 
BS.im" 
} ASD, ok 
j TOLR 
Wt ~ 
j "IW """ 
j 1R\ 
I Tfi? 
w ; 
tt&M 
TO 
a m 
i 
flrW ' 
^ t ^ f | 
rLTJH " 
a S " | 
sa j 
TKlyf* J 
rci j 
tRlOTHMD.Oij 
r».o^A$D t/oij 
moTN.Asaosj 
m ..] 
TRl ' ( 
w j 
T »^ 
*n^4 , 
J $7JD^ 
1 $3.9? 
j $^ 5S 
$ai.«r"~ 
?13.3? 
j $6.20 
$6.16 
$3.17 
$ff80 
| $).$S 
$T.80 
| $1.55 
$3L3S> 
$L50 
$LS0 
$L47 
$2.U 
SI .55 
$L6$> 
$Z25 
$4.07 
$2JZ0 
$Uo9 
$1-59 
$U« 
$7JS 
$5.2e 
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] ttexkosi 
D&drosi 
I fexhttit 
} Dextrose 
I a$xtfca* 
j Dexfro*« 
| Chkxkte 
} cwwfcte 
Chbrkte 
j textile wifa Sodium 
CMmfcfc 
j Dwxfrose wftft Sodium 
1 CWoird* 
j &*xfrtt<» wfth- Socfiiftn 
F ttextroze with Sodium 
\ 0*xtmsewHb&>dfam\ 
Chhrtd*\ 
[ Chloride* f 
j &exta>*& wUft Sodium j 
| Otkxldm] 
T £#xtro$e * # h Sodfvm j 
1 Ctoe*kte 
1 CWetfefe 
f bexftTwe W#r Sodium j 
1 aie**** 
Chterfd* 
1 Ctoodcfc 
r Nozepam j 
[~ Dtmspamh 
r f (MC$<*tf>/(GU5S W AIR 
TUBS} 
>j (McGaw)/(GUSSW/SOUS 
SlfiffBL.. 
J (McGaw)/C<KA$SW/SOttt> 
STOWS, OU5S) 
-j (Mc(k?w)/fNJ,UO0OWL 
} {McCkiwVWJ,Ua50ML 
PA*) 
j {Abbott H<?$p,l 
[AbboftHo^J 
(Abbott KospJ 
(AbbohHosp.) 
(Abbott Harp*) 
{AbbotfHojpJ 
(Baxter) 
(Baxter) 
(Scoter) 
(Baxter) 1 
(Baxter) 1 
(fcaxler) 
[McGaw) j 
(McGaw) 
(Mfi£cro>) 1 
CMcGqw) 
(McGaw) | 
(McGttW) j 
{Abbott Ho^ytCARKyKH 
'Abbott «oi^)/(CAftpyj£CTr 
T 70&200bmf 
7Wt.«Wirt 
Sp&SOOrnJ 
J 
50&2Q00mi ' 
SQrof 
| 5& JOOml 
$%r0>4$%,i&>rtt 
500rm 
ICXJQmi 
£%-#*& 250mi 
SQOmf 
. fOOOml 
| 5%0.4S%, 250 m* 
500ml ! 
' JQOOifit " 
5 M . 9 & 250 irt 
500 mf J 
lOOOmi 
joodmi 
sboni 
&LrQ.9%, 2$0mJ ] 
IOOO mT"" H 
soomi 
J5«W5St2sbfnf 
$mg/ro!£mLeaC- (1 lv
 f 
(002^4-1129^ j ^ T 
002tS^1290-55 TW 
r00264^12SI-5s| W 
1002^1285-55 
002$4*I5!0-3I 
J0M«-153O^ 
00074~792*-02 
00074-7926-03 
4 
i ^74 -W6*0? 
00074*7*4!*O2 
[60074-7941^)5 
100074-7^41 -09 
0033^0085^02 
0Q#&QQ$&<)3 
oattfrODSS-flij 
00338^0^-02 j 
0033^6^-03 
0033frG089^4 
0G2<S4-7<5T043O 
oo2^-7^ic^bj 
00264^7^)^30 
00264^7* 12-00 
O02^7i)2-10j 
D02M-76I2-20 
XX>74^27i-32 
)0074-l 273^2} 
\J TRi 
Tfi^aiN 
7KlrC*N 
tJ&H/OS" 
j OS 
OS 
j m 
mow.Asii'ft. 
[ OS 
ri»;oTMrAstJ,la 
! OS 
*Ffa,FI 
W ft | 
« 
'•tta 
R 
R j 
t F j 
TftLB 
TR{ 
ma^o I 
m« J 
"TRlft 
eg | 
3E.F1 j 
j m.Bs 
j ' isia 
I «2J^7~ 
l^ ii r^ v 
} ?K61 
| $1^2 
tHsV.ao 
j ii*£ 
$2.6^ 
I $L?3; 
$]35 
1 $2,24 
$2.47 
"
r$l90""J 
«WS." 
$2,^3. 
$^oo 
$Z25 
$2J0 
*1.BT 
$K7S 
$1.65 
$LS5 
$1.89 
$2,0$ 
$2J2 
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Btomptm [<Abto& Bosp,>/l*aiJ (AMP} 
FtfTOHtflrftf* 
jfarowwnide 
6 w r f a 5 ^ c M « 5 ^ 
sarfaMfrif i fo^ 
SmB/rii3mliEA(> 
(AbbotWoJp.J/iNi. !><VtM, 
•V.". "J'""—J"™'.,'c , < m K U \ 
topfriMtefrftffflte 
HepatinkQckftosh 
Heparin Ixx&flMh 
HepettolocfcWWft 
N, 
Smg/nitOrokea, 
CMV 
00074*32*3-0. j 
10^74*321 (MS 
f6&3<M^S2^54 
10m$/ml2mi25s j 0 0 0 7 4 - 6 1 0 ^ 1 ASD.W M« j $14,36 
7omg/murtf2$s |obo7«iOM4 
40mp/friSfttt*L 
40ro3/mt.20frt,, 
AS3 
$250 
$ U ? 
$2,50 
Q$,ASCbCfet,BB. 
•jfi32B^ipffi. 
004694000-40 
^ W M ^ ^ ^ " ^ ; , " ^ -•!• ••• •.-••—••.• 
(Abbott Ho*p.)/INJ, U (VIAL, 1 10 u/ml 10 ml 2fe 
TAbb<^HaspO/M«,tt (V**1* 
Hydr©corffcw*e 
(Abbot* Ho$p,)/!*a U (VlAl, 
rowor) 
(Phom>acla/Up)ohn> Soiu-
tfydfpcotf&OftB 
Immune Gta&wW/i 
v>w>w»j,i Y^'T;^.![~..nil i i*1 " 
immwieOtofcurfrft 
^ 2 3 ^ 0 - 3 0 1 "8B,"MK T $3,50 
-J ..Mil m M I H I I H I l 1 . U M l ! . , ! <" I l l * ' I '« I 
3 5 ^ ^ tewTSa-Ta ^ « * T » * 
15mS5^S R5555MWOCJ-I3 
E*»iJrito^WSorrow iOOOOWW^ W 
SOOrr^^o re6ooW»iW 
(rh«mocJa/Up)ohn) Soft* 
jmiiwweGtofcufS* 
immune Otobufin 
(Alpha 1bwap#tffes) 
(Alpbe therapeutics) 
(Alpha ffr^ap'Hrttes) 
g jm/Vkrt, w/Aauto. Set) 
towno-dei [boc»M»2£w5 
7domfl/n* w i T f t w t f W ^ W 
TC0mg/mi,2Q0mt 4966^1624^011 
l o O ^ m L S O m ! 4»^W622-01 
(Baxter HyJarKf/JmmiHrto} 
Gamntttflcird S/p/ggklL 
"isgrn-ea""" jod944^6a>-W 
tffmme&toto®) 
tomxtm GtabuBn 
(6axter Hytand/tmmuno) 
Oarnmogotd,S/E?/f PI, U 
(Baxter Hykaiui/immvm^) 
50^m.ea fo0944^fiat>4)8 
lBay^>^mimurv» 
loF^Ceo K5944-^WM 
>0CK)2^ 0iS4S-7} 
C P W ^ O O Q ^ D I MK.W T^ $7,00 
M K , ^ 
w 
»74-i 151^70 j " OS.OTK f $t$ <^ 0 
^20.2fl 
a os 
B 
roOmgM JOOmJ 
lODrng/^^KJmJ 
^00n^/ml.50^ 
00026-O64S-24 
i 00026-044^2$ 
J 
57DO 
$S.40 
$2*3 
sua 
$5.B9 
$11-57 
$780.00 
#,$#..00 
$39aa> 
5^17500 
^35000 
$70000 
Fl, ASO OS &tiyerj 
R, OS, Bayer 
n,ASO.OS.Boy«r] 
$727 50 
$L50U3 
$362,50 
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to 
torwmwe Gfrbttiti 
I tmmmv Gtefcuft 
I itGfittexhm 
J iofot&parr 
I Lorazefxtn] 
I L&xn&pQm 
I tmx&pom 
j tiircuedpom 
| " iorosf^pwn 
j Loraz&pam 
I iiirazfcpara 
j torca&pam 
1 Ic^Wponi 
„ 
| lonaatptfm 
j tvprorr 
[ lupron 
j UiprorH 
I lupfpnl 
t Lvpt&n] 
j Suffate 
J Sodium Svcctrxxlm j 
1 Sodium Succtootz] 
1 ME^hytpfed i^xoJon j^ 
Bedim Succinatej 
i>] (CftRtoon) Oomme*-
*| (Ceirteon)CammaT' 
Mtt/PBUJMd!fo*R*> 
r {3cheJrt)flllJfa(lD.V.) 
J (AbbofrHo^.J/(lfrrAK 
smwm 
\\ {At^itep.yfmx} 
r <AbbtftHfc*pJ/{V1At) 
(Ab^Bo»p.)/(VIAl) 
J (Abbott H o ^ j / 
(V*At,Rtt*TOtt 
j (Abbott Ho**)/ 
(YlAtRiFTOF} 
' (AteottHOS|>,)/ 
rviAM^frTor) 
(Abbott Hospj/ 
fVlAt.fUPTO^ 
! (AbboH HMP4/WJ, U (VIAl) 
1 { V ^ f l ^ y ^ 
A*va*/(M.D.V.) 
(Wy^m-Ayeert) 
(Wydh-Ayertf) 
t Attam/fkfcV) {tap>iupr©n&*pot/($ 
{fop) Luproft DepoVP 
(fap) Lwproo Itepo*/r w, P 
RJMtt 
[Top)UrprGrtI>*po»/rDUJ 1 
frftY,). 
C&eyVSOi, IH (SULFATE PRK) I 
(&ey)/SOW IB (SUIFAIE 1*85) 
(Abbott Hasp.) A-
Meftopr**/? DL u ftfNIViAi} 
{AbbottHosp.)A- I 
[Abbott rtosp.) A* 
Metbaprod/ra, lifUNJVIAL} 
(Abbt^Ho^p^A-
MeJbaprikd/PDMJfADD-
VANtASH} j 
|^h0rmQekj/tip]c&n}SoHi* J 
MsdWACT-O-VJAU j 
IWVMlIM llHIHIBl hHWII • I l | l | 1 »••«« 
[ 10gm/eo 
I 50mg/n&2mi 
j 2rr$/roUmtC-fV 
4mg/mUrotC>iV 
Uct^/ir&IOmJ,orV 
|.2nig*nl!arr»l/C4V 
1 2irig/mUmhC4V 
j 4mg/mUmlC-iV 
p.mg/fnir1QmlCr/ 
4 rog/ttJ, IGml. CMV 
2mg/ml)^C*fV/ 
4w>^rrM0nr£CMV 
|2mg/ml»l0mtCMV 
2mg/iml hnl,G4V 
22.5 mg, sa 
n.26 m^/Oa j 
30rng*ea j 
7,5nD&&a 1 
375 mg, eo 1 
0,6%. 2500 mtJSs. 
0.4%, 2500 mi, 2&> 
lgm,eo j 
40mg.ea j 
I25mQ>©CJ | 
500mg,&a j 
12&mg,ea 
SOOm&aa ( 
(00053-7486-05 j Hetfft C©aWton> f $96.67 
\ | AHXOS j 
j f A50, OS 
100364-8012^ 
00074-4776^] 
100674*3539-01 
\WQ74>*\$39-IQ 
p0074rlW5-10 
0007^773-01 
<X»74-*779-0* 
00074-67S«rt 
00074*6781-0) 
\QOD74')9B5^1 
00008-O57<H)f 
O0D0WS81-O1 
iO00O8-O58)-04 
00300-333^)1 
003003343*011 
0(^3673-01 
od$oo-3429-oi 
0030CK&394H 
49$02^ <$7M>3 
49S02-O678-O3 
00074-563 i-08 
00074-5*84*01 
C^74-5685-02j 
0OO74-S6&I-44 
30009-019CW 
)0009-O?^5^2 
' j M&.OS^KQTh 
j B* 
| MJC 
1 M ) C 
j 8fc 
j BS.R 
1 SB 
A$O,0TN,ft 
B&.R 
j JWK. 
n "> 
I 'ri 
R 
ASO^FtOTHOS 
R 
R,A$ao$ j 
A&D,O$,'R,D*N 
R,OS 
B6,M*C 
B.B,MK j 
OTN | 
OTtf 
OTM 
OTM 
ft^OS j 
SB" 
I.| ^ 3 . 3 3 
>j $24.5? 
j " ».60 
j $3^0 
$30.66" 
$2?,S3 
52-SO 
$3.80 
$24.42 
$28,75 
#M» 
$48.00 
$29.^0 
i $a^s 
51,447^0 
JUW.O0 
51,902.30 
$482.52 
$404-00 
$n.2? 
$11.29 
$16,75 
$Z30 
55.35 
$9,40 
$2.52 
$5,51 
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fPbarmacla/tf pjohn) SOHJ- !gm,eci **33W-OT 
)) 
e&,ASD.R,C$ ] $IU9 
Sodium Suetinate 
(Pfcormctcki/iJpJohn} Soto- *gm,ea 09-0698-01 BS. a, os $?u? 
M*frylprectols*>km6 
Sodium Succinate 
5G0rng,^o a&aos $6.37 
Stttfym Succinate 
(Ph»wottto/Up|phn} Soli** 
M#dfot/(W/DILtigNri 
2gm,so BS,fc SK4) 
500mg,ea to?*Qa87-0J ASO MA? 
•40mg,<&a M>ua-i* AS&&.05 $1.45 
Mffomycfo {&&ctfofd/^Pf,fJ(S,p>vj -j.fflg .^oo B90-025I-01 a os. ASD $&.*3 
Mtftnttycfrt gactftteyFPUJ (SX>,vj 2Qmg,eo 55390-02524*! a ASD, os JU6-67 
fifltomycfr? (fauttfrHri/Pt If 3Qmg>eo &703-03Q6-5Q ASO, OS *V 34.00 
foeeMongfe 
300mg,eo 57317-021CM36 $36,00 
(Fujisovfo) Nefcmp*rti/PDR, IH 300 m& eo £&23*Q&77-15 £J6J)C 
(G«rwlo)/PDlfU{S^YJ 3O0mg,ea 5MQ00-O5 $29.00 
$o<tf^Oitotf<fe [Afctott Hosp,)#ADfc*VAW. o.*&$0trt &74-71GH* TRUBB $3.22 
.todfcmi Ofttifctoi o.9&100mf &A-7W14Z TRt^ US $3.22 
SodfumCWatfcte (Abiatft Bp*p.y(A&&*VA*tt 
UfECAIte) 
G,9&25Drol D74-710V4B Tftt,*6 *4J9 
^tfumCttwkte (Abbott Hoip.yilflffCAKE} o.Wt»ml 374-79&4-3<$ mAsnO&oiH *t.4S 
tocffomCWctffcte {Abbott Hasp.)/(UFECAW) 0.9%, ?00ml D74~7?S4-3? TRkASao&OlH. •1-45 
SotfmCWotfda (Abfcott Hosp.J/fUFECAIt 
pu$Tycco^ 
a?&5Q0mi i74-79S34>3 B,ASafcfi,GS $U9 
OOSTWS^O? . $odfom Cftfoifde {A&btfiKa$p*]/0JF£GA*k &9&itt»n* R,ASO,$&,OS $2,17 
Sodfom CfckwWe! (Abto^HospJ/tUFECAIS, 
PiASlTC} 
0.9%, 250 mt D74-I5BWJ2 % c m a os $1.94 
$o<tfumCWc«kte (Abbott Ho*p#{UFECARE, 0.9%, 2 5 0 mf D74-7983-02 a*sa&& $ M I 
SodfrmCMNfefe] (Abbott H<*p4/(ttfECA*fc 
HASTtC) 
0.9%,i$omf 074-79B3-4J «,ASO,OS,OTN $1,43 
$oc&/mCtofcte; (toder)/^HI-EAG PLUS) 0.9%rS0irt D33&-Q55B-U TRL $3.32 
S&dtotaCftaffcte (fe<^deQ/(Mm^gA^fU/$) 0.9& 100 mi 0(B38*D553-I& TRl $3.17 
$o<ifr>mC/*fof*w (fcjotefVCMUttl PACK, MWI- 0.9&50mi 033e-OQ49-ai 
0te38-OO4^^j 
ro.« $1.55 
JtotfumCWaifcte (S&xlerfciMBLtl PACICMIMb tfc'WUQOmf Tfcl.ft $1*5$ 
SwBvmChloikt* 
Sadfvm Ctihfht& 
{fcsxtef)/{&tJAD PACK, MINI-
PACtt) 
0,9%, 50 mi 00338-004*-) f TR1 $L50 
^orf«)/f OUAO PACK, MWt-
PACQf 
0.95^100 rnl b338-0049-ia T« $i,ao 
SocBum CMofide* {IkW^VfSWGlgPACK, a«t mm\ M38-004^0t TRKR $1.5? 
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12 
| Sa^Cltotkti 
J tadfeirmCftforkft 
1 ZodtemCifakk 
j Se&mCMxkk 
| Sodlttm CWorftf* 
rtnOi« 
j SadfwnCfeiftte 
J SotfvmCMojftte 
I iod&umChhrkt* 
j Sadfiwt Cftfwfcfe 
| f*fitosfefC>It* 
L Cypfanate 
j Tobramycin Sulfate 
j ro&ramyakt $vffctt*\ 
j TdJS>mr»v^5t^c*^ 
I toJtJranryc^^ffflf^j 
j "Yofapt^^^trtej 
j Tobramyc^ySaMc^l 
1 Hyx3rc>chlo<ida\ 
j HytkothhMtt) 
| Vaacomycm 
j VoncomKCtfij 
j Hydtt>ctitot1de\ 
j #(/rfrocW0rfd©j 
V<&ccmycto\ 
MINI-BAG) _ 
MWMAG) 
Mlffl-SAG) 
» (BaxterV(S|HG^PACIC, 
MWKIAG) 
(MCGrttW) 
< {McOewVnsOMLfAB) 
{McGw)/(fXCa} 
(Mc<Skiw}/{6XCa} 
j CMcGcw)/(EXCBl) 
.
 ir.ite«l»*Br&ine_m 
(fbcarmacta/Upjohn) Oepo-
(Scb^yiNJJJCM^V,} 
(Abbft»Ho??>,MSaNJ 
(Ab^Hoj^MVW, Mk) 
fAb toH Hosp, V{ VfcUlptop) 
(AJbho«HospO/»NJJi(V^ 
Ffiplop) J 
(<5e«^q)/IMi,U<M.0.V,> 
(0«iaJd)/}Ni, U (MA V,) 
(Atoott Hwp,)/(BUIK VJAl) 
{AbijoMHosp.^{ViAt 
(Abbott Bo*p.)/(VtAL 
<Abfc*ffHtfsp,)/OtfAI, 
(Abfrotf Ho«p.)/^t» ^ (ADD-
VANTAGE) 
(VlAi) 
(Fujhtowo)iyphDcln/PI>ni j 
(VIA!) 
MAi ) 
{hdl$owt»}LyphocJn/?DiU j 
WAL1 
(WW 
(Fuiffeawa)i.yphodn/PCHii | 
(VlAi) [ 
T QSJL ajbirt ~" 
0.9%>5QON 
a«.KX»mi 
o . ^ 5 0 m l ~ 
0,9%, 100mJ 
50IYJI 
0.93fc loom* 
{ " • - - - „ • - , , „ „ , 
| Cttft&Bfrt 
a,9%>2£>mi 
j 003384)049^2 j *«*«' 
joo33S-6b -^d3 t* «" 
00338*0049^ 
J 00330-0049-*) 
00338-Q049-4B 
002^>800-3) 
00264-1800-32 
0026+^00-00 
j 00264~78QO-10 
|6K^B0£fi0 
1206 mg/ml, 1 iH, G4B j 00009-34 J 7-01 
1200 mg/it i 10 mi, C-
1
 18 
..4Dmg/rftl2mi 
|40n&/ml,£0irf 
4Dmg/nri2tTtf 
)0mgJtvl2m | 
40mg/mL2mi I 
4Q.rng/m(,30mt 
$Qm,&Q 
5GGrog,lQ*,e^ J 
i g n v U X e a j 
Jsm,Kfc,ea j 
50Omg, ICfc, feo j 
500mg.ea j 
I gm,eo J 
5£m,ec 1 
lsm,eo 
Ssrrvea " J, 
lOsrrteo < 
[6boo9^4W& 
jQD364-<$* 17-54 
00074-358^1 
00074-3590^02 
00074*3578*0* 
00074~3$77-O) 
00703-9402*04] 
002^9414.01 j 
00074^509-01 
00074-4332-OJ 
00074^533-01 j 
00074-5535^1 
00O74-6$34-0t 
004^-2210^30 
004^9-?B4(M6,| 
064W-»St'^00 
&2B2iaSt» 
M32S-0M5-41 
S332a<33lftl] 
i\ m.n 
' tm 
j TRJ,R 
| xzun 
m,& 
TRlOTN.aASD 
T» OW,R AS> 
j rf&diN,RAsb 
j ' fiS OTH 
BkOTM 
A$D,MtCR 
66 
SS, MK 
$B,Mfc 
&&,MK j 
FI.MK "j 
1
 n j 
"n'M&i* 
OS ( 
R,(SrMMK,HS j 
a MiL a& 
as.MJC 
fea, rrtk j 
BB 
1 
6B ' J 
" MK 
j $1.4?" 
j " $iie1,u 
j $2.03 ^ 
$1.71 
j '*'1.SS"" 
j $IA9 
I $W9 
{ $2.19 
$"il53 
$1.5? _ 
j *n>9 
$2475 " 
$13-59 
*5.$4 
^>03.M 
$4.99 
$2,94 
$<5,9B 
$3<S,90 
$41.24 
^4.?S 
$9,05 
$12.17 
$5.09 
$7,00 
$13.00 
$7150 
$1100 
$7150 
V 43,00 
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1 Va&comycfrt 
1 Vcftcwycifi 
1 Vcmcortjyctfi 
1 Hr&ocMotfdB 
i Vanctmycin 
U^nrfioSD/ 
WMio'ff iFj 
1 --..1 
(le^teSfckhod.) 
1 9etM».»cLlwdJl 
Vdffeol«*/PIMIHJ;« 
]$diefa}pttt, UfluLtW.) 
fSefeefj^Dlli0.D*V.) 
(Nc*bJ)ito(d)frnmt/mr 
{NabJ)rtK><<i)frmmme 
(Nobl)rha{d) fanmtm* 
| 500mg,ea 
&gt&&0 
ytpt ife-ee 
1 SQDmgJOs/eo 
IgrruK&eci 
500mg,H2s,eo 
5000*u,ea j 
d00lii,ea 
isobfeBq1 
Up32S-22TO 0^ 
uW-3tS4^5 
00205-3154-15 
i<TO0$4t£44» 
003^24^91 
i»s«Ji472^a 
to49MG2«l 1 
io492^X)2l-01 
io4«MKJ2W)"i 
13 
1 33>W 
MK,B& 
MO& 
[ M£,BS 
I OTN 
M£ 
ASO.aOTMb5 j 
ASUFLQS 
"ASkaoiwJos 
j $7,00 
&$m 
[ &M 
$4,51 
JJ2.90 
53-54 
J505.56 
*S4,?6 
$152.30 
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14 
Att> » AS& $p*eto*K H*d&hcate (14W*74**62n) 
*ft * terpen Btunswig (t*S0Ch?46~&m) 
fi*tiwkktfoto$ten 0-*OO-6U+OtS2) 
MK a McKetsou (l*m~?$Sl-tU6) 
ANDA MWAfl-«0M3f-243$) 
JUom&t PlU* 3/99 "Bkm&dmss toe p~m-BD9*230% 
HeatoCotfBffon-H^fcCocrfiffen {!-#Hhi*5dv7a$$) 
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15 
Ai1acbment2 - Do not use these data to update, the HCPtfcS billing codes that 
correspond to the drugs on this list Instead use your usual source for averoge 
whotesate prices. 
SmMsm ftfrflfflfr tt&&&£32&& li£& 
$973&m9>C7 
js&stakr 
e a 
55^1^32 
v.od 
3Gmg/rhl,5ml OS $74DS 
!5u«ea OOOTSsKHIO-20 EOS.A5D 
6001^3^3-01 
$255^ 
Bteottrfz** $**<** 30aea 
'000!3-)4^ 
a os i$w& 
Bk&nycto Sulfate {Pb<rnnocWU#ohn}/PD I5u,eo ASt>,aOS $m>6? 
30u, ea OOQtW $ W M ASD, ft OS 
(is-st 
$322,00 
Cfc/tfrifta (APP}/iW,li 
SOKW 
43323-01 
SiSSi^J? 
OS.Fi $!50.9B 
Clsplofin i*r*\tmu OS,FI 
A3^S^535 
$$03.50 
Ckptottn (AFr)/JNJ,U 
)0Om* 
OS,ff 
0 ^ 1 5 ^ M T 
9301.58 
Cyctophaspamide 
Cyetophospemfcfei 
(IWflof-Myer Onc/Jrnm) 
Cytoxan 
iyopbJH2»d/H3rUJ 
(VjAl) 
!G0mg>ea ASD, OS, Om 
(8ri$*oi-Myer Onc/lmm) 
Cytoxan 
LyophmHrti/Fl^U 
2G0m£,ea cSois-osiMi ASD. OS. OIN 
K1B 
$7.03 
Cyftf^o«pqmW#! (Er!$W'My«f Ofts/tmm} 
Cytoxan 
50$mg,.ea QCKH 6-0547-41 ASD, OS, GIN 
^ M U 
m$9 
Cyck>pho$pamide\ (Bffcfcrt^y*rOm:/imm) 
Cytoxan 
\grnt&o 00015 ASD, OS, OIN $23J? 
Cyctepli^p^fc** (Brfsicrf*Myef Onc/lrom) 
CyfcDxcm 
Lyfcp«Jfced/W,U 
2gm,ea 0dO}'54)5jlWl' A$D,OS,OTN 
00DI3'56i)^3 
$45.83 
Cypk>pha&pamld$ (Phctfrftetfa/Upjohn) 
Hsow/PPUJr(S&tf«) 
!0Omg,eo ASD, OTri OS, $3.*2 
Cycleph&pQMkl* 20Gnr>£,ea OOG^&ll^S ASD. R OS, 
I OTN 
b0O?3^6-?3 
$5.04 
Cyclop Jvospamfcte (Pham*acfci/Ufc{ohn) 500mg,ea ASD.B.OS, 
OTN 
$7.33 
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i<& 
i 'cytorQbte& j (J^crd)/tt& i ) (Vt*0 
[ Cyfcrcdbftwi 
j CytorofeflM 
I Cytaafetoe 
j • ^orab&ie 
[ <ty*arabtoe 
j C^^iaiiMe 
j CWkrlaJbei* 
I Cytorat&m 
j Cyfarabitoe 
I Cytarobftfe 
| CytoraWaa 
j Cytorabfofcl 
j Cyfaabttiei i 1 
J CyfcraW^ej 
1 Cylctti^kt^] 
I Cytarabto* I 
1 ttottebtefoi 
Ooxarvbicinl 
1 Hj/drccMorfcte 
1 DOXOCUbfCffll 
1 «KC*rt>c/itenW |^ 
1 Jtydrcthkxidal 
A(Mk^)fHA,iiimi) 
|{6edtefd}/FOlril(VIAt) 
(»^rofd)^DMi{VJAi) 
(S«dford)/?&JlIJ(ViAl) 
(ft«dlord)/PDXU^i/a} 
\&e&6&)WMtionAl) 
(Bf«if^/FDiU{VUL) 
1 ri&.v^F^ 
j [Foyldiftfl}/JNJrU 
<Phartwida/Up}ohn) j 
(Fhatmacla/UpjQito) j 
Cyto*fl¥>U/PW,U 
(WW 
CyfosaNMPDWJ 
<S^h«lfi)/WJJ(MI>.V.) 
(Sch¥ft)/f W/U (Miiy.} 
{B#d«Ofd)/WJ,W{MJ&,V}J 
(**drord}/JNJ, U £$>&,V) j 
(fi»dfctfd3/{Niu($4?;V) j 
(todta*yittr U (S£,V) 
{^drord)7pbUi{S.D.y) 
(»«H6rd}/FDllJ($,D,V) 
(fitedford)/rDUJ(S^vj 
(Fwp»Owa/A?F)/(VfAy 
1 lgm,ec 
j 2§m,ec 
J }0Omg.ea 
1 50Omg,ea 
Ignxea 
} 2graea 
j |00rr»9^ea; 
1 50am9>9a 
j _Vgm,$ci 
I 2gm,ea 
PACKAGE) 2D 
20mg/mL25rot 
1
 fM.D,V) 
JOOrc^ea 
$0C>mg,ea j 
30ml vial, 1 gm, j 
2$m,fco 
ioDmg,ep I 
500mg,ea j 
2mg/mi10Ofmi 
2mg/nril,SnS i 
10ml j 
25ml 
lOmg 
20mg 
SO rng, eo 
! — , -nrrrr - - , -« { 
1 OS 
|553&4I3WC 
$53?0-O!$2«lfl 
}553ttHH$MH 
|553^&>Q134HD1 
!J55a9CK5ab )^P 
}55i9*0aQ7-]O 
555f0^30S-cr 
J5^0NJS05S>7: 
Ul^0303-5O 
[^7030304-2^ 
$1703^30S-0* 
00QD?*-O3734H 
00W4W73-OC j 
00009*3295-01 
0OD0^v329^O1 
00344^467*53 
00*54^448-54 
55390^3^01 
55390^35-101 
&3904323WO 
5$$9CM)237^ 01 
55390-023M0 
5539CM)23^10 
S^6w6233-01 
2m$/mU0OmJ |.0p4^J60W)j 
I $u.#1 
' $2t# j 
^ASad$ fa^tKJ $3*55 1 
A&a.os.n, 
OtNrMlCSB 
j ASD.OS.ft. 
OTMBB.MK 
BS 
j BB 
j BS. 
I 8& 
BkM£ 
A$D,B8,PJ.bS 
&&.MK"fi 
*&D,OS.OTN, 
ASD,0&O7Kj 
a-Mic 
ASD,O$.OTN, 
ASD,OS,OTH 
aMK [ 
&&,MK 
BB..MftQTN 
FLOTN 
' ad™ 
a am 
aOTRGS 
FL OTN 
ROW' 
a-owos j 
A5D 
| mM | 
1 $£U< 
| $47.94 
| $3,S0 • 
$10.50 I 
*22.6a.f 
j $44,^ 0 
•S'xfo"'J 
$12^3 j 
| 4^^ 62 
$4*0* 
*13.)» 
$25.TI 
?4?,$2 
$4.16 * 
$?2,H 
$139.75 
^10.3$ 
$'20,20 j 
$37.97 
$9.dS 
i j 8,48 
135.93 
$|4O.D0 
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(Ftf#ow*/APP)/{V*AL) 2mg/mUG&ml \ &322rO\Q\~(>\ OS $w.n 
Doxwbkh 
ft&V^PJF.) 
2mg/ni 5?r^  004*9 OS 57,35 
f$i>X>P.Ff 
10 ml 004*?<6&31<a0 05 $UJC 
004**3^50 zsrrt ASD ?3S.0C 
$3323*0^3-05 <Pu)kcwaMPP)/l*jJ,M 
ft&.¥JP.r,) 
2rns/ml£nr>] 0$ 
SSJoS^Tol 
$7,35 
|fyi^ »cfcfeyfcj» (SUV, My) 
Tom* 
Wttioisb-SO 
OS $14.70 
25 ml 
00703-SOkcMn 
ASD $34*00 
(&entey(JU>»V. 2rng/nvU0GmJ Asaos 
o575a5oS5^ 
SU2.00 
2<D£//niSntf ASD,OS,BB 
OOToSSSt^ Ol 
$12.<S3 
POtVMgK) 
25nrtf ASD,OS 
0 0 0 1 S - H ( ^ 8 3 
$35.50 
Hydrochkxictel Adjiftroyefo/foiP,V* W&) 
2mg/roJ, )00m| ASD,Ok& $150.86 
Doxorubicin 
Aefaiqmycrto/(A<iD>VJ 
150mpr«o oooi3*nli4~83 
000!SM "lf&Wl 
ASO, o$. a 
am 
$U3.73 
boxorvbicln (Phorniocto/Upfchn) 
Addq^drt/Pit$INJ,« 
Smg/raUSwvl 
000*3-? | |4^1 
A$D, os, a 
CRN 
$ M 9 
Hy&ocKtotfdi* 
(fhonrnttcto/UpJohrt) 
Adfomydn/PJ$IW,U 
10 ml ASD.OS,a 
OTN 
00013-11^7* 
$i&74 
(Pjhonmjckr/Upltfw) 
A&taW^*t/Pr$*N.UJ 
25 ml ASO. horn *3?-W 
Hydrochloride 
{Phormodo/Uric^rt) 
Adnaroycto/PFSIRUJ 
(ytAl>.fy 
$7,500 ml 000^1176-67 ASt>,ROH 
0$ 
oo6id»i<W? 
$5?.5? 
OoxOfl/JWcft (fhormocfa/upjoho) K>m0,aa A$D, R, OtNr 
OS 
$a*24 
Hydrochlortd* A<kfcmvcfn/*DFPtH,!J 
5Dmg,ea OOOTMUW-W 
#opa$k** 20mg/m?.5mf 553?S5FroT 
Asaos,a 
OTN 
a os 
$37 J 5 
18.45 
Boposkt* 25 m! 55390-0^^01 ao$ 
55390-0^3-01 
$45 J 3 
tfopostete 50 ml OS, PI 
iteso 
$$7 4£ 
ftopesfcto 7,5 ml 00015 OS 
$3$95 
*5I,4$ 
Bopotfefo (&rfcfo**fAy«tf Onc/kwrO 
V^sWtNJJJ(MJP.y<$ 
20m$/rnl5mt 000^^ 0 ^20 OS 
0 0 7 0 3 ^ ^ 0 1 
067QS:g^4^0f 
£34,30 | 
flfopoifrk (Gemto)/{WJLK 
PACKAGE 
2Dmg/roi,50mi ASD, OS $7Z.6$ 
ifoposkhl fGen»fd)/{MJ),V,) ) 20ffigt/ml25 ml Asa os $40,00 
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[ &Qpotfdi 
Boposidi 
t £&potfdft 
J £top&$ktt 
I fodorto 
j factor J* 
j tttcforiX 
j ""foetorflT 
factor IX 
j fbctarfld 
J foctorVtff! 
1 " " ^ fa rVJ t f i 
j fe^VWH 
i 
*0lYMJ:ft) 
> j ( f h&nnada/UpJohft) 
CoaguJatiofi FoetorPDl, 
» 
1 (Centeon) 
I CoasuktfJott Factor fDJ. 
(Centeon) 
Coagtjfoflorr factor FDI, 
U 
(GeneHcslnsi) 
tentsflx/foctociX 
Coo0uEafiDn factor FM, 
!rJI{$JCJ,V.w/cflhiimi100O 
to 
feftnefiX/ftfcforiX ] 
Coagiifcrtioft Factor *Dk I 
• » 
(Genetic* fosi} 1 
fceasflx/FoctorlX 
Coagutoffoa Faeiof I'M, 
(ftaxter Hyfond/immuno) j 
hemophilic fcic*orr j 
hem&pMttc factor, 
human K>J,U{apAf«x, I 
fteeambfncrte/ottH* j 
humaaPDUJ(approx. 
(Bay** Phorm) Kott* 
HP/arfl-h<mwpWic 
factor, human fDUJ j 
j 20 mg/ml 5ml 
j 2Oin0/mt$ni| 
)0ml 
25ntf 
f t iu, eq 
j ) fc/, ea 
[ 
| 1iu,ea 
I iu, ea 
l l u e a 
? &J, ea | 
1 iu, ea I 
I H a a j 
1 iu. eo j 
100703^653-01 
00013-733^1 
j 000* 3-7346^ 
O0Dt3-735.5-8fi 
00053-7^M>1 
000$^76684>2 
|000$3-7<&8-O4 
583M~OOCH*0I 
58394-0002^)1 
^?4-Q0Q3-0t 
6»44£93W1 
0094^2933-02} 
00944^933^03 
30026^0664-50 
it'^ ASDros 
ASD,OS,ft 
( A$D,Q$,B 
rj ASDmiH 
j ASD3/*9 
nASD3/99' 
{ -ASD3/99 
ASD2/00 
ASD2/0Q 
A$D 2/0Q 
ail sizes, 3/9? I 
Uti sees, 3/W [ 
ASDaRsrzss j 
1 $rm") 
1 $9.47 
j IJftMM 
$44;00 I 
$079 
$0.79 
SOT? 
50c81 
$asV | 
$aav f 
$0.95 
"$0.92-
$Q,?a | 
$0.42 
««, —.. >. J 
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1? 
J ~~~ fbcshrW 
| FodocVn 
1 lfccstarv» 
| fochrW 
j factor VB/ 
AidtirVffl 
fcrctorVW 
Facte ViH 
factor V2W 
foctaW// 
facta VW 
facrfarVJffj 
J frielwVflM 
J f 
jj 
Pk^imcm 
r i^orcwodlj 
I fspprox TWO ti/Vtaf} 
J HWefifr-h&mfrpW&c 
1 facta, hymen PCI, U 
u (»«#» NKOT**) Koat* 
J W/an0*fc*m©phIfc 
j facte, human Mtf,l J 
f (BoVNfifWKwm) 
| hamophfte factor, 
j (fcq/erPhann) 
J hftmoph$c facto. 
(6<iyerttKJfiri) 
Kogenote/aftft* 
h*«wphiifc factor. 
(Cen^nJ^octattt/ootf^ 
hemophilic *oct«. 
(Centean) ateclato/anfi- j 
hentophftc factor* 
recombinant fD?,!J 
(Centeoft) Helfxate/antf- j 
tiamQphBte factor, ] 
recombinant PW, U 
hcjmophlfic factor* J 
r»tfombInaniFDUJ j 
{C*htee>n) H^<rt*/an& 
fc«m?phlffc factor, j 
(Cftnteoft) Monocyte- | 
r/<mtf-hemopwjfc factor,! 
human M)J, U 
(c^rite<>ft) Monocles*- j 
human PDUi f 
P/antf-h*jnoph8Jc fctcfetf J 
(VIAL) 
f^fcawa/AfP}flH4,U 
(VIAL) [ 
T ilu>W 
| I ki,6£ 
1 1 h, ea 
} I iu ea 
1 1 iu ea 
[ llu,fea 
I'UiQO 
Ifofca ] 
*k j ,ea" 
! fu, ©a j 
5 >U, 00 I 
Viuveo 
J tu,ea | 
1 *t\ so 1 
i fu eo j 
SOFrsg/rtU 10ml' 1 
Jgm,2Droi U 
I 3/99 
flOCEdHD664.2a ASD off tee* 
lQa6i<W3664^3C 
j 0002^70-20 
0002^70-30 
C002M)670*50 
00Q53-8H0-0I 
^ 5 ^ 8 U 0 - 0 2 l 
0005^BT1(W)4| 
00053*8120-01 
OOOsi&l 20*02 
GK)0i»-8t2O^4J 
00053-765&*Of 
O0053-765M)2 
00053.7636-04 
« 3 3 » 9 h W 0 | 
^332iot!7-20 
j ASOcrti sizes 
3/99 
cdt&es,S/99 
alUI*es,$/99 
tfllsfees,£/99 
Bioirhedf*feti^  
! all sfcas 3/99 
MbfPZ6/n 
ASaafsi^as 1 
S/99 
ASD,olives j 
aw 
{Uftft)r?F.S/99 
aft sfcas 3/99 j 
ASDolJSii^5 j 
2/00 
ASD a l l i e s 
2/00 
ASD all sizes j 
2/00 1 
OSAft [ 
OS.fl 
"['" '#M | 
$6,42 1 
$G<42 
$0,92 
$0-92 
$0.92 j 
$0*91 
$O;B4 
$0.78 
$OTS 
$0.84 1 
#&?.* 
$0.70 
$0.70 j 
$070 
$S20 
$JW0 
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momrw& {FaJkowa/AI*)/HU.J 
WAD 
2igmr56inl £32Wlft|»* 
iSX^ilf4t ] 0$,B 
05fB 
20 
ttuoWF&cB Zgm, JODjyj) 
W 
jiKoa 
Adr«c#/iNj,U(VIAi) 
'§Dn?gyml lO.iml 0Q013-I03£l 
OOOtM046^4, 
ASD,0$,OH :$L47 
JfoofaiimeS {FHannacta/tfRjQtm) SO ml A 5 D . O H F M $8-1$ 
flworowaep (Ffcamacio/tfpjftfen) 
Adwca/l*UU(VlAi) 
Kttml 00013-105^4 A$D,OHfLJ $14.44 
_ OS 1 
Kyttf (SKte&cham 
I tamjmuriDlV, ) 
Im&toilmi |DD05»-4i49-b! 
ooS^iTS^F 
a OS, O H 
ASD 
$J3?,CM 
tfyfr* (SKSeechom Img/mUm* 
L&tfCGvafa Cafcfom (Afcbolt»osp;)/{VlAt 10mg/rnl.25m$ 00074-4541-iM 
Ft O H ASD* 
OS 
& 
Ft, OIK ASD. 
OS 
$555.4? 
$G.5d 
t^ycc vortn C&Jcfom (A&bc#Hoxp«)/mj,U 
f\rtALFli>TW) 
Kttng/ni. JOmi QD07*4$4l 
W5?H 
ft, O H OS $3.85; 
tevcavwfrr Cate&m (B«*lfcrd)/FDUJ{VlAi> 50 mg, Kteea 553PJ a O H ASD, 
OS 
3>ZX4 
ley covcwi Cakxkim H&ihfdj/ttllJiVlW )QQm& )0$ea SB&OOOSWO 
"2OOm0r"eo jS5#0O053-|ctt 
a DTK ASD. 
05 
$$£4 
tetfcovow* Calcium (fi$dterd}/i»0l)J{VlAJL3 
iSfe? 
a O H ASD. 
OS • 
$&w 
I*t/c0*w*n Cotefuro 10Dms*ea 00703^5*4' OIK, ASD, OS 
sfci 
$5.49 
leaeowpnft Ca/cfi/ro 350rofi,eo 00703-5145*1 O H ASD, OS $15,83 
tetfcovrorfn Colc/wn (lii^ uh&y)rfDtMCFJF.) 35D trip, fro S80^O62W OH^OS .$.1*5$ 
Methotrexate SsdSfrm f**dtol#mu(3J&.V>) 25 mg/mt 2 m). &3fr043D3f-il& A5D/OHB :$2.63 
Ateteotoexof* Sodft/m {N»dfor4)/IMJ,U(mvb) 25mg/ml4ml 5539G-0032-IIO ASD, O H R 
5S39O-0033JIO 
W^5 
Mafhotawcate Sodium t&«cllo«i>/mirU{5.DfcVJ 2SFng/nrt,'6ml ASD. O H R 
S63*b-0b»4lO 
$5.0$ 
Melftofroxate Sodium (&*dtordyittJ,!KUXV.) 25rogtotf, 10 ml ASD, O H FJ 
35wf 
$5.70 
Ateffcofrsxate Sodium (Jmmunex>iFF/INJJ4 25mg/miBnrrt 58406 T2 
iS^5S5fi$ 
ASD, 05* O H $5,84 
Metooteaate Sodium {ImwwwxyiFf/t^U 2Smg/nM.2mi A$Dr ASD, OS, 
n 
$2,?* 
Mefhotosxat* Sodium {Jmtwine>c)lFF/iMJJi 
fS*XV.,Kfc) 
2Smg/mlJ0ml 5&4MW&&\4 
mMros&i-iB 
ASD. O H a 
OS 
$7 JO 
Meffiofrexote So&vm 25mg/mi.4ml ft MK, O H OS 
$8m<om\»u 
$4.32 
M&matrttmte Sodfrm (lRimim«R}/mi.U{ViAif 25mg/mJ,2ml A$D,O$,0H 
Fl 
UAZ 
MetfiOfttsxote $odft/ffr igmeo S&40M87W5 OS. O H MK *45,?7 
10mg,ea | 5 » 5 ? t l 0 
L __ 
Vinblastine Sulfate (&^dfOf<i)/W,0{ViAl) A$D.O$ fOH 
Ff 
$$.)* 
ytobkm**su#Qfo {fe^ldkig)nHi,U(Vmi) { Wm&.eo »ifrre iV7a^ttM* ASD. 57:9$ 
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1 vSbfcttffca Suflofe 
| VktbkzfitteSvffQte 
j V»X3ftfcteSu3ote 
Vfticris&jeSofote 
j Wi&&kte$u8ote 
[ XQimktine Sulfate 
i Zofrsttj 
j 2o*cm 
2©*oi*j 
1 ffM}towa/APP} 
( l^wq/Af?) 
«4 
ViiM:tiwyiWiJJ{YiML 
{MJB.V.} j 
{Cmnex)/f»U,U 
I Img/rrtUOml 
)mg/™UDrrt 
[ 1 ma/ml 1 art 
1 ImQ/mUm! 
1 mg/jnt) ml 
lmd/mt,'2fri ! 
2mg/rol,2Qmi j 
»mo/5bml,S0 
"imB/ni2iYd 
[00469-iErw-abJ A S X O S 
^332^27^)01 OTRR 
j*liW:W»0*« 
|*)7DWJ»M6 
(Xm&74$6~&6-
O0O1W4**66. 
00 
00 j 
02 , j 
[ASD^OTN. 
A5bG& 0W, 
A$0,OW,R 
OS 
OS- .1 
& 0 T H A $ D , 
•OS 
r J^WT] 
$10.93 J 
[ $4.34 
$?*<# 
$5.10 
'#8,35 
$U?.& J 
R,OTM,Fi,OS j $52S.O? j 
ROIHOS $22.61 [ 
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HIGHLY CONFIDENTIAL 
FILED UNDER SEAL 
EXHIBIT C 
to Complaint 
State of Alaska v. Abbott 
Laboratories, et al. 
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LAWRENCE G. WASDEN 
ATTORNEY GENERAL 
STATE OF IDAHO 
BRETT DELANGE, ISB #3628 
JANE HOCHBERG, ISB #5465 
Deputy Attorneys General 
Consumer Protection Unit 
Office of the Attorney General 
Len B. Jordan Building, Lower Level 
650 W. State Street, P. 0. Box 83720 
Boise, Idaho 83720-0010 
Telephone: (208)334-2424 
Facsimile: (208) 334-2830 
MICHAEL WENGET-HERNANDEZ (pro hac vice application pending) 
Winget-Hernandez, LLC 
3112 Windsor Road #228 
Austin, TX 78703 
Telephone: (512) 474-4095 
Facsimile: (512) 697-0080 
Texas State Bar # 21769650 
ATTORNEYS FOR THE STATE OF IDAHO 
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF THE 
STATE OF IDAHO, IN AND FOR THE COUJNTY OF ADA 
STATE OF IDAHO, 
Plaintiff, 
vs. 
ABBOTT LABORATORIES, 
DSPUTY 
COMPLAINT AND DEMAND 
FORlfURY TRIAL 
Defendant. 
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The plaintiff, State of Idaho, by Lawrence G. Wasden the Attorney General for the State 
of Idaho, brings this action on behalf of the State and taxpayers complaining of the above-
captioned pharmaceutical manufacturer defendant as follows for its illegal conduct which lias 
resulted in windfall profits at the expense of the State and its taxpayers: 
NATURE OF THE ACTION 
1, This action is brought on behalf of the State of Idaho, by Lawrence G, Wasden, 
Idaho Attorney General, pursuant to the Idaho Consumer Protection Act (ICPA), Idaho Code 
§ 48-601 et seq. and rules promulgated thereunder, 
2. Idaho brings this lawsuit to recover damages and obtain injunctive relief from 
defendant, who is a manufacturer of prescription drugs. As described in this complaint, 
defendant has taken advantage of the enormously complicated and non-transparent market for 
prescription drugs to engage in an unlawful scheme to cause the State of Idaho to pay inflated 
prices for prescription drugs in connection with its Medicaid Program. The scheme involves the 
publication by defendant of phony "average wholesale prices" ("AWPs"), which then become the 
basis for calculating the cost at which "providers" - the physicians and pharmacies who provide 
these prescription drugs to patients - are reimbursed by the State of Idaho, Defendant reinforces 
this basic tactic with other deceptive practices described in this complaint, including the use of 
secret discounts and rebates to providers and the use of various devices to keep secret the prices 
of its drugs currently available in the marketplace to other purchasers. By engaging in this 
unlawful scheme, defendant has succeeded in having Idaho*s taxpayers finance windfall profits 
to these providers. Defendant attempts to profit from its scheme by using the lure of these 
windfall profits competitively to encourage providers to buy more of its drugs instead of 
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competing in the marketplace solely on the basis of legitimate Ifactors such as price and the 
medicinal value of its drugs. 
AUTHORITY 
3. The Attorney General of Idaho is authorized and empowered to enforce the TCP A 
by Idaho Code.§48-606. 
PARTIES AND JURISDICTION! 
4. The Attorney General for the State of Idaho brings this action on behalf of the 
State of Idaho and its citizens* As described in this complaint, defendants unlawful scheme has 
resulted in higher prices for prescription drugs being paid by Idaht> under the Medicaid program, 
The Attorney General has reason to believe that defendant has used and continues to use the 
methods, acts, and practices set forth in this complaint and which, among other violations, are 
illegal under the ICPA, and that these proceedings are in the public interest, 
5. Defendant is a pharmaceutical company whose fraudulent schemes, including the 
publication of excessive and inflated prices for prescription drugs |as described in this complaint, 
have caused to be presented to officers and/or employees of the Stfcte of Idaho false or fraudulent 
claims for payment or approval of certain drugs to get these falsi© or fraudulent claims paid or 
approved by the State of Idaho Medicaid program, and have resumed in Idaho's taxpayers paying 
for drugs at inflated prices, as detailed below. 
6* At all times material to this civil action, the defendant has transacted business in 
the State of Idaho by, including but not limited to, selling directly or through wholesalers its 
drugs, including those identified hi this complaint, to purchasers Within the State of Idaho. 
7. Defendant Abbott Laboratories ("Abbott11) is ah Illinois corporation with its 
principal place of business at 100 Abbott Park R&, Abbott Park, I3p 60064-6400. 
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8. This Court has jurisdiction over plaintiffs claims as they involve claims arising 
exclusively under Idaho statutes and authority of the Attorney General to act on behalf of the 
State of Idaho. The Attorney General has previously given notice in writing to the defendant that 
these proceedings were contemplated and the defendant had the opportunity to appear before the 
Attorney General and enter into an assurance of voluntary compliance or consent judgment. The 
defendant has declined to enter into such an agreement 
9. Venue is proper in the district court of Ada County, Idaho pursuant to Idaho Code 
§ 48-606(2). 
FACTUAL BACKGROUND 
A. The market for prescription drugs. 
10. The market for prescription drugs is enormously complex and non-transparent. It 
is composed of over 65,000 separate national drug codes ("NDCs'1) (there is a separate NDC 
number for each quantity of each drug manufactured by the defendant). The essential structure 
of the market is as follows. The drugs are manufactured by pharmaceutical companies such as 
the defendant. Defendant sells its drugs (usually with intermediaries and agents involved in the 
process) to physicians* hospitals* and pharmacies. These physicians, hospitals, and pharmacies 
are commonly referred to as "providers," The providers then, in essence, resell the drugs to their 
patients when the drugs are prescribed for, administered, or dispensed to those patients. Most 
patients have private or public health insurance coverage, Where a patient has such insurance, 
the payment that is made for the patient's prescribed drug ultimately will be made, in whole or in 
large part, by a private insurance company, a self-insured entity, or a government entity (in the 
case of the Medicare and Medicaid programs). These private insurance companies, self-insured 
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entities, and government entities are commonly known as "payers.11 More often than not, the 
payer makes the reimbursement payment directly to the provider, ifiot to the patient. 
11. This market structure means that the market for pilescription drugs differs in two 
crucial respects from most markets. 
12. Firsts in most markets, the ultimate consumers pf the product determine the 
demand for a product. This is not the case for prescription drugs. In the prescription drag 
market, the decision to use a prescription drug is overwhelmingly made not by the consumer of 
the drug ~- the patient - but by physicians, hospitals in which the patient is treated, home health-
care agencies, long-term care facilities, or (with respect to the Idecision to use generic drugs 
versus brand-name drugs) pharmacies. Because prescription dj-ugs are dispensed only on a 
physician's order, the physician has the principal say as to wha[t drug will be chosen for the 
patient. However, hospitals also have considerable influence oyer this choice. If a hospital 
decides to put one drug as opposed to a competing drug on its "fotmulary" (the list of drugs that 
the hospital stocks), physicians (particularly residents and attending physicians who are 
employed by the hospital) likely will choose the drug on the formulary rather than a competing 
drug, Likewise, although pharmacies do not prescribe drugs, pharmacies can exert important 
influence over the choice of which drug the patient will purchas|e if there is a choice between 
generic versions of the drug the physician has prescribed. 
13. A second difference between the prescription drag market and ordinary markets is 
that in ordinary markets, the ultimate consumer of the product pays for it directly. In the 
prescription drug market, however, most payments for drugs ate made by "payers" through 
private or public insurance programs. 
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14. This structure of the prescription drug market produces the following fundamental 
fact that underlies defendant's unlawful scheme. If a defendant drug manufacturer can cause a 
"payer" to reimburse the provider for defendant's drug at a higher price than the price the 
provider paid to buy the drug from the defendant, there will be a "spread" between the two 
prices, and that "spread" is retained by the provider as additional profit. The larger the "spread" 
that can be created for a particular drug, the greater the incentive the provider has to choose, or 
influence the choice of? that drug rather than a drug of a competing manufacturer. 
B. The purpose of the Medicaid program and how it responds to the complexity of the 
drug market. 
15. The purpose of the Idaho Medicaid program is to provide medical assistance to 
the state's neediest citizens. 
16. Idaho, through its Medicaid program, is an enormous purchaser of drugs, 
purchasing over $166 million in fiscal year 2005. Although defendant's participation in the 
Idaho Medicaid program is purely voluntary, the defendant has chosen to participate and sell 
drugs to Idaho Medicaid participants because of the size of the Idaho Medicaid program. Thus, 
Idaho may at any given time have to reimburse a provider for any of the drugs of the defendant 
17. Idaho's task is further complicated in that federal law places limits on what Idaho 
may pay providers for any particular drug. Specifically, Idaho'must not reimburse providers 
more than, "the lower of the - (1) Estimated acquisition costs plus reasonable dispensing fees 
established by the agency; or (2) Providers' usual and customary charges to the general public." 
42 C.F.R. § 447331. "Estimated acquisition cost" is defined as "the agency's best estimate of the 
price generally and currently paid by providers for a drug marketed or sold by a particular 
manufacturer or labeler hi the package size of drug most frequently purchased by providers," 
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42 C.F.R, § 447.301. Thus, pursuant to federal law, the highest pjice Idaho can pay for a drag is 
the provider's cost to acquire that drug. 
18. Because defendant has hidden both the prices it which it sells its drugs to 
wholesalers, and its knowledge about the prices at which wholesalers sell their drugs to providers 
(as described in more detail herein), Idaho has no access to the pricing information it needs to 
estimate accurately the providers' acquisition cost of defendants drugs. Because neither Idaho 
nor any other state has sufficient resources to compile complete ajjid accurate lists of defendant's 
drug prices, entire businesses have grown up to provide pricing information to the states and 
others. Three of these are of particular importance in this case. They are First DataBank} the 
Red Book, and Medispaa. These compendia purport to supply accurate price information on the 
defendant's drugs through surveys of wholesalers and information Obtained from defendant itself. 
19. Idaho, like most other states* has chosen First Databank as its primary cost source 
because it supplies up-to-date pricing information hi electronic foritn which can be integrated into 
Idaho's payment structure. First DataBank purports to supply the states with accurate 
information about the-AWP of all drugs, information it receives | from the drug manufacturers 
themselves. As First DataBank explained AWP to its customers in I September, 1991: 
Average Wholesale Price (AWP) is perhaps the most misunderstood concept in 
the pharmaceutical industry. The purpose of this article is to describe what is 
meant by AWP and to explain some of the underlying concepts involved in the 
acquisition, determination and maintenance of First DataBank^ AWP, 
AWP represents an average price which a wholesaler wotild charge a pharmacy 
for a particular product The operative word is average. AWP never means that 
every purchase of that product will be exactly at that price. There are many 
factors involved in pricing at the wholesale level which can modify the prices 
charged even among a group of customers from the same wholesaler. AWP was 
developed because there had to be some price which all pajties could agree upon 
if machine processing was to be possible. 
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At First DataBank, all pricing information is received in hard copy from the 
inanufacturers. Catalogs, price updates, and other information reach us by fax, 
Federal Express, or U.S. mail In the past two years, fax transmission has 
streamlined the acquisition of data to a large extent. 
20. For virtually the entire time period relevant hereto, First DataBank has 
represented that its published AWPs reflect actual average wholesale prices consistent with the 
definition of AWP. 
2L Because Idaho, like most states, has no in-house source of comprehensive 
information about providers1 acquisition cost for defendants drugs, Idaho has relied on the prices 
the defendant reported to First DataBank. Consistent with First DataBank's suggestion that some 
providers were paying less than AWP, Idaho agreed to pay providers an amount consisting of 
AWP minus a certain percentage (currently AWP minus 12%), Idaho has also continued to pay 
a separate dispensing fee to providers to reimburse them for the service provided in dispensing 
drugs to customers. 
22 • As a practical matter, Idaho, like with most other states, is dependent on the First 
DataBank pricing reports for the maintenance of its Medicaid claims processing system* When a 
pharmacy fdls a prescription and dispenses a drug to a Medicaid patient, information on the 
reimbursement price for that prescription is communicated electronically between Idaho*s 
electronic claim processor, EDS, to the pharmacy provider at the point of sale. The information 
EDS uses to determine that reimbursement originates from First DataBank, and is downloaded 
into EDS' database. On a weekly basis, First DataBank electronically sends its updated AWPs 
for the thousands of NDC-numbered drugs listed in its database to EDS. These prices become 
the basis for Id-aho1 reimbursements to providers. There is no other electronic source for this 
information, besides Medispan which publishes the same prices. Accordingly, Idaho is 
functionally dependent on the accuracy of the data the defendant supplies to First DataBank in 
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meeting its obligation to pay providers no more than their actual Acquisition cost of defendant's 
drugs, 
C. Defendants corruption of the government Medicaid assistance programs. 
23. Defendant has defeated the intent of the Medicaid I program to pay providers no 
more than their acquisition cost by reporting false and inflated AWPs to First DataBank and/or 
by reporting prices that it knew, because of the maimer of First t)ataBank's operations, would 
misrepresent defendant's true wholesale prices. One purpose of this scheme was and is to create 
the spread between a drug's true wholesale price and the false anki inflated AWP published by 
First DataBank and thereby increase the incentive for providers| to choose the drug for their 
patients, or, at a minimum, to counteract the same tactic used by a Competitor. 
24. The higher (he spread between the AWP and the tfrie wholesale price, the more 
profit a provider can make. Defendant often markets its products by pointing out (explicitly and 
implicitly) that its drug's spread is larger than the spread of a competing drug. 
25. The defendant has inflated its drugs' reported AWP^ to levels far beyond any real 
average wholesale price for its drugs. One high-ranking industry executive has described it as 
the industry practice to do so. 
26. In 2004, high-ranking executives of certain pharmaceutical manufacturers 
testified before Congress that their AWPs do not reflect the actual selling prices of their drags. 
At the same meeting when asked why his generic drug manufacturer doesn't lower its AWP on 
generic drugs, a chief financial officer of one of the manufacturers! testified: "The simple answer 
is that given the system that now exists our customers won't buy frbm us if we lower our AWP." 
27. Attached as Exli. A to this complaint is a list of (thugs manufactured by certain 
pharmaceutical companies including the defendant and/or itb subsidiaries that the U.S. 
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Department of Justice, after an extensive invest!gation, found to have inflated AWPs. The U.S. 
Department of Health and Human Services concluded, with respect to ail drugs utilized in the 
Medicare program that r,[a] general conclusion reached in reviewing the GAO [General 
Accounting Office] and OIG [Office of Inspector General] data is that there is a level of 
overstatement in the listed AWP for all drugs....* Payment Reform for Part B Drugs, 68 Fed, 
Reg. 50,431 (August 20,2003) (emphasis added). 
28, Plaintiff has obtained the false prices defendant caused to be published by 
FirstData Bank Plaintiff has also obtained data showing the true AWPs of defendant's drugs 
from two of the largest national drug wholesalers: Cardinal and AmerisourceBergen. Attached 
as Exh, B to this complaint is a chart containing additional examples of defendant's drugs that 
have false and inflated AWPs. Exh. B identifies (a) the NDC; (b) the name of the drug; (c) the 
false AWP published by First DataBank as of the end of each year from 2001 to 2003; (d) the 
average AWP published by First DataBank for each year from 2001 to 2003; (e) a market price 
for the NDC for each year from 2001 to 2003; and (f) the spread between the market price and 
the AWP, The AWPs and market prices are unit prices. The source of the market prices is 
AmerisourceBergen, one of the three largest wholesalers. The market price is the average price 
at which AmerisourceBergen sold the NDC numbered drug to the classes of trade that are 
reimbursed by the Idaho Medicaid program, Le.9 retail pharmacies, chain pharmacies, and long-
term care facilities. The spread, expressed as a percentage, is calculated as average AWP minus 
market price. The NDC numbered drugs on Exh, B are those for which the Idaho Medicaid 
program paid more than $10,000.00 between 2001 and 2003, Plaintiff has similar data for years 
prior to 2001 and after 2003, which data will be produced to defendant upon request during 
discovery. The NDC numbered drugs identified in Exh. B constitute most, but not necessarily 
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all, of the NDC numbered drugs upon which the stale is seeking damages. The following 
provides an example of Exh. B: 
I Drug 
NDC 
BiAXIN 
[ 74316315 
Year-end 
Reported 
I FDBAWP 
; 2001 
; 0,362 
AV0 
Reported 
FDBAWP 
2001 
0361 
Avg 
Market 
I Price 
2001 
0.28G 
AWPMkt 
Pnce 
I Spread 
2001 
! 26% 
Year-end 
Reported 
FDBAWP 
2002 
0,383 
Avg 
Reported 
FDBAWP 
2002 
0 377 
Avg Market 
Price 2002 
0301 
AWPMkt 
Pnce 
Spread 
2002 
| 35% 
Year-end : 
Reported 
FDB AWP 
!
 2003 
0,398 
Avg | 
Reported 
i FDBAWP 
! 2003 
j "" 0.395 
Avg 
Market 
Pnce 
ZOOS 
0.313 
AWPMkt] 
Pnce 
Spread 
2003 
26% 
29. As it has done with its AWPs> defendant ha£ illegally and deceptively 
misrepresented and inflated the wholesale acquisition cost ("WACj") of its drugs. WAC is the 
price at which defendant sells its drugs to wholesalers. Defendant has made it appear that any 
reduction in the purchase price below the listed WAC would resiilt in a loss to the wholesaler 
and was, hcace, unachievable, when in fact defendant Boordijy discounted the WAC io 
purchasers other than the Medicaid program. 
DEFENDANT'S EXACERBATION OF THE COMPLEXITIES OF THE 
MARKET AND AFFIRMATIVE CONCEALMENT OF ITS WRONGDOING 
30. Defendant has been able to succeed in its drug pribing scheme for more than a 
decade by exacerbating the complexities of the huge and complex 4rug market, and by purposely 
concealing its pricing scheme from Idaho and other payers, as set fqrth below. 
31. The published wholesale price of any of the thousands of NDC numbered dings 
might, and often does, change at any time. As a consequence, just |to tack the current published 
prices of drugs utilized by a state's citizens requires resources and| expertise that most states do 
not have. 
32. Defendant has further exacerbated the inherent complexities of the drug market 
by utilizing marketing schemes that conceal the true price of its dxlugs in the following different 
ways. 
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33. First, defendant sells its drugs in a unique manner that hides fhe true prices. This 
scheme works as follows. Upon agreeing on a quantity and price of a drug with a provider or 
group of providers, defendant purports to sell the agreed-upon drugs at the WAC price to a 
wholesaler with whom the defendant has a contractual arrangement The wholesaler then ships 
the product to the provider, charging the provider the price originally agreed upon by the drug 
manufacturer and the provider, which price is lower than the WAC. When the wholesaler 
receives payment from the provider, it sends a bill to the defendant, called a "charge back;' for 
the difference between the WAC and the lower price actually paid by the provider. These charge 
backs (or "shelf adjustments" or economic inducements with varying names) are kept secret from 
the payers, including the State of Idaho, so that it appears that the wholesaler actually purchased 
the drug at the higher WAC price. The effect of this practice is to create the impression of a 
higher than actual wholesale price paid by the wholesaler and passed on to the provider. 
Defendant hides other actual price reductions by directly paying providers market share rebates 
and other off-invoice rebates and discounts that are calculated long after the actual purchase date 
of the drugs. 
34. Second, defendant further inhibits the ability of Idaho and other payers and 
ultmiate purchasers to learn the true cost of its drugs by wrapping the sales agreements it 
negotiates with providers in absolute secrecy, terming them trade secrets and proprietary, to 
preclude providers from telling others the actual price they paid. 
35. Third, defendant further obscures the true prices for its drugs through its policy of 
treating so-called classes of trade differently. Thus, for the same drug, pharmacies are given one 
price, hospitals another, and doctors yet another. 
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36. Defendant has further concealed its conduct by mailing sure that all of the entities 
that purchase drugs directly from the defendant (and thus know the true price of its drugs) have 
had an incentive to keep defendant's scheme secret. Defendant's Scheme permits all providers -
pharmacies, physicians, and hospitals/clinics - to make some profit off defendant's inflated 
spread, because all of them are reimbursed in some manner on thd basis of the AWP for at least 
some of the drugs they sell or administer. For providers, therefore, the greater the difference 
between the actual price and the published AWP, the more mone^ they make Thus, providers 
willingly sign drug sales contracts requiring them to keep secret th^ prices they pay for drugs. 
37. Defendant has continuously concealed the true I price of its drugs and has 
continued to report and cause to be published false and inflated A f^lfPs and WACs as if they were 
real, representative prices. Indeed, in the 2000 edition of pharmaceutical manufacturer Novartis' 
Pharmacy Benefit Report, an industiy trade publication, the glossary defines AWP as follows: 
Average wholesale price (AWP) - A published suggested! wholesale price for a 
drug> based on the average cost of the drug to a pharmacy from representative 
sample of drug wholesalers. There are many AWPs available within the industry, 
AWP is often used by pharmacies to price prescriptions. Health plans also use 
AWP - usually discounted ~ as the basis foi reimbursement of covered 
medications, 
Novartis Pharmacy Benefit Report: Facts and Figures, 20001 edition, East Hanover, NJ, 
Novartis Pharmaceuticals Corporation, p, 43. 
3$. Defendant's unlawful scheme has completely corrupted the market for 
prescription drugs. Instead of competing on price and medicinal value alone, defendant has 
deliberately sought to create a powezful financial incentive for providers to prescribe drugs based 
primarily on the spread between the true price of a drug and rj:s published AWP or WAC, 
Creating incentives for providers to prescribe drugs based on such| a spread is inconsistent with 
Idaho law and public policy, Large price spreads on higher priced Idrugs encourage providers to 
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prescribe more expensive drugs instead of their lower priced substitutes, thereby increasing the 
cost of healthcare. Competition on the basis of such spreads also has the potential to influence 
providers (consciously or unconsciously) to prescribe less efficacious drugs over ones with 
greater medicinal value. Because of defendant's concealment of its scheme, Idaho has 
unknowingly underwritten this perversion of competition in the drug market. In sum, defendant 
has been, and continues to be, engaged in an insidious, deceptive scheme that is causing Idaho to 
pay millions of dollars a year more than it should for its prescription drugs, and may well be 
inducing some providers to prescribe less efficacious drugs, 
THE GOVERNMENTAL INVESTIGATIONS OF DEFENDANT'S CONDUCT 
39. hi 2000, Congress began its investigation of the pricing practices of certain 
pharmaceutical manufacturers in connection with the Medicare program based on documents 
Congress had subpoenaed from those manufacturers in connection with a confidential qui tain 
filing. On September 28, 2000, as part of this investigation, U.S. representative Pete Stark wrote 
to the president of the Pharaiaceutical Research and Manufacturers of America (the main 
pharmaceutical trade association of which most pharmaceutical manufacturers are members) as 
follows: 
Drug company deception costs federal and state governments, private insurers and 
others billions of dollars per year in excessive drug costs. This corruptive scheme 
is perverting the financial integrity of the Medicare program and banning 
beneficiaries who are required to pay 20% of Medicare^ current limited drug 
benefit. Furthermore, these deceptive, unlawful practices have a devastating 
financial impact upon the states1 Medicaid Program..., 
The evidence I have obtained indicates that at least some of your members have 
knowingly and deliberately falsely inflated their representations of the average 
wholesale price ("AWP"), wholesaler acquisition cost (f,WACft) and direct price 
("DP") which are utilized by the Medicare and Medicaid programs in establishing 
drug reimbursements to providers. The evidence clearly establishes and exposes 
the drug manufacturers themselves that were the direct and sometimes indirect 
sources of the fraudulent misrepresentation of prices. Moreover, this 
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unscrupulous "cartel" of companies has gone to extreme lengths to "mask" their 
drugs' true prices and their fraudulent conduct from federal t^nd state authorities, I 
have learned that the difference between the falsely inflated representations of 
AWP and WAC versus the true prices providers are paying is regularly referred to 
in your industry as "the spread".,, 
The evidence is overwhelming that this "spread" did not oticur accidentally but is 
the product of conscious and fully informed business decisions by certain PliRMA 
members.,.. 
146 Cong. Rec. E1622 (daily ed. September 28, 2000) (September 28, 2000 letter from House 
Committee on Ways and Means, Subcommittee on Health* to Alan R Holmer, President, 
Pharmaceutical Research and Manufacturers of America, Washington, D.C.). 
40, On December 21, 2000, Congress passed the Medicare, Medicaid and SCHIP 
Benefits Improvement and Protection Act of 2000 ("BIPA"), Pijib. L. No. 106-554, § 429(c) 
(2000), which required a comprehensive study of drug pricing. 
41, In 2003, the House Committee on Energy and Commerce expanded Congress* 
Medicare investigation into pricing practices in the state Medicaid program. On June 26, 2003, 
Chairman Billy Tauzin (R~La.) and Oversight and Investigations Subcommittee Chairman 
James Greenwood (R.-Pa.) wrote as follows to 26 drug companies: 
an investigation into The Committee on Energy and Commerce is conducting 
pharmaceutical reimbursements and rebates under Medicaid. This'inquiry builds 
upon the earlier work by this Committee on the relationship between the drug 
pricing practices of certain pharmaceutical companies ana reimbursements rates 
under the Medicare program. In that investigation, the Committee uncovered 
significant discrepancies between what some pharmaceutical companies charged 
providers for certain drugs and what Medicare then reimbursed those providers 
for dispensing those drugs. This price difference resulted in profit incentives for 
providers to use the drugs of specific companies as well I as higher costs to the 
Medicare system and the patients it serves. For example, we learned that one 
manufacturer sold a chemotherapy drug to a health care provider for $730, when 
the reported price for Medicare was $740. The taxpayer therefore reimbursed the 
doctor almost $600 for dispensing the drug and the cancer patient had a $148 co-
payment Such practices are unacceptable in the view of the Committee, which is 
why we are in the process of moving legislation to address these abuses. 
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The Committee has similar concerns regarding drug prices in Medicaid, which 
has a substantially larger pharmaceutical benefit than Medicare. 
House Committee on Energy and Commerce Press Release, Tauzin, Greenwood Expand 
Medicaid Fraud Investigation (June 26, 2003), available at <http://energycommerce 
.house.gov/108/News/06262003_1002.htrn>. 
42. The Congressional investigation is continuing. On December 7> 2004, the House 
Subcommittee of Oversight and Investigation of the Commerce and Energy Committee 
conducted a hearing on "Medicaid Prescription Drug Reimbursement: Why the Government 
Pays Too Much." In his opening remarks, Chairman Joe Barton (R-TX) stated: 
Data obtained by the Committee from five of the largest retail pharmacy chains 
reveals that during the period July 1, 2002 to June 20, 2003, the average 
acquisition costs for seven widely prescribed generic drugs was $0>22? while the 
average Medicaid reimbursement; just for those drugs alone* was $056-more than 
double the cost.. 
"Medicaid Prescription Drug Reimbursement: Why the Government Pays Too Much," Hearing 
Before the House Subcomm. on Oversight and Investigations, No. 108-126, at 5 (2004), 
available at <http://fhvebgate.access,gpo.gov/cgi-bin/useftp.cgi?IPaddress:=l 62.140.64.52 
&filenanie=97275.pdf&directory^/disk2/wais/data/108_house_hearings>. 
43, The importance to Idaho and the other states of the information being sought by 
this investigation was explained by Hemy Waxman duiing the December, 2004 House 
Committee on Energy and Commerce hearings on Medicaid pricing practices. Congressman 
Waxman explained that even though the federal government had access to the manufacturers' 
actual average manufacturers prices ("AMPs1'), the states did not: 
the drug industry was powerful, and they succeeded in securing a provision in the 
basic legislation that kept the best price and the AMP information a secret. 
Can you imagine that? The Federal Government knew this information* but we 
kept it a secr&t from the States. This has proved to be a costly error. Without this 
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crucial piece of information, States who are, after all, responsible for establishing 
the reimbursement rates for prescription drugs could not sit their reimbursement 
rates appropriately. 
As a result, [the states] continued to rely on the average Wholesale price minus 
some arbitrary amount simply because they did not havq the information they 
needed to set a more appropriate reimbursement rate, 
#,8174, 
44. As a result of all these investigations, many states befgan to investigate defendant's 
and other pharmaceutical manufacturers' drug pricing practices on Kheir own, leading to lawsuits 
by more than 20 separate states, including Idaho, Notwithstanding these investigations and 
lawsuits, defendant continues to publish, or participate in the publication of, inflated wholesale 
prices, and continues to hide the true prices of its drugs. 
THE INJURY TO THE MEDICAID PROGRAM 
CAUSED BY DEFENDANT'S FALSE WHOLESALE PRICES 
45. Medicaid is a joint federal and state health-care entitlement program authorized 
by federal law, with mandatory and optional provisions for eligibility and benefits covered, 
including pharmacy. Idaho' Medicaid program is administered |by the Idaho Department of 
Health and Welfare. 
46. Idaho Medicaid drug expenditures have increased dramatically. In fiscal year 
1999 (covering the period July 1, 1998 to June 30, 1999), Idaho| Medicaid drug expenditures 
totaled over $64 million. In fiscal year 2005 (covering the period Jhlv 1,2004 to June 30,2005), 
Idaho Medicaid drug expenditures totaled over $166 million, which constitutes approximately 
15.5% of the overall Medicaid budget As of December, 2004, ihe number of Idaho citizens 
enrolled in Medicaid is approximately 171,000, which represents (approximately 12.5% of the 
state population. 
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47, During the relevant time period, with some exceptions, reimbursement to 
pharmacies, physicians, and hospitals for drugs covered by the Idaho Medicaid program has been 
made at defendants published AWP minus a percentage (currently 12%), plus a dispensing fee. 
48, For a minority of the drugs purchased by Idaho, the state sets its reimbursement 
rate at the lesser of the published AWP minus a percentage (currently 12%), the federal upper 
limit ("FUL"), or at a rate established by the state maximum allowable cost ("MAC") program. 
For multi-source drugs that have at least three suppliers, the Center for Medicaid Services 
("CMS1') generally establishes FULs, defined as 150% of the least costly therapeutic equivalent 
(using all national compendia) that can be purchased by pharmacies in quantities of 100 tablets 
or capsule or, in the case of liquids, the commonly listed size. 42 C.F.R, § 447332, As a 
practical matter, CMS has relied on the defendant's inflated prices to set most of its FULs. The 
states also may set reimbursement rates for these drugs at rates lower than the FUL pursuant to 
the state MAC program and Idalio has done so in a number of instances. Had defendant reported 
truthful prices, the FULs and state MACs would have been lower. 
49. At all relevant times, defendant was aware of the reimbuisement formula used in 
the Idaho Medicaid program and the dependence of the Medicaid program on defendant's 
reported AWPs, 
50. By reporting false and inflated wholesale prices, and by keeping its true wholesale 
prices secret, defendant has knowingly created a situation that enabled providers of drugs to 
Medicaid recipients to receive reimbursements from Idaho that are higher than they would be if 
the tme wholesale prices were reported, and interfered wilh Idaho1 ability to set reasonable 
reimbursement rates for these drugs. 
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51. As a consequence, the Idaho Medicaid program his paid more for prescription 
drugs than it would have if defendant had reported its true wholesale prices. 
DEFENDANTS CONDUCT WAS INTENTIONALLY 
IN DISREGARD OF ESTABLISHED IJAW 
52. Defendant had a duty to deal truthfully and honestly |with the State of Idaho and it 
so knew. 
53. Moreover, it has uniformly been the law for over 60 [years that it is unlawful for a 
seller to cause to be circulated a price at which no, or few, sales arel actually expected, whether it 
is called a list price, suggested price, or benchmark price. E.g., F,T\C. v. Colgate-Palmolive Co,, 
380 U.S. 374 (1965). Defendant either knew of this law or abted in reckless and willful 
disregard of it 
54. Defendant purposefully took advantage of a systeiti designed to assist Idaho's 
neediest citizens with medical care and established a system designed to plunder it 
55* Defendant has willfully ignored, and continues to ignore: (a) its duty to Idaho to 
behave with scrupulous honesty; (b) case law uniformly holding that its pricing practices are 
unlawful; and (c) the reprimands of Congress. 
56. As a result, civil penalties, consistent with Idaho's statutory scheme, are mandated 
in this case. 
HARM TO IDAHO 
57, Defendant's unlawful activities have significantly an|d adversely impacted Idaho. 
Idalio has paid more for the dmgs it purchases through its Medicaid| program than it would have 
if defendant had reported the true wholesale prices of its drugs. 
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58. Defendant's conduct materially affected the ability of Idaho to provide medical 
caxe to its neediest citizens by forcing Idaho to pay higher costs thereby reducing the availability 
of medical assistance to Idaho's neediest citizens. 
COUNTI 
Violations of the Idaho Consumer Protection Act 
59. Plaintiff hereby realleges all previous paragraphs. 
60. Idaho Code § 48-603(17) declares that it is unlawful to engage "in any act or 
practice which is otherwise misleading, false, or deceptive to the consumer,'* 
61. Moreover, the Idaho Administrative Code, IDAPA 04.02.01.066.04 states that it 
is an unfair and deceptive act or practice for a seller to "state or imply that any goods or services 
are being offered at' wholesale' prices or to use a term of similar meaning unless the prices are in 
fact at or below the current prices which most retailers in the trade area usually and customarily 
pay when they buy such goods or services for resale." 
62. Finally, IDAPA 04.02.01.031 places the burden on the defendant "to substantiate 
all claims or offers made before such claims or offers are advertised. Sellers must maintain 
sufficient records to substantiate all representations made in their advertisements/' 
63. By committing the acts alleged above, defendant has violated the above statute 
and administrative rules. 
64. Idaho has been harmed by defendant's unfair and deceptive conduct in that it has 
paid far more for defendant's drugs than it would have paid had defendant truthfully reported the 
AWPs of its drugs. 
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COUNT II 
Unjust Enrichment 
65. Plaintiff hereby realleges all previous paragraphs, 
66. As a result of defendant's misleading pricing information, Idalio purchased drugs 
at prices greater than they would have had defendant not engaged ih unlawful conduct. 
67. The defendant knew that Idaho was being overcharged by pharmacy providers 
and physicians as a direct result of defendant's misleading pricing information. 
68. As a result of defendant's unlawful conduct, defendant obtained increased sales, 
market share and profits at the expense of Idaho, 
69. The defendant knew that it was not entitled to the profits it realized from the 
increased sales and mai'ket share that resulted from the excessive payments made by Idalio. 
WHEREFORE, plaintiff prays that this Court: 
A. declare that defendant's conduct as described abbve constitutes unfair and/or 
deceptive acts or practices within the meaning of Idaho Code § 48-603 and the 
Idaho Administrative Code; 
B. grant j udgment for plaintiff; 
C. pemianently enjoin defendant and its employee^ officers, directors, agents, 
successors, assigns, affiliates, merged or acquired predecessors, parent or 
controlling entities, subsidiaries, and any and all persons acting in concert or 
participation with defendant, from continuing thq unlawful conduct, acts, and 
practices described above; 
D. award plaintiff State of Idaho actual damages for ill excessive prescription-drug 
payments paid as a result of defendant's unlawful conduct; 
E. award penalties for each violation found by the Coiirt to have been committed by 
the defendant in the amount of $5,000.00 pursuant tp Idaho Code § 48-606(l)(e); 
F. require the defendant to disgorge all profits it realised as a result of its unlawful 
conduct; 
G. award plaintiff its costs and attorneys' fees; and 
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H. award any other relief to which plaintiff is entitled or the Court deems appropriate 
and just. 
PLAINTIFF DEMANDS TRIAL BY JURY OF 12. 
Dated this ,o?6 day of January, 2007. 
LAWRENCE G. WASDEN 
ATTORNEY GENERAL 
STATE OF IDAHO 
By; U 
-Beputy Attorney General 
Michael Winget-Hernandez (pro hac vice application pending) 
Winget-Hernandez, LLC 
3112 Windsor Road #228 
Austin TX 78703 
(512) 474-4095/(512) 697-0080 (fax) 
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IN DISTRICT COURT OF WYANDOTTE COUNTY, KANSAS 
CIVIL COURT DEPARTMENT ^ 
STATE OF KANSAS, ex rel. STEVE SIX, in 
Iii$ official capacity as Attorney General for 
the State of Kansas, 
Plaintiff, 
v* 
ABBOTT LABORATORIES, INC., 
Serve Registered Agent: 
The Corporation Company, Inc. 
515 South Kansas Avenue 
Topeka, Kansas 66603 
Defendant. 
*»*?s 
Case Number; 
Division: —7 
fJTJRJ TRIAL DEMANDED^ 
fl<*U7> 
CERTIFICATE OF SERVICE 
COME NOW Plaintiffs and hereby certify to the Court h^at Plaintiffs* First 
InteiTogatories and First Request for Production of Documents Ito the Defendants listed 
above were served simultaneously with the Petition for Damages, with copies to be 
served on the Defendant by certified mail. 
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Respectfully Submitted, 
THE ST A' 
#Y: ATTORNEY GENERAL" 
'MEMORIAL HAKEr 
120 SW 10TH STREET 
TOPEKA, KS 66612 
Tel: 785.296.2215 
Fax: 785,296.6296 
and 
BARTIMUS, 
& GORNY, 
BY: 
?T&m B A R M ' S KB #22303 
>WARD 1). ROBERTSON HI KS #23028 
11150 OVERBROOK ROAD, STUTl 200 
LEAWOOD, KS 66211-2298 
(913) 266-2300 
(913) 266-2366 FAX 
ATTORNEYS FOR PLAINTIFF 
and 
BEASLEY, ALLEN, CROW, METHVIN ' 
PORTIS& MILES, P.C. 
W. DANIEL MILES, III (pro hac vice pending) 
CLINTON C CARTER (pro Iiac vice pending) 
218 Commerce Street 
PO Box 4160 
Montgomery, AL 36103-4160 
Telephone: (334)269-2343 
Fax: (334) 954-7555 
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IN DISTRICT COURT OF WYANDOTTE COUNTY, 
CIVIL COURT DEPARTMENT 
STATE OF KANSAS, ex rel. STEVE SIX, in 
his official capacity as Attorney General for 
the State of Kansas, 
Plaintiff, 
ABBOTT LABORATORIES, INC, 
Serve Registered Agent: 
The Corporation Company, Inc. 
515 South Kansas Avenue 
Topeka, Kansas 66603 
Defendant. 
J i ?*< LZ LJ 
2h AN 9^23 
CJUR^ TRIAL DEMANDED^ 
Case Number 
Division: 
PETITION PURSUANT TO K.S A. CHAPTERS 50 AND 60 
The State of Kansas, by and through its Attorney General .(hereinafter "the 
State"), files this Petition against the above-named Defendant ahd alleges the following: 
I INTRODUCTION 
1. The Defendant has engaged in false, misleading^ willful, unfair, deceptive 
and unconscionable acts and practices in the pricing and marketing of its prescription 
drug products. The Defendant's fraudulent pricing and marketing of its prescription 
drugs has impacted the citizens of the State of Kansas by causing the Kansas Medicaid 
plan to over-pay for the Defendant's prescription drugs by grossly excessive amounts. 
2. Fan and honest drug pricing is a matter of paramount importance to the 
State and its citizens. Each year, Kansas spends hundreds pf millions of dollars on 
prescription drugs under the State Medicaid program. In thei past year alone, Kansas 
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Medicaid has spent over $160,431,177 on prescription drugs. Expenditures by the State 
and its agencies for prescription drug reimbursement have increased exponentially since 
.1990 as a result, in part, of Defendant's fraudulent pricing scheme. This increase in 
prescription drug costs in recent years has contributed to a health care funding crisis 
within the State that requires action to ensure reimbursement and fair dealing between the 
Defendant and the State and its agencies, 
3. The State is accountable to its citizens and taxpayers as to how it spends 
limited State resources, and it is obligated to pursue any party whose unlawful conduct 
has led to the overspending of State funds. Consequently, Ihe State, by and through its 
Attorney General, brings this action to recover amounts overpaid for prescription drugs 
by Medicaid and civil penalties as a result of the fraudulent and willful conduct of 
Defendant. The State further seeks to prohibit and permanently enjoin Defendant from 
continuing to perpetrate its drug-pricing scheme, to require Defendant to publicly 
disclose true drug prices, and to require Defendant to account for and disgorge all profits 
obtained by Defendant as a result of their improper and unlawful actions. 
4. This lawsuit seeks legal and equitable redress for the fraudulent and 
willful marketing and pricing conduct of Defendant, who have profited from its wrongful 
acts and practices at the expense of the State. 
II, PARTIES 
PLAINTIFF 
5. Plaintiff is the State of Kansas. The State brings this action in its capacity 
as sovereign and on behalf of the Kansas Medicaid program. The Attorney General of the 
State of Kansas, Steve Six, as chief law officer of the State of Kansas is statutorily 
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authorized to prosecute and maintain this action. As an officeif of the State of Kansas, the 
Attorney General is except ftom payment of a docket fee ijor filling this action, See 
K.S.A. 60-2005. 
DEFENDANT 
6. Defendant Abbott Laboratories Inc. ("Abbott") is an Illinois corporation 
with it^nncipal~place of business aflOO AlJbott Park Rd:, A^bott~Park, IE 60064-6400. 
Abbott is engaged in the business of manufacturing, distributing, marketing, and/or 
selling prescription drugs to healthcare providers that are reimbursed by state Medicaid 
agencies, including the Kansas state Medicaid agency, nationwide. Pharmaceuticals that 
are manufactured, distributed, marketed, and/or sold by Apbott and reimbursed by 
Kansas Medicaid. 
Ill, JURISDICTION AND VENUIif 
7. This Court has jurisdiction over the State's claitns as they involve claims 
arising exclusively under Kansas law. 
8. This Court has personal jurisdiction over Defendant pursuant to ICS.A. § 
60-308 because Defendant transacts business in Kansas, has i committed a tortious act 
•witliin Kansas, and purposefully directs or has directed its actions toward Kansas, and/or 
has the requisite minimum contacts with Kansas necessary to Constitutionally permit the 
Court to exercise jurisdiction. 
9. This Court also has jurisdiction pursuant to JLS.A, § 50-638 as the 
Defendant engaged in consumer transactions within this state ttiat form the basis for the 
causes of action alleged in this petition. 
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10. Venue is proper in Wyandotte County, Kansas pursuant to K.S.A. § 60-
604 as the cause of action arose in such county in that State has paid reimbursement 
through Kansas Medicaid for prescription drugs dispensed in this County and throughout 
the State. The events giving rise to the claims herein arose, in substantial part, in every 
County of the state including Wyandotte County. Furthermore, venue is proper in this 
County pursuant to K.S.A, § 60-604 as Defendant regularly and systematically conducts 
business in this County. 
11. Venue is also proper in Wyandotte County, Kansas pursuant to K.S.A. § 
50-638 as the Defendant caused the state Medicaid Agency to be overcharged for 
prescription drug reimbursement in Wyandotte County such that the Defendant 
committed an act or practice declared to be in violation of the Kansas Consumer 
Protection Act in Wyandotte County, Kansas. 
IV, FACTUAL BACKGROUND 
Kansas Medicaid 
12. The Kansas Medicaid program is a state-administered program performing 
a governmental function, which, among other things, pays for prescription drug benefits 
for Kansas' citizens. The Kansas Health Policy Authority oversees the Kansas Medicaid 
program that currently covers approximately 260,000 individuals. 
13. Kansas Medicaid reimburses medical providers, including physicians and 
pharmacists, for drugs prescribed for, and dispensed to, Kansas Medicaid recipients 
pursuant to statutory and administrative formulas. 
14. Reimbursement for pharmacy-dispensed prescription drugs under the 
Kansas Medicaid program is based on internal maiicet and pricing information supplied 
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by Defendant to industry reporting services, This information includes the following 
price indices: (i) Average Wholesale Price ("AWP"), which isj commonly understood as 
the average price charged by wholesalers to retailers, such las hospitals, doctors and 
pharmacies, for prescription drugs, (ii) Wholesale Acquisition Cost ("WAC"), which is 
commonly understood as the average price paid by wholesalers to the manufacturers for 
prescription drugs, and (iii) Direct Price, which is commonfy understood as the price 
charged by drug manufacturers to non-wholesaler customers fat prescription drugs. 
15. At all times relevant to this action, Defendant was aware of Kansas 
Medicaid's drug reimbursement formulas and procedures for pharmacy-dispensed drugs, 
The Defendant's Reporting of Inflated Pricing Information 
16. Defendant knowingly, willfully, wantonly, anchor intentionally provided, 
or caused to be provided, false and inflated AWP, WAC, and/o|r Direct Price information 
for its drugs to various nationally known drug industry reporting services, including First 
DataBanlc (a/k/a Blue Book), Medical Economics, Inc. (a/k/a Hed Book), and Medispan 
(collectively referred to herein as "various nationally knowrjL drug industry reporting 
services" or "reporting services"). These reporting services published the pricing 
information to various reimbursers, including Kansas, who hav0 contracted to receive the 
information (either in electronic or hard copy form) as a basis to provide reimbursement 
to the medical or pharmacy providers who provide the drugs to patients. 
17. The pricing information published by the Defendant was and is used by 
Kansas Medicaid with respect to reimbursement for pharmacy-dispensed drugs. 
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18. At all relevant times to this action, Kansas Medicaid relied upon the AWP, 
WAC, and/or Direct Price provided by Defendant to the industry reporting services in 
determining the amount Kansas Medicaid reimbursed providers of prescription drugs. 
19. Defendant knew the false and deceptive inflation of AWP, WAC, and/or 
Direct Price for its drugs would inflate the reimbursement amount determined by the 
Kansas reimbursement formula, and thus cause Kansas Medicaid to over-pay for these 
drugs by grossly excessive amounts. Defendant's inflated AWPs, WACs, and Direct 
Prices greatly exceeded the actual prices at which they sold their drugs to retailers 
(physicians, hospitals, and pharmacies) and wholesalers. Defendant's reported AWPs, 
WACs, and/or Direct Prices were false and misleading and bore no relation to any price, 
much less a wholesale or actual sales price. 
20. Defendant knowingly, willfully, wantonly, and/or intentionally concealed 
the true AWP, WAC, and/or Direct Price information for their respective drugs from 
Kansas Medicaid. Defendant knows its own AWP, WAC, and Direct Price which it 
reports to the industry reporting services for use by Kansas Medicaid, Defendant also 
knows whether the prices it reports to the reporting services accurately and truthfully 
represent the actual prices as reflected by market experience and conditions, Unless 
governmental or industry surveys, lawsuits, or criminal or regulatory investigations 
publicly reveal the true AWP, WAC, or Direct Price for a particular drug at issue, Kansas 
Medicaid is not privy to the actual market prices which it can then compare against the 
reported prices. Defendant has concealed true market pricing information from the State 
for the pmpose of avoiding detection of the fraudulent scheme described herein. 
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21. Defendant used undisclosed discounts, rebate^ and other inducements, 
Which had the effect of lowering the actual wholesale or s&les prices charged to its 
customers as compared to the reported prices, In addition, Defendant employed secret 
agreements to conceal the lowest prices charged for its pharmaceutical products. As a 
result of these concealed inducements, Defendant prevented third parties, including 
Kansas Medicaid, from detennining the true prices it charges customers. 
Defendant's Marketing of the "Spread" 
22. Defendant refers to the difference between the Reported AWP and WAC, 
on the one hand, and the actual price of a drug, on the other, as the "spread" or, 
alternatively, "return to practice" or "return on investment" Defendant knowingly and 
intentionally created a "spread" on its drugs and used the "spread" to increase its sales 
emd market share of these drugs, thereby increasing its profits. Defendant induced 
physicians, pharmacies, and pharmacy chain stores to purchase its dings, rather than 
competitors' drugs, by persuading them that the larger "spread" on Defendant's drugs 
would allow the physicians and pharmacies to receive mord money, and make more 
profit, through Medicaid reimbursement at the expense of Kansas Medicaid. 
23. Defendant manipulated and controlled the size df the "spread" on its drugs 
by both increasing its reported AWPs, WACs, and Direct Pricefs and decreasing its actual 
prices to wholesalers and providers over time. 
24. In addition to manipulating the reported AWP, WAC5 and/or Direct Price, 
Defendant used free goods, educational grants and other incentives to induce providers to 
purchase its drugs, all of which lowered the actual prices <bf the Defendant's drugs, 
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resulting in increased profits for providers, as well as increased market share and profits 
of the Defendant, at the expense of Kansas Medicaid. 
25. The unfair, fraudulent, willful, wanton, deceptive and unconscionable 
practices engaged in by the Defendant in creating and reporting, or causing to be 
reported, false and inflated AWP, WAC, and/or Direct Price information for its drugs, or 
otherwise concealing actual pricing information, and marketing the "spread" on its drugs 
as an inducement to providers to utilize Defendant's drugs, has resulted in the State 
paying millions of dollars in excess Medicaid payments, while at the same time enriching 
Defendant with excessive, unjust and illegal profits. 
26. The unfair, fraudulent, willful, wanton, deceptive and unconscionable 
practice engaged in by the Defendant has been continuing in nature and has persisted on a 
day by day basis since 1991. 
V, CAUSES OF ACTION 
27. The State asserts only state law claims in this Petition and makes no 
claims herein under die United States Constitution or any federal law. Additionally, none 
of the claims at issue are subject to federal preemption. 
FIRST CAUSE OF ACTION 
(K.S.A. CHAPTER 50: KANSAS CONSUMER PROTECTION ACT) 
28. The State hereby repeats, incorporates by reference and realleges each and 
every allegation set forth above in this Petition. 
29. In providing reimbursement for prescription drugs through the State 
Medicaid Program, the Attorney General brings suit to enforce fee provisions of the 
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Kansas Consumer Protection Act (KCPA), on behalf of thfl State of Kansas and its 
Medicaid recipients, as consumers of prescription drugs, 
30. The Defendant, as a pharmaceutical manufacturer, is a supplier of 
prescription drugs. 
31. The Defendant willfully represented the pricing (information outlined more 
fully above to the State by reporting such information to industry reporting agencies 
knowing that the State depended on the reporting agencies to determine the amount they 
would reimburse providers for prescription drugs. 
32. Defendant's pricing data representations to the |State, outlined more fully 
above, were false in the manner more fully delineated above. 
33. Defendant's pricing data misrepresentations to| the State, outlined more 
fully above, were material as the Defendant had knowledge tftat the State would utilize 
such data to determine the amount they would reimburse providers for prescription drugs 
and thus, pay gross and excessive amounts for such prescription drugs. 
34. The misrepresentations, actions and practices of the Defendant as 
described above constitute unfair and/or deceptive methods as defined by the Kansas 
Consumer Protection Act (KCPA), K.S.A. 50-623, etseq, 
35. The misrepresentations, actions and practice^ of the Defendant as 
described above also constitute unconscionable methods as defined by K.S.A.§ 50-627. 
36. The Defendant's aforementioned practices are Offensive to public policy, 
immoral, unethical, and/or oppressive and violate sections K,S.[A. §§ 50-626 and 50-627. 
Furthermore, Defendant's actions have a direct impact upon th^ public interest since said 
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actions and deceptive/unconscionable practices are longstanding and possess the 
continued potential for repetition. 
37. As an actual and proximate result of the Defendant's deceptive practices, 
the State has suffered actual damages. 
38. In addition to actual damages, and on account of the Defendant's 
continuing deceptive and unconscionable conduct the State is entitled to all penalties, 
costs, fees, etc, prescribed in K.S.A. § 50-634, as the Defendant has willfully used a 
method, act, and/or practice, which it knew or should have known is unlawful pursuant to 
K.S.A. 50-623. 
WHEREFORE, the State prays for judgment on Count I of this Petition for such 
sums that are fair and reasonable in excess of seventy-five thousand dollars ($75,000,00), 
for all statutory fees, expenses and penalties pursuant to K.S.A. § 60-636, for any and all 
costs expended or incurred, and for any and all relief permitted by law this Court deems 
just and proper. 
SECOND CAUSE OF ACTION 
(FRAUD AND MISREPRESENTATION) 
39. The State hereby repeats, incorporates by reference and realleges each and 
every allegation set forth above in this Petition. 
40. There existed at all relevant times a duty owed to the State and its agency, 
Kansas Medicaid, by the Defendant not to mislead the State when voluntarily repoiting 
the prices of its drugs to the various nationally known drug industry reporting services, 
41. Defendant breached its duty of care to provide accurate pricing 
information to the State and its agency, Kansas Medicaid by reporting false and/or 
misleading prices to the various nationally known drug industry reporting services, 
10 
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42. In falsely inflating its AWP, WAC, and/or Direct Price information for its 
drugs when reporting that information to various nationally known drug industry 
reporting services, the Defendant made false and untrue representations of existing and 
material fact to the State. 
43. Defendant also provided false information to Ithe State and its agency, 
Kansas Medicaid, by providing inaccurate pricing information, which representations 
were material, and the Defendant knew the representations Were false at the time they 
were made and/or had a reckless disregard for the truth or falsity of those representations. 
44. Defendant fraudulently concealed the falsity ahd inaccuracy of the price 
representations from the State. 
45. The misrepresentations made to the State and its agency, Kansas 
Medicaid, were intended by Defendant to induce the Statel to pay higher Medicaid 
reimbursement resulting in a larger "spread" on its drugs apd ultimately resulting in 
larger market share for its drugs. 
46. The State and its agency, Kansas Medicaid, di<|l not know that the prices 
reported to the various nationally Icnown drug industry reporting services were, in fact, 
false. 
47. The State and its agency, Kansas Medicaid, reasonably relied on 
Defendant's pricing representations and did in fact pgly the higher Medicaid 
reimbursements. 
48. The State and its agency, Kansas Medicaid, fyad a right to rely on the 
pricing representations made by the Defendant. 
11 
Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU. 
Machine-generated OCR, may contain errors.
49, The State and its agency, Kansas Medicaid, have suffered and continue to 
suffer pecuniary loss as a result of the Defendant's fraudulent and illegal conduct. 
50, The State and its agency, Kansas Medicaid, are entitled to judgment 
against the Defendant for the pecuniary loss it has suffered as a direct and proximate 
result of the Defendant's fraudulent conduct. 
WHEREFORE, the State prays for judgment against the Defendant for such sums 
as are fair and reasonable in excess of seventy-five thousand dollars ($75,000t00), 
together with any and all costs expended and incurred, and for any and all other relief 
permitted by law this Court deems just and proper. 
THIRD CAUSE OF ACTION 
(UNJUST ENRICHMENT) 
51. The State hereby repeats, incorporates by reference and realleges each and 
every allegation set forth above in this Petition, 
52, As a result of the false and misleading statements and representations 
regarding drug prices contained in each Defendant's reporting of AWP, WAC, and Direct 
Price, Kansas Medicaid has paid excessive amounts in connection with purchases or 
reimbursements of purchases of Defendant's prescription drugs. 
53. Defendant knew that medical providers, including pharmacies and 
physicians, who obtained Medicaid reimbursement for Defendant's drug products were 
not entitled to improperly inflated reimbursement rates that were based on Defendant's 
falsely reported AWPs, WACs, and Direct Prices, 
54. As a result of the excessive payments to providers by Kansas Medicaid of 
all or part of the "spread/' Defendant obtained increased sales and market share for its 
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products, and, therefore, increased profits, and was unjustly Enriched at the expense of 
Kansas Medicaid. 
55. Defendant knew it was not entitled to the unjust and increased profits that 
resulted from the sales obtained through the use of the spread^ it created, and Defendant 
should be required to account for and make restitution to the State all such amounts 
obtained through the use of such spreads. 
56. The fraudulent and illegal method by whicli the Defendant obtained 
increased profits make it inequitable for Defendant to retain such benefit without 
payment of its value. 
WHEREFORE, the State prays for judgment on Count till of this Petition for such 
sums as are fair and reasonable in excess of seventy-five thousand dollars ($75,000.00), 
for any and all costs expended and incurred, and for any and all other relief permitted by 
law this Court deems just and proper, 
VI JURY DEMAND 
Plaintiff hereby demands a trial by jury on all claims sc\ triable pursuant to K.S.A, 
§ 60-238. 
VII PRAYER FOR RELIEF 
Wherefore, Plaintiff prays for relief as follows: 
(1) An award of actual damages to the State in sufch amount as is proved at 
trial, together with prejudgment interest; 
(2) All statutory penalties, expenses and fees awarded under the KCP A; 
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(3) An accounting of all profits or gains derived in whole or in pail by 
Defendant through the misconduct complained of herein and disgorgement of all 
improper and ill-gotten profits; 
(4) An order enjoining Defendant from continuing the fraudulent, wanton, 
deceptive and/or unfair acts or practices complained of herein, and requiring corrective 
measures; 
(5) An award of costs and prejudgment interest on all actual damages at the 
statutory rate; and 
(6) Such other and further relief as the Court may deem appropriate and just. 
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COMMONWEALTH OF KENTUCKY 
FRANKLIN CIRCUIT COURT - DIV. II 
CIVIL ACTION NO. 03-CI-1135| 
COMMONWEALTH OF KENTUCKY, ex rel PLAINTIFF 
GREGORY D> STUMBO, ATTORNEY GENERAL 
v. 
WARRICK PHARMACEUTICALS CORPORATION, et al DEFENDANTS 
SECQND AMEPWP COMPLAESJT 
The Plaintiff, Commonwealth of Kentucky, by its Attorney General, Gregory D. Stumbo, for 
its Second Amended Complaint against the Defendants Warrick I Pharmaceuticals Corporation, 
Schering-Plough Corporation, Schering Corporation and Dey, Inc^  (hereafter the "Defendants"), 
alleges as follows: 
I. INTRODUCTION 
1. The Defendants have engaged in fraudulent, unfair, fMse, misleading and deceptive 
acts and practices in the pricing and marketing of their prescription djrug products. The Defendants' 
fraudulent pricing and marketing of their prescription drugs, including, but not limited to those 
identified in Exhibit 1, have impacted elderly, disabled and poor Kentucky citizens covered by the 
Commonwealth of Kentucky's Medicaid program (hereafter "Kentucky Medicaid"), by causing the 
Kentucky Medicaid program to pay grossly excessive prices for the Qefendants' prescription drugs. 
2, Fair pricing of prescription drugs is of paramount coitcern to the Commonwealth of 
Kentucky and its citizens. The exponential increase in prescription! drug costs in recent years has 
contributed to a health care crisis within the Commonwealth of Kentucky that requires action to 
ensure fair dealing between the Defendants and the Kentucky Medicaid program covering senior 
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citizens, the disabled and the poor. 
3. Plaintiff, Commonwealth of Kentucky, by its Attorney General, Gregory D. Stumbo, 
seeks to permanently enjoin the Defendants from continuing to engage in fraudulent, unfair, false, 
misleading and deceptive drug pricing acts and practices, to recover damages and/or restitution on 
behalf of the Commonwealth of Kentucky, and to impose civil penalties and punitive damages 
against the Defendants for their fraudulent, illegal and erroneous pricing and marketing practices. 
n.PAHTIgS 
4. Plaintiff, Gregory D. Stumbo, is the duly elected Attorney General of the 
Commonwealth of Kentucky and is authorized pursuant to Kentucky Revised Statutes (KRS) 
Chapter 15,060, Chapter 367, and Kentucky common law, including the Attorney General's parens 
patriae authority, to bring this action on behalf of the Commonwealth of Kentucky and its citizens. 
The Attorney General has determined that these proceedings are in the public interest. 
5. Defendant Warrick Pharmaceuticals Corporation, ("Warrick") is a Delaware 
corporation with its principal places of business in Reno, Nevada and Kenilworth, New Jersey. 
Warrick is a wholly owned subsidiary of Schering-Plough Corporation. At all relevant times 
material to this action, Warrick transacted business in the Commonwealth of Kentucky by, including, 
but not limited to, the marketing, distribution and selling of pharmaceutical drug products, directly 
or indirectly, to wholesalers, retailers and Medicaid providers in the Commonwealth of Kentucky. 
6. Defendant, Schering-Plough Corporation ("Schering-Plough") is a corporation 
organized under the laws of New Jersey with its principal offices in Madison, New Jersey. At all 
times material to this civil action, Schering-Plough and its subsidiaries have transacted business in 
the Commonwealth of Kentucky by, including, but not limited to, the marketing, distribution and 
2 
Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU. 
Machine-generated OCR, may contain errors.
selling of pharmaceutical drug products, directly or indirectly, to purchasers in the Commonwealth 
of Kentucky, including, but not limited to Kentucky Medicaid providers in the Commonwealth of 
Kentucky. 
7. Defendant Sobering Corporation, ("Schering") is a ^ few Jersey corporation with its 
principal offices located at 1 Giralda Farms, P.O. Box 1000, Madison, New Jersey 07940, 
8. Defendant Dey, Inc., ("Dey")> formerly known a& Dey Laboratories, Inc., is a 
Delaware corporation with its principal place of business in Napa, California. At all times material 
to this action, Dey transacted business in the Commonwealth of Kentucky by, including, but not 
limited to, the marketing, distribution and soiling of pharmaceutical drug products to Kentucky 
Medicaid providers in the Commonwealth of Kentucky. 
HI, JURISDICTION AND VENUft 
9. This Court has jurisdiction over the Plaintiff, Commonwealth of Kentucky's claims 
as they involve claims arising exclusively under Kentucky statutes, Kentucky common law and the 
parens patriae authority of the Attorney General to act on behalf of th[e Commonwealth of Kentucky 
and its citizens. The Defendants have failed to designate an agent to receive service of process 
within the Commonwealth of Kentucky. Therefore, pursuant to KtRS 454.210 (3)(a), service of 
process may be made upon the Kentucky Secretary of State, who shajl be deemed to be the statutory 
agent of the Defendants. 
10. Venue is proper in Franklin County, Kentucky, pursuant to KRS 452.460 because the 
injuries to the PlaintifFoccurred in Franklin County, Kentucky, and pursuant to 367.190 (1) because 
the unlawful method, acts and/or practices of the Defendants were Committed in Franklin County, 
Kentucky. 
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IV, FACTUAL BACKGROUND 
A. The Kentucky Medicaid Program 
11. The Kentucky Medicaid program is a joint state and federal program which pays for 
medical care, including prescription drug benefits, for Kentucky's poor citizens. Medicaid currently 
covers approximately 669,000, or one (1) in six (6), Kentuckians. Twenty percent (20%) of 
Kentucky's entire state budget goes to the Medicaid program. Prescription drug benefits are the 
largest component of the Kentucky Medicaid budget Since 1995, the total annual cost of 
prescription drugs to Kentucky Medicaid has increased approximately 300% from total annual costs 
of $237,102,055 in 1995 to $798,296,942.00 for fiscal year 2004. Kentucky consistently ranks near 
the top nationally in the number of prescriptions obtained per person annually. The number of 
Kentuckians covered by Medicaid and the costs associated with providing care for them continue 
to increase annually, while the Kentucky Medicaid Program's ability to keep pace with these 
increases has been diminished due to state budget shortfalls. 
12. The Kentucky Medicaid program is administered by the Kentucky Cabinet for Health 
and Family Services, Kentucky Medicaid reimburses medical providers ("providers"), including 
pharmacists and physicians, and otherwise pays for covered drugs dispensed and administered to 
Medicaid recipients pursuant to statutory formulas. 
13. KRS 205.560 and Kentucky Administrative Regulations 907 KAR 1:018 establish 
the formulas used by Kentucky Medicaid to reimburse providers for prescription drugs dispensed 
or administered to Medicaid recipients by Kentucky Medicaid providers. 
14. At all times material hereto prior to April 1, 2003, pursuant to 907 KAR 1:021, 
Kentucky Medicaid reimbursed providers the lesser of (a) The Federal maximum allowable cost 
4 
Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU. 
Machine-generated OCR, may contain errors.
(FMAC), plus a dispensing fee, (b) average wholesale price ("AW^") of the drug minus 10%, plus 
a dispensing fee, or (c) usual and customary billed charges. On April 1,2003,907 KAR 1:018E 
became effective, replacing 907 KAR 1:021, It provides reimbursement to Kentucky Medicaid 
providers at the lesser of (a) The federal upper limit, (b) State maximum allowable cost, plus a 
dispensing fee, (c) AWP minus 12%, plus a dispensing fee, or d^) usual and customary billed 
charges. Many state Medicaid programs use similar reimbursement formulas based upon AWP. 
15. At all relevant times material to this action, the [Defendants were aware of the 
Commonwealth of Kentucky's Medicaid drug reimbursement fornjmlas, 
B. The Defendants' Reporting of Inflated AWP information 
16. At all relevant times material to this action the Defendants knowingly, willfully and 
intentionally provided false and inflated AWP and other pricing information for their drugs, 
including, but not limited to, those in Exhibit 1, to various nationally known pharmaceutical price 
reporting services, including First Data Bank, a/k/a Blue Book, Medical Economics Co., Inc., a/k/a 
Red Book, and Medispan. 
17. In 2004, high ranking executives of Dey testified in Congress that the AWP was not 
a legitimate price and Dey*s chief financial officer testified beforfc Congress as follows: "Why 
doesn't Dey lower its AWP on generic drugs? The simple answer is| that given the system that now 
exists our customers won't buy from us if we lower our AWP.11 
18. At all relevant times material to this action, First |Data Bank, a/k/a Blue Book, 
Medical Economics Co., Inc., a/k/a Red Book, and Medispan do ncft independently determine the 
Defendants' drug AWP information. The Defendants provide the AWP pricing information on their 
drug products, or other pricing information from which the AW£ is derived, to the reporting 
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services, which then publish the prices, or provide the pricing information to entities such as 
wholesalers whom the Defendants know will supply the information to the reporting services, 
19. At all relevant times material to this action Kentucky Medicaid purchased the 
Defendants* published AWP pricing information from nationally recognized pharmaceutical price 
reporting services, including First Data Bank and Medispan. 
20. At all relevant times material to this action, the Defendants also provided AWP and 
other pricing information directly to Kentucky Medicaid. 
21. At all relevant times material to this action, Kentucky Medicaid relied upon the AWP 
and other pricing information provided by the Defendants to nationally known price reporting 
services in determining the amount Kentucky Medicaid reimburses providers. 
22. At all relevant times material to this action, the Defendants were aware that Kentucky 
Medicaid relied upon the Defendants* AWP and other pricing information, as provided by the 
Defendants to the various price reporting agencies, including First Data Bank, to determine the 
amounts it reimbursed to providers for covered prescription drugs. 
23. The Defendants had a duty to report pricing information which the Defendants knew 
fairly and reasonably reflected the prices in the marketplace, 
24. At all relevant times material to this action, the Defendants knowingly, willfully, and 
intentionally concealed their drugs' true AWP and other pricing information from Kentucky 
Medicaid. 
25. Dey brought a lawsuit against First DataBank, the publisher of the medical 
compendium that Wisconsin Medicaid relies on for prescription drug pricing, because it published 
the actual average wholesale price of Deys drugs instead of the false average wholesale price sent 
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to the publisher by Dey. Dey*s principal allegation in that lawsuit [was that the publication of its 
actual prices for drugs was inconsistent with the practice in the industry of accepting and publishing 
reported, inflated AWPs, and that such publication put Dey at a competitive disadvantage because 
it had no "spread" to advertise, 
26. Defendants have hidden their motives for utilizing anlinflated AWP from the public. 
Indeed, one official, a high ranking employee of Dey, even went s0 far as to lie under oath about 
Dey*s marketing of its spread. Only with the disclosure of material^ secured by litigants in recent 
discovery has it become apparent that one reason defendants were Intentionally manipulating the 
nation's drug reimbursement system was to compete for market sharfc on the basis of a phony price 
spread, instead of the true selling price of their drugs or the medicinal lefficacy of these drugs to their 
users. 
27. At all relevant times material to this action, the Defendants' false and inflated 
reporting of AWP drug pricing information greatly exceeded the actual prices at which the 
Defendants and/or other sellers sold their drugs to Kentucky Medicaid providers. 
28. At all relevant times material to this action, the Defendants' reported AWP bears no 
relation to any price, much less an average wholesale price. 
C* The Defendant's Marketing of the "Spread" 
29. At all relevant times material to this action, the Defendants commonly refer to the 
difference between the reported AWP pricing information and the i actual price of a drug as the 
"spread", "return to practice", or Return on investment." 
30. At ail relevant times material to this action, the Defendants knowingly, willfully, and 
intentionally created a "spread" on their drugs, and marketed the "spread" on their drugs with the 
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intent of inducing Kentucky Medicaid providers to purchase and prescribe their drugs rather than 
competitors' drugs, thereby increasing the profit of Kentucky Medicaid providers and the market 
share and profits of the Defendants, at the expense of the Kentucky Medicaid program. 
31. At all relevant times material to this action, the Defendants manipulated and 
controlled the size of the "spread" on their drugs by increasing their reported AWP and other pricing 
information, while decreasing their actual sale price to wholesalers and providers over time, 
32. At all relevant times material to this action, in addition to manipulating the reported 
AWP and other pricing information, the Defendants used free goods, educational grants and other 
incentives to induce providers to purchase their drugs, all of which lowered the actual prices of the 
Defendants* drugs, resulting in increased profits for providers, as well as market share and profits 
of the Defendants, at the expense of the Kentucky Medicaid program. 
33. Exhibits 2 and 3 attached to this Complaint provide examples of Dey's false and 
inflated AWP pricing information and the impact of the reported AWP information on the "spread." 
34. Exhibits 4 and 5 attached to this Complaint provide examples of Warrick's false 
AWP pricing information and the impact of the reported AWP information on the "spread." 
D. Damages to the Kentucky Medicaid Program 
35. The fraudulent practices engaged in by the Defendants in creating and reporting false 
and inflated AWP or other pricing information for their drugs, or otherwise concealing actual pricing 
information, and marketing the "spread" on their drugs as an inducement to providers to utilize 
Defendants' drugs, has resulted in the Commonwealth of Kentucky paying millions of dollars in 
excess Medicaid payments, while at the same time enriching the Defendants with excessive* unjust 
and illegal profits, 
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V, CLAIMS 
ACTION TO RECOVER MONEY] 
DUE COMMONWEALTH PURSUANT TO C^RS 15,060 
36. Plaintiff hereby incorporates by reference paragraphs \ through 35. 
37. KRS 15.060 (2) provides the Attorney General shallt "When he believes that any 
fraudulent, erroneous or illegal fee bill, account, credit, charge or claim has been erroneously or 
improperly approved, allowed or paid out of the Treasury to any person, institute the necessary actions 
to recover the same." 
38. The Defendants have caused fraudulent, erroneous and/or illegal claims to be paid out 
of the Kentucky State Treasury by (a) reporting false and inflated AWP pricing information on their 
drugs, including, but not limited to, those drugs in Exhibit 1, to reporting services relied upon by the 
Kentucky Medicaid program for reimbursement of Kentucky Medicaid providers, while at the same time 
concealing actual AWP pricing information, (b) marketing the "spread!' between the actual costs of the 
drugs and the reported AWP pricing information to Kentucky Medicaid providers to induce the use of 
Defendants' drags, and thereby (c) obtaining excessive, unjust and illegal profits. 
39. As a direct result of the Defendants' actions, Defendants have caused damages to the 
Kentucky Treasury and Kentucky Medicaid through the payment of grossly excessive prices for the 
Defendants' prescription drugs. 
COUNT II 
PER SE VIOLATION OF THE KENTUCKY 
CONSUMER PROTECTION ACT KRS 367.170 
VIOLATION OF KENTUCKY MEDICAID FRAUD STATUTE. KRS 205.8463 (4) 
40. Plaintiff hereby incorporates by reference paragraphs t through 39, 
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41. KRS 205.520 (2) provides; 'The General Assembly of the Commonwealth of Kentucky 
recognizes and declares that it is an essential function, duty, and responsibility of the state government 
to provide medical care to its indigent citizenry; and it is the purpose of KRS 205.510 to 205,630 to 
provide such care/* 
42. KRS 205.8463 (4) provides: 4tNo person shall, in any matter within the jurisdiction of 
the Cabinet for Health Services under this chapter, knowingly falsify, conceal, or cover-up by any trick, 
scheme, or device a material fact, or make any false, fictitious, or fraudulent statement or representation, 
or make or use any false writing or document knowing the same to contain any false, fictitious, or 
fraudulent statement or entry," 
43. KRS 205.8463 is designed to protect the Commonwealth of Kentucky, to protect the 
quality of health care of Kentucky's poor citizens and the investment of the Kentucky public in the 
health care of its poor citizens. 
44. KRS 367.170 (1) provides: "Unfair, false, misleading, or deceptive acts or practices in 
the conduct of any trade or commerce are hereby declared unlawful." 
45. The Defendants violated KRS 205.8463, and thereby committed per se violations of KRS 
367.170 by, including, but not limited to, knowingly and willfully (a) engaging in a scheme to falsify 
the true AWP of their drugs, including, but not limited to, those drugs in Exhibit 1, (b) reporting false 
and inflated AWP pricing information on their drugs to reporting services relied upon by the Kentucky 
Medicaid program for reimbursement of Kentucky Medicaid providers, while at the same time 
concealing actual AWP pricing information, (c) marketing the "spread" between the actual costs of the 
drugs and the reported AWP pricing information to Kentucky Medicaid providers to induce the use of 
Defendants' drugs, and thereby (d) obtaining excessive, unjust and illegal profits. 
46. As a direct result of the Defendants' per se violations of KRS 367.170 resulting from 
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violations of KRS 205.8463 (4), Defendants have caused damages to the Kentucky Medicaid program 
through the payment of grossly excessive prices for the Defendants' prescription drugs. 
COUNTm 
PER SE VIOLATION OF THE KENTUCKY 
CONSUMER PROTECTION ACT KRS 367.170 
VIOLATION OF KENTUCKY FALSE ADVERTISING STATUTE-KRS 517.030 
47. PlaintifFhereby incorporates by reference paragraphs 1 through 46. 
48. KRS 517.030 provides that: "A person is guilty of false (advertising when, in connection 
with the promotion of the sale of or to increase the consumption of property or services, he knowingly 
makes or causes to be made a false or misleading statement in any advertisement addressed to the public 
or to a substantial number of persons," 
49. In KRS 517.030 the Kentucky General Assembly has dvinced a public policy designed 
to protect the public from persons who use false and misleading statements to increase the sale or 
consumption of their products. 
50. KRS 367.170 (1) provides that "Unfair, false, misleading, or deceptive acts or practices 
in the conduct of any trade or commerce are hereby declared unlawfai" 
51. The Defendants violated KRS 517.03 0, and thereby con|imitted per se violations of KRS 
367,170, by knowingly and willfully reporting false, misleading and inflated AWP pricing information 
on its drug products to national reporting services, while at the same tim^ concealing actual AWP pricing 
information. The reporting services in turn published the Defendants' KWP information to substantial 
numbers of persons, including, but not limited to, the Kentucky Medicaid program, in connection with 
promotion of the sale of or to increase the consumption of Defendants^ prescription drugs. 
52. As a direct result of the Defendants* per se violations bf KRS 367.170 resulting from 
violations of KRS 517.030, Defendants have caused damages to th^ Kentucky Medicaid program 
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through payment of grossly excessive prices for the Defendants' prescription drugs, 
COUNT IV 
VIOLATION OF THE KENTUCKY 
CONSUMER PROTECTION ACT-KRS 367,170 
53. Plaintiff hereby incorporates by reference paragraphs 1 through 52, 
54. KRS 367.170 (1) provides: "Unfair, false, misleading, or deceptive acts or practices in 
the conduct of any trade or commerce are hereby declared unlawful." 
55. The Defendants have committed violations of KRS 367.170 by willfully (a) engaging 
in a scheme to falsify the true AWP of its drugs, including, but not limited to, those drugs in Exhibit 1, 
(b) reporting false and inflated AWP pricing information on their drugs to reporting services relied 
upon by the Kentucky Medicaid program for reimbursement of Kentucky Medicaid providers, while at 
the same time concealing actual AWP pricing information (c) marketing the "spread" between the 
actual costs of the drugs and the reported AWP pricing information to Kentucky Medicaid providers to 
induce the use of Defendants' drugs, and thereby (d) obtaining excessive, unjust and illegal profits. 
56. A direct result of Defendants' violations of KRS 367.170, Defendants have caused 
damages to the Kentucky Medicaid program through the payment of grossly excessive prices for the 
Defendants' prescription drugs. 
COUNT V 
VIOLATIONS OF KENTUCKY 
MEDICAID FRAUD STATUTE-KRS 205.8463 (4\ KRS 446.070 
57. Plaintiff hereby incorporates by reference paragraphs 1-56, 
58. KRS 205,8463 (4) provides: "No person shall, in any matter within the jurisdiction of 
the Cabinet of Health Services under this chapter, knowingly falsify, conceal, or cover-up by any trick, 
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scheme, or device a material fact, or make any false, fictitious, orfraudulbnt statement or representation, 
or make or use any false writing or document knowing the same to contain any false, fictitious, or 
fraudulent statement or entry." 
59. KS 446.070 provides that: "A person injured by the violation of any statute may recover 
from the offender such damages as he sustained by reason of the violation, although a penalty or 
forfeiture is imposed for such violation, 
60. The Defendants violated KRS 205.8463 (4) by including, but not limited to knowingly 
(a) engaging in a scheme to falsify the true AWP of its drugs, including but not limited to, those drugs 
in Exhibit I, (b) reporting false and inflated AWP pricing information on their drugs to reporting 
services relied upon by the Kentucky Medicaid program for reimbursement of Kentucky Medicaid 
providers, while at the same time concealing actual pricing information, (c) marketing the "spread" 
between the actual costs of the drugs and the reported AWP pricing information to Kentucky Medicaid 
providers to induce the use of Defendants' drugs, and thereby (d) obtaining excessive, unjust and illegal 
profits, 
6L As a direct result of the Defendants' violations of KRS |205,8463 (4), Defendants have 
caused damages to the Kentucky Medicaid program through the payment of grossly excessive prices 
for the Defendants' prescription drugs. 
COUNT VI 
VIOLATIONS OF KENTUCKY 
FALSE ADVERTISING STATUTE-KRS 517.030.JKRS 446.070 
62, Plaintiff hereby incorporates by reference paragraphs 1|-61. 
63. KRS 517.030 provides that: "A person is guilty of false Advertising when, in connection 
with the promotion of the sale of or to increase the consumption of property or services, he knowingly 
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makes or causes to be made a false or misleading statement in any advertisement addressed to the public 
or to a substantial number of persons/' 
64. KRS 446.070 provides: UA person injured by the violation of any statute may recover 
from the offender such damages as he sustained by reason of the violation, although a penalty or 
forfeiture is imposed for such violation. 
65. The Defendants violated KRS 517.030, by knowingly reporting false, misleading and 
inflated AWP pricing information on its drug products to national reporting services, while at the same 
time concealing actual pricing information. The reporting services in turn published the Defendants' 
AWP information to substantial numbers of persons, including, but not limited to, the Kentucky 
Medicaid program, in connection with the promotion of the sale of or to increase the consumption of 
Defendants' prescription drugs, including, but not limited to, those identified in Exhibit 1. 
66. As a direct result of the Defendants' violations of KRS 517.030, Defendants have caused 
damages to the Kentucky Medicaid program through the payment of grossly excessive prices for the 
Defendants* prescription drugs. 
VI PRAYER FOR RELIEF 
WHEREFORE, the Plaintiff, Commonwealth of Kentucky, by counsel, Attorney General 
Gregory D. Stumbo , prays for the following relief; 
1. Judgment that the Defendants committed repeated knowing and willful per se violations 
of KRS 367.170 by violating 205.8463 (4); 
2. Judgment that the Defendants committed repeated knowing and willful per se violations 
ofKRS 367.170 by violating 517.030; 
3. Judgment that the Defendants committed repeated willful violations of KRS 367.170; 
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4. Judgment pursuant to KRS 446,070 that the Defendants Icommitted repeated violations 
of KRS 205.8463 (4); 
5. Judgment pursuant to KRS 446.070 that the Defendants Icommitted repeated violations 
of KRS 517.030; 
6. Judgment that the Defendants have engaged in conduct, $cts or practices which resulted 
in fraudulent, erroneous or illegal payments out of the Kentucky Stlate Treasury. 
7. Permanently enjoining the Defendants and their employees, officers, directors, agents, 
successors, assigns, affiliates, merged or acquired predecessors, | parent or controlling entities, 
subsidiaries, and any and all persons acting in concert or participation with Defendants, from their 
unlawful conduct, acts and practices, 
8. Awarding treble damages pursuant to KRS 205.8467 and 446.070 and restitution pursuant 
to KRS 15.060 to the Kentucky Medicaid program for excessive prescription drug reimbursements 
as a result of the Defendants' unlawful conduct; 
9. Awarding civil penalties of $2,000 for each willful violation of the Kentucky Consumer 
Protection Act pursuant to KRS 367.990 (2); 
10. Awarding civil penalties of $10,000 for each violation of the Kentucky Consumer 
Protection Act pursuant to KRS 367.990 (2), where the Defendants' <tonductwas directed at aperson 
aged sixty (60) or older; 
11. Awarding punitive damages against the Defendants pursuant to KRS 411.184; 
12. Awarding the Commonwealth of Kentucky its costs aAd attorneys fees; 
13. Trial by jury on ail issues so triable; 
14. Awarding any other relief to which the Commonwealth is entitled or the Court deems 
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By: 
Respectfully Submitted, 
GREGORY D.STUMBO 
Jeneral of Kei 
'(re~— 
C. David JSfcfistoi! 
Paula J. Holbrook' 
Pamela J. Murphy 
OFPICE OF THE ATTORNEY GENERAL 
1024 Capital Center Drive, Suite 200 
Frankfort, Kentucky 40601 
(502) 696-5300 
(502) 573-7150 FAX 
Charles Bamhill, Jr. 
William P. Dixon 
MINER BARNHILL & GALLAND, P.C. 
Suite 803 
44 East Mifflin St 
Madison, Wisconsin 53703 
(608) 255-5200 
(60S) 255-5380 FAX 
George F. Galland, Jr. 
Robert S. Libman 
MINER, BARNHILL & GALLAND, P.C. 
14 West Erie Street 
Chicago, Illinois 60610 
(312)751-1170 
(312) 751-0438 FAX 
P. Jeffrey Archibald 
ARCHIBALD CONSUMER LAW OFFICE 
1914 Monroe Street 
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EXHIBIT 1 
Warrick and Bey Subject Pharmaceutical Products 
1 Manufacturer 
1 Warrick 
j Warrick 
J. Warrick 
1 Warrick 
1 Warrick 
j Warrick 
j Warrick 
j Warrick 
1 Warrick 
I Warrick 
1 Warrick 
I Warrick 
j Warrick 
1 Warrick 
[ Warrick 
I Warrick 
Dey 
Dey i 
Dey , 
Dey 
Dey 
Dey . 
•Dey 
• Dey 
Dey. 
1 Product 
Albuterol Sulfate .083% 
Albuterol Sulfate .083% 
Albuterol Sulfate .5% 
Albuterol Sulfate 90 meg 
Aerosol Inhaler 
I Albuterol 90 meg 
1 Aerosol Refill 
Cimetidine 
| Cimetidine 
1 Cimetidine 
Cimetidine 
Perphenazine 
Perphenazine 
Perphenazine 
Perphenazine 
Isosorbide Mononitrate 
Isosorbide Mononitrate 
Isosorbide Mononitrate 
Albuterol Sulfate .083% 
Albuterol Sulfate .083% 
Albuterol Sulfate .083% | 
Albuterol Sulfate 
5mg/ml Solution 
Albuterol Sulfate 
5mg/ml Solution 
Acetylcysteine Solution 1 
10% 
Acetylcysteine Solution j 
10% 
Acetylcysteine Solution 1 
10% 
Acetylcysteine Solution j 
20% 1 
] Size 
3 ml 25s 
3ml 60s 
20ml 
17gm 
17gm 
300 mg 
1 400 mg 
400 mg 
400 mg 
2rng 
4mg 
8mg 
16 mg 
30 mg 
60 mg 
120 mg 
25s 
30s 
60s 
20ml 
20ml , 
4ml 
10ml 
30ml 
4ml 
1 NBC No] 
59930-1500-08 
59930-1500-06 
59930-1515-04 
59930-1560-01 
59930-1560-02 
59930180101 
59930180202 
59930180203 
! 59930180201 
! 59930160501 
59930160301 
59930160501 
59930161001 
59930150201 
59930154901 
59930158701 
49502-0697-03 
49502-0697-33 
49502-0697-60 
49502-0105-01 
49502-0196-20 
49502-0181-04 
49502-0181-10 
49502-0181-30 
49502-0182-04 
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| Dey 
Dey 
Dey 
Dey 
Dey 
Dey 
Dey 
{ Dey 
Dey 
f #«r 
Dey 
j Acetylcysteine Solution 
20% 
1 Acetylcysteine Solution 
20% 
Acetylcysteine Solution 
! 20% 
! Cromolyn Sodium 2ml 
Cromolyn Sodium 2ml 
Ipratropium Bromide 
2.5ml 
Ipratropium Bromide 
2.5mi 
Ipratropium Bromide 
2.5ml 
Albuterol 90mcg 
Aerosol Inhaler 
Albuterol 90mcg 1 
Aerosol Inhaler 
Albuterol 90mcg I 
AgrosolRejilj | 
10ml ' 
f~30ml 
100ml 
[Z60s 
120s 
25s 
30s 
60s 
I7gm 
I7gm 
17gm 
I 49502-0182-10 j 
49502-0182-30 
1
 49502-0182-00 | 
49502-0689-02 j 
49502-0689-12 
49502-0685-03 
49502-0685-33 
49502-0685-60 
49502-0333-17 
49502-0303-17 
49502-0303-27 
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Exhibit 2 
Defendant-Dey (1997 reported vs. actual prices) 
| Drug 
1 Albuterol 
Sulfate, 
0.083%, 
3 ml, 25s 
[ Cromolyn 
Sodium, 2 
! mi, 60s 
Drug 
Type 
Inhalant 
Inhalant 
NDC# 
49502-
0697-03 
49502-
0689-02 
Dey's 
Reported 
AWP 
$30.25 
$42.00 
Actual 
Price 
$11.84 
$29.21 
"Spread" 1 
$18.41 
$12.79 
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Exhibit 3 
Defendant-Dey (2001 reported vs. actual prices) 
J Drug 
| Albuterol 
Sulfate, 
0.083%, 
3 ml, 60s 
Albuterol 
Sulfate, 
0.083%, 
3 ml, 30s 
1 Cromolyn 
Sodium, 2 
ml, 120s 
Drug 
Type 
Inhalant 
Inhalant 
Inhalant 
NDC# 
49502-
0697-60 
49502-
0697-33 
49502-
0689-12 
Dey's 
Reported 
AWP 
$72.60 
$36.30 
$84.00 
Actual 
Price 
$ld.22 
$5.60 
$20l77 
"Spread" 
$62*38 
$30.70 
$63.23 
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Exhibit 4 
Defendant-Warrick (1997 reported vs. actual prices) 
Drug ' 
] Albuterol 
Sulfate, 
0.083%, 
20ml 
Albuterol 
Sulfate, 
0.083%, 
3 ml, 25s 
Drug 
Type 
Inhalant 
Inhalant 
NDC# 
59930-
1515-04 
59930-
1500-08 
Warrick's 
Reported 
AWP 
$14.00 
$30.25 
Actual 
Price 
$6.29 
$10.53 
"Spread" 
$7.71 
$19.72 
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Exhlbit5 
Defendant-Warrick (2002 reported vs. actual prices) 
Drug 
I Albuterol 
Sulfate, 
0.083%, 
3 ml, 60's 
1 Albuterol 
Sulfate, 
I 0.083%, 
1 3 ml, 25s 
Drug 
Type 
Inhalant 
Inhalant 
NDC# 
59930-
1500-06 
59930-
1500-08 
Warrick's 
Reported 
AWP 
$72.60 
$30.25 
Actual 
Pr«e 
$12.^ 4 
$545 
1 
"Spread" 1 
$60.26 1 
A 
$24.90 
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IN THE CHANCERY COURT OF HINDS COUNTY, MISSISSIPPI 
FIRST JUDICIAL DISTRICT 
THE STATE OF MISSISSIPPI PLAINTIFF 
V. CIVIL ACTION NO. G2005-2021 
ABBOTT LABORATORIES, INC.; DEFENDANTS 
ABBOTT PHARMACEUTICALS; 
ALCON LABORATORIES, INC.; 
ALLERGAN, INC.; 
ALPHARMA, INC.; 
PUREPAC PHARMACEUTICAL CO.; 
ALPHA THERAPEUTIC CORP.; 
AMGEN, INC.; 
IMMUNEX CORPORATION; 
ANDRX PHARMACEUTICALS, INC.; 
ASTRAZENECA PHARMACEUTICALS, L.P.; 
ASTRAZENECA L.P.; 
AVENTIS PHARMACEUTICALS, INC.; 
AVENTIS BEHRTNG, L.L.C.; 
ZLB BEHRING, L.L.C.; 
DERMIK LABORATORIES, INC.; 
BARR PHARMACEUTICALS, INC.; 
BARR LABORATORIES, INC.; 
BAXTER INTERNATIONAL, INC.; 
BAXTER HEALTHCARE CORPORATION; 
BAYER CORPORATION; 
BAYER PHARMACEUTICALS CORPORATION; 
BAYER HEALTHCARE, LLC; 
BIOVAIL PHARMACEUTICALS, INC.; 
BOEHRINGERINGELHEIM CORPORATION; 
BOEHRINGERINGELHEIM PHARMACEUTICALS, INC.; 
ROXANE LABORATORIES, INC.; 
BEN VENUE LABORATORIES, INC.; 
B. BRAUN OF AMERICAN, INC.; 
MCGRAW, INC.; 
BRISTOL-MYERS SQUIBB COMPANY; 
ONCOLOGY THERAPEUTICS NETWORK CORP.; 
CHIRON CORP.; 
DEY INC.; 
EISAI INC.; 
ELI LILLY AND COMPANY; 
ELKTNS-SINN,INC; 
ENDO PHARMACEUTICALS INC.; 
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FOREST LABORATORIES, INC.; 
FOREST PHARMACEUTICALS; 
FUJISAWA HEALTHCARE, INC.; 
FUJISAWA USA, INC.; 
GENZYME CORPORATION; 
GILEAD SCIENCES, INC.; 
GLAXOSMITHKLINE, P.L.C.; 
SMITHKLINE BEECHAM CORPORATION; 
GLAXO WELLCOME, INC.; 
HOFFMAN-LAROCHE, INC.; 
ROCHE LABORATORIES, INC.; 
IVAX CORPORATION; 
IVAX PHARMACEUTICALS INC.; 
JOHNSON & JOHNSON; 
ALZA CORPORATION; 
JANSSEN PHARMACEUTICAL PRODUCTS, L.P.; 
ORTHO-MCNEIL PHARMACEUTICAL INC.; 
ORTHO BIOTECH PRODUCTS, L.P.; 
MCNEIL-PPC,INC; 
KING PHARMACEUTICALS, INC.; 
MONARCH PHARMACEUTICALS, INC.; 
K-V PHARMACEUTICAL COMPANY; 
ETHEX CORPORATION; 
MEDIMMUNE,INC; 
MERCK & CO., INC.; 
MYLAN LABORATORIES, INC.; 
MYLAN PHARMACEUTICALS, INC.; 
UDL LABORATORIES, INC.; 
NOVARTIS CORPORATION; 
SANDOZ, INC.; 
NOVO NORDISK PHARMACEUTICALS, INC.; 
ORGANON PHARMACEUTICALS USA, INC.; 
PAR PHARMACEUTICAL COS., INC.; 
PURDUE PHARMA, L.P.; 
SANOFI-SYNTHELADO, INC.; 
SCHERING-PLOUGH CORP.; 
WARRICK PHARMACEUTICALS INDUSTRIES, LTD.; 
SERONO, INC.; 
TAKEDA PHARMACEUTICALS NORTH AMERICA, INC.; 
TAP PHARMACEUTICAL PRODUCTS, INC.; 
TEVA PHARMACEUTICALS USA, INC.; 
NOVOPHARMUSA, INC.; 
SICOR PHARMACEUTICALS, INC.; 
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WATSON PHARMACEUTICALS, INC; 
WATSON LABORATORIES, INC.; 
WATSON PHARMA, INC.; 
WYETH, INC.; 
WYETH PHARMACEUTICALS, INC.; 
OTSUKA AMERICA PHARMACEUTICALS, INC.; AND 
SCHERING CORPORATION. 
FIRST AMENDED COMPLAINT 
1 
Plaintiff, the State of Mississippi, by and through its Attorney General (hereinafter "the • 
State") files this First Amended Complaint against the above-nam0d Defendants and alleges, on 
information and belief, the following: 
1. This lawsuit is brought by the Attorney General on behalf of the state and the citizens 
of Mississippi. 
2. Jurisdiction and venue lie in Mississippi and Hinds (Jounty in chancery. 
3. This lawsuit is one of a number of similar lawsuits brought against defendants for 
similar conduct by states and counties across the country, and by the United States, These lawsuits 
are the result of the discovery by the government, through the advice lof a whistle blower,l that drug 
manufacturers were illegally injecting themselves into the Medicaid reimbursement process by 
misrepresenting the average wholesale price of their drugs, knowing ihat states use that information 
as a basis for reimbursing Medicaid providers for providing prescription drugs to Medicaid 
beneficiaries. This complaint likewise asserts that defendants are intentionally providing 
fraudulent information which is in turn relied upon by Mississippi! in estimating the acquisition 
^en-A-Care of the Florida Keys, an independent infusion pharmacy in Key West, FL. 
3 
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cost to providers which results in overpayments to the providers by Mississippi in violation of 
state law. The defendants in this case have been named in lawsuits in other jurisdictions for similar 
conduct. As a result, they are aware of their conduct which forms the basis of the many claims that 
have been made against them, and these claims are similar. (Extensive and relevant background 
information is contained in the Original Complaint and is incorporated by reference to it.) 
4. The defendants are all engaged in the manufacture, sale, or marketing of drugs 
which have been paid for by the state and the citizens of Mississippi through its Medicaid program. 
Those drugs, and the defendant responsible for each of them, have been specifically identified the 
attached Exhibit A. 
5. While it is clear that this complaint "does not involve the unlawful invasion of 
State Medicaid policy decisions'*2 by the Attorney General, the same cannot be said for the unlawful 
involvement in that process, through fraudulent representations, by defendants. This lawsuit is 
brought to redress the usurpation by defendants of Mississippi' s sovereign right to determine its own 
Medicaid reimbursement rate. Defendants have usurped this right by misleading Mississippi about 
the average wholesale price of their drugs, and by preventing Mississippi from discovering the true 
average wholesale prices of those drugs. Even now, defendants have in their possession the actual 
prices at which their drugs were generally and currently available in the pharmaceutical marketplace 
during the relevant period of these claims3 and refuse to make them available to the state of 
2R&RNo. 19 of the Special Masters Denying the Motion to Dismiss, p. 5 
3The currently available (as of the time of any claim for reimbursement) wholesale prices 
are the proper basis for determining the Average Wholesale Price. This is not the same, as 
defendants contend, as seeking to reimburse on Actual Acquisition Cost. Actual Acquisition 
Cost ("AAC") is a reimbursement methodology that relies on the providers to submit their actual 
cost with each claim for reimbursement, and which employs either the submission of invoices or 
4 
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Mississippi, requiiing instead that Mississippi guess at this infoitmation both for purposes of 
reimbursement and for asserting these claims with greater particularity. 
6. It is the sovereign right of the state of Mississippi to bet the rate at which these 
payments are made, subject to certain specific limitations imposed|by federal law. This lawsuit 
brought to protect and defend that right, and to redress the abridgement of that right by defendants, 
but not to exercise it. Mississippi is not attempting by this lawsuit |to revise or alter or amend its 
reimbursement rate or formula. The reimbursement rate and formuH are for the legislature and the 
Department of Medicaid to address. It is up to the Attorney General, through civil action such as 
this, to seek redress for the fraudulent conduct of the defendant^  to this point, and to obtain 
injunctive relief that prevents future conduct of a similar nature. 
7. This lawsuit is brought to obtain legal and equitable relief from the defendants' 
failure or refusal to abide by Mississippi law by misrepresenting their average wholesale prices. 
Mississippi contends that whatever the reimbursement rate or formula determined by Medicaid or 
the legislature, that rate can only function properly if it is based on tjie truth, of which defendants 
have had possession, but which they have so far failed or refused to provide, according to their legal 
duty. This lawsuit is simply to enforce Mississippi law requiring tmthful price reporting by 
defendants. This lawsuit seeks damages as a result of defendants'! failure to operate within the 
bounds of Mississippi law, and injunctive relief compelling them |to comply with their duty to 
periodic invoice audits to assure and maintain the providers' accountability. Mississippi has not 
chosen to use AAC, probably because it is too expensive to administer. Mississippi simply 
wants to use the AWP-based methodology it has chosen, without the burden and expense of false 
Average Wholesale Prices, which it has the legal right not to tolerate. 
5 
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provide true average wholesale prices.4 By forcing defendants to report only true, accurate AWP 
prices, Mississippi seeks to eject defendants from the reimbursement process, where they do not 
belong. 
8. Specifically, this lawsuit attacks the defendants' "standard," or "typical" industry 
practice of setting and publishing, or causing to be published, inflated average wholesale prices, 
blowing that Mississippi relies on the average wholesale price as the basis for determining its 
reimbursement to Medicaid providers. This allegation of "setting and publishing" or "falsely 
inflating" also includes the typical generic drug industiy practice of setting or publishing an AWP 
with or without reference to the anticipated wholesale price of the product, and then simply failing 
or declining to correct that price as the market price drops. This allegation furthermore includes the 
practice of publishing prices other than AWP, where custom and industry practice, as well as 
information obtained directly from defendants, leads foreseeably to the publication of false, inflated 
AWPs by pharmaceutical pricing compendia. This lawsuit is also about, in many instances, 
defendants acting in atypical or non-standard ways to inflate the AWP even more, and to create an 
environment of competition among themselves based on the extent to which each is willing to inflate 
4Circumstances other than defendants' frankness concerning prices have led Mississippi 
to understand in a vague and imprecise way that as to some specific drugs at least, the drug 
manufacturing industry has been inflating AWP for some time. This vague, general impression 
has resulted in the legislature and the Division of Medicaid arriving at reimbursement rates that 
blindly strike out in the direction of the estimated acquisition cost of drugs to the providers by 
discounting the AWP in the reimbursement formula. If this lawsuit is successful, Mississippi 
assumes that the question of an appropriate reimbursement formula, given what Mississippi 
believes will be this court's injunction prohibiting defendants from inflating AWP above the 
average wholesale price, will be revisited by Medicaid, or by the legislature, or both, with the aid 
of a true price benchmark, rather than one loaded by the manufacturers with kickbacks to the 
providers which are impossible today for these rate-making bodies to actually see at all, much 
less with clarity. What Medicaid or the legislature choose to do with that information is beyond 
the scope of this case. 
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its AWP to the greatest extent above the actual average of the wholesale prices paid by the retail 
classes of trade. 
9. While the defendants' motivations for falsely inflating AWP are many and varied, 
some are common and well-understood. In the case of generic drug rrianufacturers, where providers 
are faced with the choice between two or more products which are therapeutically equivalent, the 
manufacturers often compete with one another on the difference between the AWP and the actual 
acquisition cost. This difference, or spread, operates in every case as| a kickback to the provider, of 
the margin between what he pays for the product and what Mississippi will reimburse him based on 
the inflated AWP. As a result, the mere prospect that a customer inlthe retail class of trade might 
prefer a greater kickback over a lesser one, or none, provided Sufficient incentive for these 
manufacturers to trade on the spread, which they completely control ft is important to recognize that 
the term "marketing the spread" is also being co-opted by defendants. "Marketing the spread" as 
used in this complaint, and as understood by the Attorney General, encompasses not only explicit 
marketing tactics designed to emphasize it to the decision maker, but the creation of the spread in 
the first place. This is because the profit motive (and the fact that basic arithmetic is not beyond the 
ken of those who make decisions about purchasing pharmaceuticals) cteates the driving force behind 
the effectiveness of this illegal practice. The spread markets itself. 
10. Brand manufacturers, on the other hand, have been illegally injecting themselves 
into the reimbursement process through falsely inflated AWPs for allong time, and though it may 
be difficult to understand why they have done this, they clearly have the power to do so, and doing 
so results in a benefit to their customers in the retail trade at no additibnal cost to them, because the 
cost of this benefit is borne entirely by the taxpayer. Clearly, over tijme, the practice of interfering 
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with Mississippi's reimbursement process became so widespread that even now, in response to this 
lawsuit, defendants who are in the brand drug business point to the longstanding "industry standard" 
as though it were a legal defense. 
11. The pervasiveness or tenacity of an illegal business practice is not a legal defense, 
and provides no justification whatever for the defendant brand companies' conduct. Moreover, 
Mississippi intends to prove at trial that the brand companies' uniform practice of falsely inflating 
AWP by a minimum of 17% created a climate of tolerance for illegal spreads within the 
pharmaceutical manufacturing industry as a whole in which illegal spreads (resulting in part from 
the kind of spread-competition among generic manufacturers just described) flourished and 
burgeoned to spectacular levels of hundreds and even thousands of percentage points over the 
average wholesale prices generally and currently available to the retailers, ultimately resulting in the 
inception of this litigation against the generic manufacturers roughly a decade ago. This is not to say 
that Mississippi does not intend to obtain redress in cases where the difference between a defendant' s 
real average wholesale price and the AWP he caused to be injected into the stream of commerce was 
less than 17%. It is defendants' duty to ascertain with a high degree of certainty that prices they 
report or cause to be injected into the stream of commerce be accurate when they know, as they are 
deemed to know, and as they actually do know, that the government intends to use those prices as 
the basis for spending taxpayer dollars in federal entitlement programs such as Medicaid. 
Mississippi intends by this lawsuit to recover such damages as she has suffered, and such penalties 
as are prescribed by law, regardless of the magnitude of the spread, and relying on the existence of 
civil penalties for the conduct complained-of to justify the costs of their collection, as they are 
intended to do. 
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12. It is Mississippi's intention, furthermore, to provide Evidence at trial of the manner 
in which the pharmaceutical industry has chosen to react and respond to this litigation as a whole, 
and in particular, because of the probative effect that the various positions taken by those defendants 
who have faced similar suits in other jurisdictions and the timing of those positions has upon 
credibility of the defenses and positions they now espouse in this c^se. The very presence in this 
matter of the brand drug manufacturers is in part a function of the manner in which this litigation has 
unfolded. Generally, this is because when at least one of the generic manufacturers was sued in other 
jurisdictions, it denied the alleged conduct, which in the beginning fodused on the explicit marketing 
of the spread. Its executives testified under oath that they did not m&rket the spread and that they 
would not condone the marketing of the spread under their watch. After years of difficult litigation, 
and protracted battles for the discovery of documentary and electronic evidence, as well as scores 
of depositions of former employees and expert witnesses, the evidenpe of its use of the spread as a 
marketing tool which was not simply condoned, but which was in sortie cases incorporated into the 
very compensation plan of their sales and marketing departments, malde it clear that the allegations 
were right on target. Then, the defendant changed its tack, arguing that spread was actually the 
invention of the states, and that it was something that the states wanted the manufacturers to build 
into their products in order to achieve federally-mandated "access" to Medicaid benefits. Suddenly, 
in a complete about-face, "spread was good," and if spread is good, "how can marketing the spread 
be bad?" 
13. By this time, in response to the whistle blower's lawsuits and the federal 
government's investigations of the whistle blower's specific allegation^ concerning particular drugs, 
two important things began to happen. One was that the federal government began to publish 
9 
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information about a small number of drugs and manufacturers that it had investigated as a result of 
the whistle blower's filings that showed that most of the investigated drugs were selling to the retail 
classes of trade at prices vastly different from the AWPs those companies had been introducing into 
the stream of commerce. Another was that the drug manufacturing industry, and its puppets, the 
drug pricing services, began publishing self-serving "studies" and "definitions," and sending self-
serving letters to Medicaid departments around the country contending on one hand, that AWP was 
not the "actual price" at which drugs were sold in the marketplace,5 and on another, that AWP has 
never meant average wholesale price. Of course, none of these disclaimers regarding AWP were 
ever accompanied by any representation of what the true average wholesale price actually was.6 
14. Evidence about what the legal meaning of AWP is which predates the whistle 
5This particularly insipid argument has been, and will continue to be made by defendants. 
The fact that the average price is not the actual price is in one sense well-known: it is the average, 
and therefore, by definition, not the actual. Letters (and lawyers) that repeat this contention ad 
nauseam do so without adding anything to the debate. This is a ploy which should be 
transparent. The fact that a letter to a state Medicaid department says that an AWP is not the 
actual price paid, or that it does not reflect the actual price paid, without also saying that it is 
neither an average of the true prices paid, nor for that matter, a good faith estimate of the average 
of the true prices paid, (or on the other hand, offering the true average wholesale prices,) says 
nothing that the Medicaid officials don't already understand, but only because an average and an 
actual price are two different things. Furthermore, even if information such as this had been 
received by Mississippi, it would not support a defense to this action any more than a bank 
robber's note to the teller that says, "THIS IS A STICK-UP!," would constitute a defense to the 
robbery charge. 
6Some defendants provided other kinds of prices to the state Medicaid offices. This was 
also a clever ruse. Defendants know that the Medicaid departments need a particular baseline 
price in order to compute the reimbursements for thousands of real-time reimbursements every 
day, and that their reimbursement formula are arrived at globally, through an administrative rule-
making, if not a legislative process. They also know, with respect to AMP, that the Center for 
Medicaid and Medicare Services, which oversees the operation of the Medicaid programs by the 
states, has forbidden them to base reimbursement on AMP (or upon any price resulting from the 
reverse-engineering of the unit rebate amount). So providing the states with AMP or ASP or 
some other price which they now say was sufficient to "inform" the state of their "true prices" 
was of little practical, and Mississippi contends, of no legal effect. 
10 
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blower's claims in 1995-6 is often the result of the industry's reaction to the fact that it has been 
caught red-handed. 
15, In its investigation of the allegations of the other jurisdictions and of the whistle 
blower, Mississippi came to the conclusion that the current state of thb law requires that defendants, 
having voluntarily entered the Mediciad program, are legally bouiid to tell the truth about their 
average wholesale prices, and that there is no need, from a legal perspective, to distinguish between 
those who lied as a matter of course, and those who lied spectacularly, or between those who lied 
in furtive whispers, or by omission, and those who trumpeted their lies and made them the basis of 
sales presentations to their customers. This court, at the conclusion bf the evidence at trial, will be 
able to sort out these distinctions, to the extent that they are relevant, i i determining the damages and 
assessing the civil penalties.7 
Identity of Defendants 
ABBOTT 
16. Defendant, Abbott Laboratories, Inc. ("Abbott"), is a|ii Illinois corporation engaged 
in the business of manufacturing and selling pharmaceuticals. Abbott has been served with process. 
Abbott does business under the following address and Labeler Cod^ registered with the Food and 
Drug Administration: 
7
 At the suggestion of the Special Masters, and in an attempt to reduce the administrative 
overhead of this lawsuit without unduly reducing the salutary effect intended hereby, Plaintiff has 
offered to enter agreed orders dismissing numerous defendants without prejudice, with the 
present intention to file suit against them after some of the issues in 
resolved. The decision to dismiss some and not others should not be seen as an indication of 
There are two principal 
lis the magnitude of the 
their relative merit, but rather, merely a matter of judicial economy, 
factors in the selection of defendants and in their prioritization: one |: 
spread they have created. The other is the magnitude of damage thdy have inflicted. These 
factors in some cases act in combination with one another to requirq that a defendant stay in this 
case, hi other cases, one factor or the other sufficed. 
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Firm: ABBOTT LABORATORIES 
Address: 100 ABBOTT PARK RD D 3QA AP6C 1 
ABBOTT PARK, EL, 600346091 
FDA Labeler Code: 00074 
Plaintiffs claims against Abbott pertain to the pharmaceuticals listed in the attached Exhibit 
A, bearing this Labeler Code. The pharmaceuticals are listed by NDC number and the first ten 
characters of the FDA Short Description. Abbott caused false Average Wholesale Prices for each 
of the listed pharmaceuticals to enter the stream of commerce knowing that they would be used by 
Mississippi as the principal means of estimating the acquisition cost of pharmaceuticals dispensed 
to beneficiaries of the Medicaid program, causing Mississippi to overpay Abbott's customers in 
violation of state law as alleged below. The difference between the Average Wholesale Price this 
defendant caused to enter or to be maintained in the stream of commerce and the true Average 
Wholesale Price in the marketplace at the time of each claim for reimbursement for each of its 
products listed in Exhibit A. was at least 17%. 
ALPHARMA 
17. Defendant, Alpharma, Inc. ("Alpharma"), is a Delaware corporation engaged in the 
business of manufacturing and selling pharmaceuticals. Alpharma has been served with process. 
Alpharma does business under the following address and Labeler Code registered with the Food and 
Drug Administration: 
Firm: ALPHARMA USPD INC 
Address: 200 ELMORA AVE 
ELIZABETH, NJ, 07207 
FDA Labeler Code: 00472 
Firm: PUREPAC PHARMACEUTICAL CO 
Address: ONE NEW ENGLAND AVE 
PISCATAWAY, NJ, 08854 
FDA Labeler Code: 00228 
12 
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Plaintiffs claims against Alpharma pertain to the pharma4euticals listed in the attached 
Exhibit A, bearing this Labeler Code. The pharmaceuticals are listed by NDC number and the first 
ten characters of the FDA Short Description. Alpharma caused falsel Average Wholesale Prices for 
each of the listed pharmaceuticals to enter the stream of commerce knowing that they would be used 
by Mississippi as the principal means of estimating the acquisition cos|t of pharmaceuticals dispensed 
to beneficiaries of the Medicaid program, causing Mississippi to overpay Alpharma's customers in 
violation of state law as alleged below. The difference between thei Average Wholesale Price this 
defendant caused to enter or to be maintained in the stream of commerce and the true Average 
Wholesale Price in the marketplace at the time of each claim for feimbursement for each of its 
products listed in Exhibit A. was at least 17%. 
AMGEN 
18. Defendant, Amgen, Inc. ("Amgen"), is a California corporation engaged in the 
business of manufacturing and selling pharmaceuticals. Amgen doek business under the following 
address and Labeler Code registered with the Food and Drug Administration: 
Firm: AMGEN INC 
Address: 1 AMGEN CENTER DR 
THOUSAND OAKS, CA, 913201799 
FDA Labeler Code: 55513 
Plaintiff s claims against Amgen pertain to the pharmaceuticals listed in the attached Exhibit 
A, bearing this Labeler Code. The pharmaceuticals are listed by NDC number and the first ten 
characters of the FDA Short Description. Amgen caused false Average Wholesale Prices for each 
of the listed phannaceuticals to enter the stream of commerce knowing that they would be used by 
Mississippi as the principal means of estimating the acquisition cosfl of pharmaceuticals dispensed 
to beneficiaries of the Medicaid program, causing Mississippi to overpay Amgen's customers in 
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violation of state law as alleged below. The difference between the Average Wholesale Price this 
defendant caused to enter or to be maintained in the stream of commerce and the true Average 
Wholesale Price in the marketplace at the time of each claim for reimbursement for each of its 
products listed in Exhibit A. was at least 17%. 
ASTRAZENECA 
19. Defendant, AstraZeneca Pharmaceuticals, L.P. and AstraZeneca, L.P., are 
Delaware limited partnerships engaged in the business of manufacturing and selling pharmaceuticals. 
These defendants (collectively, "AstraZeneca") do business under the following addresses and 
Labeler Codes registered with the Food and Drug Administration: 
Firm: ASTRAZENECA LP 
Address: 1800 CONCORD PIKE 
WILMINGTON, DE, 19850 
FDA Labeler Code: 00186 
Fiim: ASTRAZENECA PHARMACEUTICALS LP 
Address: 1800 CONCORD PIKE15437 
WILMINGTON, DE, 19850 
FDA Labeler Code: 00310 
Plaintiffs claims against AstraZeneca pertain to the pharmaceuticals listed in the attached 
Exhibit A, bearing these Labeler Codes. The pharmaceuticals are listed by NDC number and the 
first ten characters of the FDA Short Description. AstraZeneca caused false Average Wholesale 
Prices for each of the listed pharmaceuticals to enter the stream of commerce knowmg that they 
would be used by Mississippi as the principal means of estimating the acquisition cost of 
pharmaceuticals dispensed to beneficiaries of the Medicaid program, causing Mississippi to overpay 
AstraZeneca's customers in violation of state law as alleged below. The difference between the 
Average Wholesale Price this defendant caused to enter or to be maintained in the stream of 
14 
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reimbursement for each of its products listed in Exhibit A. w£s a t least 17%-
AVENTIS 
20. Defendant, Aventis Pharmaceuticals, Inc., is a Pelawsire corporation engaged in the 
business of manufacturing and selling pharmaceuticals. Defendant, Aventis Behring, LLC, is a 
Delaware corporation engaged in the business of manufacturing find selling pharmaceuticals. 
Defendant, ZLB Behring, L.L.C., is a Delaware limited liability company engaged in the business 
of manufacturing and selling pharmaceuticals. Defendant, S*aofi-SJaithelabo, Inc., is a Delaware 
corporation engaged in the business of manufacturing and selling pharmaceuticals. These defendants 
(collectively, "Aventis")liavebeen s e r v e d 
the following addresses and Labeler Codes registered with the Food |and Drug Administration: 
Firm: AVENTIS PHARMACEUTICAL PRODUCTS INC 
Address: MAILSTOP H4 M23169627 
KANSAS CITY, KS, 641340627 
FDA Labeler Code: 00075 
Firm: AVENTIS PHARMACEUTICALS IN~C 
Address: 300 SOMERSET CORPORATE BLVD SC3 B20A 
BRTDGEWATER, NJ, 08807 
FDA Labeler Code: 00088 
Firm: AVENTIS PHARMACEUTICALS NJ 
Address: 10236 MARION PARK DR 
KANSAS CrTY, MO, 64137 
FDA Labeler Code: 00039 
Firm: DERMIK LABORATORIES DIV AVENTIS PHARMACEUTICALS INC 
Address: 1050 WESTLAKES DR 
BERWYN, PA, 19312 
FDA Labeler Code: 00066 
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Firm: ZLB BEHRING LLC 
Address: 1020 1ST AVE61501 
KING OF PRUSSIA, PA, 194060901 
FDA Labeler Code: 00053 
Plaintiff s claims against Aventis pertain to the pharmaceuticals listed in the attached Exhibit 
A, bearing these Labeler Codes. The pharmaceuticals are listed by NDC number and the first ten 
characters of the FDA Short Description. Aventis caused false Average Wholesale Prices for each 
of the listed pharmaceuticals to enter the stream of commerce knowing that they would be used by 
Mississippi as the principal means of estimating the acquisition cost of pharmaceuticals dispensed 
to beneficiaries of the Medicaid program, causing Mississippi to overpay Aventis 's customers in 
violation of state law as alleged below. The difference between the Average Wholesale Price this 
defendant caused to enter or to be maintained in the stream of commerce and the true Average 
Wholesale Price in the marketplace at the time of each claim for reimbursement for each of its 
products listed in Exhibit A. was at least 17%. 
BARR 
21. Defendant, Ban* Laboratories, Inc. ("Barr"), a wholly owned subsidiary of Barr 
Pharma, is a New York corporation engaged in the business of manufacturing and selling 
phamiaceuticals. Ban* does business under the following address and Labeler Code registered with 
the Food and Drug Administration: 
Firm: BARR LABORATORIES INC 
Address: P.O. Box 2900 
POMONA, NY, 10970-0519 
FDA Labeler Code: 00555 
Plaintiffs claims against Barr pertain to the pharmaceuticals listed in the attached Exhibit 
A, bearing this Labeler Code. The pharmaceuticals are listed by NDC number and the first ten 
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characters of the FDA Short Description. Barr catised false Averag^ Wholesale Prices for each of 
the listed pharmaceuticals to enter the stream of commerce knowing that they would be used by 
Mississippi as the principal means of estimatmg the acquisition cost of pharmaceuticals dispensed 
to beneficiaries of the Medicaid program, causing Mississippi toi overpay Barr's customers in 
violation of state law as alleged below. The difference between thel Average Wholesale Price this 
defendant caused to enter or to be maintained in the stream of commerce and the true Average 
Wholesale Price in the marketplace at the time of each claim for reimbursement for each of its 
products listed in Exhibit A. was at least 17%. 
BAXTER 
22. Defendant, Baxter Healthcare Corporation ("Baxter'j), is a Delaware corporation 
engaged in the business of manufacturing and selling pharmaceuticals. Baxter has been served with 
process in this lawsuit. Baxter Healthcare's principal place of business is located at One Baxter 
Parkway, Deerfield, IL 60015. Baxter does business under the following addresses and Labeler 
Codes registered with the Food and Drug Administration: 
Finn: BAXTER BIOSCIENCE 
Address: 550 NORTH BRAND BLVD 
GLENDALE, CA, 91203 
FDA Labeler Code: 64193 
Firm: BAXTER HEALTHCARE CORP 
Address: 1620 WAUKEGAN RD MPGRAL 
WAUKEGAN, IL, 60085 
FDA Labeler Code: 00338 
Firm: BAXTER HEALTHCARE CORP BAXTER BIOSCIENCE 
Address: 1 BAXTER PKY 
DEERFIELD, IL, 60015 
FDA Labeler Code: 00944 
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Finn: BAXTER HEALTHCARE CORP CHERRY HILL NJ 
Address: 95 SPRING ST 
NEW PROVIDENCE, NJ, 07974 
FDA Labeler Code: 00641 
Plaintiffs claims against Baxter pertain to the pharmaceuticals listed in the attached Exhibit 
A, bearing these Labeler Codes. The pharmaceuticals are listed by NDC number and the first ten 
characters of the FDA Short Description. Baxter caused false Average Wholesale Prices for each 
of the listed pharmaceuticals to enter the stream of commerce knowing that they would be used by 
Mississippi as the principal means of estimating the acquisition cost of pharmaceuticals dispensed 
to beneficiaries of the Medicaid program, causing Mississippi to overpay Baxter 's customers in 
violation of state law as alleged below. The difference between the Average Wholesale Price this 
defendant caused to enter or to be maintained in the stream of commerce and the true Average 
Wholesale Price in the marketplace at the time of each claim for reimbursement for each of its 
products listed in Exhibit A. was at least 17%. 
BAYER 
23„ Defendant, Bayer Corporation, a wholly owned United States subsidiary of a German 
corporation, Bayer AG, is an Indiana corporation engaged in the business of manufacturing and 
selling pharmaceuticals. Defendant, Bayer Pharmaceuticals Corporation, a wholly owned subsidiary 
of Bayer, is a Delaware corporation engaged in the business of manufacturing and selling 
pharmaceuticals. Defendant, Bayer Healthcare, LLC, a wholly owned subsidiaiy of Bayer, is a 
Delaware limited liability company engaged in the business of manufacturing and selling 
pharmaceuticals. These defendants (collectively, "Bayer") do business under the following 
addresses and Labeler Codes registered with the Food and Drug Administration: 
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Firm: BAYER CORP PHARMACEUTICAL DIV 
Address: 8368 US RT 70 WEST 
CLAYTON, NC, 27520 
FDA Labeler Code: 00026 
Plaintiff's claims against Baxter pertain to the pharmaceutical^ listed in the attached Exhibit 
A, bearing these Labeler Codes. The pharmaceuticals are listed by NDC number and the first ten 
characters of the FDA Short Description. Baxter caused false Average Wholesale Prices for each 
of the listed pharmaceuticals to enter the stream of commerce knowing that they would be used by 
Mississippi as the principal means of estimating the acquisition cost Df pharmaceuticals dispensed 
to beneficiaries of the Medicaid program, causing Mississippi to overpay Baxter 's customers in 
violation of state law as alleged below. The difference between the Average Wholesale Price this 
defendant caused to enter or to be maintained in the stream of conlimerce and the true Average 
Wholesale Price in the marketplace at the time of each claim for reimbursement for each of its 
products listed in Exhibit A. was at least 17%. 
Plaintiff acknowledges that the Special Masters have recomqiended the dismissal without 
prejudice of Bayer. Nevertheless, these allegations, which are limited to pharmaceutical products 
other than the qui tarn drugs referred to in the 2001 settlement agreement and release, are different 
from the allegations which formed the basis of that settlement agreement and release to the extent 
that this lawsuit attacks the industiy practice of introducing a an Average Wholesale Price into the 
stream of commerce which is at least 17% above the average wholesale price of its drugs to the retail 
classes of trade, knowing that it would be relied upon by Mississippi in establishing Estimated 
Acquisition Cost. To the extent that the investigation which lead to thfc 2001 settlement and release 
focused upon products and practices where spread and spread marketing techniques were more 
extreme or flagrant, and in view of the allegations of this complaint, thit these pharmaceuticals bore 
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an AWP which was inflated by a minimum of 17%, Plaintiff reasserts her claims against Bayer as 
permitted by the Report and Recommendation of the Special Masters, No. 2. 
BOEHRINGER 
24. Defendant, Boehringer Ingelheim Pharmaceuticals, Inc. is a Delaware corporation 
engaged in the business of manufacturing and selling pharmaceuticals. Defendant, Roxane 
Laboratories, Inc. ("Roxane"), is a Delaware corporation engaged in the business of manufacturing 
and selling pharmaceuticals. These defendants, (collectively, "Boehringer") have been served with 
process in this lawsuit. Boehringer does business under the following addresses and Labeler Codes 
registered with the Food and Drug Administration: 
Firm: BOEHRINGER INGELHEIM PHARMACEUTICALS INC 
Address: 900 RTDGEBURY RD 
RTDGEFIELD, CT, 06877 
FDA Labeler Code: 00597 
Firm: BEDFORD LABORATORIES 
Address: 300 NORTHFIELD RD 
BEDFORD, OH, 44146 
FDA Labeler Code: 55390 
Film: ROXANE LABORATORIES INC 
Address: PO BOX 16532 
COLUMBUS, OH, 43216 
FDA Labeler Code: 00054 
Plaintiffs claims against Boehringer pertain to the pharmaceuticals listed in the attached 
Exhibit A, bearing these Labeler Codes. The pharmaceuticals are listed by NDC number and the 
first ten characters of the FDA Short Description. Boehringer caused false Average Wholesale 
Prices for each of the listed pharmaceuticals to enter the stream of commerce knowing that they 
would be used by Mississippi as the principal means of estimating the acquisition cost of 
pharmaceuticals dispensed to beneficiaries of the Medicaid program, causing Mississippi to overpay 
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Boehringer 's customers in violation of state law as alleged below, The difference between the 
Average Wholesale Price this defendant caused to enter or to be maintained in the stream of 
commerce and the true Average Wholesale Price in the marketplace) at the time of each claim for 
reimbursement for each of its products listed in Exhibit A. was at least 17%. 
BRISTOL-MYERS 
25. Defendant, Bristol-Myers Squibb Company ("Bristolj-Myers"), is a Delaware 
coiporation engaged in the business of manufacturing and selling pharmaceuticals. Bristol-Myers 
has been served with process in this lawsuit. Bristol-Myers does business under the following 
addresses and Labeler Codes registered with the Food and Drug Administration: 
Firm: BRISTOL MYERS SQUIBB CO 
Address: RT 206 AND PROVINCELINE RD 
PRINCETON, NJ, 08540 
FDA Labeler Code: 00087 
Firm: BRISTOL MYERS SQUIBB PHARMA CO 
Address: CHESTNUT RUN PLAZA 974 CENTRE RD 
WILMINGTON, DE, 19805 
FDA Labeler Code: 00056 
Firm: BRISTOL MYERS SQUIBB SANOFI PHARMACEUTICALS 
PARTNERSHIP 
Address: 90 PARK AVE 
NEW YORK, NY, 10016 
FDA Labeler Code: 63653 
Firm: ER SQUIBB AND SONS INC 
Address: 1 SQUIBB DR 
CRANBURY.NL 08512 
FDA Labeler Code: 00003 
Firm: MEAD JOHNSON AND CO SUB BRISTOL MYERS CO 
Address: RT 206 AND PROVINCE LINE RD 
PRINCETON, NJ, 08540 
FDA Labeler Code: 00015 
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Plaintiffs claims against Bristol-Myers pertain to the pharmaceuticals listed in the attached 
Exhibit A, bearing these Labeler Codes. The pharmaceuticals are listed by NDC number and the 
first ten characters of the FDA Short Description. Bristol-Myers caused false Average Wholesale 
Prices for each of the listed pharmaceuticals to enter the stream of commerce knowing that they 
would be used by Mississippi as the principal means of estimating the acquisition cost of 
pharmaceuticals dispensed to beneficiaries of the Medicaid program, causing Mississippi to overpay 
Bristol-Myers's customers in violation of state law as alleged below. The difference between the 
Average Wholesale Price this defendant caused to enter or to be maintained in the stream of 
commerce and the true Average Wholesale Price in the marketplace at the time of each claim for 
reimbursement for each of its products listed in Exhibit A. was at least 17%. 
DEY 
26. Defendant, Dey Inc. ("Dey"), formerly Dey Laboratories, is a Delaware corporation 
engaged in the business of manufacturing and selling pharmaceuticals. Dey has been served with 
process in this lawsuit. Dey does business under the following addresses and Labeler Codes 
registered with the Food and Drug Administration: 
Firm: DEY LP 
Address: 2751 NAPA VALLEY CORPORATE DR 
NAPA, CA, 94558 
FDA Labeler Code: 49502 
Plaintiffs claims against Dey pertain to the pharmaceuticals listed in the attached Exhibit 
A, bearing these Labeler Codes. The pharmaceuticals are listed by NDC number and the first ten 
characters of the FDA Short Description. Dey caused false Average Wholesale Prices for each of 
the listed pharmaceuticals to enter the stream of commerce knowing that they would be used by 
Mississippi as the principal means of estimating the acquisition cost of pharmaceuticals dispensed 
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to beneficiaries of the Medicaid program, causing Mississippi to overpay Dey's customers in 
violation of state law as alleged below. The difference between the Average Wholesale Price this 
defendant caused to enter or to be maintained in the stream of coitnmerce and the true Average 
Wholesale Price in the marketplace at the time of each claim for Keimbursement for each of its 
products listed in Exhibit A. was at least 17%. 
EISAI 
27. Defendant, Eisai Inc. ("Eisai"), is a Delaware corporation engaged in the business 
of manufacturing and selling pharmaceuticals. Eisai has been served with process in this lawsuit. 
Eisai does business under the following addresses and Labeler Code^ registered with the Food and 
Drug Administration: 
Firm: EISAI INC 
Address: 500 FRANK W BURR BLVD 
TEANECK, NJ, 076666741 
FDA Labeler Code: 62856 
Plaintiffs claims against Eisai pertain to the pharmaceuticals llisted in the attached Exhibit 
A, bearing these Labeler Codes. The pharmaceuticals are listed by NDC number and the first ten 
characters of the FDA Short Description. Eisai caused false Average Wholesale Prices for each of 
the listed pharmaceuticals to enter the stream of commerce knowing that they would be used by 
Mississippi as the principal means of estimating the acquisition cost of pharmaceuticals dispensed 
to beneficiaries of the Medicaid program, causing Mississippi to overpay Eisai's customers in 
violation of state law as alleged below. The difference between the Average Wholesale Price this 
defendant caused to enter or to be maintahied in the stream of comtnerce and the true Average 
Wholesale Price in the marketplace at the time of each claim for reimbursement for each of its 
products listed in Exhibit A. was at least 17%. 
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FOREST 
28. Defendant, Forest Pharmaceuticals ("Forest"), is in the business of manufacturing 
and selling pharmaceuticals. Forest has been served with process in this lawsuit. Forest does 
business under the following addresses and Labeler Codes registered with the Food and Drug 
Administration: 
Firm: FOREST PHARMACEUTICALS INC 
Address: 3941 BROTHERTON RD 
CINCINNATI, OH, 45209 
FDA Labeler Code: 00456 
Plaintiffs claims against Forest pertain to the pharmaceuticals listed in the attached Exhibit 
A, bearing these Labeler Codes. The pharmaceuticals are listed by NDC number and the first ten 
characters of the FDA Short Description. Forest caused false Average Wholesale Prices for each of 
the listed pharmaceuticals to enter the stream of commerce knowing that they would be used by 
Mississippi as the principal means of estimating the acquisition cost of pharmaceuticals dispensed 
to beneficiaries of the Medicaid program, causing Mississippi to overpay Forest 's customers in 
violation of state law as alleged below. The difference between the Average Wholesale Price this 
defendant caused to enter or to be maintained in the stream of commerce and the true Average 
Wholesale Price in the marketplace at the time of each claim for reimbursement for each of its 
products listed in Exhibit A. was at least 17%. 
GLAXO 
29. Defendant, GlaxoSmithKline, P.L.C., created through the merger of Glaxo 
Wellcome, P.L.C. and SmithKlineBeecham P.L.C., is a British corporation engaged in the business 
of manufacturing and selling pharmaceuticals. Defendant, SmithKline Beecham Corporation, a 
wholly owned subsidiary of GlaxoSmithKline, P.L.C, is a Delaware corporation engaged in the 
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business of manufacturing and selling pharmaceuticals. Defendant, Glaxo Wellcome, Inc., a wholly 
owned subsidiary of GlaxoSmithKline, P.L.C., is a North Carolina corporation in the business of 
manufacturing and selling pharmaceuticals. These defendants (collectively, "Glaxo") have been 
served with process in this lawsuit. Glaxo does business under the following addresses and Labeler 
Codes registered with the Food and Drug Administration: 
Firm: SMITHKLINE BEECHAM PHARMACEUTICALS DIV SMITHKLINE 
BEECHAM CO 
Address: 1011 NORTH ARENDELL AVE 
ZEBULON, NC, 27597 
FDA Labeler Code: 00007 
Firm: BEECHAM DIV SMITHKLINE BEECHAM |CORP 
Address: 1011 NORTH ARENDELL AVE 
ZEBULON, NC, 27597 
FDA Labeler Code: 00029 
Firm: GLAXO WELLCOME DIVISION SMITHKLINE BEECHAM CORP 
Address: 5 MOORE DR SOUTH D 1561 
RESEARCH TRIANGLE PARK, NC, 27709 
FDA Labeler Code: 00173 
Plaintiffs claims against Glaxo pertain to the pharmaceuticals! listed in the attached Exhibit 
A, bearing this Labeler Code. The pharmaceuticals are listed by NJ)C number and the first ten 
characters of the FDA Short Description. Glaxo caused false Average] Wholesale Prices for each of 
the listed pharmaceuticals to enter the stream of commerce knowing that they would be used by 
Mississippi as the principal means of estimating the acquisition cost df pharmaceuticals dispensed 
to beneficiaries of the Medicaid program, causing Mississippi to oyerpay Glaxo's customers in 
violation of state law as alleged below. The difference between the Average Wholesale Price this 
defendant caused to enter or to be maintained in the stream of commerce and the true Average 
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Wholesale Price in the marketplace at the time of each claim for reimbursement for each of its 
products listed in Exhibit A. was at least 17%. 
LAROCHE 
30. Defendant, Hoffman-LaRoche, Inc. ("LaRoche"), is a New Jersey corporation in the 
business of manufacturing and selling pharmaceuticals. LaRoche has been served with process in 
this lawsuit. LaRoche does business under the following addresses and Labeler Codes registered 
with the Food and Drug Administration: 
Firm: HOFFMANN LA ROCHE INC 
Address: 340 KINGSLAND ST 
NUTLEY,NJ,07110 
FDA Labeler Code: 00004 
Plaintiffs claims against LaRoche pertain to the pharmaceuticals listed in the attached 
Exhibit A, bearing these Labeler Codes. The pharmaceuticals are listed by NDC number and the 
first ten characters of the FDA Short Description. LaRoche caused false Average Wholesale Prices 
for each of the listed pharmaceuticals to enter the stream of commerce knowing that they would be 
used by Mississippi as the principal means of estimating the acquisition cost of pharmaceuticals 
dispensed to beneficiaries of the Medicaid program, causing Mississippi to overpay LaRoche 's 
customers in violation of state law as alleged below. The difference between the Average Wholesale 
Price this defendant caused to enter or to be maintained in the stream of commerce and the tme 
Average Wholesale Price in the marketplace at the time of each claim for reimbursement for each 
of its products listed in Exhibit A. was at least 17%. 
IMMUNEX 
31. Defendant, Immunex Corporation ("Immunex"), is a Washington corporation in the 
business of manufacturing and selling pharmaceuticals. Immunex does business under the following 
addresses and Labeler Codes registered with the Food and Drug Administration: 
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Firm: MMUNEX CORP 
Address: 51 UNIVERSITY ST 
SEATTLE, WA, 98101-2936 
FDA Labeler Code: 58406 
Plaintiffs claims against Immunex pertain to the pharmaceuticals listed in the attached 
Exhibit A, bearing these Labeler Codes. The pharmaceuticals are listed by NDC number and the 
first ten characters of the FDA Short Description. Immunex caused false Average Wholesale Prices 
for each of the listed pharmaceuticals to enter the stream of commerce knowing that they would be 
used by Mississippi as the principal means of estimating the acquisition cost of pharmaceuticals 
dispensed to beneficiaries of the Medicaid program, causing Mississippi to overpay Immunex 's 
customers in violation of state law as alleged below. The difference between the Average Wholesale 
Price this defendant caused to enter or to be maintained in the stream of commerce and the true 
Average Wholesale Price in the marketplace at the time of each claim for reimbursement for each 
of its products listed in Exhibit A. was at least 17%. 
TVAX 
32. Defendant, Ivax Pharmaceuticals Inc. ("Ivax"), is a Florida corporation engaged in 
the business of manufacturing and selling pharmaceuticals. Ivax does business under the following 
addresses and Labeler Codes registered with the Food and Drag Administration: 
Firm: IVAX PHARMACEUTICALS INC 
Address: 4400 BISCAYNE BLVD 
MIAMI, FL, 33137 
FDA Labeler Code: 00172 
Firm: IVAX RESEARCH INC 
Address: 4400 BISCAYNE BLVD 
MIAMI, FL, 33137 
FDA Labeler Code: 00575 
27 
Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU. 
Machine-generated OCR, may contain errors.
Plaintiffs claims against Ivax pertain to the pharmaceuticals listed in the attached Exhibit 
A, bearing these Labeler Codes. The pharmaceuticals are listed by NDC number and the first ten 
characters of the FDA Short Description. Ivax caused false Average Wholesale Prices for each of 
the listed pharmaceuticals to enter the stream of commerce knowing that they would be used by 
Mississippi as the principal means of estimating the acquisition cost of pharmaceuticals dispensed 
to beneficiaries of the Medicaid program, causing Mississippi to overpay Ivax 's customers in 
violation of state law as alleged below. The difference between the Average Wholesale Price this 
defendant caused to enter or to be maintained in the stream of commerce and the true Average 
Wholesale Price in the marketplace at the time of each claim for reimbursement for each of its 
products listed in Exhibit A. was at least 17%. 
JOHNSON & JOHNSON 
33. Defendant, Johnson & Johnson ("J&J"), is a New Jersey corporation engaged in the 
business of manufacturing and selling pharmaceuticals. Defendant, ALZA Corporation, a wholly 
owned subsidiary of J&J, is a Delaware corporation engaged in the business of manufacturing and 
selling pharmaceuticals. Defendant, Janssen Pharmaceutical Products, L.P., a wholly owned 
subsidiary of J&J, is a New Jersey corporation engaged in the business of manufacturing and selling 
pharmaceuticals. Defendant, Ortho-McNeil Pharmaceutical Inc., a wholly owned subsidiary of J&J, 
is a Delaware coiporation engaged in the business of manufacturing and selling pharmaceuticals. 
Defendant, Ortho Biotech Products, L.P., a wholly owned subsidiary of J&J, is a Delaware limited 
partnership engaged in the business of manufacturing and selling pharmaceuticals. Defendant, 
McNeil-PPC, Inc., a wholly owned subsidiary of J&J, is a New Jersey corporation engaged in the 
business of manufacturing and selling pharmaceuticals. Defendants, (collectively, "Johnson & 
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Johnson") have been served with process in this lawsuit. Johnson & Johnson does business under 
the following addresses and Labeler Codes registered with the Food and Drug Administration: 
Finn: JANSSEN PHARMACEUTICA INC 
Address: RT 202300 
RARITAN, NJ, 08869 
FDA Labeler Code: 50458 
Firm: ALZA CORP 
Address: 1900 CHARLESTON RD 7210 
MOUNTAIN VIEW, CA, 940397210 
FDA Labeler Code: 17314 
Firm: OMP DIV 
Address: 1000 RT 202 
RARITAN, NJ, 08869 
FDA Labeler Code: 00045 
Firm: ORTHO BIOTECH PRODUCTS LP 
Address: 1000 RT 202 SOUTH300 
RARITAN, NJ, 088690602 
FDA Labeler Code: 59676 
Firm: ORTHO MCNEIL PHARMACEUTICAL INC 
Address: RT 202300 
RARITAN, NJ, 08869 
FDA Labeler Code: 00062 
Plaintiffs claims against Johnson & Johnson pertain to the pharmaceuticals listed in the 
attached Exhibit A, bearing this Labeler Code. The pharmaceuticalls are listed by NDC number and 
the first ten characters of the FDA Short Description. Johnson <&[ Johnson caused false Average 
Wholesale Prices for each of the listed pharmaceuticals to enter the stream of commerce knowing 
that they would be used by Mississippi as the principal means of estimating the acquisition cost of 
pharmaceuticals dispensed to beneficiaries of the Medicaid prograr^, causing Mississippi to overpay 
Johnson & Johnson's customers in violation of state law as alleged below. The difference between 
the Average Wholesale Price this defendant caused to enter or toi be maintained in the stream of 
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commerce and the true Average Wholesale Price in the marketplace at the time of each claim for 
reimbursement for each of its products listed in Exhibit A. was at least 17%. 
LILLY 
34. Defendant, Eli Lilly and Company ("Lilly*'), is a Indiana coiporation engaged in the 
business of manufacturing and selling pharmaceuticals. Lilly has been served with process in this 
lawsuit. Lilly does business under the following addresses and Labeler Codes registered with the 
Food and Drug Administration: 
Firm: ELI LILLY AND CO 
Address: PO BOX 2568 
VALLEY CENTER, CA, 92082 
FDA Labeler Code: 00002 
Finn: DISTA PRODUCTS CO DIV ELI LILLY AND CO 
Address: LILLY CORPORATE CENTER DROP CODE 2543 
INDIANAPOLIS, IN, 46285 
FDA Labeler Code: 00777 
Plaintiffs claims against Lilly pertain to the pharmaceuticals listed in the attached Exhibit 
A, bearing these Labeler Codes. The pharmaceuticals are listed by NDC number and the first ten 
characters of the FDA Short Description. Lilly caused false Average Wholesale Prices for each of 
the listed pharmaceuticals to enter the stream of commerce knowing that they would be used by 
Mississippi as the principal means of estimating the acquisition cost of pharmaceuticals dispensed 
to beneficiaries of the Medicaid program, causing Mississippi to overpay Lilly 's customers in 
violation of state law as alleged below. The difference between the Average Wholesale Price this 
defendant caused to enter or to be maintained in the stream of commerce and the true Average 
Wholesale Price in the marketplace at the time of each claim for reimbursement for each of its 
products listed in Exhibit A. was at least 17%. 
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MEDIMMUNB 
35. Defendant, Medlmmune, Inc. ("Medlmmune"), is a| Delaware corporation engaged 
in the business of manufacturing and selling pharmaceuticals. Medimmune has been served with 
process in this lawsuit. Medimmune does business under the following addresses and Labeler Codes 
registered with the Food and Drug Administration: 
Film: MEDIMMUNE INC 
Address: 35 WEST WATKINS MILL RD 
GAITHERSBURG, MD, 20878 
FDA Labeler Code: 60574 
Plaintiffs claims against Medimmune pertain to the pharmaceuticals listed in the attached 
Exhibit A, bearing this Labeler Code. The pharmaceuticals are listed by NDC number and the first 
ten characters of the FDA Short Description. Medimmune caused Ifalse Average Wholesale Prices 
for each of the listed pharmaceuticals to enter the stream of commerce knowing that they would be 
used by Mississippi as the principal means of estimating the acquisition cost of pharmaceuticals 
dispensed to beneficiaries of the Medicaid program, causing Mississippi to overpay Medimmune's 
customers in violation of state law as alleged below. The difference between the Average Wholesale 
Price this defendant caused to enter or to be maintained in the stream of commerce and the true 
Average Wholesale Price in the marketplace at the time of each claim for reimbursement for each 
of its products listed in Exhibit A. was at least 17%. 
MERCK 
36. Defendant, Merck & Co., Inc. ("Merck"), is aNew Jjersey corporation engaged in the 
business of manufacturing and selling pharmaceuticals. Merck haslbeen served with process in this 
lawsuit. Merck does business under the following addresses and Labeler Codes registered with the 
Food and Drug Administration: 
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Firm: MERCK AND CO INC 
Address: 770 SUMNEYTOWN PIKE 
WEST POINT, PA, 194860004 
FDA Labeler Code: 00006 
Plaintiff s claims against Merck pertain to the pharmaceuticals listed in the attached Exhibit 
A, bearing this Labeler Code. The pharmaceuticals are listed by NDC number and the first ten 
characters of the FDA Short Description. Merck caused false Average Wholesale Prices for each 
of the listed pharmaceuticals to enter the stream of commerce knowing that they would be used by 
Mississippi as the principal means of estimating the acquisition cost of pharmaceuticals dispensed 
to beneficiaries of the Medicaid program, causing Mississippi to overpay Merck's customers in 
violation of state law as alleged below. The difference between the Average Wholesale Price this 
defendant caused to enter or to be maintained in the stream of commerce and the true Average 
Wholesale Price in the marketplace at the time of each claim for reimbursement for each of its 
products listed in Exhibit A. was at least 17%. 
MYLAN 
37. Defendant, Mylan Laboratories, Inc. ("Mylan"), is a Pennsylvania corporation 
engaged in the business of manufacturing and selling pharmaceuticals. Defendant, Mylan 
Pharmaceuticals, Inc., a wholly owned subsidiary of Mylan, is a West Virginia corporation engaged 
in the business of manufacturing and selling pharmaceuticals. Defendants, (collectively, "Mylan") 
have been served with process in this lawsuit. Mylan does business under the following addresses 
and Labeler Codes registered with the Food and Drug Administration: 
Firm: MYLAN BERTEK PHARMACEUTICALS INC 
Address: 14149 
RESEARCH TRIANGLE PARK, NC, 277094149 
FDA Labeler Code: 62794 
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Firm: MYLAN PHARMACEUTICALS INC 
Address: 781 CHESTNUT RIDGE RD4310 
MORGANTOWN, WV, 265044310 
FDA Labeler Code: 00378 
Plaintiffs claims against Mylan pertain to the pharmaceuticals listed in the attached Exhibit 
A, bearing this Labeler Code. The pharmaceuticals are listed by KDC number and the first ten 
characters of the FDA Short Description. Mylan caused false Average Wholesale Prices for each 
of the listed pharmaceuticals to enter the stream of commerce knowing that they would be used by 
Mississippi as the principal means of estimating the acquisition co$t of pharmaceuticals dispensed 
to beneficiaries of the Medicaid program, causing Mississippi to overpay Mylan5s customers in 
violation of state law as alleged below. The difference between thfc Average Wholesale Price this 
defendant caused to enter or to be maintained in the stream of commerce and the true Average 
Wholesale Price in the marketplace at the time of each claim fori reimbursement for each of its 
products listed in Exhibit A. was at least 17%. 
NOVARTIS 
38. Defendant, Novartis Corporation ("Novartis"), is a ])^ ew Jersey corporation 
engaged in the business of manufacturing and selling pharmaceuticals. Defendant, Sandoz, Inc. 
("Sandoz"), a wholly owned subsidiary of Novartis, formerly kno\yn as Geneva Pharmaceuticals, 
Inc., is a Delaware coiporation engaged in the business of manufacturing and selling 
pharmaceuticals. Defendants (collectively, "Novartis") have be$n served with process in this 
lawsuit. Novartis does business under the following addresses and| Labeler Codes registered with 
the Food and Drug Administration: 
Firm: NOVARTIS CONSUMER FIEALTH INC 
Address: 560 MORRIS AVE BLDG F 
SUMMIT, NJ, 079011312 
FDA Labeler Code: 00067 
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Firm: NOVARTIS OPHTHALM3CS INC 
Address: 11695 JOHNS CREEK PKY 
DULUTH, GA, 300971523 
FDA Labeler Code: 58768 
Firm: NOVARTIS PHARMACEUTICALS CORP 
Address: 1 HEALTH PLAZA DRA BLDG 419 1409 
EAST HANOVER, NJ, 07936 
FDA Labeler Code: 00078 
Firm: NOVARTIS PHARMACEUTICALS CORP DBA GEIGY 
PHARMACEUTICALS DTV 
Address: 1 HEALTH PLAZA BLDG 419 1409 
EAST HANOVER, NJ, 07936 
FDA Labeler Code: 00028 
Firm: SANDOZ INC 
Address: 2555 WEST MIDWAY BLVD446 
BROOMFIELD, CO, 800380446 
FDA Labeler Code: 00781 
Plaintiffs claims against Novartis pertain to the pharmaceuticals listed in the attached 
Exhibit A, bearing this Labeler Code. The pharmaceuticals are listed by NDC number and the first 
ten characters of the FDA Short Description. Novartis caused false Average Wholesale Prices for 
each of the listed pharmaceuticals to enter the stream of commerce knowing that they would be used 
by Mississippi as the principal means of estimating the acquisition cost of pharmaceuticals dispensed 
to beneficiaries of the Medicaid program, causing Mississippi to overpay Novartis's customers in 
violation of state law as alleged below. The difference between the Average Wholesale Price this 
defendant caused to enter or to be maintained in the stream of commerce and the true Average 
Wholesale Price in the marketplace at the time of each claim for reimbursement for each of its 
products listed in Exhibit A. was at least 17%. 
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OTSUKA 
39. Defendant, Otsuka America Pharmaceuticals Inc. ("Ofcsuka"), is aforeign corporation 
engaged in the business of manufacturing and selling pharmaceuticals. Defendant, Otsuka does 
business under the following addresses and Labeler Codes registered with the Food and Drug 
Administration: 
Firm: OTSUKA AMERICA PHARMACEUTICALS INC 
Address: 2440 RESEARCH BLVD 
ROCKVEXE, MD, 20850 
FDA Labeler Code: 59148 
Plaintiffs claims against Otsuka pertain to the pharmaceuticals listed in the attached Exhibit 
A, bearing this Labeler Code. The pharmaceuticals are listed by pSfDC number and the first ten 
characters of the FDA Short Description. Otsuka caused false Average Wholesale Prices for each 
of the listed pharmaceuticals to enter the stream of commerce knowing that they would be used by 
Mississippi as the principal means of estimating the acquisition cost of pharmaceuticals dispensed 
to beneficiaries of the Medicaid program, causing Mississippi to Overpay Otsuka's customers in 
violation of state law as alleged below. The difference between the Average Wholesale Price this 
defendant caused to enter or to be maintained in the stream of cqmmerce and the true Average 
Wholesale Price in the marketplace at the time of each claim fori reimbursement for each of its 
products listed in Exhibit A. was at least 17%. 
PAR 
40. Defendant, Par Pharmaceutical Cos., hie. ("Par"), is $ Delaware corporation engaged 
in the business of manufacturing and selling pharmaceuticals. Par has been served with process in 
this lawsuit. Par does business under the following addresses and Labeler Codes registered with the 
Food and Ding Administration: 
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Firm: PAR PHARMACEUTICAL INC 
Address: 1 RAM RIDGE RD 
SPRING VALLEY, NY, 10977 
FDA Labeler Code: 49884 
Plaintiffs claims against Par pertain to the pharmaceuticals listed in the attached Exhibit A, 
bearing this Labeler Code. The pharmaceuticals are listed by NDC number and the first ten 
characters of the FDA Short Description. Par caused false Average Wholesale Prices for each of the 
listed pharmaceuticals to enter the stream of commerce knowing that they would be used by 
Mississippi as the principal means of estimating the acquisition cost of pharmaceuticals dispensed 
to beneficiaries of the Medicaid program, causing Mississippi to overpay Par's customers in 
violation of state law as alleged below. The difference between the Average Wholesale Price this 
defendant caused to enter or to be maintained in the stream of commerce and the true Average 
Wholesale Price in the marketplace at the time of each claim for reimbursement for each of its 
products listed in Exhibit A. was at least 17%. 
SCHERING 
41. Defendant, Schering-Plough Corp., ("Schering-Plough") is a New Jersey 
corporation engaged in the business of manufacturing and selling pharmaceuticals. Defendant 
Schering Corporation is a New Jersey corporation with its principal place of business at 1 Giralda 
Farms, Madison, NJ 07940. Defendant, Warrick Pharmaceuticals Industries, Ltd. ("Warrick"), is 
a Delaware corporation engaged in the business of manufacturing and selling pharmaceuticals. 
Schering-Plough and Warrick have been served with process in this lawsuit. Defendants 
(collectively, "Schering") do business under the following addresses and Labeler Codes registered 
with the Food and Drug Administration: 
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Firm: SCHERING CORP 
Address: 50 LAWRENCE RD 
SPRINGFIELD, NJ, 07081 
FDA Labeler Code: 00085 
Firm: WARRICK PHARMACEUTICALS CORP 
Address: 50 LAWRENCE RD 
SPRINGFIELD, NJ, 07081 
FDA Labeler Code: 59930 
Plaintiffs claims against Schering pertain to the pharmaceuticals listed in the attached 
Exhibit A, bearing this Labeler Code. The pharmaceuticals are listed by NDC number and the first 
ten characters of the FDA Short Description. Schering caused false; Average Wholesale Prices for 
each of the listed pharmaceuticals to enter the stream of commerce knowing that they would be used 
by Mississippi as the principal means of estimating the acquisition cost of pharmaceuticals dispensed 
to beneficiaries of the Medicaid program, causing Mississippi to overpay Schering's customers in 
violation of state law as alleged below. The difference between the Average Wholesale Price this 
defendant caused to enter or to be maintained in the stream of commerce and the true Average 
Wholesale Price in the marketplace at the time of each claim for reimbursement for each of its 
products listed in Exhibit A. was at least 17%. 
TAKEDA 
42. Defendant, Takeda Pharmaceuticals North America, Ihc. ("Takeda"), is a corporation 
engaged in the business of manufacturing and selling pharmaceuticals. Takeda has been served with 
process in this lawsuit. Takeda does business under the following addresses and Labeler Codes 
registered with the Food and Drug Administration: 
Firm: TAKEDA PHARMACEUTICALS NORTHI AMERICA INC 
Address: 475 HALF DAY RD STE 500 
LINCOLNSHIRE, IL, 60069 
FDA Labeler Code: 64764 
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Plaintiffs claims against Takedapertain to the pharmaceuticals listed in the attached Exhibit 
A, bearing this Labeler Code. The pharmaceuticals are listed by NDC number and the first ten 
characters of the FDA Short Description. Takeda caused false Average Wholesale Prices for each 
of the listed pharmaceuticals to enter the stream of commerce knowing that they would be used by 
Mississippi as the principal means of estimating the acquisition cost of pharmaceuticals dispensed 
to beneficiaries of the Medicaid program, causing Mississippi to overpay Takeda's customers in 
violation of state law as alleged below. The difference between the Average Wholesale Price this 
defendant caused to enter or to be maintained in the stream of commerce and the true Average 
Wholesale Price in the marketplace at the time of each claim for reimbursement for each of its 
products listed in Exhibit A. was at least 17%. 
TAP 
43. Defendant, TAP Pharmaceutical Products, Inc. ("TAP"), is a joint venture between 
Abbott and Takeda Chemical Industries, Ltd., engaged in the business of manufacturing and selling 
pharmaceuticals. TAP has been served with process in this lawsuit. TAP does business under the 
following addresses and Labeler Codes registered with the Food and Drug Administration: 
Finn: TAP PHARMACEUTICALS INC 
Address: 675 NORTH FIELD DR 
LAKE FOREST, IL, 60045 
FDA Labeler Code: 00300 
Plaintiffs claims against TAP pertain to the pharmaceuticals listed in the attached Exhibit 
A, bearing this Labeler Code. The pharmaceuticals are listed by NDC number and the first ten 
characters of the FDA Short Description. TAP caused false Average Wholesale Prices for each of 
the hsted pharmaceuticals to enter the stream of commerce laiowing that they would be used by 
Mississippi as the prmcipal means of estimatmg the acquisition cost of pharmaceuticals dispensed 
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to beneficiaries of the Medicaid program, causing Mississippi to overpay TAP's customers in 
violation of state law as alleged below. The difference between th0 Average Wholesale Price this 
defendant caused to enter or to be maintained in the stream of commerce and the true Average 
Wholesale Price in the marketplace at the time of each claim for reimbursement for each of its 
products listed in Exhibit A. was at least 17%. 
TEVA 
44. Defendant, Teva Pharmaceuticals USA, Inc. ("Tevd"), is a Delaware corporation 
engaged in the business of manufacturing and selling pharmaceuticals. Defendant, Sicor 
Pharmaceuticals, Inc. f/k/a Gensia Sicor Pharmaceuticals, Inc., a wholly owned subsidiary of Teva, 
is a Delaware corporation engaged in the business of manufacturing and selling pharmaceuticals. 
Defendants (collectively, "Teva") have been served with process in this lawsuit. Teva does business 
under the following addresses and Labeler Codes registered with the iFood and Drug Administration: 
Firm: TEVA PHARMACEUTICALS USA INC 
Address: 1090 HORSHAM RD1090 
NORTH WALES, PA, 19454 
FDA Labeler Code: 00093 
Firm: SICOR PHARMACEUTICALS INC 
Address: 19 HUGHES 
IRVINE, CA 92618 
FDA Labeler Code: 00703 
Plaintiffs claims against Teva pertain to the pharmaceuticals listed in the attached Exhibit 
A, bearing this Labeler Code. The pharmaceuticals are listed by |NDC number and the first ten 
characters of the FDA Short Description. Teva caused false Average Wholesale Prices for each of 
the listed pharmaceuticals to enter the stream of commerce knowing that they would be used by 
Mississippi as the principal means of estimating the acquisition cost of pharmaceuticals dispensed 
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to beneficiaries of the Medicaid program, causing Mississippi to overpay Teva's customers in 
violation of state law as alleged below. The difference between the Average Wholesale Price this 
defendant caused to enter or to be maintained in the stream of commerce and the true Average 
Wholesale Price in the marketplace at the time of each claim for reimbursement for each of its 
products listed in Exhibit A. was at least 17%. 
WATSON 
45. Defendant, Watson Pharmaceuticals, Inc. ("Watson"), is a Nevada corporation 
engaged in the business of manufacturing and selling pharmaceuticals. Defendant, Watson 
Laboratories, Inc. ("Watson Labs"), a wholly owned subsidiaiy of Watson, is a Nevada corporation 
engaged in the manufacturing and selling of pharmaceuticals. Defendant, Watson Pharma, Inc. 
("Watson Pharma"), a wholly owned subsidiary of Watson, is a Delaware corporation engaged in 
the business of manufacturing and selling pharmaceuticals. These defendants (collectively, 
"Watson") have been served with process in this lawsuit. Watson does business under the following 
addresses and Labeler Codes registered with the Food and Drug Administration: 
Firm; WATSON LABORATORIES INC 
Address: 39 MT EBO RD SOUTH 
BREWSTER, NY, 10509 
FDA Labeler Code: 00591 
Firm: WATSON PHARMA INC 
Address: 39 MT EBO RD SOUTH 
BREWSTER, NY, 10509 
FDA Labeler Code: 52544 
Plaintiff s claims against Watson pertain to the pharmaceuticals listed in the attached Exhibit 
A5 bearing this Labeler Code. The pharmaceuticals are listed by NDC number and the first ten-
characters of the FDA Short Description. Watson caused false Average Wholesale Prices for each 
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of the listed pharmaceuticals to enter the stream of commerce knowing that they would be used by 
Mississippi as the principal means of estimating the acquisition cost of pharmaceuticals dispensed 
to beneficiaries of the Medicaid program, causing Mississippi to overpay Watson's customers in 
violation of state law as alleged below. The difference between thel Average Wholesale Price this 
defendant caused to enter or to be maintained in the stream of commerce and the true Average 
Wholesale Price in the marketplace at the time of each claim for reimbursement for each of its 
products listed in Exhibit A. was at least 17%. 
WYETH 
46. Defendant, Wyeth, Inc., formerly American Home products Corp., is a Delaware 
coiporation engaged in the business of manufacturing and selling pharmaceuticals. Defendant, 
Wyeth Pharmaceuticals, Inc., a wholly owned subsidiary of Wyeth, Inc., is a Delaware corporation 
engaged in the manufacture and sale of pharmaceuticals. These defendants (collectively, "Wyeth") 
have been served with process in this lawsuit. Wyeth does businessi under the following addresses 
and Labeler Codes registered with the Food and Drug Administration: 
Firm: WYETH BIOPHARMA 
Address: 500 ARCOLA RD E DOCK 
COLLEGEVILLE, PA, 19426 
FDA Labeler Code: 58394 
Firm: WYETH PHARMACEUTICAL DIV WYETH HOLDINGS CORP 
Address: 500 ARCOLA RD E DOCK 
COLLEGEVILLE, PA, 19426 
FDA Labeler Code: 00005 
Firm: WYETH PHARMACEUTICALS CO 
Address: 500 ARCOLA RD E DOCK 
COLLEGEVILLE, PA, 19426 
FDA Labeler Code: 00008 
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Firm: WYETH PHARMACEUTICALS INC 
Address: 500 ARCOLA RD E DOCK 
COLLEGEVILLE, PA, 19426 
FDA Labeler Code: 00046 
Plaintiffs claims against Wyeth pertain to the pharmaceuticals listed in the attached Exhibit 
A, bearing this Labeler Code. The pharmaceuticals are listed by NDC number and the first ten 
characters of the FDA Short Description. Wyeth caused false Average Wholesale Prices for each 
of the listed pharmaceuticals to enter the stream of commerce knowing that they would be used by 
Mississippi as the principal means of estimating the acquisition cost of pharmaceuticals dispensed 
to beneficiaries of the Medicaid program, causing Mississippi to overpay Wyeth's customers in 
violation of state law as alleged below. The difference between the Average Wholesale Price this 
defendant caused to enter or to be maintained in the stream of commerce and the true Average 
Wholesale Price in the marketplace at the time of each claim for reimbursement for each of its 
products listed in Exhibit A. was at least 17%. 
Offers to Dismiss 
47. Abbott Pharmaceuticals, Alcon Laboratories, Allergan, Inc., Alpha Therapeutic 
Corp., And DC Pharmaceuticals, Inc., B. Braun of America(n), Inc., Barr Pharmaceuticals, Inc., Baxter 
International, Inc., Biovail Pharmaceuticals, hie, Boehringer Ingelheim Corporation, Chiron Corp., 
Elkins-Sinn, Inc., Endo Pharmaceuticals, hie, Ethex Corporation, Forest Laboratories, Inc., Fujisawa 
Healthcare. Inc., Fujisawa USA, Inc., Genzyme Corporation, Gilead Sciences, Inc., Ivax 
Corporation, King Pharmaceuticals, Inc., KV Pharmaceutical Company, McG(r)aw, Inc., Monarch 
Pharmaceuticals, Inc., Novo Nordisk Pharmaceuticals, Inc., Oncology Therapeutics Network Corp., 
Organon Pharmaceuticals USA, Inc., Purdue Pharma, L.P., Serono, Inc., and UDL Laboratories, Inc., 
are all defendants in this action which have been served with process. No allegations are made in 
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this amended complaint against these defendants because Plaintiff I has offered to enter an agreed 
order dismissing them without prejudice. Plaintiff has every reason to expect that this will be 
accomplished in short order, but will seek leave to amend its complaint against any or all of them 
in the unlikely event that such an order with respect each is not entered. 
Damages 
48. Defendants have damaged Mississippi by causing h$r to overpay Medicaid claims 
for their products. Mississippi's conservative estimate of the actual damages, that is, the difference 
between what Mississippi should have paid had defendants told thei truth about average wholesale 
price and what Mississippi actually did pay in reliance on defendants' phony average wholesale 
prices is in excess of $100,000,000, the exact amount of which shall be proved at trial. 
Statutory Claims 
49. By causing phony average wholesale prices to enter fche stream of commerce, 
knowing that Mississippi would use them to calculate Medicaid reimbursement, eveiy defendant 
violated Mississippi law, as follows: 
50. Every defendant violated the the Mississippi Medicaid Fraud Control Act, as follows: 
a. Every defendant violated the Mississippi Medicaid fraud Control Act, Miss. Code 
Ami. § 43-13-207. The Defendants offered kickbacks or bribes to providers in the 
form of a difference, or "spread" between the average wholesale price of its 
pharmaceutical products and the false AWP it caused to enter the stream of 
commerce, either by reporting this AWP directly to Mississippi or to a pricing 
compendia, such as First Databank or Redbook, or by providing pricing compendia 
with other information calculated to result in the publication of a phony, inflated 
AWP. 
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Every defendant violated the Mississippi Medicaid Fraud Control Act, Miss. Code 
Ann. § 43-13-21 1. Every defendant entered into agreements to defraud the State by 
aiding providers in obtaining payments for false, fictitious or fraudulent claims for 
Medicaid benefits by falsifying their products' AWPs. The essence of each of these 
agreements was the agreement, either express or implied, with its customers, that the 
purchase price of the product would include as a feature or benefit of its 
pharmaceutical product an AWP which exceeded the average wholesale price by at 
least 17%. 
Every defendant violated the Mississippi Medicaid Fraud Control Act, Miss. Code 
Ann. § 43-13-213. Each defendant's falsification of the Average Wholesale Price of 
its products listed in Exhibit A resulted intentionally in providers causing to be made 
or presented claims for Medicaid benefits which would become false, fictitious or 
fraudulent due to the fact that each claim actually coalesces into a completed claim 
at the point where the information which is submitted by the provider is 
electronically combined with the false Average Wholesale Price information 
provided and maintained in the stream of commerce by each applicable defendant. 
These violations of the Mississippi Fraud Control Act result in direct liability by each 
defendant to the State, including forfeiture, civil penalties equal to the full amount 
received by the Defendants, plus an additional civil penalty equal to triple the full 
amount received by the Defendants. Miss. Code Ann. 5 43-1 3-225. 
Every defendant engaged in unfair or deceptive trade practices in or affecting 
in violation of Mississippi Code §75-24-5, as follows: 
44 
Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU. 
Machine-generated OCR, may contain errors.
be maintained there, as to each of its products listed! in Exhibit A, each defendant 
violated §75-24-5(1) and (2)(e) by representing that goods have characteristics or 
benefits or quantities that they do not have. 
f. By causing phony Average Wholesale Prices to enterl the stream of commerce and to 
be maintained there, as to each of its products listed in Exhibit A, each defendant 
violated §75-24-5(1) and (2)(k) by making misrepresentations of fact concealing the 
reasons for, existence of, or amounts of price reductions. 
g. This action is brought pursuant to Mississippi Coc^ e §75-24-5 and §75-24-9, for 
injunctive reYiei, as well as SOT compensatory damage, statutory trebte damages, and 
civil penalties. 
Common Law Claims 
52. Every defendant committed common law fraud against the State of Mississippi. Each 
defendant reported directly, or caused to be reported AWPs for thpir products on a periodic and 
continuing basis for publication and dissemination to Mississippi. Each defendant knew that the 
AWP information which they provided and caused to be reported was false. Each defendant 
misrepresented the pricing information with the intent of inducing Ivlississippi to rely on the false 
information in reimbursing its customers, the Medicaid providers. Mississippi's Medicaid program 
reasonably relied on the false Average Wholesale Prices to reimburse the providers. Each 
defendant's misrepresentations are continuing, as they regularly and|periodically continue to issue, 
cause to be issued, and maintain, false and inflated Average Wholesale Prices for publication by the 
industry reporting services. As a result of each defendant's fraudulent conduct, the State has been 
45 
Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU. 
Machine-generated OCR, may contain errors.
damaged by overpaying for each defendant's pharmaceutical products listed in the attached Exhibit 
A. 
53. By engaging in acts and practices described above, each defendant has engaged and 
continues to engage in repeated fraudulent acts and practices in violation of Mississippi common 
law. 
54. Each defendant's conduct was and is knowing, intentional, gross, oppressive, 
malicious, or wanton, and was committed with the intention to cause injury to the State of 
Mississippi. 
Prayer for Relief 
55. WHEREFORE, PREMISES CONSIDERED, Plaintiff, the State of Mississippi, by 
and tlirough Jim Hood, its duly elected Attorney General, requests that this Court grant the following 
relief against each of the defendants as follows: 
h. an order enjoining each and every defendant from continuing the fraudulent, 
deceptive and unfair acts or practices complained of herein, and requiring correcting 
measures; 
i, an order enjoining each and every defendant from reporting an Average Wholesale 
Price which is false, from utilizing any definition or description of the term Average 
Wholesale Price in connection with this Court's order which deviates in any 
significant respect from the plain meaning of the words "average wholesale price," 
and mandating that each and every defendant publish a true Average Wholesale Price; 
j . an accounting of all profits or gains derived in whole or in part by each Defendant 
through its fraudulent, unfair and/or deceptive acts or practices complained of herein; 
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k. a constructive trust of the moneys illegally and impermissibly obtained from the 
Defendants' scheme; 
1. an order imposing a constructive trust on and/or requiring disgorgement by each 
defendant of all profits and gains earned in whole or i|n part through the fraudulent, 
unfair and deceptive acts or practices complained of herein; 
m. an award of compensatory damages to the State in sudh amount as is proved at trial; 
n. an award of all civil penalties provided for by statute} 
o. an award of punitive damages; 
p. an award of costs and prejudgment interest; 
q. such other and further relief as the Court may deem appropriate ad just. 
RESPECTFULLY SUBMITTED, this the 5th day of October^  2006. 
THE STATE OF MISSISSIPPI 
JIM HOOD, ATTORNEY GENERAL 
Rickey T. Moore, Assistant Attorney General 
Attorney General's Office 
P.O. Box 220 
Jackson, MS 39205-0220 
Telephone: (601) 359-3680 
Facsimile: (601) 359-5025 
COPELAND, COOK, TAYLOR & BUSH 
BY: ^ n d ^ r f t i 
Charles G/cUeland (MBN 6516) 
J. Leray MfcNaUara (MBN 2784) 
Ronnie Musgnhe (MBN 3868) 
Frank Kolb (MBN 101092) 
Post Office Box 6020 
Ridgeland,Mskl58 
Telephone: (601) 856-7200 
Facsimile: (601) 856-7626 
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I, J. Leray McNamara, do hereby certify that I have this 5th day of October, 2006, caused to 
be electronically mailed, a true and correct copy of the above and forgoing to the following: 
Walker W. Jones, IE 
David F. Maron 
Jason R. Bush 
Baker, Donelson, Bearman, Caldwell & 
Berkowitz 
4268 1-55 North 
Meadowbrook Office Park 
Jackson, MS 39211 
Jonathan Rees 
Greg Petouvis 
Hogan & Hartson, LLP 
555 13th Street NW 
Washington, DC 20004 
ATTORNEYS FOR AVENTIS 
PHARMACEUTICALS, INC., AVENTIS 
BEHRING, LLC, ZLB BEHRING, LLC, 
AND SANOFI-SYNTHELABO, INC. 
George Q. Evans 
Douglas E. Levanway 
Felice D. Wicks 
Wise, Carter, Child & Caraway, P.A. 
P.O. Box 651 
Jackson, MS 39205 
Ryan Mitchell, Esq. 
Jones Day 
77 West Wacker 
Chicago, IL 606001-1692 
Toni-Ann Citera, Esq. 
Jones Day 
222 East 41st Street 
New York, NY 10017-6702 
ATTORNEYS FOR DEFENDANT 
ABBOTT LABORATORIES, INC., AND 
TAP PHARMACEUTICAL PRODUCTS, 
INC. 
John Corlew 
Kathy Smith 
Watkins & Eager 
P.O. Box 650 
Jackson, MS 39205-0650 
ATTORNEYS FOR TAKEDA 
PHARMACEUTICALS NORTH 
AMERICA, INC. 
Frank A. Wood, Jr. 
William F. Goodman, III 
C. Lyce Hall 
Watkins & Eager, PLLC 
P.O. Box 650 
Jackson, MS 39205 
Richard D. Raskin 
Michael Doss 
Sidley & Austin 
One South Dearborn Street 
Chicago, IL 60603 
ATTORNEYS FOR ALLERGAN, INC., 
NOVO NORDISK 
PHARMACEUTICALS, INC., BAYER 
CORPORATION, BAYER 
PHARMACEUTICALS 
CORPORATION, AND BAYER 
HEALTHCARE, LLC 
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Deborah D. Kuchler 
Darren M. Guillot 
Abbott, Simses & Kuchler 
400 Lafayette Street, Suite 200 
New Orleans, LA 70130 
ATTORNEYS FOR ALPHA 
THERAPEUTIC CORP. AND SERONO, 
INC. 
R. Pepper Crutcher, Jr. 
Heather W. Martin 
Balch & Bingham 
401 E. Capitol Street, Suite 200 
Jackson, MS 39201 
ATTORNEYSl FOR ALPHARMA, INC. 
AND PURPACp PHARMACEUTICAL 
CO. 
Mark Dreher, Esq. 
Chelye Amis, Esq. 
Stephanie M. Rippee, Esq. 
Butler, Snow, O'Mara, Stevens & Cannada, 
PLLC 
Post Office Box 22567 
Jackson, MS 39225-2567 
ATTORNEYS FOR ALCON 
LABORATORIES, INC., AND PAR 
PHARMACEUTICAL COS., INC. 
H. Mitchell Cowan 
Kathryn H. Hester 
Watkins, Ludlam, Winter & Stennis, P.A. 
633 North State Street 
Jackson, MS 39202 
Daniel F. Attridge, P.C. 
Kirkland& Ellis, LLP 
655 Fifteenth Street, N.W. 
Washington, D.C. 20005 
Karin B. Torgerson 
John P. McDonald 
C. Michael Moore 
Locke Liddell & Sapp, LLP 
2200 Ross Avenue, Suite 2200 
Dallas, TX 75201 
Alan W.Perry 
Jason D. Watkins, Esq. 
Foreman, Perry[ Watkins, Krutz 
& Tardy, LLP 
Post Office Box 22608 
Jackson, MS 39225-2608 
Steven F. Barlev, Esq. 
Joseph H. Young, Esq. 
Hogan & Hartson, LLP 
111 South Calvert Street, Suite 1600 
Baltimore, MD 21210 
ATTORNEYS 
AMGEN, INC, 
FOR DEFENDANT 
Brook Ferris 
Richard O. Burson 
Ryan J. Mitchell 
Ferris, Burson, Entrekin & Follis, PLLC 
P.O. Drawer 1289 
Laurel, MS 39441-1289 
Robert J. Muldoon, Jr. 
James W. Matthews 
Katy E. Koski 
Sherin & Lodgein, LLP 
101 Federal Striet 
Boston, MA 02110 
ATTORNEYS FOR B. BRAUN OF 
AMERICA, INC. AND MCGAW, INC. 
ATTORNEYS [FOR DEFENDANT 
ANDRX PHARMACEUTICALS, INC. 
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John B. Clark 
Tom Julian 
Daniel, Coker, Horton & Bell, P.A. 
P.O. Box 1084 
Jackson, MS 39215-1084 
Karen N. Walker 
Edwin John U 
Judson Brown 
Kirkland & Ellis, LLP 
655 Fifteenth Street NW 
Washington, DC 20005 
ATTORNEYS FOR DEFENDANTS 
BARR PHARMACEUTICALS, INC. 
AND BARR LABORATORIES, INC. 
Raymond L. Brown 
Brown, Buchanan, Sessoms, P.A. 
Post Office Box 2220 
Pascagoula, MS 39569-2220 
Michael S. Flynn 
Carlos Pelayo 
Davis, Polk & Wardwell 
450 Lexington Avenue 
New York, NY 10017 
ATTORNEYS FOR ASTRAZENECA, 
L.P. AND ASTRAZENECA 
PHARMACEUTICALS, L.P. 
Frank Holbrook 
Chelye Amis 
Stephanie M. Rippee 
Butler, Snow, O'Mara, Stevens 
& Cannada. PLLC 
Post Office Box 22567 
Jackson, MS 39225-2567 
ATTORNEYS FOR DEFENDANTS 
BAXTER INTERNATIONAL, INC. AND 
BAXTER HEALTHCARE 
COPORATION 
Paul Davis 
Butler, Snow, O'Mara, Stevens & Cannada, 
PLLC 
P.O. Box 22567 
Jackson, MS 39225-2567 
ATTORNEYS FOR DEFENDANTS BEN 
VENUE LABORATORIES, INC., 
BOEHRINGERINGELHEIM 
CORPORATION, BOEHRINGER 
INGELHEIM PHARMACEUTICALS, 
AND ROXANE LABORATORIES, INC. 
Michael T. Mervis 
Proskauer Rose, LLP 
1585 Broadway 
New York, NY 10036 
James R. Mozingo 
Upshaw, Williams, Biggers, 
Beckham & Riddick 
Post Office Box 9147 
Jackson, MS 39286 
ATTORNEYS FOR BIOVAIL 
PHARMACEUTICALS, INC. 
Lyndon M. Tretter 
Hogan & Hatson, LLP 
875 Third Avenue 
New York, NY 10022 
Christopher Shapley 
Joseph Anthony Sclafini 
Brunini, Grantham, Grower & Hewes, PLLC 
Post Office Drawer 119 
Jackson, MS 39205 
ATTORNEYS FOR BRISTOL-MYERS 
SQUIBB COMPANY, ONCOLOGY 
THERAPEUTICS NETWORK CORP., 
AND PURDUE PHARMA, L.P. 
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Michael Cory, Jr. 
Robert D. Gholson 
Burr & Forman, LLP 
The Heritage Building 
401 East Capitol Street, Suite 100 
Jackson, MS 39201 
Christopher C. Palmero 
Kelley, Drye & Warren, LLP 
101 Park Avenue 
New York, NY 10178 
Craig Holden 
Kelly J. Davidson 
Ober, Kaler, Grimes & Shriver 
120 East Baltimore Street 
Baltimore, MO 21202 
Edward J. Petets 
Lee Bowie 
Davidson, Bow| 
2506 Lakeland 
ie & Sims, PLLC 
Drive, Suite 501 
Jackson, MS 39232 
ATTORNEYS FOR DEY, INC. 
Larri A. Short 
D. Jacques Smith 
Arent Fox PLLC 
1050 Connecticut Avenue, NW 
Washington, DC 20036 
Stephanie M. Rippee 
Butler, Snow, O'Mara, Stevens & Cannada, 
PLLC 
P.O. Box 22567 
Jackson, MS 39225-2567 
ATTORNEYS FOR DEFENDANT 
CHIRON CORPORATION 
Roy Campbell 
Danielle Daigle Ireland 
Bradley, Arant, Rose & White, LLP 
Post Office Box 1789 
Jackson, MS 39215-1789 
Brien O'Connor 
Abim Thomas 
Ropes & Gray, LLP 
One International Place 
Boston, MA 02110 
ATTORNEYS FOR EISAI, INC. 
ATTORNEYS FOR ELKINS-SINN, 
INC., WYETH, INC., AND WYETH 
PHARMACEUTICALS, INC. 
Ryan Beckett 
Tommie S. Caijdin 
M. Melissa Balp 
Butler, Snow, O'Mara, Stevens, 
& Cannada, PLLC 
Post Office BOJL 22567 
Jackson, MS 39225-2567 
ATTORNEYS; FOR ELI LILLY AND 
COMPANY 
Jonathan L. Stern 
David D. FauWe 
Joshua M. Glasper 
Arnold & Ported, LLP 
555 Twelfth Stleet, NW 
Washington, DC 20004-1202 
ATTORNEYS) FOR ENDO 
PHARMACEUTICALS, INC. 
Frank M. Holbijook 
Stephanie M. Rippee 
Butler, Snow, O'Mara, Stevens & Cannada, 
PLLC 
P.O. Box 22567 
Jackson, MS 39225-2567 
ATTORNEYSIFOR FUJISAWA 
HEALTHCARE, INC. AND FUJISAWA 
USA, INC. 
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Rick A. La Trace 
Johnston, Adams, Baily, Gordon & Harris, 
LLC 
P.O. Box 1988 
Mobile, AL 36602 
Brian Rafferty 
Peter Venaglia 
Dornbush, S chaffer, Strongin and Weinstein, 
LLP 
747 3ri Avenue 
New York, NY 10017 
ATTORNEYS FOR FOREST 
LABORATORIES, INC. AND FOREST 
PHARMACEUTICALS, INC. 
Roy Campbell 
Danielle Daigle Ireland 
Bradley, Arant, Rose & White, LLP 
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Jackson, MS 39215-1789 
Brien O'Connor 
Eric P. Christofferson 
Ropes & Gray, LLP 
One International Place 
Boston, MA 02110 
ATTORNEYS FOR GENZYME 
CORPORATION 
Robert S. Litt 
Rebecca L. Dublin 
Geoffrey J. Michael 
Arnold & Porter, LLP 
555 Twelfth Street, NW 
Washington, DC 20004-1202 
Jessica L. Medina 
Arnold & Porter, LLP 
555 Twelfth Street, NW 
Washington, DC 20004-1202 
ATTORNEYS FOR GLAXO 
WELLCOME, INC. 
Frederick Herold 
Dechert, LLP 
1117 California Avenue 
Palo Alto, CA 94304-1106 
Mark Lynch 
Frank Hunger 
Covington & Burlington 
1201 Pennsylvania Avenue, N.W. 
Washington, DC 20004-2401 
ATTORNEYS FOR 
GLAXOSMITHKLINE, PLC AND 
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Stephanie M. Rippee 
Lee Davis Thames 
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Luther T. Munford 
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Phelps Dunbar 
Post Office Box 23066 
Jackson, MS 39225-3066 
David J. Burnham 
Kathleen M.O'Sullivan 
Perkins Coie, LLP 
1201 Third Avenue, Suite 4800 
Seattle, WA 98101-3099 
ATTORNEYS FOR IMMUNEX 
CORPORATION 
Neville H. Boschert 
Douglas T. Miracle 
Watkins, Ludlam, Winter, Stennis, P.A. 
P.O. Box 427 
Jackson, MS 39205 
ATTORNEYS FORIVAX 
CORPORATION, IVAX 
PHARMACEUTICALS, INC., TEVA 
PHARMACEUTICALS USA, INC., 
NOVOPHARM USA, INC., AND SICOR, 
INC. 
James L. Jones 
C. Brad Clanton 
Baker, Donelson, Bearman, Caldwell & 
Berkowitz, P.C. 
P.O. Box 14167 
Jackson, MS 39236 
ATTORNEYS FOR KING 
PHARMACEUTICALS, INC. AND 
MONARCH PHARMACEUTICALS, 
INC. 
Ed Peters 
Lee Bowie 
Davidson, Bowie & Sims, PLLC 
Post Office Bok 321405 
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Robert S. Litt 
Steven S. Diamond 
Justin S. Antonipillai 
Emily N. Glatfelter 
Joseph M. Meadows 
Arnold & Porter, LLP 
555 Twelfth St, NW 
Washington, DC 20004-1202 
ATTORNEYS FOR K-V 
PHARMACEUTICAL COMPANY AND 
ETHEX CORPORATION 
Michael B. Hewes 
Jack C. Crawfqrd 
Mark A. Drehet 
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ATTORNEYS FOR MEDIMMUNE, 
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P.O. Box 22725 
Jackson, MS 39225-2725 
William F. Cavanaugh, Jr. 
Andrew D. Schau 
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1133 Avenue of Americas 
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JOHNSON, ALZA CORPORATION, 
JANSSEN PHARMACEUTICALS, 
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John Henegan 
Ben Watson 
J. Kennedy Turner 
Butler, Snow, O'Mara, Stevens 
& Cannada, PLLC 
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John M. Townsend 
Rob Reznick 
Rob Fundhouser 
Hughes, Hubbard & Reed , LLP 
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Baltimore, MD 21202 
Edward J. Peters 
Lee Bowie 
Davidson, Bowie & Sims, PLLC 
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|ELI LILLY AND CO 
I ELI LILLY AND CO 
[ELI LILLY AND CO 
[ELI LILLY AND CO 
IELI LILLY AND CO 
ELI LILLY AND CO 
ELI LILLY AND CO 
ELI LILLY AND CO 
ELI LILLY AND CO 
ELI LILLY AND CO 
ELI LILLY AND CO 
ELI LILLY AND CO 
ELI LILLY AND CO 
ELI LILLY AND CO 
ELI LILLY AND CO 
ELI LILLY AND CO 
ELI LILLY AND CO 
ELI LILLY AND CO 
ELI LILLY AND CO 
ER SQUIBB AND SONS IN0 
ER SQUIBB AND SONS IN0 
ER SQUIBB AND SONS INO 
|ER SQUIBB AND SONS INq 
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00003-3631-12 
00003-3624-12 
00003-3522-15 
00003-1967-01 
00003-1967-01 
00003-1967-01 
00003-1966-01 
00003-1965-01 
00003-1837-10 
00003-1834-10 
00003-1738-40 
00003-1738-45 
00003-1737-40 
00003-1737-45 
00003-0874-60 
00003-0830-50 
00003-0749-60 
00003-0593-20 
00003-0569-15 
00003-0485-50 
00003-0482-50 
00003-0482-75 
00003-0452-50 
00003-0452-75 
00003-0450-54 
00003-0450-75 
00003-0429-50 
00003-0390-50 
00003-0384-50 
00003-0349-50 
00003-0338-50 
00003-0283-50 
00003-0241-50 
00003-0207-50 
00003-0178-50 
00003-0154-50 
00003-0134-60 
00003-0116-75 
00003-0109-60 
00003-0101-60 
00004-1965-01 
00004-1964-01 
00004-1964-04 
00004-1964-04 
00004-1963-01 
00004-1963-02 
00004-1506-03 
[00004-1101-16 
FDA Prod I 
REYATAZ20 
REYATAZ15 
NPH INSULI 
ZERIT40M 
ZERIT 40MG 
ZERIT 
ZERIT 
ZERIT 
NOVOLIN70/ 
NOVOLIN N 
TRIMOX 250 
TRIMOX250 
TRIMOX 125 
TRIMOX 125 
CEPHALEXIN 
HYDREA 
CEPHALEXIN 
MYCOSTATIN 
PROLIXIN 
CAPOTEN 
CAPOTEN 
CAPOTEN 
CAPOTEN 
CAPOTEN 
CAPOTEN 
CAPOTEN 
FLORINEF A 
CAPOZIDE 5 
CAPOZIDE 5 
CAPOZIDE 2 
CAPOZIDE 2 
CORZIDE 40 
CORGARD 80 
CORGARD 40 
iPRAVACHOL 
PRAVACHOL 
PRINCIPEN 
VEETIDS 50 
TRIMOX 500 
TRIMOX 250 
ROCEPHIN 2 
ROCEPHIN 1 
ROCEPHIN V 
ROCEPHIN 1 
ROCEPHIN 5 
ROCEPHIN 5 
EFUDEXCRE 
jXELODA 500 
Firm I 
ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
|ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
ER SQUIBB AND SONS INC 
HOFFMANN LA ROCHE INC 
HOFFMANN LA ROCHE INC 
HOFFMANN LA ROCHE INC 
HOFFMANN LA ROCHE INC 
HOFFMANN LA ROCHE INC 
HOFFMANN LA ROCHE INC 
HOFFMANN LA ROCHE INC 
[HOFFMANN LA ROCHE INC 
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00004-1101-50 XELODA 500 HOFFMANN LA ROCHE INC 
00004-0810-95 TAMIFLU OR HOFFMANN LA ROCHE INC 
00004-0800-85 TAMIFLU 75 HOFFMANN LA ROCHE INC 
00004-0380-39 FUZEON CON HOFFMANN LA ROCHE INC 
00004-0352-39 PEGASYS18 HOFFMANN LA ROCHE INC 
00004-0350-09 PEGASYS18 HOFFMANN LA ROCHE INC 
00004-0350-39 PEGASYS CO HOFFMANN LA ROCHE INC 
00004-0350-39 PEGASYS18 HOFFMANN LA ROCHE INC 
00004-0289-57 SORIATANE HOFFMANN LA ROCHE INC 
00004-0278-48 CYTOVENE 5 HOFFMANN LA ROCHE IN 
00004-0269-48 CYTOVENE 2 HOFFMANN LA ROCHE INC 
00004-0265-01 DEMADEX10 HOFFMANN LA ROCHE INC 
00004-0264-01 DEMADEX 20 HOFFMANN LA ROCHE INC 
00004-0260-01 CELLCEPT 5 HOFFMANN LA ROCHE INC 
00004-0259-01 CELLCEPT 2 HOFFMANN LA ROCHE IN0 
00004-0259-01 CELLCEPT C HOFFMANN LA ROCHE IN 
00004-0256-52 Xenical ca HOFFMANN LA ROCHE IN 
00004-0250-01 VESANOID 1 HOFFMANN LA ROCHE IN 
00004-0246-48 FORTOVASE HOFFMANN LA ROCHE INC 
00004-0245-15 INVIRASE 2 HOFFMANN LA ROCHE IN0 
00004-0245-15 INVIRASE C HOFFMANN LA ROCHE INC 
00004-0221-01 HMD 0.75 HOFFMANN LA ROCHE INC 
00004-0214-57 SORIATANE HOFFMANN LA ROCHE INC 
00004-0181-22 CARDENE SR HOFFMANN LA ROCHE INC 
00004-0169-49 ACCUTANE 2 HOFFMANN LA ROCHE INC 
00004-0162-01 BUMEX TABL HOFFMANN LA ROCHE INC 
00004-0156-49 ACCUTANE 4 HOFFMANN LA ROCHE INC 
00004-0144-01 ROCALTROL HOFFMANN LA ROCHE INC 
00004-0143-01 ROCALTROL HOFFMANN LA ROCHE INC 
00004-0143-23 ROCALTROL HOFFMANN LA ROCHE INC 
00004-0125-01 BUMEX TABS HOFFMANN LA ROCHE INC 
00004-0121-01 BUMEX TABS HOFFMANN LA ROCHE INC 
00004-0121-14 BUMEX TABL HOFFMANN LA ROCHE INC 
00004-0098-01 KLONOPIN T HOFFMANN LA ROCHE INC 
00004-0098-01 KLONOPIN 2 HOFFMANN LA ROCHE INC 
00004-0086-94 COPEGUS 20 HOFFMANN LA ROCHE INC 
00004-0081-01 POSICOR10 HOFFMANN LA ROCHE INC 
00004-0080-01 POSICOR TA HOFFMANN LA ROCHE INC 
00004-0068-01 KLONOPIN 0 HOFFMANN LA ROCHE INC 
00004-0068-01 KLONOPIN T HOFFMANN LA ROCHE INC 
00004-0058-01 KLONOPIN 1 HOFFMANN LA ROCHE INC 
00004-0058-01 KLONOPIN T HOFFMANN LA ROCHE INC 
00004-0038-22 VALCYTE 45 HOFFMANN LA ROCHE INC 
00004-0018-14 TICLID TAB HOFFMANN LA ROCHE INC 
00004-0018-22 TICLID TAB HOFFMANN LA ROCHE INC 
00004-0018-23 TICLID 250 HOFFMANN LA ROCHE INC 
00005-9270-29 DECLOMYCIN WYETH PHARMACEUTICAL DIV WYETH HO 
WYETH PHARMACEUTICAL DIV WYETH HO 00005-9218-23 DECLOMYCIN 
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00005-4570-23 
00005-4507-23 
00005-4464-43 
00005-3898-40 
00005-3898-42 
00005-3898-46 
00005-3897-18 
00005-3897-23 
00005-3752-34 
00005-3709-34 
00005-3700-46 
00005-3700-49 
00005-3700-60 
00005-3551-43 
00005-3417-32 
00005-3356-49 
00005-3352-23 
00005-3286-43 
00005-3285-43 
00005-3238-23 
00005-3235-38 
00005-3234-23 
00005-3182-23 
00005-3181-34 
00005-3180-34 
00005-2491-23 
00005-2491-23 
00005-2490-23 
00005-2490-23 
00005-2489-23 
00005-0753-23 
00006-3841-30 
00006-3822-10 
00006-3801-06 
00006-3801-06 
00006-3628-03 
00006-3628-10 
00006-3628-10 
00006-3628-35 
00006-3628-35 
00006-3628-36 
00006-3628-36 
00006-3558-03 
00006-3558-03 
00006-3538-92 
00006-3519-03 
00006-3519-10 
|00006-3519-36 
FDA Prod I 
NEPTAZANE 
METHOTREXA 
MAXZlDE-25 
SUPRAX ORA 
SUPRAX ORA 
SUPRAX ORA 
SUPRAX 400 
SUPRAX 400 
HYDROCHLOR 
FUROSEMIDE 
ERYTHROMYC 
ERYTHROMYC 
ERYTHROMYC 
SULINDAC T 
CIMETIDINE 
CEFACLOR S 
CEFACLOR 2 
KETOPROFEN 
KETOPROFEN 
ZIAC TAB 2 
ZIAC 10MG/ 
ZIAC TAB 5 
CLONIDINE 
CLONIDINE 
CLONIDINE 
VERELAN PE 
VERELAN CA 
VERELAN PE 
VERELAN CA 
VERELAN CA 
DIAMOX SEQ 
SINGULAIR 
CANCIDAS I 
MAXALT-MLT 
MAXALT MLT 
COSOPT N/A 
COSOPT EYE 
COSOPT N/A 
COSOPT 0.5 
COSOPT EYE 
iCOSOPT 0 5 
[COSOPT EYE 
TIMOPTIC X 
TIMOPTIC-X 
PEPCID 40M 
TRUSOPT 2% 
TRUSOPT 2% 
I TRUSOPT 2% 
Firm I 
WYETH PHARMACEUTICAL DIV WYETH HO 
WYETH PHARMACEUTICAL DIV WYETH HO 
WYETH PHARMACEUTICAL DIV WYETH HO 
WYETH PHARMACEUTICAL DIV WYETH HO 
WYETH PHARMACEUTICAL DIV WYETH HO 
WYETH PHARMACEUTICAL DIV WYETH HO 
WYETH PHARMACEUTICAL DIV WYETH HO 
WYETH PHARMACEUTICAL DIV WYETH HO 
WYETH PHARMACEUTICAL DIV WYETH HO 
WYETH PHARMACEUTICAL DIV WYETH HO 
WYETH PHARMACEUTICAL DIV WYETH HO 
WYETH PHARMACEUTICAL DIV WYETH HO 
WYETH PHARMACEUTICAL DIV WYETH HO 
WYETH PHARMACEUTICAL DIV WYETH HO 
WYETH PHARMACEUTICAL DIV WYETH HO 
WYETH PHARMACEUTICAL DIV WYETH HO 
WYETH PHARMACEUTICAL DIV WYETH HO 
WYETH PHARMACEUTICAL DIV WYETH HO 
WYETH PHARMACEUTICAL DIV WYETH HO 
WYETH PHARMACEUTICAL DIV WYETH HO 
WYETH PHARMACEUTICAL DIV WYETH HO 
WYETH PHARMACEUTICAL DIV WYETH HO 
WYETH PHARMACEUTICAL DIV WYETH HO 
WYETH PHARMACEUTICAL DIV WYETH HO 
WYETH PHARMACEUTICAL DIV WYETH HO 
WYETH PHARMACEUTICAL DIV WYETH HO 
WYETH PHARMACEUTICAL DIV WYETH HO 
WYETH PHARMACEUTICAL DIV WYETH HO 
WYETH PHARMACEUTICAL DIV WYETH HO 
WYETH PHARMACEUTICAL DIV WYETH HO 
WYETH PHARMACEUTICAL DIV WYETH HO 
MERCK AND CO INC 
iMERCKANDCOINC 
IMERCKANDCOINC 
MERCK AND CO INC 
MERCK AND CO INC 
MERCK AND CO INC 
MERCK AND CO INC 
MERCK AND CO INC 
MERCK AND CO INC 
MERCK AND CO INC 
MERCK AND CO INC 
MERCK AND CO INC 
MERCK AND CO INC 
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IMERCKANDCOINC 
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00006-3367-03 
00006-3367-03 
00006-3367-10 
00006-3367-10 
00006-3367-12 
00006-3367-12 
00006-0964-31 
00006-0964-58 
00006-0963-28 
00006-0963-31 
00006-0963-56 
00006-0963-72 
00006-0963-82 
00006-0960-31 
00006-0960-54 
00006-0960-58 
00006-0952-31 
00006-0952-54 
00006-0952-54 
00006-0952-58 
00006-0952-58 
00006-0951-54 
00006-0951-58 
00006-0936-31 
00006-0936-58 
00006-0931-68 
00006-0925-31 
00006-0749-31 
00006-0749-31 
00006-0749-54 
00006-0749-54 
00006-0749-61 
00006-0749-61 
00006-0747-31 
00006-0747-54 
00006-0747-58 
00006-0742-28 
00006-0742-31 
00006-0740-31 
00006-0740-31 
00006-0740-54 
00006-0740-54 
00006-0740-61 
00006-0740-61 
00006-0740-82 
00006-0735-31 
00006-0735-31 
[00006-0735-54 
- FDA Prod I 
TIMOPTIC 0 
TIMOPTIC . 
TIMOPTIC 0 
TIMOPTIC . 
TIMOPTIC . 
TIMOPTIC 0 
PEPCID 40M 
PEPCID 40M 
PEPCID 20M 
PEPCID 20M 
PEPCID 20M 
PEPCID 20M l 
PEPCID 20M 
COZAAR 100 
COZAAR100 
COZAAR 100 
COZAAR 50M 
COZAAR 50 
COZAAR 50M 
COZAAR 50 
COZAAR 50M 
COZAAR 25M 
COZAAR 25M 
FOSAMAX10 
FOSAMAX10 
FLEXERIL 1 
FOSAMAX 5M 
ZOCOR 40MG 
ZOCOR 40 M 
ZOCOR 40MG 
ZOCOR 40 M 
ZOCOR 40 M 
ZOCOR 40MG 
IHYZAAR100 
HYZAAR100 
HYZAAR 100 
PRILOSEC 2 
PRILOSEC 2 
ZOCOR 20 M 
ZOCOR 20MG 
ZOCOR 20 M 
ZOCOR 20MG 
ZOCOR 20 M 
ZOCOR 20MG 
ZOCOR 20MG 
ZOCOR 10 M 
ZOCOR 10MG 
I ZOCOR 10M 
Firrrj I 
MERCKANDCOINC 
MERCK AND CO INC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCK AND CO INC 
MERCKANDCOINC 
MERCK AND CO INC 
MERCKANDCOINC 
MERCK AND CO INC 
MERCKANDCOINC 
MERCK AND CO INC 
MERCK AND CO INC 
MERCK AND CO INC 
MERCK AND CO INC 
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MERCK AND CO INC 
MERCK AND CO INC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCK AND CO INC 
MERCK AND CO INC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCKANDCOINC 
iMERCKANDCOINC 
[MERCKANDCOINC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCKANDCOINC 
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JMERCKANDCOINC 
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00006-0735-54 
00006-0735-61 
00006-0732-61 
100006-0731-61 
100006-0726-61 
! 00006-0720-68 
(00006-0717-31 
00006-0717-54 
100006-0717-58 
00006-0714-68 
00006-0714-82 
00006-0713-68 
100006-0713-82 
100006-0712-68: 
00006-0712-82 
00006-0711-31 
00006-0711-54 
00006-0707-68 
00006-0705-20 
00006-0705-68 
00006-0697-61 
00006-0693-61 
00006-0573-54 
00006-0573-62 
00006-0543-31 
00006-0543-31 
00006-0543-54 
00006-0543-54 
00006-0543-61 
00006-0452-58 
00006-0451-58 
00006-0275-31 
00006-0275-54 
00006-0267-06 
00006-0237-58 
00006-0207-58 
00006-0173-68 
00006-0142-31 
00006-0142-58 
00006-0140-31 
00006-0140-31 
00006-0140-58 
00006-0140-58 
00006-0117-31 
00006-0117-54 
00006-0114-68 
00006-0110-31 
J00006-0110-68 
FDA Prod I 
ZOCOR 10MG 
ZOCOR10MG 
MEVACOR 40 
MEVACOR 20 
ZOCOR 5MG 
VASERETIC 
HYZAAR 50-
HYZAAR 50-
HYZAAR 50-
VASOTEC 20 j 
VASOTEC 20 
VASOTEC 10 
VASOTEC 10 
VASOTEC 5M 
VASOTEC 5M 
SINGULAR 
SINGULAIR 
TONOCARD 4 
NOROXIN 40 
NOROXIN 40 
DOLOBID 50 
INDOCIN SR 
CRIXIVAN 4 
CRIXIVAN 4 
ZOCOR 80 M 
ZOCOR 80MG 
ZOCOR 80MG 
ZOCOR 80 M 
ZOCOR 80MG 
PLENDIL10 
PLENDIL 5M 
SINGULAIR 
SINGULAIR 
MAXALT10M 
^PRINIVIL4 
IPRINIVIL2 
[VASERETIC 
PRINZIDE 2 
PRINZIDE 2 
PRINZIDE 1 
PRINZIDE 2 
PRINZIDE 1 
PRINZIDE 2 
SINGULAIR 
SINGULAIR 
VIOXX 50MG 
VIOXX 25MG 
IVIOXX 25MG 
Firm ] 
MERCK AND CO INC 
MERCK AND CO INC 
MERCK AND CO INC 
MERCK AND CO INC 
MERCK AND CO INC 
MERCK AND CO INC 
MERCK AND CO INC 
MERCK AND CO INC 
MERCK AND CO INC 
MERCK AND CO INC 
MERCK AND CO INC 
MERCK AND CO INC 
MERCK AND CO INC 
MERCK AND CO INC 
MERCK AND CO INC 
MERCK AND CO INC 
MERCK AND CO INC 
MERCK AND CO INC 
MERCK AND CO INC 
MERCK AND CO INC 
MERCK AND CO INC 
MERCK AND CO INC 
MERCK AND CO INC 
MERCK AND CO INC 
MERCK AND CO INC 
MERCK AND CO INC 
MERCK AND CO INC 
MERCKANDCOINC 
MERCK AND CO INC 
MERCKANDCOINC 
MERCKANDCOINC 
iMERCKANDCOINC 
iMERCK AND CO INC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCK AND CO INC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCKANDCOINC 
IMERCKANDCOINC 
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00006-0110-82 
00006-0106-58 
00006-0077-44 
00006-0074-68 
00006-0072-31 
00006-0072-31 
00006-0072-58 
00006-0072-58 
00006-0067-68 
00006-0047-68 
00006-0031-21 
00006-0031-44 
00006-0031-44 
00006-0019-58 
00006-0014-68 | 
00007-5290-20 
00007-4890-20 
00007-4879-18 
00007-4142-20 
00007-4142-20 
00007-4142-20 
00007-4141-20 
00007-4141-20 
00007-4140-20 
00007-4140-20 
00007-4139-20 
00007-4139-20 
00007-4117-13 
00007-4117-13 
00007-4010-20 
00007-3533-20 
00007-3519-20 
00007-3514-15 
00007-3513-15 
00007-3513-20 
00007-3367-20 
00007-3346-15 
00007-3168-18 
00007-3168-20 
00007-3167-18 
00007-3167-20 
00007-3166-18 
00007-3164-18 
00008-4188-04 
00008-4187-01 
00008-4187-02 
00008-4181-01 
100008-4179-01 
FDA Prod j 
VIOXX 25MG 
PRINIVIL 1 
FOSAMAX 35 
VIOXX 12.5 
PROSCAR 5 
PROSCAR 5M 
PROSCAR 5 
PROSCAR 5M 
TIMOLIDE 1 
VIVACTIL 1 
FOSAMAX 70 
FOSAMAX ON 
FOSAMAX 70 
PRINIVIL 5 
VASOTEC 2. i 
URISPAS(FL 
REQUIP 0.2 
RIDAURA(AU 
COREG(CARV 
COREG 25MG 
COREG 25 M 
COREG(CARV 
COREG 12.5 
COREG(CARV 
COREG 6.25 
!COREG(CARV 
COREG 3.12 
FAMVIR (FA 
JFAMVIR(FAM 
ESKALITH C 
DIBENZYLIN 
DEXEDRINE( 
DEXEDRINE( 
DEXEDRINE( 
DEXEDRINE( 
COMPAZINE( 
COMPAZINE( 
AVANDAMET 
AVANDAMET 
AVANDAMET 
AVANDAMET 
AVANDAMET 
AVANDAMET 
CORDARONE 
ORUDIS 75M 
ORUDIS 75M 
ORUDIS 50M 
|SECTRAL40 
Firm j 
MERCKANDCOINC 
MERCK AND CO INC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCKANDCOINC 
MERCKANDCOINC 
SMITHKLINE BEECHAM PHARMACEUTICAL 
SMITHKLINE BEECHAM PHARMACEUTICAL 
SMITHKLINE BEECHAM PHARMACEUTICAL | 
SMITHKLINE BEECHAM PH ARMACEUTtCAL | 
SMITHKLINE BEECHAM PHARMACEUTICAL I 
SMITHKLINE BEECHAM PHARMACEUTICAL 
SMITHKLINE BEECHAM PHARMACEUTICAL 
SMITHKLINE BEECHAM PHARMACEUTICAL 
iSMITHKLINE BEECHAM PHARMACEUTICAL | 
SMITHKLINE BEECHAM PH 
SMITHKLINE BEECHAM PH 
SMITHKLINE BEECHAM PH 
SMITHKLINE BEECHAM PH 
SMITHKLINE BEECHAM PH 
ARMACEUTICAL I 
ARMACEUTICAL 
ARMACEUTICAL 
ARMACEUTICAL 
ARMACEUTICAL | 
SMITHKLINE BEECHAM PHARMACEUTICAL I 
SMITHKLINE BEECHAM PHARMACEUTICAL 
SMITHKLINE BEECHAM PHARMACEUTICAL 
SMITHKLINE BEECHAM PHARMACEUTICAL 
SMITHKLINE BEECHAM PHARMACEUTICAL 
SMITHKLINE BEECHAM PHARMACEUTICAL 
SMITHKLINE BEECHAM PHARMACEUTICAL 
SMITHKLINE BEECHAM PHARMACEUTICAL 
SMITHKLINE BEECHAM PHARMACEUTICAL 
SMITHKLINE BEECHAM PHARMACEUTICAL 
SMITHKLINE BEECHAM PHARMACEUTICAL 
SMITHKLINE BEECHAM PH 
SMITHKLINE BEECHAM PH 
SMITHKLINE BEECHAM PH 
WYETH PHARMACEUTICAl 
WYETH PHARMACEUTICAl 
WYETH PHARMACEUTICAl 
WYETH PHARMACEUTICAl 
|WYETH PHARMACEUTICAl 
ARMACEUTICAL 
ARMACEUTICAL 
ARMACEUTICAL 
Jsco 
Jsco 
Jsco 
Jsco 
.pco 
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NDC 
00008-4177-01 
00008-2576-02 
00008-2564-01 
00008-2536-01 
00008-2533-02 
00008-2514-02 
00008-2511-02 
00008-1031-05 
00008-1031-05 
00008-1030-07 
00008-0926-81 
00008-0926-81 
00008-0926-81 
00008-0925-81' 
00008-0909-01 
00008-0902-02 
00008-0901-03 
00008-0841-81 
00008-0841-81 
00008-0837-01 
00008-0836-01 
00008-0833-01 
00008-0822-01 
00008-0800-01 
00008-0800-03 
00008-0781-01 
00008-0771-01 
00008-0705-01 
00008-0704-01 
00008-0701-01 
00008-0690-01 
00008-0498-01 
00008-0472-01 
00008-0229-01 
00008-0212-01 
00008-0074-01 
00008-0073-01 
00015-5436-60 
00015-3091-45 
00015-1177-19 
00015-1177-60 
00015-1177-60 
00015-0596-41 
00015-0508-42 
00015-0508-42 
00015-0503-01 
00026-8897-50 
100026-8889-50 
FDA Prod I 
SECTRAL 20 
ALESSE-28 
NORPLANT S 
TRIPHASIL-
NORDETTE-2 
LO/OVRAL-2 
OVRAL-28 T 
RAPAMUNE T 
RAPAMUNE 1 
RAPAMUNE L 
SONATA 10 
SONATA10M 
SONATA CAP 
SONATA CAP 
DURACT 25 
NAPRELAN 5 
NAPRELAN 3 
PROTONIX T 
PROTONIX 4 
EFFEXOR XR 
EFFEXOR XR 
EFFEXOR XR 
ORUVAIL CA 
ADVIL SUSP 
ADVIL SUSP 
EFFEXOR 37 
ISMO TABLE 
EFFEXOR 10 
EFFEXOR 75 
EFFEXOR 25 
ORUVAIL 20 
PHENERGAN 
BASALJEL C 
iPHENERGAN 
PHENERGAN 
IWYTENSIN T 
WYTENSIN T 
SALUTENSIN 
VEPESID 
TEQUIN 
TEQUIN 
TEQUIN 400 
MEGACE 
MEGACE40M 
MEGACE 
CYTOXAN 
CIPRO XR 1 
ICIPRO XR 5 
-Firm "I 
WYETH PHARMACEUTICALS CO 
WYETH PHARMACEUTICALS CO 
WYETH PHARMACEUTICALS CO 
WYETH PHARMACEUTICALS CO 
WYETH PHARMACEUTICALS CO 
WYETH PHARMACEUTICALS CO 
WYETH PHARMACEUTICALS CO 
WYETH PHARMACEUTICALS CO 
WYETH PHARMACEUTICALS CO 
WYETH PHARMACEUTICALS CO 
WYETH PHARMACEUTICALS CO 
WYETH PHARMACEUTICALS CO 
WYETH PHARMACEUTICALS CO 
WYETH PHARMACEUTICALS CO 
WYETH PHARMACEUTICALS CO 
WYETH PHARMACEUTICALS CO 
WYETH PHARMACEUTICALS CO 
WYETH PHARMACEUTICALS CO 
WYETH PHARMACEUTICALS CO 
WYETH PHARMACEUTICALS CO 
WYETH PHARMACEUTICALS CO 
WYETH PHARMACEUTICALS CO 
WYETH PHARMACEUTICALS CO 
WYETH PHARMACEUTICALS CO 
WYETH PHARMACEUTICALS CO 
WYETH PHARMACEUTICALS CO 
WYETH PHARMACEUTICALS CO 
WYETH PHARMACEUTICALS CO 
WYETH PHARMACEUTICALS CO 
IWYETH PHARMACEUTICALS CO 
jWYETH PHARMACEUTICALS CO 
WYETH PHARMACEUTICALS CO 
WYETH PHARMACEUTICALS CO 
WYETH PHARMACEUTICALS CO 
WYETH PHARMACEUTICALS CO 
WYETH PHARMACEUTICALS CO 
WYETH PHARMACEUTICALS CO 
MEAD JOHNSON AND CO SUB BRISTOL M 
MEAD JOHNSON AND CO SUB BRISTOL M 
MEAD JOHNSON AND CO SUB BRISTOL M 
MEAD JOHNSON AND CO SUB BRISTOL M 
MEAD JOHNSON AND CO SUB BRISTOL M 
MEAD JOHNSON AND CO SUB BRISTOL M 
MEAD JOHNSON AND CO SUB BRISTOL M 
MEAD JOHNSON AND CO SUB BRISTOL M 
MEAD JOHNSON AND CO SUB BRISTOL M 
BAYER CORP PHARMACEUTICAL DIV 
| BAYER CORP PHARMACEUTICAL DIV 
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NDC 1 
00026-8861-51 
00026-8861-51 
00026-8851-51 
00026-8841-51 
00026-8581-41 
00026-8581-41 
00026-8581-69 
00026-8514-50 
00026-8514-50 
00026-8513-48 
00026-8513-50 
00026-8513-51 
00026-8513-51 
00026-8512-50 
00026-8512-51 
00026-8512-51 ! 
00026-3095-55 
00026-2885-51 
00026-2885-69 
00026-2885-86 
00026-2884-51 
00026-2862-51 
00026-2861-51 
00026-2861-51 
00026-0648-20 
00026-0648-24 
00026-0648-71 
00026-0601-35 
00026-0372-50 
00028-0264-01 
00028-0262-01 
00028-0205-01 
00028-0164-01 
00028-0164-10 
00028-0162-01 
00028-0151-01 
00028-0105-01 
00028-0073-01 
00028-0072-01 
00028-0071-01 
00028-0053-01 
00028-0051-01 
00028-0051-10 
00028-0035-01 
00028-0020-01 
00029-6160-32 
00029-6096-28 
100029-6096-40 
FDA Prod I 
ADALAT CC 
NIFEDIPINE 
NIFEDIPINE 
NIFEDIPINE 
Avelox 400 
AVELOXABC 
Avelox 400 
CIPRO 750M 
CIPROFLOXA 
CIPROFLOXA 
CIPROFLOXA 
CIPRO 500M 
CIPROFLOXA 
CIPROFLOXA 
CIPRO 250M 
CIPROFLOXA 
CLOTRIMAZO 
Baycol .4m 
Baycol .4m 
Baycol .4m 
Baycol .3m 
PRECOSE AC 
PRECOSE 50 
PRECOSE AC 
Gamimune N 
Gamimune N 
Gamimune N 
PROLASTIN 
Kogenate F 
VOLTAREN( 
VOLTAREN( 
VOLTAREN-X 
VOLTAREN( 
VOLTAREN( 
VOLTAREN( 
CATAFLAM ( 
!BRETHINE( 
ILOPRESSOR/ 
[BRETHINE ( 
ILOPRESSOR 
LOPRESSOR/ 
LOPRESSOR 
LOPRESSOR 
LOPRESSOR/ 
TOFRANIL-P 
BEEPEN-VK( 
AUGMENTIN 
jAUGMENTIN 
Firm I 
BAYER CORP PHARMACEUTICAL DIV 
BAYER CORP PHARMACEUTICAL DIV 
BAYER CORP PHARMACEUTICAL DIV 
BAYER CORP PHARMACEUTICAL DIV 
BAYER CORP PHARMACEUTICAL DIV 
BAYER CORP PHARMACEUTICAL DIV 
BAYER CORP PHARMACEUTICAL DIV 
BAYER CORP PHARMACEUTICAL DIV 
BAYER CORP PHARMACEUTICAL DIV 
BAYER CORP PHARMACEUTICAL DIV 
BAYER CORP PHARMACEUTICAL DIV 
BAYER CORP PHARMACEUTICAL DIV 
BAYER CORP PHARMACEUTICAL DIV 
BAYER CORP PHARMACEUTICAL DIV 
BAYER CORP PHARMACEUTICAL DIV 
BAYER CORP PHARMACEUTICAL DIV 
BAYER CORP PHARMACEUTICAL DIV 
BAYER CORP PHARMACEUTICAL DIV | 
BAYER CORP PHARMACEl 
BAYER CORP PHARMACEl 
BAYER CORP PHARMACEL 
BAYER CORP PHARMACEL 
BAYER CORP PHARMACEL 
BAYER CORP PHARMACEL 
BAYER CORP PHARMACEL 
BAYER CORP PHARMACEl 
BAYER CORP PHARMACEL 
BAYER CORP PHARMACEL 
BAYER CORP PHARMACEl 
INOVARTIS PHARMACEUTI 
NOVARTIS PHARMACEUTI 
NOVARTIS PHARMACEUTI 
NOVARTIS PHARMACEUTI 
NOVARTIS PHARMACEUTI 
JTICAL DIV I 
JTICAL DIV 
JTICAL DIV 
JTICAL DIV 
JTICAL DIV 
JTICAL DIV 
JTICAL DIV 
JTICAL DIV 
JTICAL DIV 
JlTICAL DIV 
ITICAL DIV 
tALS CORP DBA 
CALS CORP DBA 
CALS CORP DBA 
CALS CORP DBA 
(pALS CORP DBA j 
NOVARTIS PHARMACEUTICALS CORP DBA I 
NOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
BEECHAM DIV SMITHKLINS BEECHAM CO 
BEECHAM DIVSMITHKLINB BEECHAM CO 
[BEECHAM DIVSMITHKLINB^ BEECHAM CO 
Exhibit A 
Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU. 
Machine-generated OCR, may contain errors.
Exhibit A 
NDC 1 
00029-6096-48 
00029-6096-60 
00029-6094-22 
00029-6094-24 
00029-6094-29 
00029-6094-39 
00029-6094-45 
00029-6094-51 
00029-6092-29 
00029-6092-39 | 
00029-6092-51 | 
00029-6092-51 
00029-6090-22 
00029-6090-22 
00029-6090-23 
00029-6090-23 
00029-6090-39 
00029-6087-29 
00029-6087-39 
00029-6087-51 
00029-6087-51 
00029-6086-12 
00029-6086-12 
00029-6085-22 
00029-6085-22 
00029-6085-23 
00029-6085-39 
00029-6080-12 
00029-6080-12 
00029-6080-27 
00029-6080-31 
00029-6075-27 
00029-6075-27 
00029-6074-47 
00029-6072-12 
00029-6072-12 
00029-6049-59 
00029-6049-59 
00029-6048-59 
00029-6048-59 
00029-6038-39 
00029-6009-22 
00029-6009-22 
00029-6009-23 
00029-6008-21 
00029-6008-22 
00029-6008-23 
100029-6007-30 
FDA Prod I 
AUGMENTIN 
AUGMENTIN 
AUGMENTIN 
AUGMENTIN 
AUGMENTIN 
AUGMENTIN 
AUGMENTIN 
AUGMENTIN 
AUGMENTIN( 
AUGMENTIN( 
AUGMENTIN 
AUGMENTIN( 
AUGMENTIN 
AUGMENTIN( 
AUGMENTIN 
AUGMENTIN( 
AUGMENTIN( 
AUGMENTIN( 
AUGMENTIN( 
AUGMENTIN 
AUGMENTIN( 
AUGMENTIN 
AUGMENTIN( 
AUGMENTIN 
AUGMENTIN( 
AUGMENTIN( 
AUGMENTIN( 
AUGMENTIN 
AUGMENTIN( 
AUGMENTIN( 
AUGMENTIN( 
AUGMENTIN 
iAUGMENTIN( 
jAUGMENTIN( 
AUGMENTIN 
AUGMENTIN( 
AMOXIL(AMO 
AMOXIL 400 
AMOXIL 200 
AMOXIL(AMO 
AMOXIL(AMO 
AMOXIL 250 
AMOXIL(AMO 
AMOXIL(AMO 
AMOXIL(AMO 
AMOXIL(AMO 
AMOXIL(AMO 
|AMOXIL(AMO 
Firm I 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
iBEECHAM DIV SMITHKLINE BEECHAM CO 
!BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
BEECHAM DIV SMITHKLINE BEECHAM CO 
|BEECHAM DIV SMITHKLINE BEECHAM CO 
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NDC FDA Prod Firm 
00029-6007-32 AMOXIL(AMQ BEECHAM DIV SMITHKUNB BEECHAM CO 
00029-6006-30 AMOX)l_(AMO BEECHAM DIV SMITHKUNB BEECHAM CO 
00029-6006-32 AMOXIL(AMO BEECHAM DIV SMITHKUNB BEECHAM CO 
00029-4852-20 RELAFEN BEECHAM DIV SMITHKUNE BEECHAM CO 
00029-4852-20 RELAFEN(NA BEECHAM DIV SMITHKUNE BEECHAM CO 
00029-4851-20 RELAFEN(NA BEECHAM DIV SMITHKUNE BEECHAM CO 
00029-4851-20 RELAFEN(N BEECHAM DIV SMITHKUNE BEECHAM CO 
00029-3213-13 PAXIL 40MG BEECHAM DIV SMITHKUNE BEECHAM CO 
00029-3213-13 PAXIL(PARO BEECHAM DIV SMITHKUNE BEECHAM CO 
00029-3212-13 PAXIL (PAR BEECHAM DIV SMITHKUNE BEECHAM CO 
00029-3212-13 PAXIL 30MG BEECHAM DIV SMITHKUNE BEECHAM CO 
00029-3212-13 PAXIL(PARO BEECHAM DIV SMITHKUNE BEECHAM CO 
00029-3211-13 PAXIL (PAR BEECHAM DIV SMITHKUNE BEECHAM CO 
00029-3211-13 PAXIL 20MG BEECHAM DIV SMITHKUNE BEECHAM CO 
00029-3211-13 PAXIL(PARO BEECHAM DIV SMITHKUNE BEECHAM CO 
00029-3211-20 PAXIL (PAR BEECHAM DIV SMITHKUNE BEECHAM CO 
00029-3211-20 PAXIL 20MG BEECHAM DIV SMITHKUNE BEECHAM CO 
00029-3211-20 PAXIL(PARO BEECHAM DIV SMITHKUNE BEECHAM CO 
00029-3210-13 PAXIL 10MG BEECHAM DIV SMITHKUNE BEECHAM CO 
00029-3210-13 PAXIL(PARO BEECHAM DIV SMITHKUNE BEECHAM CO 
00029-3208-13 PAXIL CR 3 BEECHAM DIV SMITHKLIN E BEECHAM CO 
00029-3207-13 PAXIL CR 2 BEECHAM DIV SMITHKLIN EBEECHAM CO 
00029-3206-13 PAXIL CR 1 BEECHAM DIV SMITHKLIN E BEECHAM CO 
00029-3160-13 AVANDIA 8 BEECHAM DIV SMITHKLIN BEECHAM CO 
00029-3160-13 AVANDIA(RO BEECHAM DIV SMITHKLIN E BEECHAM CO 
00029-3160-13 AVANDIA 8M BEECHAM DIV SMITHKLIN E BEECHAM CO 
00029-3160-20 AVANDIA 8M BEECHAM DIV SMITHKUNE BEECHAM CO 
00029-3160-20 AVANDIA 8 BEECHAM DIV SMITHKUNE BEECHAM CO 
00029-3160-20 AVANDIA(RO BEECHAM DIV SMITHKUNE BEECHAM CO 
00029-3159-13 AVANDIA 4 BEECHAM DIV SMITHKUNE BEECHAM CO 
00029-3159-13 AVANDIA 4M BEECHAM DIV SMITHKUNE BEECHAM CO 
00029-3159-13 AVANDIA(RO BEECHAM DIV SMITHKUNE BEECHAM CO 
00029-3159-18 AVANDIA 4 BEECHAM DIV SMITHKUNE BEECHAM CO 
00029-3159-18 AVANDIA 4M BEECHAM DIV SMITHKUNE BEECHAM CO 
00029-3159-18 AVANDIA(RO BEECHAM DIV SMITHKUNE BEECHAM CO 
00029-3159-20 AVANDIA 4M BEECHAM DIV SMITHKUNE BEECHAM CO 
00029-3159-20 AVANDIA 4 BEECHAM DIV SMITHKUNE BEECHAM CO 
BEECHAM DIV SMITHKUNE BEECHAM"CO" 00029-3159-20 AVANDIA(RO 
00029-3158-18 AVANDIA 2M BEECHAM DIV SMITHKUNE BEECHAM CO 
00029-3158-18 AVANDIA 2 BEECHAM DIV SMITHKUNE BEECHAM CO 
00029-1527-22 BACTROBAN( BEECHAM DIV SMITHKUNE BEECHAM CO 
00029-1527-22 BACTROBAN BEECHAM DIV SMITHKUNE BEECHAM CO 
00029-1527-25 BACTROBAN ( BEECHAM DIV SMITHKUNE BEECHAM CO 3 00029-1527-25 BACTROBAN BEECHAM DIV SMITHKU E BEECHAM CO 
00029-1525-22 BACTROBAN( BEECHAM DIV SMITHKUNE BEECHAM CO 
00029-1525-25 BACTROBAN( BEECHAM DIV SMITHKUNE BEECHAM CO 
00029-1525-44 BACTROBAN BEECHAM DIV SMITHKUNE BEECHAM CO 
00039-0223-10 AMARYL 4 M AVENTIS PHARMACEUTICALS NJ 
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100039-0223-10 
[00039-0222-10 
100039-0222-10 
100039-0106-10 
00039-0105-10 
00039-0104-10 
00039-0078-10 
00039-0078-11 
00039-0052-10 
00039-0052-50 
00039-0052-70 
00039-0051-10 
00039-0009-30 
00045-1530-05 
00045-1530-20 
00045-1530-50 
00045-1525-50 
00045-1525-50 
00045-1520-50 
00045-1520-50 
00045-0810-15 
00045-0810-15 
00045-0801-04 
00045-0801-16 
00045-0659-60 
00045-0659-60 
00045-0659-70 
00045-0659-70 
00045-0650-60 
00045-0650-60 
00045-0647-65 
00045-0647-65 
00045-0645-65 
00045-0645-65 
00045-0642-65 
00045-0642-65 
00045-0641-65 
00045-0641-65 
00045-0640-65 
00045-0639-65 
00045-0639-65 
00045-0526-60 
00045-0469-04 
00045-0469-16 
00045-0448-04 
00045-0448-16 
00045-0416-60 
J00045-0414-60 
FDA Prod I 
AMARYL 4MG 
AMARYL 2 M 
AMARYL 2MG 
ALTACE(RA 
ALTACE(RA 
ALTACE(RA 
TRENTAL (P 
TRENTAL (P 
DIABETA (G 
DIABETA (G 
DIABETA (G | 
DIABETA (G j 
LOPROX (CI 
LEVAQUIN 7 
LEVAQUIN 7 
LEVAQUIN 7 
LEVAQUIN ( 
LEVAQUIN 5 
LEVAQUIN ( 
LEVAQUIN 2 
REGRANEX 0 
REGRANEX( 
PEDIA PROF 
PEDIA PROF 
ULTRAM 50M 
ULTRAM (TR 
ULTRAM 50M 
ULTRAM (TR 
ULTRACET( 
ULTRACETT 
TOPAMAX (T 
TOPAMAX15 
TOPAMAX (T 
TOPAMAX 25 
| TOPAMAX (T 
TOPAMAX20 
TOPAMAX (T 
TOPAMAX10 
TOPAMAX 50 
TOPAMAX (T 
TOPAMAX 25 
TYLOX (r) 
PEDIA-PROF 
PEDIA-PROF 
MOTRIN SUS 
MOTRIN SUS 
TOLECTIN ( 
jTOLECTIN ( 
Firm I 
AVENTIS PHARMACEUTICALS NJ 
AVENTIS PHARMACEUTICALS NJ 
AVENTIS PHARMACEUTICALS NJ 
AVENTIS PHARMACEUTICALS NJ 
AVENTIS PHARMACEUTICALS NJ 
AVENTIS PHARMACEUTICALS NJ 
AVENTIS PHARMACEUTICALS NJ 
AVENTIS PHARMACEUTICALS NJ 
AVENTIS PHARMACEUTICALS NJ 
AVENTIS PHARMACEUTICALS NJ 
AVENTIS PHARMACEUTICALS NJ 
AVENTIS PHARMACEUTICALS NJ 
AVENTIS PHARMACEUTICALS NJ 
OMP DIV 
OMP DIV 
OMP DIV 
OMP DIV 
OMP DIV 
OMP DIV 
OMP DIV 
OMP DIV 
OMP DIV 
OMP DIV 
OMP DIV 
OMP DIV 
OMP DIV 
OMP DIV 
OMP DIV 
OMP DIV 
OMP DIV 
iOMP DIV 
OMP DIV 
OMP DIV 
OMP DIV 
OMP DIV 
OMP DIV 
OMP DIV 
OMP DIV 
OMP DIV 
OMP DIV 
OMP DIV 
OMP DIV 
OMP DIV 
OMP DIV 
OMP DIV 
OMP DIV 
OMP DIV | 
JOMP DIV 
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100045-0346-60 
100045-0343-60 
100045-0343-60 
00045-0342-60 
100045-0342-60 
00045-0254-14 
00045-0254-14 
00045-0254-46 
00045-0253-01 
[00045-0253-03 
00045-0253-46 
100045-0095-60 
00045-0095-69 
00046-2573-06 
00046-1104-81 
00046-0975-06 
00046-0875-01 
00046-0875-02 
00046-0875-05 
00046-0875-06 
00046-0872-93 
00046-0868-81 
00046-0868-81 
00046-0867-81 
00046-0867-81 
00046-0867-91 
00046-0867-91 
00046-0867-95 
00046-0866-81 
00046-0866-81 
00046-0866-91 
00046-0866-91 
00046-0866-95 
00046-0865-81 
00046-0864-81 
00046-0864-81 
00046-0839-81 
00046-0829-81 
00046-0787-81 
00046-0761-81 
00046-0739-81 
00046-0738-81 
00046-0479-81 
00046-0473-81 
00046-0471-81 
00046-0470-81 
00046-0455-81 
100053-8130-01 
FDA Prod I 
PANCREASE 
PANCREASE 
PANCREASE/ 
PANCREASE 
PANCREASE/ 
HALDOL DEC 
HALDOL (r) 
HALDOL (r) 
HALDOL (r) | 
HALDOL (r) 
HALDOL (r) 
PANCREASE 
PANCREASE 
PREMPHASE 
PREMARIN 1 
PREMPRO .6 
PREMPRO 0 
PREMPRO 0 
PREMPRO 0. 
PREMPRO 0. 
PREMARIN V 
PREMARIN 0 
PREMARIN T 
PREMARIN 0 
PREMARIN T 
PREMARIN 0 
PREMARIN T 
PREMARIN T 
PREMARIN 1 
PREMARIN T 
PREMARIN 1 
PREMARIN T 
PREMARIN T 
PREMARIN T 
PREMARIN 0 
PREMARIN T 
LODINE XL 
LODINE XL 
LODINE TAB 
LODINE 400 
LODINE 300 
!LODINE 200 
INDERAL LA 
INDERAL LA 
INDERAL LA 
INDERAL LA 
INDERIDEL 
HELIXATE F 
Firm I 
OMP DIV 
OMP DIV 
OMP DIV 
OMP DIV 
OMP DIV 
OMP DIV 
OMP DIV 
OMP DIV 
OMP DIV 
OMP DIV 
OMP DIV 
OMP DIV 
OMP DIV 
WYETH PHARMACEUTICALS INC 
WYETH PHARMACEUTICALS INC 
WYETH PHARMACEUTICALS INC 
WYETH PHARMACEUTICALS INC 
WYETH PHARMACEUTICALS INC 
WYETH PHARMACEUTICALS INC 
WYETH PHARMACEUTICAL'S INC | 
WYETH PHARMACEUTICAl 
WYETH PHARMACEUTICAl 
WYETH PHARMACEUTICAl 
WYETH PHARMACEUTICAl 
WYETH PHARMACEUTICAl 
WYETH PHARMACEUTICAl 
WYETH PHARMACEUTICAl 
WYETH PHARMACEUTICAl 
WYETH PHARMACEUTICAl 
WYETH PHARMACEUTICAl 
IWYETH PHARMACEUTICA 
IWYETH PHARMACEUTICA 
IWYETH PHARMACEUTICA 
WYETH PHARMACEUTICA 
WYETH PHARMACEUTICA 
WYETH PHARMACEUTICA 
WYETH PHARMACEUTICAl 
WYETH PHARMACEUTICA 
WYETH PHARMACEUTICA 
WYETH PHARMACEUTICA 
WYETH PHARMACEUTICA 
WYETH PHARMACEUTICA 
WYETH PHARMACEUTICA 
WYETH PHARMACEUTICA 
IS INC I 
Is INC 
is INC 
.S INC 
.S INC 
.S INC 
.S INC 
.S INC 
.S INC 
.S INC 
-S INC 
_S INC 
-S INC 
-S INC 
.S INC 
LS INC 
LS INC 
LS INC 
_S INC 
LS INC 
LS INC 
LS INC 
LS INC 
LS INC 
WYETH PHARMACEUTICALS INC 
WYETH PHARMACEUTICALS INC 
WYETH PHARMACEUTICALS INC 
IZLB BEHRING LLC 
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00054-4741-25 ' 
00054-4650-25 
00054-4647-21 
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00056-0474-92 
00056-0188-70 
00056-0188-70 
00056-0176-70 
00056-0176-70 
00056-0174-70 
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FDA Prod I 
HELIXATE F 
HELIXATE F 
HELIXATE 2 
HELIXATE 5 
HELIXATE 1 
BIOCLATE 
BIOCLATE 
MONOCLATE-
MONOCLATE-
IPRATROP 0 
ORAMORPHS 
ORAMORPHS 
ORAMORPHS | 
PREDNISONE ! 
ROXICET TA 
VIRAMUNE T 
VIRAMUNE T 
FUROSEMIDE 
FUROSEMIDE 
AZATHIOPRI 
SOD POLYST 
MEGESTROL 
DIPHENOX/A 
ROXILOX 5M 
MARINOL CA 
LITH CARB 
LITH CARB 
HYDROXYURE 
SINEMET 
SINEMET 
ISINEMET 
SINEMET CR 
SINEMET CR 
SUSTIVA 60 
SUSTIVA 
SUSTIVA 20 
COUMADIN 3 
COUMADIN, 
COUMADIN, 
COUMADIN 
COUMADIN 
COUMADIN 7 
COUMADIN, 
COUMADIN 
COUMADIN 5 
COUMADIN, 
COUMADIN 
|COUMADIN 5 
Firm I 
ZLB BEHRING LLC 
ZLB BEHRING LLC 
ZLB BEHRING LLC 
ZLB BEHRING LLC 
ZLB BEHRING LLC 
ZLB BEHRING LLC 
ZLB BEHRING LLC 
ZLB BEHRING LLC 
ZLB BEHRING LLC 
ROXANE LABORATORIES INC 
ROXANE LABORATORIES INC 
ROXANE LABORATORIES INC 
ROXANE LABORATORIES INC 
ROXANE LABORATORIES INC 
ROXANE LABORATORIES INC 
ROXAN E LABORATORIES INC 
ROXANE LABORATORIES INC 
ROXANE LABORATORIES INC 
ROXANE LABORATORIES INC 
ROXANE LABORATORIES INC 
ROXANE LABORATORIES INC 
ROXANE LABORATORIES INC 
ROXANE LABORATORIES INC 
ROXANE LABORATORIES INC 
ROXANE LABORATORIES INC 
ROXANE LABORATORIES INC 
ROXANE LABORATORIES INC 
ROXANE LABORATORIES INC 
BRISTOL MYERS SQUIBB PHARMA CO 
[BRISTOL MYERS SQUIBB PHARMA CO 
BRISTOL MYERS SQUIBB PHARMA CO 
BRISTOL MYERS SQUIBB PHARMA CO 
BRISTOL MYERS SQUIBB PHARMA CO 
BRISTOL MYERS SQUIBB PHARMA CO 
BRISTOL MYERS SQUIBB PHARMA CO 
BRISTOL MYERS SQUIBB PHARMA CO 
BRISTOL MYERS SQUIBB PHARMA CO 
BRISTOL MYERS SQUIBB PHARMA CO 
BRISTOL MYERS SQUIBB PHARMA CO 
BRISTOL MYERS SQUIBB PHARMA CO 
BRISTOL MYERS SQUIBB PHARMA CO 
BRISTOL MYERS SQUIBB PHARMA CO 
BRISTOL MYERS SQUIBB PHARMA CO 
BRISTOL MYERS SQUIBB PHARMA CO 
BRISTOL MYERS SQUIBB PHARMA CO 
BRISTOL MYERS SQUIBB PHARMA CO 
BRISTOL MYERS SQUIBB PHARMA CO 
|BRISTOL MYERS SQUIBB PHARMA CO 
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100056-0172-90 
[00056-0172-90 
(00056-0170-70 
100056-0170-70 
100056-0170-70 
00056-0169-70 
00056-0169-70 
100056-0168-70 
00056-0168-70 
00056-0168-70 
00056-0080-50 
00062-5460-01 
00062-5460-02 
00062-5434-01 
00062-5426-01 
00062-5356-01 
00062-5351-01 
00062-5350-01 
00062-2085-06 
00062-1920-15 
00062-1903-15 
00062-1901-15 
00062-1796-15 
00062-1781-15 
00062-1781-20 
00062-1761-15 
00062-1542-01 
00062-1542-02 
00062-1541-02 
00062-1540-02 
00062-1411-01 
00062-1251-15 
00062-0214-60 
00062-0206-04 
00066-8008-01 
00066-8008-02 
00066-0510-23 
00066-0510-46 
00066-0494-25 
00066-0494-50 
00066-0272-60 
00066-0071-60 
00067-4345-04 
00074-9492-02 
00074-7984-23 
00074-7804-13 
00074-7349-11 
100074-7126-13 
FDA Prod I 
COUMADIN, 
COUMADIN 
COUMADIN 2 
COUMADIN, 
COUMADIN 
COUMADIN, 
COUMADIN 
COUMADIN 4 
COUMADIN 
COUMADIN, 
TREXAN 
SPECTAZOLE 
SPECTAZOLE 
MONISTAT-D 
MONISTAT*-
TERAZOL 3 
TERAZOL 3 
TERAZOL 7 
AXERT12 5 
ORTHO EVRA 
ORTHO TRI-
ORTHO CYCL 
ORTHO-CEPT 
ORTHO NOVU 
NORETHINDR 
ORTHO NOVU 
FLOXIN TAB 
FLOXIN TAB 
FLOXIN TAB 
FLOXIN TAB 
MICRONOR T 
ORTHO TRI-
GRIFULVIN 
GRIFULVIN 
iPENLACNAI 
PENLAC8% 
BENZAMYCIN 
IBENZAMYCIN 
|BENZACLIN 
iBENZACLIN 
PSORCON E 
iPsorcon Oi 
TRANSDERM-
NORVIRRIT 
0 9% SODCH 
K-TAB10ME 
K-LOR20ME 
I DEPAKOTE E 
Firm 
BRISTOL MYERS SQUIBB PHARMA CO 
BRISTOL MYERS SQUIBB PHARMA CO 
BRISTOL MYERS SQUIBB PHARMA CO 
BRISTOL MYERS SQUIBB PHARMA CO 
BRISTOL MYERS SQUIBB PHARMA CO 
BRISTOL MYERS SQUIBB PHARMA CO 
BRISTOL MYERS SQUIBB PHARMA CO 
BRISTOL MYERS SQUIBB PHARMA CO 
BRISTOL MYERS SQUIBB PHARMA CO 
BRISTOL MYERS SQUIBB PHARMA CO | 
BRISTOL MYERS SQUIBB F 
ORTHO MCNEIL PHARMAC 
ORTHO MCNEIL PHARMAC 
ORTHO MCNEIL PHARMAC 
HARMA CO | 
EUTICAL INC 
EUTICAL INC 
EUTICAL INC I 
ORTHO MCNEIL PHARMACEUTICAL INC | 
ORTHO MCNEIL PHARMAC 
ORTHO MCNEIL PHARMAC 
EUTICAL INC I 
EUTICAL INC I 
ORTHO MCNEIL PHARMACEUTICAL INC I 
ORTHO MCNEIL PHARMACEUTICAL INC 
ORTHO MCNEIL PHARMACEUTICAL INC 
ORTHO MCNEIL PHARMACEUTICAL INC 
ORTHO MCNEIL PHARMACEUTICAL INC 
ORTHO MCNEIL PHARMACEUTICAL INC 
ORTHO MCNEIL PHARMACEUTICAL INC 
ORTHO MCNEIL PHARMACEUTICAL INC 
ORTHO MCNEIL PHARMACEUTICAL INC 
ORTHO MCNEIL PHARMACEUTICAL INC 
ORTHO MCNEIL PHARMACEUTICAL INC 
ORTHO MCNEIL PHARMACEUTICAL INC 
ORTHO MCNEIL PHARMACEUTICAL INC | 
ORTHO MCNEIL PHARMAC 
ORTHO MCNEIL PHARMAC 
ORTHO MCNEIL PHARMAC 
jORTHO MCNEIL PHARMAC 
DERMIK LABORATORIES D 
DERMIK LABORATORIES D 
DERMIK LABORATORIES ffi 
DERMIK LABORATORIES Q 
DERMIK LABORATORIES ft 
DERMIK LABORATORIES ft 
DERMIK LABORATORIES E 
DERMIK LABORATORIES C 
NOVARTIS CONSUMER Hf 
EUTICAL INC I 
EUTICAL INC 
EUTICAL INC 
EUTICAL INC 
IV AVENTIS P 
IV AVENTIS P 
IV AVENTIS P 
IV AVENTIS P 
IV AVENTIS P 
IV AVENTIS P 
IV AVENTIS P 
>IV AVENTIS P 
ALTH INC 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
UBBOTT LABORATORIES 
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100074-7126-53 
00074-7069-13 
00074-7068-13 
00074-6854-01 
00074-6838-01 
00074-6633-22 
00074-6633-22 
00074-6624-13 
00074-6533-01 
00074-6471-32 
00074-6470-08 
00074-6470-32 
00074-6463-32 
00074-6415-90! 
00074-6320-13 
00074-6316-13 
00074-6290-60 
00074-6215-11 
00074-6215-13 
00074-6215-53 
00074-6214-11 
00074-6214-13 
00074-6214-53 
00074-6212-13 
00074-6151-13 
00074-6151-60 
00074-6123-90 
00074-6114-13 
00074-6114-13 
00074-5088-13 
00074-6073-13 
00074-6057-13 
00074-5783-30 
00074-5682-16 
00074-5182-13 
00074-4552-13 
00074-4013-90 
00074-4013-90 
00074-3959-77 
00074-3959-77 
00074-3956-46 
00074-3946-04 
00074-3943-04 
00074-3904-13 
00074-3826-13 
00074-3808-13 
00074-3807-13 
100074-3806-13 
FDA Prod I 
DEPAKOTE E 
SYNTHROID 
SYNTHROID 
ENDURONYL 
ENDURONYL 
NORVIR SGC 
NORVIR100 
SYNTHROID 
VANCOMYCIN 
PEDIALYTE 
PEDIALYTE, 
PEDIALYTE 
GENGRAF 25 
TRICOR 200 
ERY-TAB 33 
ERYTH ST 5 | 
PCE 333MG 
DEPAKOTE 5 
DEPAKOTE 5 
DEPAKOTE 5 
DEPAKOTE 2 
DEPAKOTE 2 
DEPAKOTE 2 
DEPAKOTE 1 
OMNICEF25 
OMNICEF 25 
TRICOR 145 
DEPAKOTE 1 
DEPAKOTE S 
iCYLERT CHW 
ICYLERTTAB 
CYLERTTAB 
RONDECDRO 
DEPAKENES 
SYNTHROID 
SYNTHROID 
TRICOR - F 
TRICOR 160 
KALETRA CA 
KALETRA SO 
KALETRA OR 
OGEN1.25 
OGEN 625 
GABITRIL -
DEPAKOTE E 
HYTRIN 10M 
HYTRIN 5MG 
JHYTRIN 2MG 
Firm I 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES | 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES I 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
jABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
lABBOTT LABORATORIES 
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i 00074-3799-02 
i 00074-3799-02 
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i 00074-3771-13 
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00074-3771-60 | 
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00075-1506-16 
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FDA Prod I 
HYTRIN 1MG 
HUMIRA 40M 
HUMIRA40 
OMNICEF (1 
OMNICEF 12 
OMNICEF (1 
OMNICEF 12 
OMNICEF 30 
OMNICEF (3 
OMNICEF 30 
PCE 500MG 
BIAXIN 250 
HYTRIN 10M 
HYTRIN 5MG | 
HYTRIN 2MG 
HYTRIN 1MG 
TARKA 4/24 
TARKA 2/24 
TARKA 2/18 
BIAXIN 250 
BIAXIN FOR 
BIAXIN 250 
BIAXIN XL 
BIAXIN XL 
BIAXIN 125 
CLARITHROM 
BIAXIN 125 
BIAXIN 500 
DEFEROXAMI 
MAVIK4MG 
IMAVIK4MG 
MAVIK2MG 
IMAVIK2MG 
IVICOPROFEN 
RILUTEK50 
LOVENOX15 
LOVENOX12 
DDAVP 0 01 
DDAVP RTS 
DDAVP IN J 
DDAVP INJE 
DDAVP RHIN 
DDAVP 0 1 
DDAVP NASA 
DDAVP SPRA 
NASACORT1 
NASACORT A 
I NASACORT 
Firm I 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES ' 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES 
ABBOTT LABORATORIES ' 
ABBOTT LABORATORIES 
IABBOTT LABORATORIES 
jABBOTT LABORATORIES 
ABBOTT LABORATORIES | 
AVENTIS PHARMACEUTIC 
AVENTIS PHARMACEUTIC 
AVENTIS PHARMACEUTIC 
AVENTIS PHARMACEUTIC 
AVENTIS PHARMACEUTIC 
AVENTIS PHARMACEUTIC 
AVENTIS PHARMACEUTIC 
AVENTIS PHARMACEUTIC 
AVENTIS PHARMACEUTIC 
AVENTIS PHARMACEUTIC 
AVENTIS PHARMACEUTIC 
AVENTIS PHARMACEUTIC 
AVENTIS PHARMACEUTIC 
JAVENTIS PHARMACEUTIC, 
kL PRODUCTS I I 
AL PRODUCTS I 
AL PRODUCTS I 
AL PRODUCTS I 
AL PRODUCTS I 
AL PRODUCTS I 
AL PRODUCTS I 
AL PRODUCTS I 
:AL PRODUCTS I 
IAL PRODUCTS I 
:AL PRODUCTS I 
:AL PRODUCTS I 
:AL PRODUCTS I 
:AL PRODUCTS I 
Exhibit A Page 18 
Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU. 
Machine-generated OCR, may contain errors.
Exhibit A 
NDC 1 
i 00075-1505-43 
100075-1306-01 
00075-1306-01 
00075-0850-84 
00075-0700-00 
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00075-0060-37 
00075-0026-00 
00075-0026-00 
00075-0016-00 
00078-0426-20 
00078-0408-05 
00078-0402-15 
00078-0401-05 
00078-0383-05 
00078-0383-34 
00078-0375-40 
00078-0375-46 
00078-0375-49 
00078-0375-63 
00078-0373-66 
00078-0372-05 
00078-0371-05 
00078-0370-05 
00078-0368-15 
00078-0367-15 
00078-0364-05 
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100078-0358-34 
FDA Prod 
NASACORT N 
CALCIMAR 
CALCIMAR S 
NITROLINGU 
LOZOL 
LOVENOX 
LOVENOX 30 
LOVENOX10 
LOVENOX 80 
LOVENOX 60 
LOVENOX 40 
SLO-BID 
DILACOR, 2 
DILACOR, 1 
DILACOR XR 
SLO-BID 
LOZOL 
LOZOL 
AZMACORT 
AZMACORTI 
DDAVP 0.2 
DDAVP 0.2M 
DDAVP 0.1 
ZELNORM 6 
STALEVO10 
GLEEVEC 40 
GLEEVEC 10 
DIOVAN HCT 
DIOVAN HCT 
ELIDEL1% 
ELI DEL 1% 
ELI DEL 1% 
ELIDEL1% 
GLEEVEC 10 
RITALIN LA 
RITALIN LA 
!RITALIN LA 
IFAMVIR500 
IF AM VIR 250 
LOTREL10/ 
DIOVAN 320 
DIOVAN 320 
DIOVAN 80M 
DIOVAN 160 
DIOVAN 160 
DIOVAN 80 
DIOVAN 80M 
I DIOVAN 80 
Firm I 
AVENTIS PHARMACEUTICAL PRODUCTS I 
AVENTIS PHARMACEUTICAL PRODUCTS I 
AVENTIS PHARMACEUTICAL PRODUCTS I 
AVENTIS PHARMACEUTICAL PRODUCTS I 
AVENTIS PHARMACEUTICAL PRODUCTS I 
AVENTIS PHARMACEUTICAL PRODUCTS I 
AVENTIS PHARMACEUTICAL PRODUCTS I 
AVENTIS PHARMACEUTICAL PRODUCTS I 
AVENTIS PHARMACEUTICAL PRODUCTS I 
AVENTIS PHARMACEUTICAL PRODUCTS I 
AVENTIS PHARMACEUTICAL PRODUCTS I 
AVENTIS PHARMACEUTICAL PRODUCTS I 
AVENTIS PHARMACEUTICAL PRODUCTS I 
AVENTIS PHARMACEUTICAL PRODUCTS I 
AVENTIS PHARMACEUTICAL PRODUCTS I 
AVENTIS PHARMACEUTICAL PRODUCTS I 
AVENTIS PHARMACEUTICAL PRODUCTS I 
AVENTIS PHARMACEUTICAL PRODUCTS I 
AVENTIS PHARMACEUTICAL PRODUCTS I 
AVENTIS PHARMACEUTICAL PRODUCTS I 
AVENTIS PHARMACEUTICAL PRODUCTS I 
AVENTIS PHARMACEUTICAL PRODUCTS I 
AVENTIS PHARMACEUTICAL PRODUCTS I 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
iNOVARTIS PHARMACEUTICALS CORP 
|NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
JNOVARTIS PHARMACEUTICALS CORP 
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00078-0357-52 TRILEPTAL NOVARTIS PHARMACEUTICALS CORP 
00078-0356-80 ZELNORM 6M NOVARTIS PHARMACEUTICALS CORP 
00078-0356-80 ZELNORM 6 NOVARTIS PHARMACEUTICALS CORP 
00078-0354-05 LESCOL XL NOVARTIS PHARMACEUTICALS CORP 
00078-0354-15 LESCOL XL NOVARTIS PHARMACEUTICALS CORP 
00078-0352-05 STARLIX 12 NOVARTIS PHARMACEUTICALS CORP 
00078-0347-51 DESFERAL 2 NOVARTIS PHARMACEUTK ALS CORP 
00078-0342-84 SANDOSTATI NOVARTIS PHARMACEUTK ALS CORP 
00078-0338-05 TRILEPTAL NOVARTIS PHARMACEUTICALS CORP 
00078-0337-05 TRILEPTAL NOVARTIS PHARMACEUTICALS CORP 
00078-0336-05 TRILEPTAL NOVARTIS PHARMACEUTICALS CORP 
00078-0327-05 COMTAN 200 NOVARTIS PHARMACEUTICALS CORP 
00078-0326-44 EXELON 6MG NOVARTIS PHARMACEUTICALS CORP 
00078-0326-44 EXELON 6 0 NOVARTIS PHARMACEUTICALS CORP 
00078-0326-44 EXELON 6 M NOVARTIS PHARMACEUTICALS CORP 
00078-0325-44 EXELON 4 5 NOVARTIS PHARMACEUTICALS CORP 
00078-0324-44 EXELON 3 0 NOVARTIS PHARMACEUTICALS CORP 
00078-0324-44 EXELON 3MG NOVARTIS PHARMACEUTICALS CORP 
00078-0324-44 EXELON 3 M NOVARTIS PHARMACEUTICALS CORP 
00078-0323-44 EXELON 1 5 NOVARTIS PHARMACEUTICALS CORP 
00078-0319-05 ACTIGALL« NOVARTIS PHARMACEUTICALS CORP 
00078-0315-05 DIOVAN HCT NOVARTIS PHARMACEUTICALS CORP 
00078-0315-34 DIOVAN HCT NOVARTIS PHARMACEUTICALS CORP 
00078-0314-05 DIOVAN HCT NOVARTIS PHARMACEUTICALS CORP 
00078-0314-34 DIOVAN HCT NOVARTIS PHARMACEUTICALS CORP 
00078-0311-54 MIACALCIN NOVARTIS PHARMACEUTICALS CORP 
00078-0311-90 MIACALCIN NOVARTIS PHARMACEUTICALS CORP 
00078-0274-22 NEORAL SOL NOVARTIS PHARMACEUTICALS CORP 
00078-0249-15 FEMARA 2.5 NOVARTIS PHARMACEUTICALS CORP 
00078-0248-15 NEORAL100 NOVARTIS PHARMACEUTICALS CORP 
00078-0246-15 NEORAL 25M NOVARTIS PHARMACEUTICALS CORP 
00078-0243-05 FIORICET/C NOVARTIS PHARMACEUTICALS CORP 
00078-0241-15 SANDIMMUNE NOVARTIS PHARMACEUTI ;ALS CORP 
00078-0240-15 SANDIMMUNE NOVARTIS PHARMACEUTI PALS CORP 
00078-0234-05 LESCOL 40M NOVARTIS PHARMACEUTI CALS CORP 
00078-0234-15 LESCOL 40M NOVARTIS PHARMACEUTI CALS CORP 
00078-0227-05 DYNACIRC 5 NOVARTIS PHARMACEUTICALS CORP 
00078-0227-44 DYNACIRC 5 NOVARTIS PHARMACEUTICALS CORP 
00078-0226-05 DYNACIRC 2 NOVARTIS PHARMACEUTICALS CORP 
00078-0226-44 DYNACIRC 2 NOVARTIS PHARMACEUTICALS CORP 
00078-0222-31 TAVIST SYR NOVARTIS PHARMACEUTICALS CORP 
00078-0221-05 TAVIST-D T NOVARTIS PHARMACEUTICALS CORP 
00078-0201-33 ASBRON G E NOVARTIS PHARMACEUTICALS CORP 
00078-0184-25 SANDOSTATI NOVARTIS PHARMACEUTICALS CORP 
00078-0183-25 SANDOSTATI NOVARTIS PHARMACEUT CALS CORP 
00078-0181-03 SANDOSTATI NOVARTIS PHARMACEUT CALS CORP 
00078-0179-05 LAMISIL25 NOVARTIS PHARMACEUT CALS CORP 
00078-0179-05 LAMISIL TA NOVARTIS PHARMACEUT CALS CORP 
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00078-0179-15 
00078-0179-15 
00078-0176-05 
00078-0176-15 
00078-0170-40 
00078-0170-46 
00078-0149-23 
00078-0149-75 
00078-0127-05 
00078-0127-06 j 
00078-0126-05 j 
00078-0111-05 
00078-0110-22 
00078-0107-05 
00078-0102-05 
00078-0101-05 
00078-0101-08 
00078-0087-05 
00078-0079-05 
00078-0078-05 
00078-0068-33 
00078-0017-05 
00078-0017-15 
00083-4001-01 
00083-4000-01 
00083-3801-04 
00083-3801-04 
00083-2320-62 
00083-2310-62 
00083-2265-30 
00083-2265-30 
00083-2260-30 
00083-2260-30 
00083-2255-30 
00083-2255-30 
00083-0167-74 
00083-0094-30 
00083-0094-30 
00083-0079-30 
00083-0079-30 
00083-0075-30 
00083-0074-30 
00083-0072-30 
00083-0063-30 
00083-0063-30 
00083-0062-30 
00083-0062-30 
100083-0060-30 
FDA Prod I 
LAMISIL25 
LAMISIL TA 
LESCOL 20M 
LESCOL 20M 
LAMISIL CR 
LAMISIL CR 
MIACALCIN 
MIACALCIN 
CLOZARIL 1 
CLOZARIL 1 
CLOZARIL 2 
VISKEN 5MG 
SANDIMMUNE 
FIORINAL/C 
PARLODEL 5 
HYDERGINE 
HYDERGINE 
PAMELOR 25 
PAMELOR 75 
PAMELOR 50 
MELLARIL-S 
PARLODEL 2 
PARLODEL 2 
DIOVAN 160 
DIOVAN 80M 
DESFERAL M 
DESFERAL( 
ESTRADERM 
ESTRADERM 
LOTREL (AM 
ILOTREL 5/2 
i LOTREL (AM 
ILOTREL 5/1 
LOTREL 2.5 
LOTREL (AM 
FORADILAE 
LOTENSIN ( 
LOTENSIN 4 
LOTENSIN ( 
LOTENSIN 2 
LOTENSIN H 
LOTENSIN H 
LOTENSIN H 
LOTENSIN 1 
LOTENSIN ( 
TEGRETOL X 
TEGRETOL-X 
JTEGRETOL X 
Firm I 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP 
NOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
!NOVARTIS PHARMACEUTICALS CORP DBA 
INOVARTIS PHARMACEUTICALS CORP DBA 
INOVARTIS PHARMACEUTICALS CORP DBA 
INOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
JNOVARTIS PHARMACEUTICALS CORP DBA 
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00083-0060-30 
00083-0059-30 
00083-0052-30 
00083-0034-30 
00083-0027-30 
00083-0027-30 
00083-0019-76 
00083-0019-76 
00083-0016-30 
00083-0007-30 
00083-0003-30 
00085-4110-03 
00085-3330-30 
00085-3320-30 
00085-3315-30 
00085-3310-30 
00085-3306-03 
00085-3305-30 
00085-1733-01 
00085-1401-01 
00085-1385-07 
00085-1385-07 
00085-1370-01 
00085-1351-05 
00085-1351-05 
00085-1327-04 
00085-1304-01 
00085-1297-01 
00085-1291-01 
00085-1288-01 
00085-1280-01 
00085-1279-01 
00085-1264-01 
00085-1264-01 
00085-1259-01 
00085-1259-01 
00085-1259-02 
00085-1258-01 
00085-1258-02 
00085-1252-01 
00085-1241-01 
00085-1241-02 
00085-1233-01 
00085-1223-01 
00085-1223-01 
00085-1197-01 
00085-1197-01 
(00085-1194-03 
FDA Prod ) 
TEGRETOL-X 
LOTENSIN 5 
TEGRETOL ( 
RITALIN HY 
TEGRETOL 2 
TEGRETOL( 
TEGRETOL 1 
TEGRETOL S 
RITALIN SR 
RITALIN HY 
RITALIN HY 
IMDUR EXTE 
NITRO-DUR 
NITRO-DUR 
NITRO-DUR 
NITRO-DUR 
IMDUR TABL 
NITRO-DUR 
AVELOX 400 
FORADIL AE 
REBETOL CA 
REBETOL 20 
PEG-INTRON 
REBETOL CA 
REBETOL 20 
REBETOL20 
PEG-INTRON 
PEG-INTRON 
PEG-INTRON 
NASONEX50 
ICLARINEX 5 
| PEG-INTRON 
ICLARINEX T 
CLARINEX 5 
TEMODAR CA 
TEMODAR 10 
TEMODAR 10 
REBETRON 1 
REBETRON 1 
TEMODAR 25 
REBETRON 1 
REBETRON 1 
CLARITIN-D 
CLARITIN 1 
CLARITIN S 
NASONEXNA 
NASONEX50 
JREBETOL CA 
Firm I 
NOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
NOVARTIS PHARMACEUTICALS CORP DBA 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
iSCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
jSCHERING CORP 
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! 00085-1194-03 
00085-1153-03 
00085-1132-01 
00085-1128-02 
00085-1128-02 
00085-1049-01 
00085-0924-01 
00085-0924-02 
00085-0809-01 
00085-0806-01 
00085-0787-01 | 
00085-0787-06 I 
00085-0787-10 
00085-0777-01 
00085-0777-02 
00085-0752-04 
00085-0736-04 
00085-0703-04 
00085-0691-01 
00085-0649-02 
00085-0640-01 
00085-0635-01 
00085-0635-01 
00085-0635-05 
00085-0614-02 
00085-0614-03 
00085-0613-02 
00085-0613-05 
00085-0584-01 
00085-0567-01 
00085-0567-01 
00085-0567-02 
00085-0567-02 
00085-0539-01 
00085-0525-04 
00085-0525-06 
00085-0517-01 
00085-0517-04 
00085-0496-03 
00085-0458-03 
00085-0458-03 
00085-0458-05 
00085-0458-06 
00085-0458-06 
00085-0438-03 
00085-0431-02 
00085-0370-01 
100085-0370-02 
PDA Prod I 
REBETOL 20 
IMDUR EXTE 
PROVENTIL 
CLARITIN 1 
CLARITIN R 
VANCENASE 
LOTRISONE 
LOTRISONE 
LOTRISONE 
THEO-DUR E 
K-DUR TABL 
K-DUR TABL 
K-DUR TABL 
CEDAXPOWD 
CEDAX POWD 
NORMODYNE 
VANCERiL I 
TRINALIN L 
CEDAX CAPS 
VANCENASE 
CLARITIN-D 
CLARITIN-D 
CLARITIN D 
CLARITIN D 
PROVENTIL 
PROVENTIL 
LOTRIMIN C 
LOTRIMIN C 
THEO-DUR E 
ELOCON0.1 
ELOCON CRE 
ELOCON 0.1 
ELOCON CRE 
INTRONAP 
iEULEXIN CA 
IEULEXINCA 
IDIPROLENE 
DIPROLENE 
FULVICIN-U 
CLARITIN 1 
CLARITIN T 
CLARITIN T 
CLARITIN 1 
CLARITIN T 
NORMODYNE 
PROVENTIL 
ELOCON OIN 
JELOCON OIN 
Firm I 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
jSCHERING CORP 
iSCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
SCHERING CORP 
[SCHERING CORP J 
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00085-0315-02 PROVENTIL SCHERiNG CORP 
00085-0263-01 K-DUR TABL SCHERING CORP 
00085-0259-02 VANCENASE SCHERING CORP 
00085-0244-04 NORMODYNE SCHERING CORP 
00085-0209-01 PROVENTIL SCHERING CORP 
00085-0208-02 PROVENTIL SCHERING CORP 
00087-7721-50 CEFZIL 500 BRISTOL MYERS SQUIBB CO 
00087-7721-50 CEFZIL BRISTOL MYERS SQUIBB CO 
00087-7721-60 CEFZIL 500 BRISTOL MYERS SQUIBB CO 
00087-7721-60 CEFZIL BRISTOL MYERS SQUIBB 00 
00087-7720-60 CEFZIL 250 BRISTOL MYERS SQUIBB 00 
00087-7720-60 CEFZIL BRISTOL MYERS SQUIBB 00 
00087-7719-40 CEFZIL 250 BRISTOL MYERS SQUIBB 00 
00087-7719-40 CEFZIL BRISTOL MYERS SQUIBB CO 
00087-7719-62 CEFZIL BRISTOL MYERS SQUIBB 00 
00087-7719-62 CEFZIL 250 BRISTOL MYERS SQUIBB 00 
00087-7719-64 CEFZIL 250 BRISTOL MYERS SQUIBB 00 
00087-7719-64 CEFZIL BRISTOL MYERS SQUIBB 00 
00087-7718-40 CEFZIL BRISTOL MYERS SQUIBB 00 
00087-7718-62 CEFZIL 125 BRISTOL MYERS SQUIBB 00 
00087-7718-62 CEFZIL BRISTOL MYERS SQUIBB 00 
00087-7718-64 CEFZIL 125 BRISTOL MYERS SQUIBB 00 
00087-7718-64 CEFZIL BRISTOL MYERS SQUIBB 00 
00087-6674-17 VIDEX EC BRISTOL MYERS SQUIBB 00 
00087-6674-17 VIDEX EC 4 BRISTOL MYERS SQUIBB 00 
00087-6673-17 VIDEX EC 2 BRISTOL MYERS SQUIBB 00 
00087-6078-31 METAGLIP 5 BRISTOL MYERS SQUIBB 00 
00087-6077-31 METAGLIP 2 BRISTOL MYERS SQUIBB 00 
00087-6074-11 GLUCOVANCE BRISTOL MYERS SQUIBB 00 
00087-6073-11 GLUCOVANCE BRISTOL MYERS SQUIBB 00 
00087-6072-11 GLUCOVANCE BRISTOL MYERS SQUIBB 00 
00087-6071-11 GLUCOPHAGE BRISTOL MYERS SQUIBB 00 
00087-6070-05 GLUCOPHAGE BRISTOL MYERS SQUIBB 00 
00087-6063-13 GLUCOPHAGE BRISTOL MYERS SQUIBB 00 
00087-6060-05 GLUCOPHAGE BRISTOL MYERS SQUIBB 00 
00087-6060-10 GLUCOPHAGE BRISTOL MYERS SQUIBB 00 
00087-5650-41 STADOL NS BRISTOL MYERS SQUIBB CO 
00087-2776-31 AVALIDE BRISTOL MYERS SQUIBB 00 
00087-2776-31 AVALIDE 30 BRISTOL MYERS SQUIBB 00 
00087-2776-32 AVALIDE BRISTOL MYERS SQUIBB 00 
00087-2776-32 AVALIDE 30 BRISTOL MYERS SQUIBB 00 
00087-2775-31 AVALIDE BRISTOL MYERS SQUIBB 00 
00087-2775-31 AVALIDE 15 BRISTOL MYERS SQUIBB 00 
00087-2775-32 AVALIDE BRISTOL MYERS SQUIBB 00 
00087-2775-32 AVALIDE 15 BRISTOL MYERS SQUIBB 00 
00087-2773-31 AVAPRO BRISTOL MYERS SQUIBB CO 
00087-2773-31 AVAPRO 300 BRISTOL MYERS SQUIBB 00 
00087-2773-32 AVAPRO BRISTOL MYERS SQUIBB 00 
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00087-2773-32 
00087-2772-31 
00087-2772-31 
00087-2772-32 
00087-2772-32 
00087-1202-13 
00087-1202-13| 
00087-0824-81 
00087-0822-32 
00087-0822-33 
00087-0819-41 
00087-0819-43 
00087-0819-44 
00087-0818-41 
00087-0818-44 
00087-0786-41 
00087-0785-43 
00087-0784-42 
00087-0784-46 
00087-0783-41 
00087-0783-42 
00087-0782-41 
00087-0782-41 
00087-0782-42 
00087-0778-43 
00087-0771-41 
00087-0756-01 
00087-0755-01 
00087-0702-01 
00087-0609-42 
00087-0609-42 
00087-0609-50 
00087-0589-01 
00087-0589-03 
00087-0580-05 
00087-0580-11 
00087-0579-41 
00087-0578-41 
00087-0158-46 
00087-0158-46 
00087-0158-50 
00087-0039-31 
00087-0033-31 
00087-0032-31 
00088-2225-07 
00088-2220-33 
00088-2220-33 
100088-2161-30 
FDAJ>rod I 
AVAPRO 300 
AVAPRO 
AVAPRO 150 
AVAPRO 
AVAPRO 150 
MONOPRIL4 
MONOPRIL 
BUSPAR 
BUSPAR 
BUSPAR 
BUSPAR 
BUSPAR 
BUSPAR 
BUSPAR 
BUSPAR 
DURICEF 
DURICEF 
DURICEF 
DURICEF 
DURICEF 
DURICEF 
DURICEF 25 
DURICEF 
DURICEF 
DESYREL 
K-LYTE DS 
ESTRACE 
ESTRACE 
INATALINSR 
j MONOPRIL 2 
iMONOPRIL 
MONOPRIL 
QUESTRAN 
QUESTRAN 
QUESTRAN 
QUESTRAN 
OVCON 
OVCON 
MONOPRIL 1 
MONOPRIL 
MONOPRIL 
NEFAZODONE 
NEFAZODONE 
SERZONE 
KETEKPAK 
LANTUS10M 
LANTUS100 
Firm ] 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
iBRISTOL MYERS SQUIBB CO 
(BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
BRISTOL MYERS SQUIBB CO 
AVENTIS PHARMACEUTICALS INC 
AVENTIS PHARMACEUTICALS INC 
JAVENTIS PHARMACEUTICALS INC 
JARAVA 20 M JAVENTIS PHARMACEUTICALS INC 
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00088-2161-30 ARAVA 20MG AVENTIS PHARMACEUTICALS INC 
00088-2161-30 ARAVA (LEF AVENTIS PHARMACEUTICALS INC 
00088-2160-30 ARAVA 10MG AVENTIS PHARMACEUTICALS INC 
00088-2160-30 ARAVA (LEF AVENTIS PHARMACEUTICA .SINC 
00088-1799-42 CARDIZEM C AVENTIS PHARMACEUTICALS INC 
00088-1798-30 CARDIZEM C AVENTIS PHARMACEUTICALS INC 
00088-1798-42 CARDIZEM C AVENTIS PHARMACEUTICALS INC 
00088-1797-30 CARDIZEM C AVENTIS PHARMACEUTICALS INC 
00088-1797-42 CARDIZEM C AVENTIS PHARMACEUTICALS INC 
00088-1796-30 CARDIZEM C AVENTIS PHARMACEUTICALS INC 
00088-1796-42 CARDIZEM C AVENTIS PHARMACEUTICALS INC 
00088-1795-30 CARDIZEM C AVENTIS PHARMACEUTICALS INC 
00088-1795-42 CARDIZEM C AVENTIS PHARMACEUTICALS INC 
00088-1792-47 CARDIZEM ( AVENTIS PHARMACEUTICALS INC 
00088-1791-47 CARDIZEM ( AVENTIS PHARMACEUTICALS INC 
00088-1779-47 CARDIZEM S AVENTIS PHARMACEUTICALS INC 
00088-1778-47 CARDIZEM S AVENTIS PHARMACEUTICALS INC 
00088-1777-47 CARDIZEM S AVENTIS PHARMACEUTICALS INC 
00088-1772-47 CARDIZEM ( AVENTIS PHARMACEUTICALS INC 
00088-1772-55 CARDIZEM ( AVENTIS PHARMACEUTICALS INC 
00088-1771-47 CARDIZEM ( AVENTIS PHARMACEUTICALS INC 
00088-1712-47 CARAFATE( AVENTIS PHARMACEUTICALS INC 
00088-1712-47 CARAFATE1 AVENTIS PHARMACEUTICALS INC 
00088-1712-55 CARAFATE( AVENTIS PHARMACEUTICALS INC 
00088-1712-55 CARAFATE 5 AVENTIS PHARMACEUTICALS INC 
00088-1700-15 CARAFATE1 AVENTIS PHARMACEUTICALS INC 
00088-1700-15 CARAFATE( AVENTIS PHARMACEUTICALS INC 
00088-1153-30 COPAXONE 2 AVENTIS PHARMACEUTICALS INC 
00088-1150-03 COPAXONE( AVENTIS PHARMACEUTICALS INC 
00088-1109-47 ALLEGRA (F AVENTIS PHARMACEUTICALS INC 
00088-1109-47 ALLEGRA 18 AVENTIS PHARMACEUTICALS INC 
00088-1107-47 ALLEGRA 60 AVENTIS PHARMACEUTICALS INC 
00088-1106-47 ALLEGRA 30 AVENTIS PHARMACEUTICALS INC 
00088-1102-47 ALLEGRA 60 AVENTIS PHARMACEUTICALS INC 
00088-1102-47 ALLEGRA (F AVENTIS PHARMACEUTICALS INC 
00088-1090-47 ALLEGRA-D AVENTIS PHARMACEUTICALS INC 
00093-9774-01 HYDROXYCHL TEVA PHARMACEUTICALS USA INC 
00093-9634-87 MEGESTROL TEVA PHARMACEUTICALS USA INC 
00093-9633-16 VALPROIC A TEVA PHARMACEUTICALS USA INC 
00093-9380-01 URSODIOL 3 TEVA PHARMACEUTICALS USA INC 
00093-9364-10 GLYBURIDE TEVA PHARMACEUTICALS USA INC 
00093-9133-06 AMIODARONE TEVA PHARMACEUTICALS USA INC 
00093-9133-52 AMIODARONE TEVA PHARMACEUTICALS USA INC 
00093-9111-01 PRENATAL P TEVA PHARMACEUTICALS USA INC 
00093-9107-29 MEBENDAZOL TEVA PHARMACEUTICALS USA INC 
00093-8675-74 AMOX TR-K TEVA PHARMACEUTICALS USA INC 
00093-8675-75 AMOX TR-K TEVA PHARMACEUTICALS USA INC 
00093-8675-78 AMOX TR-K TEVA PHARMACEUTICALS USA INC 
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-NDC I 
00093-8544-05 
00093-8544-06 
: 00093-8544-10 
00093-8344-01 
00093-8344-10 
00093-7224-98 
00093-7223-98 
00093-7222-98 
00093-7207-56 
00093-7206-56 
00093-7204-22 
00093-7198-56 
00093-7174-01 
00093-7173-01 
00093-7130-01 
00093-7129-01 
00093-6118-16 
00093-6108-12 
00093-5502-01 
00093-5459-98 
00093-5458-98 
00093-5311-10 
00093-5195-05 
00093-5173-01 
00093-5161-01 
00093-5160-51 
00093-5150-01 
00093-5119-98 
00093-5118-98 
00093-5117-98 
00093-5116-01 
00093-5112-98 
00093-4177-73 
00093-4177-74 
00093-4175-73 
00093-4175-74 
00093-4161-73 
00093-4155-73 
00093-4155-80 
00093-4150-80 
00093-3195-01 
00093-3147-01 
00093-3147-05 
00093-3145-05 
00093-3109-05 
00093-2275-34 
00093-2274-34 
[00093-2264-01 
FDA Prod I 
RANITIDINE 
RANITIDINE 
RANITIDINE 
GLYBURIDE 
GLYBURIDE 
FOSINOPRIL 
FOSINOPRIL 
FOSINOPRIL 
MIRTAZAPIN 
MIRTAZAPIN 
FLUCONAZOL 
FLUOXETINE 
GABAPENTIN 
GABAPENTIN ! 
TORSEMIDE 
TORSEMIDE 
PREDNISOLO 
FLUOXETINE 
BUDEPRION 
QUINAPRIL 
QUINAPRIL 
POTASSIUM 
PENICILLIN 
NIFEDICAL 
HYDROCODON 
TIZANIDINE 
MOEXIPRIL 
DILTIAZEM 
DILTIAZEM 
; DILTIAZEM 
jPENTOXIFYL 
JDILTIAZEM 
ICEPHALEXIN 
CEPHALEXIN 
CEPHALEXIN 
| CEPHALEXIN 
AMOXICILLI 
AMOXICILLI 
AMOXICILLI 
AMOXICILLI 
KETOPROFEN 
CEPHALEXIN 
CEPHALEXIN 
CEPHALEXIN 
AMOXICILLI 
AMOX TR-K 
AMOX TR-K 
IAMOXICILLI 
Firm I 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA P HARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
iTEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
|TEVA PHARMACEUTICALS USA INC 
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1 NDC 
00093-2240-01 
00093-2210-01 
00093-2210-05 
00093-1115-01 
00093-1114-01 
00093-1113-01 
00093-1065-05 
00093-1061-01 
00093-1048-01 
00093-1048-05 
00093-1043-01 
00093-1041-01 
00093-1040-01 
00093-1039-01 
00093-1037-01 
00093-1036-01 
00093-1023-01 
00093-1023-01 
00093-1022-01 
00093-1022-01 
00093-1021-01 
00093-1016-01 
00093-1015-01 
00093-1010-42 
00093-1006-01 
00093-1003-01 
00093-0948-01 
00093-0897-01 
00093-0896-01 
00093-0890-05 
00093-0890-05 
00093-0852-05 
00093-0852-53 
00093-0840-15 
00093-0840-30 
00093-0840-92 
00093-0834-01 
00093-0833-01 
00093-0832-01 
00093-0819-01 
00093-0784-06 
00093-0782-56 
00093-0778-01 
00093-0755-01 
00093-0755-06 
00093-0733-10 
00093-0670-05 
100093-0670-06 
- FDA Prod 1 
CEPHALEXIN 
SUCRALFATE 
SUCRALFATE 
LISINOPRIL 
LISINOPRIL 
LISINOPRIL 
NIZATIDINE 
SOTALOL 80 
METFORMIN 
METFORMIN 
FLUOXETINE 
DICLOFENAC 
GABAPENTIN 
GABAPENTIN 
LISINOPRIL 
LISINOPRIL 
NIFEDIPINE | 
NIFEDIAC C 
NIFEDIAC C 
NIFEDIPINE 
NIFEDIPINE 
NABUMETONE 
NABUMETONE 
MUPIROC1N 
NAPROXEN 5 
BUSPIRONE 
DICLOFENAC 
FAMOTIDINE 
FAMOTIDINE 
PROPOXY-N/ 
PROPOXYPHE 
iMETRONIDAZ 
iMETRONIDAZ 
KETOCONAZO 
KETOCONAZO 
KETOCONAZO 
CLONAZEPAM 
CLONAZEPAM 
CLONAZEPAM 
NIFEDICAL 
TAMOXIFEN 
TAMOXIFEN 
CARBAMAZEP 
DIFLUNISAL 
DIFLUNISAL 
METOPROLOL 
GEMFIBROZI 
IGEMFIBROZI 
Firm 1 
TEVA PHARMACEUTICALS LiJSA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS (jSA INC | 
TEVA PHARMACEUTICALS 
TEVA PHARMACEUTICALS 
TEVA PHARMACEUTICALS 
TEVA PHARMACEUTICALS 
TEVA PHARMACEUTICALS 
TEVA PHARMACEUTICALS 
TEVA PHARMACEUTICALS 
TEVA PHARMACEUTICALS 
TEVA PHARMACEUTICALS 
TEVA PHARMACEUTICALS 
TEVA PHARMACEUTICALS 
TEVA PHARMACEUTICALS 
TEVA PHARMACEUTICALS 
TEVA PHARMACEUTICALS 
TEVA PHARMACEUTICALS 
TEVA PHARMACEUTICALS 
TEVA PHARMACEUTICALS 
TEVA PHARMACEUTICALS 
TEVA PHARMACEUTICALS 
TEVA PHARMACEUTICALS 
TEVA PHARMACEUTICALS 
TEVA PHARMACEUTICALS 
TEVA PHARMACEUTICALS 
TEVA PHARMACEUTICALS 
TEVA PHARMACEUTICALS 
TEVA PHARMACEUTICALS 
TEVA PHARMACEUTICALS 
TEVA PHARMACEUTICALS 
TEVA PHARMACEUTICALS 
|TEVA PHARMACEUTICALS 
JSA INC 1 
JSA INC 
JSA INC 
JSA INC 
JSA INC 
JSA INC 
USA INC 
USA INC 
USA INC 
USA INC 
USA INC 
USA INC 
USA INC 
USA INC 
USA INC 
USA INC 
USA INC 
USA INC 
USA INC 
USA INC 
USA INC 
USA INC 
USA INC 
USA INC 
USA INC 
USA INC 
USA INC 
USA INC 
USA INC 
USA INC 
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NDC 1 
I00093-0661-16 
100093-0658-01 
00093-0657-01 
00093-0638-01 
00093-0637-01 
00093-0590-05 
00093-0562-16 | 
00093-0542-01 ! 
00093-0537-01 j 
00093-0537-05 | 
00093-0490-05 I 
00093-0490-05 
00093-0350-01 
00093-0308-01 
00093-0294-01 
00093-0293-01 
00093-0293-05 
00093-0292-01 
00093-0265-92 
00093-0189-05 
00093-0154-01 
00093-0150-01 
00093-0150-10 
00093-0109-01 
00093-0109-10 
00093-0090-01 
00093-0089-05 
00093-0058-01 
00093-0033-01 
00093-0029-01 
00093-0028-01 
00093-0027-01 
00093-0023-01 
00093-0022-01 
00093-0017-01 
00093-0014-16 
00108-5027-13 
00108-5026-18 
00108-5014-48 
00108-5013-20 
00172-7407-14 
00172-7407-22 
00172-7407-26 
00172-7404-42 
00172-7171-60 
00172-6405-44 
00172-5728-60 
|00172-5728-70 
FDA Prod I 
ALBUTEROL 
CALCITRIOL 
CALCITRIOL 
TRAZODONE 
TRAZODONE 
PROPOXYPHE 
SULFAMETHO 
CHLORZOXAZ 
NAPROXEN S 
NAPROXEN S 
PROPOXY-N/ 
PROPOXYPHE 
ACETAMINOP 
CLEMASTINE 
CARBIDOPA/ 
CARBIDOPA/ 
CARBIDOPA/ 
CARBIDOPA/ 
FLUOCINONI 
SULFAMETHO 
TICLOPIDIN 
ACETAMINOP 
ACETAMINOP 
CARBAMAZEP 
CARBAMAZEP 
CARBAMAZEP 
SULFAMETHO 
TRAMADOL H 
OXYCODONE 
ENALAPRIL 
ENALAPRIL 
ENALAPRIL 
DILTIAZEM 
DILTIAZEM 
MOEXIPRIL 
CHLORHEXID 
|TAGAMET(CI 
TAGAMET(CI 
TAGAMET(CI 
TAGAMET(CI 
AMOX TR-K 
AMOX TR-K 
AMOX TR-K 
AMOX TR-K 
CIMETIDINE 
ALBUTEROL 
FAMOTIDINE 
[FAMOTIDINE 
Firm I 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
TEVA PHARMACEUTICALS USA INC 
|TEVA PHARMACEUTICALS USA INC 
|TEVA PHARMACEUTICALS USA INC 
SMITHKLINE BEECHAM PHARMACEUTICAL 
SMITHKLINE BEECHAM PHARMACEUTICAL 
SMITHKLINE BEECHAM PHARMACEUTICAL 
SMITHKLINE BEECHAM PHARMACEUTICAL 
IVAX PHARMACEUTICALS INC 
I VAX PHARMACEUTICALS INC 
IVAX PHARMACEUTICALS INC 
IVAX PHARMACEUTICALS INC 
IVAX PHARMACEUTICALS INC 
IVAX PHARMACEUTICALS INC 
IVAX PHARMACEUTICALS INC 
llVAX PHARMACEUTICALS INC I 
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NDC FDA Prod Firm 
00172-5728-80 FAMOTIDINE IVAX PHARMACEUTICALS INC 
00172-5712-60 GLYBURIDE- IVAX PHARMACEUTICALS INC 
00172-5711-60 GLYBURIDE- IVAX PHARMACEUTICALS INC 
00172-5623-60 NIZATIDINE IVAX PHARMACEUTICALS INC 
00172-5034-60 LISINOPRIL IVAX PHARMACEUTICALS INC 
00172-4980-60 PROPOXY-N/ IVAX PHARMACEUTICALS INC 
00172-4980-70 PROPOXYPHE IVAX PHARMACEUTICALS INC 
00172-4980-70 PROPOXY-N/ IVAX PHARMACEUTICALS INC 
00172-4980-80 PROPOXY-N/ IVAX PHARMACEUTICALS INC 
00172-4435-60 METFORMIN IVAX PHARMACEUTICALS INC 
00172-4432-60 METFORMIN IVAX PHARMACEUTICALS INC 
00172-4390-18 ALBUTEROL IVAX PHARMACEUTICALS INC 
00172-4365-60 LABETALOL IVAX PHARMACEUTICALS INC 
00172-4360-60 CLOZAPINE IVAX PHARMACEUTICALS INC 
00172-436O-70 CLOZAPINE IVAX PHARMACEUTICALS INC 
00172-4359-60 CLOZAPINE IVAX PHARMACEUTICALS INC 
00172-4331-60 METFORMIN IVAX PHARMACEUTICALS INC 
00172-4286-60 VERAPAMIL IVAX PHARMACEUTICALS INC 
00172-4286-60 VERAMAPIL IVAX PHARMACEUTICALS INC 
00172-4285-60 VERAPAMIL IVAX PHARMACEUTICALS INC 
00172-4280-60 VERAPAMIL IVAX PHARMACEUTICALS INC 
00172-4280-70 VERAPAMIL IVAX PHARMACEUTICALS INC 
00172-4234-60 BUMETANIDE IVAX PHARMACEUTICALS INC 
00172-4233-60 BUMETANIDE IVAX PHARMACEUTICALS INC 
00172-4229-80 TRIAMTEREN IVAX PHARMACEUTICALS INC 
00172-4198-60 ENALAPRIL IVAX PHARMACEUTICALS INC 
00172-4197-60 ENALAPRIL IVAX PHARMACEUTICALS INC 
00172-4196-60 ENALAPRIL IVAX PHARMACEUTICALS INC 
00172-4141-60 FENOPROFEN IVAX PHARMACEUTICALS INC 
00172-4141-70 FENOPROFEN IVAX PHARMACEUTICALS INC 
00172-4097-60 BACLOFEN T IVAX PHARMACEUTICALS INC 
00172-4097-60 BACLOFEN 2 IVAX PHARMACEUTICALS INC 
00172-4096-60 BACLOFEN T IVAX PHARMACEUTICALS INC 
00172-4096-60 BACLOFEN 1 IVAX PHARMACEUTICALS INC 
00172-4096-80 BACLOFEN 1 IVAX PHARMACEUTICALS INC 
00172-4074-60 CEPHALEXIN IVAX PHARMACEUTICALS INC 
00172-4074-70 CEPHALEXIN IVAX PHARMACEUTICALS INC 
00172-4058-48 CEFADROXIL IVAX PHARMACEUTICALS INC 
00172-4058-60 CEFADROXIL IVAX PHARMACEUTICALS INC 
00172-4030-60 INDOMETHAC IVAX PHARMACEUTICALS INC 
00172-4030-70 INDOMETHAC IVAX PHARMACEUTICALS NC 
00172-3759-60 LISINOPRIL IVAX PHARMACEUTICALS NC 
00172-3669-60 PERPHENAZI IVAX PHARMACEUTICALS NC 
00172-3668-60 PERPHENAZI IVAX PHARMACEUTICALS NC 
00172-3626-70 DOXYCYCLIN IVAX PHARMACEUTICALS NC 
00172-3001-60 QUININE SU IVAX PHARMACEUTICALS NC 
00172-2985-70 DOXYCYCLIN IVAX PHARMACEUTICALS NC 
00172-2932-60 METHYLDOPA IVAX PHARMACEUTICALS NC 
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NDC - 1 
(00172-2931-60 
00172-2929-60 
00172-2929-80 
00172-2911-60 
00172-2911-70 
00172-2909-60 
00172-2909-70 
00172-2908-80 
00172-2907-80) 
00172-2193-60 
00172-2193-60 
00172-2131-60 
00172-2130-60 
00172-2089-80 
00172-2083-80 
00173-0993-94 
00173-0993-94 
00173-0947-55 
00173-0933-03 
00173-0933-03 
00173-0933-08 
00173-0807-25 
00173-0742-00 
00173-0737-01 
00173-0736-01 
00173-0735-00 
00173-0731-01 
00173-0730-01 
00173-0722-00 
00173-0721-00 
00173-0714-00 
00173-0712-00 
00173-0697-00 
00173-0697-00 
00173-0696-00 
00173-0696-00 
00173-0695-00 
00173-0695-00 
00173-0691-00 
00173-0690-00 
00173-0672-00 
00173-0662-00 
00173-0661-01 
00173-0644-60 
00173-0644-60 
00173-0643-60 
00173-0643-60 
100173-0642-55 
FDA Prod I 
METHYLDOPA 
CYPROHEPTA 
CYPROHEPTA 
HYDROXYZIN 
HYDROXYZIN 
HYDROXYZIN 
HYDROXYZIN 
FUROSEMIDE 
FUROSEMIDE 
PROBENECID 
COL-PROBEN 
NITROFURAN 
NITROFURAN 
HYDROCHLOR 
HYDROCHLOR 
ZOVIRAX 5% 
ZOVIRAX ON 
WELLBUTRIN 
VALTREX 50 
VALTREX CA 
VALTREX 50 
PURINETHOL 
EPZICOM TA 
IMITREX10 
IMITREX 50 
IM1TREX25 
WELLBUTRIN 
WELLBUTRIN 
WELLBUTRIN 
LEXIVA 700 
EPIVIR300 
AVODART 0 
ADVAIR DIS 
iADVAIR 500 
ADVAIR DIS 
ADVAIR 250 
ADVAIR DIS 
ADVAIR 100 
TRIZIVIR T 
LOTRONEXT 
AGENERASE 
EPIVIR HBV 
ZIAGEN 300 
LAMICTALT 
LAMICTAL2 
LAMICTALT 
LAMICTAL 1 
| LAMICTALT 
Firm I 
IVAX PHARMACEUTICALS INC 
IVAX PHARMACEUTICALS INC 
IVAX PHARMACEUTICALS INC 
IVAX PHARMACEUTICALS INC 
IVAX PHARMACEUTICALS INC 
IVAX PHARMACEUTICALS INC 
IVAX PHARMACEUTICALS INC 
IVAX PHARMACEUTICALS INC 
IVAX PHARMACEUTICALS INC 
IVAX PHARMACEUTICALS INC 
IVAX PHARMACEUTICALS INC 
IVAX PHARMACEUTICALS INC 
IVAX PHARMACEUTICALS INC 
IVAX PHARMACEUTICALS INC 
IVAX PHARMACEUTICALS INC 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN | 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
jGLAXO WELLCOME DIVISION SMITHKLIN 
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00173-0642-55 LAMICTAL 1 GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0633-02 LAMICTAL 2 GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0597-55 IMURAN TAB GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0595-00 COMBIVIR 1 GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0595-00 COMBIVIR T GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0570-00 ZOFRAN ODT GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0570-04 ZOFRAN ODT GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0569-00 ZOFRAN ODT GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0565-00 VALTREX CA GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0565-02 VALTREX 1G GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0565-02 VALTREX 1 GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0562-00 AMERGE 2.5 GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0562-00 AMERGE TAB GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0555-00 CEFTIN 250 GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0555-00 CEFTIN SUS GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0527-00 LAMICTAL 2 GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0526-00 LAMICTAL 5 GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0523-00 IMITREX NA GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0521-00 SEREVENT D GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0519-00 FLOLAN FOR GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0501-00 RETROVIR 3 GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0501-00 RETROVIR T GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0495-00 FLOVENT IN GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0495-00 FLOVENT 22 GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0494-00 FLOVENT IN GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0494-00 FLOVENT11 GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0491-00 FLOVENTIN GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0491-00 FLOVENT 44 GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0479-00 IMITREX IN GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0478-00 IMITREX 6M GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0478-00 IMITREX IN GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0470-01 EPIVIR150 GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0470-01 EPIVIR TAB GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0464-00 SEREVENT 2 GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0464-00 SEREVENTI GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0460-02 IMITREX 25 GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0460-02 IMITREX TA GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0459-00 IMITREX 50 GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0459-00 IMITREX TA GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0453-01 FLONASE NA GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0453-01 FLONASE 0. GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0450-03 IMITREX TA GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0450-03 IMITREX 10 GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0449-01 IMITREX 2 GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0449-03 IMITREX Kl GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0447-00 ZOFRAN TAB GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0447-00 ZOFRAN 8MG GLAXO WELLCOME DIVISION SMITHKLIN 
00173-0447-00 ZOFRAN 8 M GLAXO WELLCOME DIVISION SMITHKLIN 
Exhibit A Page 32 
Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU. 
Machine-generated OCR, may contain errors.
Exhibit A 
| NDC 1 
[00173-0447-04 
00173-0447-04 
00173-0447-04 
00173-0446-00 
00173-0446-00 
00173-0446-00 
00173-0446-04 
00173-0446-04 j 
00173-0446-04 
00173-0442-00 
00173-0442-00 
00173-0430-01 
00173-0430-01 
00173-0428-00 
00173-0427-02 
00173-0423-00 
00173-0423-01 
03173-0406-00 
00173-0406-04 
00173-0401-01 
00173-0394-00 
00173-0394-00 
00173-0394-42 
00173-0394-42 
00173-0393-40 
00173-0389-01 
00173-0388-79 
00173-0387-00 
00173-0387-00 
00173-0387-42 
00173-0387-42 
00173-0385-58 
00173-0383-54 
00173-0383-54 
00173-0383-54 
00173-0351-54 
00173-0347-43 
00173-0344-09 
00173-0344-14 
00173-0344-16 
00173-0344-42 
00173-0344-47 
00173-0336-02 
00173-0321-88 
00173-0321-98 
00173-0312-88 
00173-0264-27 
|00173-0249-75 
FDA Prod I 
ZOFRAN TAB 
ZOFRAN 8MG 
ZOFRAN 8 M 
ZOFRAN 4MG 
ZOFRAN TAB 
ZOFRAN 4 M 
ZOFRAN TAB 
ZOFRAN 4MG 
ZOFRAN 4 M 
ZOFRAN 2MG 
ZOFRANINJ 
CUTIVATE C 
CUTIVATE 0 
ZANTAC 150 
ZANTAC 150 
OXISTAT CR 
OXISTAT CR 
CEFTIN 125 
CEFTIN 125 
ACLOVATE C 
CEFTIN TAB 
CEFTIN 500 
CEFTIN TAB 
CEFTIN 500 
ZANTAC TAB 
VENTOLIN R 
BECONASE A 
CEFTIN TAB 
CEFTIN 250 
CEFTIN TAB 
CEFTIN 250 
VENTOLIN R 
I ZANTAC 15M 
[ZANTAC 15 
ZANTAC SYR 
VENTOLIN S 
TRANDATE 2 
ZANTAC TAB 
ZANTAC TAB 
ZANTAC TAB 
ZANTAC TAB 
ZANTAC TAB 
BECONASEI 
VENTOLIN I 
VENTOLIN I 
BECLOVENT 
LANOXIN EL 
I LANOXIN 25 
Firm ~j 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
iGLAXO WELLCOME DIVISION SMITHKLIN 
[GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
GLAXO WELLCOME DIVISION SMITHKLIN 
j GLAXO WELLCOME DIVISION SMITHKLIN 
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1 NDC 1 
[00173-0249-75 
00173-0242-75 
100173-0242-75 
(00173-0178-55 
00173-0177-55 
00173-0135-55 
00173-0108-55 
00186-5040-31 
00186-5040-31 
00186-5040-54 
00186-5040-54 
00186-5040-82 
00186-5040-82 
00186-5020-31 
00186-5020-31 
00186-5020-31 
00186-1989-04 
00186-1988-04 
00186-1905-01 
00186-1516-01 
00186-1094-05 
00186-1094-05 
00186-1094-05 
00186-1092-05 
00186-1092-05 
00186-1092-05 
00186-1090-05 
00186-1090-05 
00186-1090-05 
00186-1088-05 
00186-1075-09 
00186-1070-06 
00186-1070-08 
00186-0915-42 
00186-0743-31 
00186-0743-68 
00186-0742-28 
00186-0742-31 
00186-0742-82 
00186-0606-31 
00186-0452-31 
00186-0452-58 
00186-0451-58 
00186-0451-58 
00186-0322-54 
00186-0162-54 
00186-0032-31 
100186-0032-54 
FDA Prod I 
LANOXIN TA 
LANOXIN 12 
LANOXIN TA 
WELLBUTRIN 
WELLBUTRIN 
WELLBUTRIN 
RETROVIR C ] 
NEXIUM 40 | 
NEXIUM 40M 
NEXIUM 40M 
NEXIUM 40 
NEXIUM 40 
NEXIUM 40M 
NEXIUM (es 
NEXIUM 20 
NEXIUM 20M 
PULMICORT 
PULMICORT 
FOSCAVIR ( 
EMLA Cream 
TOPROL X.L 
Toprol-XL 
TOPROL XL 
TOPROL X.L 
Toprol-XL 
TOPROL XL 
TOPROL X L 
Toprol-XL 
TOPROL XL 
TOPROL XL 
Rhinocort 
RHINOCORT 
RHINOCORT 
Pulmicort 
[PRILOSEC 4 
PRILOSEC 4 
PRILOPEC 2 
PRILOSEC 2 
PRILOSEC 2 
PRILOSEC 1 
PLENDIL 10 
PLENDIL 10 
PLENDIL 5 
PLENDIL 5M 
ATACAND HC 
ATACAND HC 
ATACAND 32 
[Atacand (c 
Firm l 
GLAXO WELLCOME DIVISI0N SMITHKLIN | 
GLAXO WELLCOME DIVISIC N SMITHKLIN | 
GLAXO WELLCOME DIVISION SMITHKLIN I 
GLAXO WELLCOME DIVISION SMITHKLIN | 
GLAXO WELLCOME DIVISIG >N SMITHKLIN | 
GLAXO WELLCOME DIVISIQN SMITHKLIN j 
GLAXO WELLCOME DIVISION SMITHKLIN 
ASTRAZENECA LP 
ASTRAZENECA LP 
ASTRAZENECA LP 
ASTRAZENECA LP 
ASTRAZENECA LP 
ASTRAZENECA LP 
ASTRAZENECA LP 
ASTRAZENECA LP 
ASTRAZENECA LP 
ASTRAZENECA LP 
ASTRAZENECA LP 
ASTRAZENECA LP 
ASTRAZENECA LP 
ASTRAZENECA LP 
ASTRAZENECA LP 
ASTRAZENECA LP 
ASTRAZENECA LP 
ASTRAZENECA LP 
ASTRAZENECA LP 
ASTRAZENECA LP 
ASTRAZENECA LP 
ASTRAZENECA LP 
ASTRAZENECA LP 
ASTRAZENECA LP 
ASTRAZENECA LP 
ASTRAZENECA LP 
IASTRAZENECA LP 
jASTRAZENECA LP 
IASTRAZENECA LP 
ASTRAZENECA LP 
ASTRAZENECA LP 
ASTRAZENECA LP 
ASTRAZENECA LP 
ASTRAZENECA LP 
ASTRAZENECA LP 
ASTRAZENECA LP 
ASTRAZENECA LP 
ASTRAZENECA LP 
ASTRAZENECA LP 
ASTRAZENECA LP 
JASTRAZENECA LP 
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00186-0032-54 
00186-0016-31 
00186-0016-54 
00228-3004-11 
00228-3004-50 
00228-3003-11 
00228-3003-50 
00228-2741-15 
00228-2718-11 
00228-2715-11 
00228-2714-11 
00228-2713-11 
00228-2713-50 
00228-2711-11 
00228-2711-50 
00228-2672-11 
00228-2667-11 
00228-2666-11 
00228-2665-11 
00228-2657-11 
00228-2637-11 
00228-2636-11 
00228-2618-11 
00228-2611-11 
00228-2611-96 
00228-2588-09 
00228-2579-09 
00228-2578-09 
00228-2577-09 
00228-2497-30 
00228-2480-10 
00228-2269-50 
00228-2221-96 
00228-2143-10 
00228-2143-50 
00228-2143-96 
00228-2129-10 
00228-2128-10 
00228-2128-50 
00228-2127-10 
00228-2127-50 
00228-2085-50 
00228-2059-50 
00228-2028-96 
00228-2001-10 
00228-2001-96 
00264-1915-00 
100300-7311-30 
FDA Prod I 
ATACAND 32 
ATACAND 16 
ATACAND 16 
CLONAZEPAM 
CLONAZEPAM 
CLONAZEPAM 
CLONAZEPAM 
TIZANIDINE 
METFORMIN 
METFORMIN 
TRAMADOL H 
ISOSORBIDE 
ISOSORBIDE 
ISOSORBIDE 
ISOSORBIDE S 
SPIRONOLAC 
GABAPENTIN 
GABAPENTIN 
GABAPENTIN 
METFORMIN 
GABAPENTIN 
GABAPENTIN 
NAPROXEN D 
PENTOXIFYL 
PENTOXiFYL 
DILTIAZEM 
DILTIAZEM 
DILTIAZEM 
DILTIAZEM 
NIFEDIPINE 
TOLMETIN 6 
METOCLOPRA 
iHYDROCHLOR 
ICARBAMAZEP 
CARBAMAZEP 
CARBAMAZEP 
CLONIDINE 
CLONIDINE 
CLONIDINE 
CLONIDINE 
CLONIDINE 
PROPOXYPHE 
LORAZEPAM 
PHENOBARB 
ACETAMINOP 
ACETAMINOP 
PROCALAMIN 
|PREVACID 3 
Firm I 
ASTRAZENECA LP 
ASTRAZENECA LP 
ASTRAZENECA LP 
PUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
iPUREPAC PHARMACEUTICAL CO 
jPUREPAC PHARMACEUTICAL CO 
IPUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
PUREPAC PHARMACEUTICAL CO 
PUREPAC P HARMACEUTICAL CO 
B BRAUN MEDICAL INC I 
JTAP PHARMACEUTICALS INC 
Exhibit A Page 35 
Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU. 
Machine-generated OCR, may contain errors.
Exhibit A 
CO 
o o 
o o 
NDC FDA Prod Firm 
TAP PHARMACEUTICALS IhJc 00300-7309-30 PREVACID 1 
00300-3702-01 PREV PAC TAP PHARMACEUTICALS INC 
00300-3702-01 PREVPAC PA TAP PHARMACEUTICALS INC 
00300-3046-11 PREVACID 3 TAP PHARMACEUTICALS INC 
00300-3046-13 PREVACID TAP PHARMACEUTICALS INC 
00300-3046-13 PREVACID 3 TAP PHARMACEUTICALS INC 
00300-3046-19 PREVACID 3 TAP PHARMACEUTICALS INC 
00300-1546-30 PREVACID N TAP PHARMACEUTICALS INC 
00300-1544-30 PREVACID 3 TAP PHARMACEUTICALS INC 
00300-1543-30 PREVACID 1 TAP PHARMACEUTICALS INC 
00300-1541-19 PREVACID 1 TAP PHARMACEUTICALS INC 
00300-1541-30 PREVACID TAP PHARMACEUTICALS INC 
00300-1541-30 PREVACID 1 TAP PHARMACEUTICALS INC 
00310-0960-36 ZOLADEX 3 ASTRAZENECA PHARMACEUTICALS LP 
00310-0894-10 SULAR 40MG ASTRAZENECA PHARMACEUTICALS LP 
00310-0893-10 SULAR 30MG ASTRAZENECA PHARMACEUTICALS LP 
00310-0892-10 SULAR 20MG ASTRAZENECA PHARMACEUTICALS LP 
00310-0891-10 SULAR 10MG ASTRAZENECA PHARMACEUTICALS LP 
00310-0752-90 CRESTOR 20 ASTRAZENECA PHARMACEUTICALS LP 
00310-0751-90 CRESTOR 10 ASTRAZENECA PHARMACEUTICALS LP 
00310-0720-50 FASLODEX 2 ASTRAZENECA PHARMACEUTICALS LP 
00310-0705-10 CASODEX 50 ASTRAZENECA PHARMACEUTICALS LP 
00310-0705-30 CASODEX 50 ASTRAZENECA PHARMACEUTICALS LP 
00310-0604-30 NOLVADEX 2 ASTRAZENECA PHARMACEUTICALS LP 
00310-0600-25 NOLVADEX T ASTRAZENECA PHARMACEUTICALS LP 
00310-0600-60 NOLVADEX T ASTRAZENECA PHARMACEUTICALS LP 
00310-0482-30 IRESSA 250 ASTRAZENECA PHARMACEUTICALS LP 
00310-0402-60 ACCOLATE 2 ASTRAZENECA PHARMACEUTICALS LP 
00310-0321-30 MERREM1GM ASTRAZENECA PHARMACEUTICALS LP 
00310-0275-10 SEROQUEL 2 ASTRAZENECA PHARMACEUTICALS LP 
00310-0275-34 SEROQUEL2 ASTRAZENECA PHARMACEUTICALS LP 
00310-0275-39 SEROQUEL2 ASTRAZENECA PHARMACEUTICALS LP 
00310-0274-39 SEROQUEL 3 ASTRAZENECA PHARMACEUTICALS LP 
00310-0274-60 Seroquel ( ASTRAZENECA PHARMACEUTICALS LP 
00310-0274-60 SEROQUEL 3 ASTRAZENECA PHARMACEUTICALS LP 
00310-0272-10 SEROQUEL 2 ASTRAZENECA PHARMACEUTICALS LP 
00310-0272-39 SEROQUEL2 ASTRAZENECA PHARMACEUTICALS LP 
00310-0271-10 SEROQUEL1 ASTRAZENECA PHARMACEUTICALS LP 
00310-0271-39 SEROQUEL1 ASTRAZENECA PHARMACEUTICALS LP 
00310-0211-25 ZOMIG 5MG ASTRAZENECA PHARMACEUTICALS LP 
00310-0211-25 ZOMIG 5 MG ASTRAZENECA PHARMACEUTICALS LP 
00310-0210-20 ZOMIG 2.5M ASTRAZENECA PHARMACEUTICALS LP 
00310-0210-20 ZOMIG 2 5 ASTRAZENECA PHARMACEUTICALS LP 
00310-0201-30 ARIMIDEX 1 ASTRAZENECA PHARMACEUTICALS LP 
00310-0145-10 ZESTORETIC ASTRAZENECA PHARMACEUTICALS LP 
00310-0142-10 ZESTORETIC ASTRAZENECA PHARMACEUTICALS LP 
00310-0141-10 ZESTORETIC ASTRAZENECA PHARMACEUTICALS LP 
00310-0134-10 ZESTRIL 40 ASTRAZENECA PHARMACEUTICALS LP 
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NDC j 
100310-0132-10 
100310-0131-10 
00310-0131-34 
00310-0130-10 
00310-0115-10 
00310-0105-10 
00310-0101-10 
00338-0502-06 
00338-0049-02 
00338-0049-18 
00378-9639-43 
00378-9116-93 
00378-9112-93 
00378-9104-93 
00378-9102-93 
00378-9012-93 
00378-9004-93 
00378-7612-02 
00378-7610-06 
00378-7610-12 
00378-7602-06 
00378-7602-12 
00378-7500-01 
00378-7250-01 
00378-6440-01 
00378-6410-01 
00378-6074-01 
00378-5750-01 
00378-5340-01 
00378-5280-01 
00378-5220-01 
00378-5150-91 
00378-5050-01 
00378-5050-05 
00378-5010-01 
00378-4250-01 
00378-4220-01 
00378-4151-01 
00378-4151-05 
00378-4010-01 
00378-4010-05 
00378-3545-93 
00378-3530-93 
00378-3515-93 
00378-3495-01 
00378-3482-01 
00378-3482-30 
100378-3475-01 
FDA Prod I 
ZESTRIL 20 
ZESTRIL10 
ZESTRIL 10 
ZESTRIL 5M 
TENORETIC 
TENORMIN 5 
TENORMIN 1 
CUNISOL 1 
SODIUM CHL 
SODIUM CHL 
BUTORPHANO 
NITROGLYCE 
NITROGLYCE 
NITROGLYCE 
NITROGLYCE 
NITROGLYCE 
NITROGLYCE 
CEFACLOR 3 
CEFACLOR 2 
CEFACLOR 2 
CEFACLOR 1 
CEFACLOR 1 
CEFACLOR 5 
CEFACLOR 2 
VERAPAMIL 
DOXPEIN HC 
FLUPHENAZI 
KETOPROFEN 
DILTIAZEM 
DILTIAZEM 
DILTIAZEM 
NIZATIDINE 
TEMAZEPAM 
TEMAZEPAM 
ITHIOTHIXEN 
jDOXEPIN HC 
FLUOXETINE 
TRAMADOL H 
TRAMADOL H 
TEMAZEPAM 
TEMAZEPAM 
MIRTAZAPIN 
MIRTAZAPIN 
MIRTAZAPIN 
NIFEDIPINE 
NIFEDIPINE 
NIFEDIPINE 
Firm I 
ASTRAZENECA PHARMACEUTICALS LP 
ASTRAZENECA PHARMACEUTICALS LP 
ASTRAZENECA PHARMACEUTICALS LP 
ASTRAZENECA PHARMACEUTICALS LP 
ASTRAZENECA PHARMACEUTICALS LP 
ASTRAZENECA PHARMACEUTICALS LP 
ASTRAZENECA PHARMACEUTICALS LP 
BAXTER HEALTHCARE CORP 
BAXTER HEALTHCARE CORP 
BAXTER HEALTHCARE CORP 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
jMYLAN PHARMACEUTICALS INC 
IMYLAN PHARMACEUTICALS INC 
JMYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
IMYLAN PHARMACEUTICALS INC 
(NIFEDIPINE |MYLAN PHARMACEUTICALS INC | 
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00378-3475-30 NIFEDIPINE MYLAN PHARMACEUTICALS INC 
00378-3422-01 NITROFURAN MYLAN PHARMACEUTICALS INC 
00378-3358-01 ORPHENADRI MYLAN PHARMACEUTICALS INC 
00378-3266-94 ETOPOSIDE MYLAN PHARMACEUTICALS INC 
00378-3125-01 DOXEPIN HC MYLAN PHARMACEUTICALS INC 
00378-3040-01 FAMOTIDINE MYLAN PHARMACEUTICALS INC 
00378-3020-01 FAMOTIDINE MYLAN PHARMACEUTICALS INC 
00378-3005-01 THIOTHIXEN MYLAN PHARMACEUTICALS INC 
00378-3000-01 MECLOFENAM MYLAN PHARMACEUTICALS INC 
00378-3000-05 MECLOFENAM MYLAN PHARMACEUTICALS INC 
00378-2685-01 AMITRIPTYL MYLAN PHARMACEUTICALS INC 
00378-2650-10 AMITRIPTYL MYLAN PHARMACEUTICALS INC 
00378-2625-10 AMITRIPTYL MYLAN PHARMACEUTICALS INC 
00378-2537-10 TRIAMTEREN MYLAN PHARMACEUTICALS INC 
00378-2150-01 MECLOFENAM MYLAN PHARMACEUTICALS INC 
00378-2146-01 SPIRONOLAC MYLAN PHARMACEUTICALS INC 
00378-2146-05 SPIRONOLAC MYLAN PHARMACEUTICALS INC 
00378-2100-01 LOPERAMIDE MYLAN PHARMACEUTICALS INC 
00378-2076-01 LISINOPRIL MYLAN PHARMACEUTICALS INC 
00378-2075-01 LISINOPRIL MYLAN PHARMACEUTICALS INC 
00378-2074-01 LISINOPRIL MYLAN PHARMACEUTICALS INC 
00378-2073-01 LISINOPRIL MYLAN PHARMACEUTICALS INC 
00378-2063-01 ATENOLOL/C MYLAN PHARMACEUTICALS INC 
00378-2025-01 LISINOPRIL MYLAN PHARMACEUTICALS INC 
00378-2020-01 PIROXICAM MYLAN PHARMACEUTICALS INC 
00378-2020-05 PIROXICAM MYLAN PHARMACEUTICALS INC 
00378-2012-01 LISINOPRIL MYLAN PHARMACEUTICALS INC 
00378-1902-01 MIDODRINE MYLAN PHARMACEUTICALS INC 
00378-1560-01 EX PHENYTO MYLAN PHARMACEUTICALS INC 
00378-1560-01 PHENYTOIN MYLAN PHARMACEUTICALS INC 
00378-1560-10 EX PHENYTO MYLAN PHARMACEUTICALS INC 
00378-1560-10 PHENYTOIN MYLAN PHARMACEUTICALS INC 
00378-1352-05 TRIAMTEREN MYLAN PHARMACEUTICALS INC 
00378-1200-01 ACEBUTOLOL MYLAN PHARMACEUTICALS INC 
00378-1190-01 GUANFACINE MYLAN PHARMACEUTICALS INC 
00378-1175-91 BUSPIRONE MYLAN PHARMACEUTICALS INC 
00378-1171-01 NADOLOL 40 MYLAN PHARMACEUTICALS INC 
00378-1165-80 BUSPIRONE MYLAN PHARMACEUTICALS INC 
00378-1165-91 BUSPIRONE MYLAN PHARMACEUTICALS INC 
00378-1160-01 GUANFACINE MYLAN PHARMACEUTICALS INC 
00378-1155-05 PROPOXYPHE MYLAN PHARMACEUTICALS INC 
00378-1134-01 KETOROLAC MYLAN PHARMACEUTICALS INC 
00378-1120-01 VERAPAMIL MYLAN PHARMACEUTICALS INC 
00378-1110-01 GLIPIZIDE MYLAN PHARMACEUTICALS INC 
00378-1110-05 GLIPIZIDE MYLAN PHARMACEUTICALS INC 
00378-1105-01 GLIPIZIDE MYLAN PHARMACEUTICALS INC 
00378-1105-05 GLIPIZIDE MYLAN PHARMACEUTICALS INC 
00378-0860-01 CLOZAPINE MYLAN PHARMACEUTICALS INC 
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00378-0810-01 
00378-0810-01 
00378-0777-01 
00378-0751-01 
00378-0751-10 
00378-0723-01 
00378-0711-01 
00378-0711-10] 
00378-0618-01 j 
00378-0616-01 ! 
00378-0616-10 
00378-0614-01 
00378-0614-10 
00378-0611-01 
00378-0611-10 
00378-0574-01 
00378-0574-05 
00378-0555-01 
00378-0555-05 
00378-0541-01 
00378-0531-01 
00378-0507-01 
00378-0505-01 
00378-0503-01 
00378-0501-01 
00378-0477-05 
00378-0471-01 
00378-0457-01 
00378-0457-05 
00378-0457-10 
00378-0451-01 
00378-0451-05 
00378-0442-01 
00378-0442-05 
00378-0421-01 
00378-0417-01 
00378-0415-01 
00378-0415-10 
00378-0414-01 
00378-0411-05 
00378-0372-01 
00378-0372-05 
00378-0370-01 
00378-0357-01 
00378-0351-01 
00378-0345-05 
00378-0330-01 
100378-0330-05 
FDA Prod I 
HCTZ12 5M 
HYDROCHLOR 
LORAZEPAM 
CYCLOBENZA 
CYCLOBENZA 
ENALAPRIL/ 
METHYLDOPA 
METHYLDOPA 
THIORIDAZI 
THIORIDAZI 
THIORIDAZI 
THIORIDAZI 
THIORIDAZI 
METHYLDOPA 
METHYLDOPA 
PERPHENAZI 
PERPHENAZI 
NAPROXEN 3 
NAPROXEN 3 
CIMETIDINE 
SULINDAC 2 
METHYLDOPA 
BISOPROLOL 
BISOPROLOL 
BISOPROLOL 
DIAZEPAM 1 
FENOPROFEN 
LORAZEPAM 
LORAZEPAM 
LORAZEPAM 
:NAPROXEN 5 
NAPROXEN 5 
PERPHENAZI 
PERPHENAZI 
METHYLDOPA 
BUMETANIDE 
DIPHENOXYL 
DIPHENOXYL 
FLUVOXAMIN 
VERAPAMIL 
CIMETIDINE 
CIMETIDINE 
BUMETANIDE 
PENTOXIFYL 
HALOPERIDO 
DIAZEPAM 5 
PERPHENAZI 
j PERPHENAZI 
Firm j 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
jMYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
JMYLAN PHARMACEUTICALS INC 
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00378-0327-01 HALOPERIDO MYLAN PHARMACEUTICALS INC 
00378-0327-10 HALOPERIDO MYLAN PHARMACEUTICALS INC 
00378-0321-01 LORAZEPAM MYLAN PHARMACEUTICALS INC 
00378-0321-05 LORAZEPAM MYLAN PHARMACEUTICALS INC 
00378-0277-01 AMITRIP/CD MYLAN PHARMACEUTICALS INC 
00378-0277-01 CHLORDIAZE MYLAN PHARMACEUTICALS INC 
00378-0277-05 AMITRIP/CD MYLAN PHARMACEUTICALS INC 
00378-0277-05 CHLORDIAZE MYLAN PHARMACEUTICALS INC 
00378-0257-01 HALOPERIDO MYLAN PHARMACEUTICALS INC 
00378-0245-01 BUMETANIDE MYLAN PHARMACEUTICALS INC 
00378-0244-01 METFORMIN MYLAN PHARMACEUTICALS INC 
00378-0234-01 METFORMIN MYLAN PHARMACEUTICALS INC 
00378-0232-01 FUROSEMIDE MYLAN PHARMACEUTICALS INC 
00378-0232-05 FUROSEMIDE MYLAN PHARMACEUTICALS INC 
00378-0231-01 ATENOLOL 5 MYLAN PHARMACEUTICALS INC 
00378-0231-10 ATENOLOL 5 MYLAN PHARMACEUTICALS INC 
00378-0216-01 FUROSEMIDE MYLAN PHARMACEUTICALS INC 
00378-0216-10 FUROSEMIDE MYLAN PHARMACEUTICALS INC 
00378-0214-01 HALOPERIDO MYLAN PHARMACEUTICALS INC 
00378-0211-01 AMITRIP/CD MYLAN PHARMACEUTICALS INC 
00378-0211-01 CHLORDIAZE MYLAN PHARMACEUTICALS INC 
00378-0211-05 AMITRIP/CD MYLAN PHARMACEUTICALS INC 
00378-0211-05 CHLORDIAZE MYLAN PHARMACEUTICALS INC 
00378-0208-01 FUROSEMIDE MYLAN PHARMACEUTICALS INC 
00378-0208-10 FUROSEMIDE MYLAN PHARMACEUTICALS INC 
00378-0199-01 CLONIDINE MYLAN PHARMACEUTICALS INC 
00378-0186-01 CLONIDINE MYLAN PHARMACEUTICALS INC 
00378-0186-10 CLONIDINE MYLAN PHARMACEUTICALS INC 
00378-0181-05 ALLOPURINO MYLAN PHARMACEUTICALS INC 
00378-0156-01 PROBENECID MYLAN PHARMACEUTICALS INC 
00378-0155-01 PROPOXYPHE MYLAN PHARMACEUTICALS INC 
00378-0155-05 PROPOXY-N/ MYLAN PHARMACEUTICALS INC 
00378-0155-05 PROPOXYPHE MYLAN PHARMACEUTICALS INC 
00378-0152-01 CLONIDINE MYLAN PHARMACEUTICALS INC 
00378-0152-10 CLONIDINE MYLAN PHARMACEUTICALS INC 
00378-0147-05 INDOMETHAC MYLAN PHARMACEUTICALS INC 
00378-0130-05 PROPOXYPHE MYLAN PHARMACEUTICALS INC 
00378-0094-01 CARBIDOPA/ MYLAN PHARMACEUTICALS INC 
00378-0093-01 FLURBIPROF MYLAN PHARMACEUTICALS INC 
00378-0088-01 CARBIDOPA/ MYLAN PHARMACEUTICALS INC 
00378-0086-01 CAPTOPRIL/ MYLAN PHARMACEUTICALS INC 
00378-0084-01 CAPTOPRIL/ MYLAN PHARMACEUTICALS INC 
00378-0081-01 CAPTOPRIL/ MYLAN PHARMACEUTICALS INC 
00378-0073-01 AMITRIP/PE MYLAN PHARMACEUTICALS INC 
00378-0073-01 PERPHENAZI MYLAN PHARMACEUTICALS INC 
00378-0052-01 PINDOLOL 5 MYLAN PHARMACEUTICALS INC 
00378-0047-01 METOPROLOL MYLAN PHARMACEUTICALS INC 
00378-0045-01 DILTIAZEM MYLAN PHARMACEUTICALS INC 
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00378-0032-01 
00378-0032-10 
00378-0027-01 
00378-0023-01 
00378-0014-01 
00378-0001-01 
00456-4300-08 
00456-4040-01 
00456-4040-01 
00456-4020-01 
00456-4020-01 
00456-4010-01 
00456-4010-01 I 
00456-3210-60 
00456-3205-60 
00456-2617-30 
00456-2617-90 
00456-2616-30 
00456-2616-90 
00456-2615-30 
00456-2615-90 
00456-2614-30 
00456-2614-90 
00456-2613-30 
00456-2613-90 
00456-2612-90 
00456-2020-01 
00456-2010-01 
00456-0678-01 
00456-0672-99 
00456-0672-99 
00456-0670-99 
00456-0527-08 
00456-0521-01 
00456-0323-01 
00456-0321-01 
00472-1627-16 
00472-1627-16 
00472-1423-16 
00472-1419-16 
00472-1419-28 
00472-1360-16 
00472-1360-16 
00472-1358-32 
00472-1320-02 
00472-1320-02 
00472-1320-16 
(00472-1320-16 
FDA Prod I 
METOPROLOL 
METOPROLOL 
CLONIDINE 
DILTIAZEM 
METHOTREXA 
CLONIDINE 
MONUROL 
CELEXA 40 
CELEXA 40M 
CELEXA 20 
CELEXA 20M 
CELEXA 10 
CELEXA 10M 
NAMENDA10 \ 
NAMENDA 5 
TIAZAC 420 
TIAZAC 420 
TIAZAC 360 
TIAZAC 360 
TIAZAC 300 
TIAZAC 300 
TIAZAC 240 
TIAZAC 240 
TIAZAC 180 
TIAZAC 180 
TIAZAC 120 
LEXAPRO 20 
LEXAPRO 10 
ESGIC-PLUS 
AEROBIDAE 
AEROBID 
AEROBID-M 
FLUMADINE 
FLUMADINE 
ILEVOTHROID 
iLEVOTHROID 
[PROMETH W/ 
IPROMETHAZI 
IOPHEN ELI 
ACETAMINOP 
ACETAMINOP 
ENULOSE 10 
ENULOSE 
CONSTULOSE 
NYSTATIN 1 
NYSTATIN O 
NYSTATIN O 
(NYSTATIN 1 
Firm 1 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
MYLAN PHARMACEUTICALS INC 
FOREST PHARMACEUTICALS INC 
FOREST PHARMACEUTICALS INC 
FOREST PHARMACEUTICALS INC 
FOREST PHARMACEUTICALS INC 
FOREST PHARMACEUTICALS INC 
FOREST PHARMACEUTICALS INC 
FOREST PHARMACEUTICALS INC 
FOREST PHARMACEUTICALS INC 
FOREST PHARMACEUTICALS INC 
FOREST PHARMACEUTICALS INC 
FOREST PHARMACEUTICALS INC 
FOREST PHARMACEUTICALS INC 
FOREST PHARMACEUTICALS INC 
FOREST PHARMACEUTICALS INC 
FOREST PHARMACEUTICALS INC 
FOREST PHARMACEUTICALS INC 
FOREST PHARMACEUTICALS INC 
FOREST PHARMACEUTICALS INC 
FOREST PHARMACEUTICALS INC 
FOREST PHARMACEUTICALS INC 
FOREST PHARMACEUTICALS INC 
FOREST PHARMACEUTICALS INC 
FOREST PHARMACEUTICALS INC 
FOREST PHARMACEUTICALS INC 
FOREST PHARMACEUTICALS INC 
FOREST PHARMACEUTICALS INC 
FOREST PHARMACEUTICALS INC 
FOREST PHARMACEUTICALS INC 
!FOREST PHARMACEUTICALS INC 
(FOREST PHARMACEUTICALS INC 
tALPHARMA USPD INC 
ALPHARMA USPD INC 
ALPHARMA USPD INC 
ALPHARMA USPD INC 
ALPHARMA USPD INC 
ALPHARMA USPD INC 
ALPHARMA USPD INC 
ALPHARMA USPD INC 
ALPHARMA USPD INC 
ALPHARMA USPD INC 
ALPHARMA USPD INC 
JALPHARMA USPD INC 
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00472-1285-16 
00472-1284-16 
00472-1270-16 
00472-1270-94 
00472-1227-16 
00472-1015-16 
00472-1001-16 
00472-1000-16 
00472-0979-16 
00472-0974-16 
00472-0972-08 
00472-0971-16 
00472-0833-16 
00472-0831-23 
00472-0831-60 
00472-0825-16 
00472-0771-16 
00472-0755-16 
00472-0727-16 
00472-0572-16 
00472-0514-08 
00472-0096-12 
00472-0082-16 
00472-0067-08 
00472-0016-99 
00555-9050-58 
00555-9049-58 
00555-9045-58 
00555-9018-58 
00555-9016-58 
00555-9014-58 
00555-0973-02 
00555-0972-02 
00555-0971-02 
00555-0969-02 
00555-0926-02 
00555-0925-02 
00555-0904-01 
00555-0904-14 
00555-0882-02 
00555-0877-02 
00555-0874-02 
00555-0869-02 
00555-0835-02 
00555-0834-02 
00555-0833-02 
00555-0833-05 
100555-0832-02 
FDA Prod 1 
SULFATRIM 
SULFATRIM 
IBUPROFEN 
IBUPROFEN 
HYDRAMINE 
PHENOBARBI 
POTASSIUM 
POTASSIUM 
ERYTHROMYC 
ERYTHROMYC 
DEXAMETHAS 
ERYTHROMYC 
AMANTADINE 
ALBUTEROL 
ALBUTEROL 
ALBUTEROL 
HYDROXYZIN 
CYPROHEPTA 
CARDEC-S S 
LINDANE SH 
CIMETADINE 
PROMETHAZI 
ACYCLOVIR 
PHENYTOIN 
AUROTO OTI 
KARIVA28 
ICRYSELLE-2 
iAVIANE-28 
ITRI-SPRINT 
tSPRINTEC 2 
lLESSINA-28 
AMPHETAMIN 
AMPHETAMIN 
AMPHETAMIN 
FLUVOXAMIN 
WARFARIN S 
WARFARIN S 
TAMOXIFEN 
TAMOXIFEN 
HYDROXYURE 
FLUOXETINE 
WARFARIN S 
WARFARIN S 
WARFARIN S 
WARFARIN S 
WARFARIN S 
WARFARIN S 
(WARFARIN S 
Firm I 
ALPHARMA USPD INC 
ALPHARMA USPD INC 
ALPHARMA USPD INC 
ALPHARMA USPD INC 
ALPHARMA USPD INC 
ALPHARMA USPD INC 
ALPHARMA USPD INC 
ALPHARMA USPD INC 
ALPHARMA USPD INC 
ALPHARMA USPD INC 
ALPHARMA USPD INC 
ALPHARMA USPD INC \ 
ALPHARMA USPD INC 
ALPHARMA USPD INC 
ALPHARMA USPD INC 
ALPHARMA USPD INC 
ALPHARMA USPD INC 
ALPHARMA USPD INC 
ALPHARMA USPD INC 
ALPHARMA USPD INC 
ALPHARMA USPD INC 
ALPHARMA USPD INC \ 
ALPHARMA USPD INC 
ALPHARMA USPD INC 
ALPHARMA USPD INC 
BARR LABORATORIES INC 
BARR LABORATORIES INC ' 
BARR LABORATORIES INC ! 
BARR LABORATORIES INC ' 
BARR LABORATORIES INC 
IBARR LABORATORIES INC ' 
BARR LABORATORIES INC 
BARR LABORATORIES INC ' 
BARR LABORATORIES INC 
BARR LABORATORIES INC' 
BARR LABORATORIES INC' 
BARR LABORATORIES INC' 
BARR LABORATORIES INC 
BARR LABORATORIES INC' 
BARR LABORATORIES INC 
BARR LABORATORIES INC 
BARR LABORATORIES INC' 
BARR LABORATORIES INC 
BARR LABORATORIES INC 
BARR LABORATORIES INC 
BARR LABORATORIES INC 
BARR LABORATORIES INC 
IBARR LABORATORIES INC 
' ... ' 1 
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00555-0831-02 
00555-0816-10 
00555-0815-02 
100555-0814-02 
00555-0732-02 
100555-0715-58 
00555-0607-02 
00555-0585-02 
00555-0572-02 
00555-0572-35 
00555-0552-22 
00555-0446-03 
00555-0446-09 
00555-0446-63 
00555-0445-21 
00555-0445-22 
00555-0445-23 
00555-0444-04 
00555-0387-02 
00555-0323-02 
00555-0323-04 
00555-0302-04 
00555-0301-38 
00555-0286-02 
00555-0286-05 
00555-0285-05 
00555-0242-71 
00555-0241-71 
00555-0198-05 
00575-6200-30 
00575-0225-01 
00591-5731-01 
00591-5708-01 
00591-5695-50 
00591-5660-01 
00591-5658-01 
00591-5658-10 
00591-5643-01 
00591-5513-01 
00591-5513-05 
00591-5513-10 
00591-5321-01 
00591-5307-01 
00591-5307-10 
00591-5238-01 
00591-5216-10 
00591-3250-01 
100591-3194-01 
FDA Prod I 
WARFARIN S 
CIPROFLOXA 
CIPROFLOXA 
CIPROFLOXA 
TRAZODONE 
CAMILA TAB 
MEGESTROL 
CHLORZOXAZ 
METHOTREXA 
METHOTREXA 
CEPHRADINE 
TAMOXIFEN 
TAMOXIFEN 
TAMOXIFEN 
EES/SULFIS 
EES/SULFIS 
EES/SULFIS 
TRIAMTEREN 
METFORMIN 
HYDROXYZIN 
HYDROXYZIN 
HYDROXYZIN 
METHYLPRED 
DIPYRIDAMO 
DIPYRIDAMO 
DIPYRIDAMO 
MIRTAZAPIN 
MIRTAZAPIN 
APAP/CODEI 
PROGLYCEM 
BICITRA 
BACLOFEN 2 
CLINDAMYCI 
iMINOCYCLIN 
SULINDAC T 
CYCLOBENZA 
CYCLOBENZA 
MINOXIDIL 
CARISOPROD 
CARISOPROD 
CARISOPROD 
PRIMIDONE 
PROMETHAZI 
PROMETHAZI 
MEPROBAMAT 
FOLIC ACID 
NITROFURAN 
JAFEDITAB C 
Firm ~| 
BARR LABORATORIES INC 
BARR LABORATORIES INC 
BARR LABORATORIES INC 
BARR LABORATORIES INC 
BARR LABORATORIES INC 
BARR LABORATORIES INC 
BARR LABORATORIES INC 
BARR LABORATORIES INC 
BARR LABORATORIES INC 
BARR LABORATORIES INC 
BARR LABORATORIES INC 
BARR LABORATORIES INC 
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IVAX RESEARCH INC 
IVAX RESEARCH INC 
WATSON LABORATORIES INC 
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00591-3137-60 
00591-2775-01 
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00591-2455-01 
00591-1118-30 
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00591-0793-05 
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00591-0698-01 
00591-0698-05 
00591-0671-01 
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00591-0540-05 
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00591-0349-05 
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LISINOPRIL 
BUPROPION 
HYDROCODON 
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HYDROXYCHL 
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HYDROCODON 
HYDROCODON 
HYDROCODON 
HYDROCODON 
HYDROCODON 
HYDROCODON 
TRAMADOL H 
TRAMADOL H 
GUANFACINE 
IBUTALBITAL 
HYDROCODON 
HYDROCODON 
LOXAPINES 
HYDROCODON 
DICLOFENAC 
LORAZEPAM 
LORAZEPAM 
LORAZEPAM 
LORAZEPAM 
LORAZEPAM 
I LORAZEPAM 
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WATSON LABORATORIES IlLlC 
WATSON LABORATORIES INC 
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NC 
NC 
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00597-0085-90 
00597-0082-14 
00597-0082-14 
00597-0082-18 
00597-0081-30 
00597-0080-62 
00597-0075-37 
00597-0070-17 
00597-0067-01 
00597-0066-01 
00597-0058-01 | 
00597-0058-01 | 
00597-0046-60 | 
00597-0046-60 
00597-0044-28 
00597-0041-28 
00597-0041-28 
00597-0040-28 
00597-0040-28 
00597-0033-34 
00597-0032-12 
00597-0031-12 
00597-0030-01 
00597-0030-01 
00597-0030-01 
00597-0029-01 
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00597-0023-01 
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00597-0013-14 
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00641-1496-35 
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MOBIC (MEL 
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MOBIC 7.5M 
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PROMETHAZI 
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00781-1506-01 
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GLYBURIDE 
ISDN 40MG 
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LORAZEPAM 
LORAZEPAM 
LORAZEPAM 
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LORAZEPAM 
HALOPERIDO 
HALOPERIDO 
HALOPERIDO 
METOPROLOL 
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LONOXTABL 
[ENALAPRIL 
ENALAPRIL 
ENALAPRIL 
LOVASTATIN 
LOVASTATIN 
AMIODARONE 
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NAPROXEN 5 
TRIAMTEREN 
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ALPRAZOLAM 
ATENOLOL 2 
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SANDOZ INC 
SANDOZ INC 
SANDOZ INC 
SANDOZ INC 
SANDOZ INC 
SANDOZ INC 
SANDOZ INC 
SANDOZ INC 
SANDOZ INC 
SANDOZ INC 
SANDOZ INC 
SANDOZ INC 
SANDOZ INC 
SANDOZ INC 
SANDOZ INC 
SANDOZ INC 
SANDOZ INC 
SANDOZ INC 
SANDOZ INC 
SANDOZ INC 
SANDOZ INC 
SANDOZINC 
SANDOZ INC 
SANDOZ INC 
SANDOZINC 
SANDOZ INC 
SANDOZ INC 
SANDOZ iNC 
SANDOZ INC 
SANDOZ INC 
SANDOZ INC 
SANDOZ INC 
SANDOZ INC 
SANDOZ INC 
SANDOZ INC 
SANDOZINC 
SANDOZ INC 
SANDOZ INC 
SANDOZ INC 
SANDOZ INC 
SANDOZ INC 
SANDOZ INC 
SANDOZ INC 
SANDOZ INC 
SANDOZ INC 
SANDOZ INC 
SANDOZ INC 
JSANDOZ INC 
Exhibit A Page 47 
Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU. 
Machine-generated OCR, may contain errors.
Exhibit A 
1 NDC I 
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00781-1047-01 
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00781-1032-01 
00944-2940-03 
00944-2938-01 
00944-2938-02 
00944-2938-03 
00944-2935-01 
00944-2935-01 
00944-2620-03 
00944-2620-04 
00944-0650-01 
17314-9300-01 
17314-9300-01 
17314-9220-01 
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17314-8502-01 
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17314-5853-02 
17314-5852-02 
17314-5852-02 
17314-5851-02 
17314-5851-02 
17314-5850-02 
17314-5850-02 
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URISPAS 10 
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CONCERTA 2 
CONCERTA ( 
CONCERTA 5 
CONCERTA ( 
CONCERTA 3 
CONCERTA ( 
CONCERTA 1 
ALBUTEROL 
DEY-LUTE A 
ALBUTEROL 
ALBUTEROL 
ALBUTEROL 
| DEY-LUTE A 
[ALBUTEROL 
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ACCUNEB 0. 
CROMOLYN S 
CROMOLYN S 
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GLYBURIDE-
|GLYBURIDE-
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(PAR PHARMACEUTICAL INC 
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PAR PHARMACEUTICAL INC 
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PAR PHARMACEUTICAL INC 
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49884-0165-10 BENZTROPIN PAR PHARMACEUTICAL INC 
49884-0087-01 DEXAMETHAS PAR PHARMACEUTICAL INC 
49884-0043-10 CYPROHEPTA PAR PHARMACEUTICAL INC 
49884-0035-10 MECLIZINE PAR PHARMACEUTICAL INC 
49884-0034-10 MECLIZINE PAR PHARMACEUTICAL INC 
50458-0510-10 HISMANAL T JANSSEN PHARMACEUTICA INC 
50458-0450-45 PROPULSID JANSSEN PHARMACEUTICA INC 
50458-0440-10 PROPULSID JANSSEN PHARMACEUTICA INC 
50458-0440-25 PROPULSID JANSSEN PHARMACEUTICA INC 
50458-0430-10 PROPULSID JANSSEN PHARMACEUTICA INC 
50458-0430-50 PROPULSID JANSSEN PHARMACEUTICA INC 
50458-0400-10 IMODIUM CA JANSSEN PHARMACEUTICA INC 
50458-0392-60 REMINYL 12 JANSSEN PHARMACEUTICA INC 
50458-0391-60 REMINYL 8M JANSSEN PHARMACEUTICA INC 
50458-0391-60 REMINYL 8 JANSSEN PHARMACEUTICA INC 
50458-0390-60 REMINYL 4 JANSSEN PHARMACEUTICA INC 
50458-0390-60 REMINYL 4M JANSSEN PHARMACEUTICA INC 
50458-0350-01 RISPERDAL JANSSEN PHARMACEUTICA INC 
50458-0350-06 RISPERDAL JANSSEN PHARMACEUTICA INC 
50458-0330-01 RISPERDAL JANSSEN PHARMACEUTICA INC 
50458-0330-06 RISPERDAL JANSSEN PHARMACEUTICA INC 
50458-0330-50 RISPERDAL JANSSEN PHARMACEUTICA INC 
50458-0325-28 RISPERDAL JANSSEN PHARMACEUTICA INC 
50458-0320-01 RISPERDAL JANSSEN PHARMACEUTICA INC 
50458-0320-06 RISPERDAL JANSSEN PHARMACEUTICA INC 
50458-0320-50 RISPERDAL JANSSEN PHARMACEUTICA INC 
50458-0315-30 RISPERDAL JANSSEN PHARMACEUTICA INC 
50458-0308-11 RISPERDAL JANSSEN PHARMACEUTICA INC 
50458-0307-11 RISPERDAL JANSSEN PHARMACEUTICA INC 
50458-0306-11 RISPERDAL JANSSEN PHARMACEUTICA INC 
50458-0305-03 RISPERDAL JANSSEN PHARMACEUTICA INC 
50458-0305-10 RISPERDAL JANSSEN PHARMACEUTICA INC 
50458-0302-06 RISPERDAL JANSSEN PHARMACEUTICA INC 
50458-0302-50 RISPERDAL JANSSEN PHARMACEUTICA INC 
50458-0301-04 RISPERDAL JANSSEN PHARMACEUTICA INC 
50458-0301-50 RISPERDAL JANSSEN PHARMACEUTICA INC 
50458-0300-01 RISPERDAL JANSSEN PHARMACEUTICA INC 
50458-0300-06 RISPERDAL JANSSEN PHARMACEUTICA INC 
50458-0300-50 RISPERDAL JANSSEN PHARMACEUTICA INC 
50458-0290-01 SPORANOX JANSSEN PHARMACEUTICA INC 
50458-0290-04 SPORANOX1 JANSSEN PHARMACEUTICA INC 
50458-0290-04 SPORANOX JANSSEN PHARMACEUTICA INC 
50458-0290-28 SPORANOX JANSSEN PHARMACEUTICA INC 
50458-0270-36 ERGAMISOL JANSSEN PHARMACEUTICA INC 
50458-0223-04 NIZORAL 2% JANSSEN PHARMACEUTICA INC 
50458-0223-04 NIZORAL SH JANSSEN PHARMACEUTICA INC 
50458-0221-15 NIZORAL CR JANSSEN PHARMACEUTICA INC 
50458-0221-30 NIZORAL CR JANSSEN PHARMACEUTICA INC 
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50458-0221-60 
50458-0220-10 
50458-0110-01 
50458-0110-30 
50458-0036-05 
50458-0035-05 
50458-0034-05 
50458-0033-05 
52544-0935-28 
52544-0920-08 
52544-0847-28 
52544-0747-01 
52544-0746-01 
52544-0658-01 
52544-0658-05 
52544-0540-01 
52544-0503-01 
52544-0503-05 
52544-0502-01 
52544-0502-05 
52544-0453-01 
52544-0444-01 
52544-0425-01 
52544-0387-01 
52544-0385-01 
52544-0385-05 
52544-0372-01 
52544-0371-01 
52544-0349-01 
52544-0349-05 
52544-0301-10 
52544-0291-28 
52544-0291-28 
52544-0241-05 
52544-0241-10 
52544-0240-01 
52544-0240-05 
55390-0465-05 
55390-0413-01 
55390-0413-05 
55513-0924-10 
55513-0924-10 
55513-0823-10 
55513-0823-10 
55513-0546-10 
55513-0546-10 
55513-0546-10 
[55513-0530-10 
•RDAProd I 
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HALOPERIDO 
HALOPERIDO 
NEUPOGEN( 
NEUPOGEN3 
EPOGEN (Ep 
EPOGEN 40, 
NEUPOGEN 3 
NEUPOGEN4 
R-MetHUG 
INEUPOGEN 3 
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55513-053O-10 
55513-0478-10 
55513-0478-10 
55513-0478-10 
55513-0348-10 
55513-0347-01 
55513-0347-10 
55513-0283-10 
55513-0267-10 
55513-0209-10 
55513-0209-10 
55513-0190-01 
55513-0177-07 
55513-0148-10 
55513-0144-10 
55513-0144-10 
55513-0144-10 
55513-0126-10 
55513-0075-30 
55513-0074-30 
55513-0073-30 
55513-0044-01 
55513-0041-04 
55513-0014-01 
55513-0013-04 
55513-0012-04 
55513-0011-04 
55513-0010-04 
58394-0011-02 
58394-0004-01 
58406-0435-04 
58406-0425-34 
58406-0425-34 
58406-0050-30 
58406-0050-30 
58406-0001-01 
58768-0610-05 
58768-0102-05 
58768-0102-05 
59148-0011-13 
59148-0010-13 
59148-0009-13 
59148-0008-13 
59148-0007-13 
59148-0007-13 
59148-0003-16 
59148-0003-16 
J59148-0002-16 
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59148-0001-01 
59148-0001-02 
59676-0340-01 
59676-0340-01 
59676-0320-01 
59676-0320-01 
59676-0312-01 
59676-0312-01 
59676-0310-01 
59676-0310-01 
59676-0310-02 
59676-0310-02 i 
59676-0304-01 ! 
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59676-0304-02 
59676-0303-01 
59676-0303-01 
59930-1714-01 
59930-1714-02 
59930-1714-03 
59930-1636-01 
59930-1587-01 
59930-1570-02 
59930-1560-01 
59930-1549-01 
59930-1517-01 
59930-1515-04 
59930-1510-05 
59930-1508-01 
59930-1502-01 
59930-1500-06 
59930-1500-08 
60574-4112-01 
60574-4112-01 
60574-4111-01 
60574-4111-01 
62794-0502-93 
62794-0204-93 
62794-0202-93 
62794-0202-93 
62794-0146-01 
62794-0146-10 
62794-0145-01 
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THE STATE OF TEXAS 
ex ret 
VEN-A-CARE OF THE 
FLORIDA KEYS, INC. 
Plaintiffs, 
v. 
No. GVO02327 
WARRICK PHARMACEUTICALS 
CORPORATION, SCHERING-PLOUGH 
§ 
§ 
§ 
§ 
§ 
§ 
§ 
§ 
§ 
§ 
§ 
§ 
IN THE DISTRICT COURT OF 
TRAVIS COUNTY, TEXAS 
CORPORATION, SCHERING 
CORPORATION 
ROXANE LABORATORIES, INC. § 
§ 
§ 53rd JUDICIAL DISTRICT Defendants. 
SEVENTH AMENDED PETITION 
TO THE HONORABLE JUDGE OF SAID COURT: 
The State of Texas, by and through the Attorney General of Texas, Greg Abbott, brings this 
cause of action. These claims are asserted pursuant to the Texas Medicaid Fraud Prevention Act, 
V.T.C.A. Human Resources Code Chapter 36 ("the Act" or "TMFPA") and common law. Pursuant 
to §36.107(a) of the Act, the State of Texas has primary responsibility for prosecuting this action. 
Private Person Plaintiff/Relator Ven-A-Care of the Florida Keys, Inc. ("VAC" or "Ven-A-Care") 
originally provided information to the State of Texas which is the basis for this suit and is included 
as a named party plaintiff in this case. 
STATEMENT TO THE COURT ONLY 
The Dey/Merck Defendants prominent in Plaintiffs' Six(h Amended Petition are not 
specifically named in this pleading because a compromise settlementlwith these parties is imminent. 
However, by the omission of naming of these parties in this pleading, Plaintiffs DO NOT intend to 
non-suit them. Separate agreed orders will be submitted at a later time to accomplish that purpose. 
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Until that time, in order to preserve claims against the Dey/Merck Defendants, Plaintiffs incorporate 
by reference the allegations against Dey/Merck as contained in Plaintiffs' Sixth Amended Petition. 
I. DEFENDANTS 
The Defendants complained of and sued in this action are: 
1.1 Warrick Pharmaceuticals Corporation ("Warrick") allegedly is a corporation 
organized under the laws of Delaware with its principal offices in Reno, Nevada. Discovery in this 
matter has revealed that Warrick's principal offices and operations are actually in the state of New 
Jersey. At all times material to this civil action, Warrick has transacted business in the State of 
Texas by, including but not limited to, selling and distributing to purchasers in the State of Texas 
pharmaceutical products that are the subject of this action, but does not maintain a regular place of 
business in this state or a designated agent for service of process 
1.2 Schering-Plough Corporation ("Schering-Plough") is a corporation organized under 
the laws of New Jersey with its principal offices in Madison, New Jersey. At all times material to 
this civil action, Schering-Plough and its subsidiaries have transacted business in the State of Texas 
by, including but not limited to, selling and distributing to purchasers in the State of Texas 
pharmaceutical products that are the subject of this action and out of which this action arises.1 
1.3 Schering Corporation ("Schering") is a corporation organized under the laws of New 
Jersey with its principal offices located at 1 Giralda Farms, P.O. Box 1000, Madison, New Jersey 
07940 
1.4 Defendant Warrick has indicated in other pleadings to this Court that Schering-Plough 
is a stock holding company and that Schering is the direct parent corporation of Warrick. Schering 
Schering Laboratories is described as "the U.S. pharmaceutical arm of 
Schering-Plough Corporation," and appears to be the operating unit of Schering-Plough 
through which Schering-Plough conducts much of its pharmaceutical business. It is unclear 
at this point whether Schering Laboratories exists as a separate corporate entity. Schering 
Laboratories is not registered with the Secretary of State for the State of Texas. 
Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU. 
Machine-generated OCR, may contain errors.
and Schering-Plough are the actual manufacturers, marketers, tellers, and/or suppliers of the 
products involved in this litigation and are Warrick's actual parent(s) or shareholder(s). Therefore, 
the State includes Schering and Schering-Plough ("Schering/Schering-Plough") in this pleading, 
1.5 Roxane Laboratories, Inc. ("Roxane") is a corporation organized under the laws of 
Delaware with its principal offices in Columbus, Ohio, and is a subsidiary of Boehringer Ingelheim 
Pharmaceuticals, Inc.. At all times material to this civil action, Rdxane has transacted business in 
the State of Texas by, including but not limited to, selling and distributing to purchasers in the State 
of Texas pharmaceutical products that are the subject of this action,! but does not maintain a regular 
place of business in this state or a designated agent for service of process. 
(All of the above named Defendants have answered and appeared in this cause.) 
II RESPONDEAT SUPERIOR AND VICARIOUS LIABILITY 
2.1 The Defendants specified in paragraphs 1.1 to 1.5 aite sometimes referred to herein 
collectively as the "Defendants" or "Defendant Drug Companies." Any and all acts alleged herein 
to have been committed by any or all of the Defendant Drug Companies were committed by said 
Defendants' officers, directors, employees, representatives or agents who at all times acted on behalf 
of their respective Defendant(s). 
2.2 The Defendants identified in paragraphs 1.1 to 1.3 inclusive are all related entities 
sharing common elements of management, finances, control, supervision, reporting and thus are 
mutually, jointly and severally liable under legal theories of Respondeat superior and the past, 
present and continuing relations and dealings by and between these related entities are so inextricably 
intertwined that for purposes of this suit, some or all of them can 4nd should be considered as a 
single entity at law and equity. 
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IIL DISCOVERY CONTROL PLAN 
3.1 Plaintiff, the State of Texas, designates this case as a Level 3 case requiring a 
discovery control plan tailored to the circumstances of this specific suit. 
IV. PRELIMINARY STATEMENT AND NATURE OF THE ACTION 
4.1 This is an action under the common law and the Texas Medicaid Fraud Prevention 
Act (hereinafter sometimes referred to as "TMFPA") for restitution, damages, pre-judgment interest, 
civil penalties of not less than $1,000.00 or more than $10,000.00 for each unlawful act, two (2) 
times the value of the payments, and recovery of costs, attorneys' fees, and expenses of the Attorney 
General of the State of Texas and Ven-A-Care against Defendants as well as any and all other 
monetary amounts as may be allowed at law or in equity under Section 36.052. 
4.2 The Defendants knowingly and intentionally made false representations of prices and 
costs for certain of their inhalation drugs directly or indirectly to the Texas Medicaid Program. The 
Defendants knew that the Texas Medicaid Program intended to base its payments of claims for the 
specified drugs on estimations of acquisition costs incurred by physicians, pharmacies, and other 
providers submitting claims for payment. The Texas Medicaid Program relied on the false and 
misleading prices and costs reported by the Defendants and thus was defrauded into paying 
reimbursement in excessive amounts. 
4.3 The Defendants, both directly and through sales visits and presentations, 
telemarketing, and other forms of contact, as well as indirectly through various pharmacy inventory 
software distributed by wholesalers and other pharmacy inventory software, as part of an unlawful 
combination, marketed their specified products to pharmacies, in part through financial inducements, 
including but not limited to: false price markups, the difference between actual cost and 
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reimbursement (the "Spread"), discounts, rebates, chargebacks, free goods, and other financial 
incentives. As specified more fully hereinafter, such conduct constitutes common law fraud as well 
as fraud under the TMFPA, Chapter 36, Tex. Hum. Res. Code. The Defendants were in a position 
to mislead the Texas Medicaid Program, in part, because other drug manufacturers typically reported 
truthful prices for brand drugs marketed under patent protection that|are not the subject of this action. 
The Defendants thus wrongfully exploited and defrauded the Texasl Medicaid Program by inducing 
it to pay the claims of pharmacies, at grossly inflated amounts thatt far exceeded a reimbursement 
based upon a reasonable estimate of acquisition costs of those defendants * pharmaceuticals to 
pharmacies, wholesalers and distributors. 
(Amendment Responsive to Special Exception) 
Plaintiffs seek redress and recovery under the TMFPA $s well as under principles of 
Common Law Fraud as an alternative claim under T.R.C.P. Rule |4-8. The Defendants Warrick, 
Schering-Plough and Schering, acting sometimes in combination ajid other times individually did 
the following: 
(a) Made material representations to the TVDP as to prices and costs of drugs which 
information was used to calculate reimbursement foLl those drugs. 
(b) Reported drug prices and costs which were false andlmisleading. 
(c) Knowingly reported such false, misleading and material information to TVDP and 
other price and cost reporting services as well as creating "dummy prices'5 and 
invoices which were misleading and concealing of tribe information. 
£d) Committed these acts and omissions with the intent ancj knowledge that TVDP would 
use and rely on directly reported information and woulfl be further misled if price and 
cost information reported to national pricing services ^ as accessed as verification of 
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directly reported information, when the TVDP made its decisions concerning 
reimbursement amounts to be paid for the drugs at issue. 
(e) That the false information supplied by Defendants was relied upon and was used to 
authorize Medicaid drug reimbursement payments greatly in excess of what should 
have been paid had Defendants provided non-fraudulent drug price/cost information 
as required by common law fraud principles and by state and federal Medicaid law 
and regulations. 
(f) The foregoing acts and omissions caused monetary loss and damage to the Medicaid 
program in Texas in amounts set forth in the "Damages" paragraphs of this pleading. 
4.4 (Amended in response to Special Exceptions.) Defendants also combined and 
otherwise acted in concert, amongst themselves, their wholesalers, their distributors, their customers, 
or their competitors, and as part of an illegal combination to defraud the Medicaid program in Texas 
of millions of dollars in payments by supplying falsely inflated price information on certain drugs. 
By definition under relevant Texas Statute Law, Tex. Penal Code Ann, § 71.01 a combination means 
three or more persons (companies) who collaborate to bring about an unlawful result although: 
(1) participants may not know each other's identity; 
(2) membership in the combination may change from time to time; and 
(3) participants may stand in a wholesaler-retailer or other arm's length relationship. 
It is not essential to the existence of such an illicit combination that the members thereof consciously 
agree and intentionally conspire in joint enterprise. Pleading in the alternative as allowed under 
T.R.C.P. 48 it is alleged that the named Defendants in this case acted intentionallyjn combination 
with each other (Warrick, Schering-Plough and Schering) and even though outside of a direct or 
indirect agreement and conspiracy, with other persons and companies in the generic pharmaceutical 
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industry to create, maintain and promote a system of reporting and marketing which would reward 
these Defendants as well as others for going along in combination to perpetuate the schemes 
described in detail herein. Not all of these "other persons and companies" are known and not all can 
be known at this time. 
The other companies who are known to have acted in combination with Warrick and/or 
Schering-Plough and or Schering are: 
(a) Wholesalers: McKesson, Bergen-Brunswig, Cardinal, AmeriSource, Fox Meyer, and 
Bindley Western 
(b) Regional Wholesalers: Walsh and Morris & Dickson 
(c) Institutional Purchasers: RDI (Respiratory Distributers, Inc.), Apria, Caremark and 
Gerimed (AKAIV. Med) 
(d) Generic Wholesalers: J.J. Balan, AND A and Harvard 
(e) Price Publishing Services: First Data Bank, Medil-Span and Red Book 
The other companies who are known to have acted in combination with Roxane are: 
(a) Cardinal, McKesson, Bergen-Brunswig, and AmeriS|ource 
(b) Morris & Dickson 
(c) Apria, RDI (Respiratory distributors, Inc.), and Gerimed (AKA LV.Med) 
(d) First Data Bank, Medi-Span and Red Book 
Some or many of these identified companies may not have bqen aware that their conduct in 
being a part of such combination was allowing or facilitating violations of the TMFPA. Whether 
or not the other members of such combination acted with intent to violate any law is irrelevant to the 
claims asserted herein against the named Defendants. For example spme wholesalers did agree or 
acquiesce to use invoices and billing records which did not overtly Idisclose and reflect multiple 
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conditions and terms which caused the actual price/cost of drugs to be much less than what was 
reflected on invoices and billing records. These other members of such combination may or may not 
have engaged in the conduct actionable under the TMFPA and without question they, whoever they 
are, have not been sued in this case. The liability of the named Defendants herein is neither 
dependent upon nor contingent upon liability of other members of the combination. The Defendants' 
creation, maintenance and promotion of the combination of persons and companies nurtured the 
scheme of creating the large "spread" on the reimbursement of the subject Medicaid drugs. The 
relevance and importance of the existence of the combination is to show that the named Defendants 
were blowing and willing participants in the creation and promotion of this combination which 
caused Texas Vendor Drug Program to be defrauded. 
4.5 (Amended in Response to Special Exception) As is usually true of illegal 
combinations, the named Defendants in this case did not enter into a formalized written and dated 
combination agreement. However, the actions they took speak even more eloquently of their intent 
to defraud the Texas Medicaid Program operated by the Texas Vendor Drug Program (TVDP) and 
the taxpayers in the State of Texas and nationwide who fund the various Medicaid pharmaceutical 
benefit programs. Such activities began before 1994 and continue in some forms to the present date. 
The officers, managers, sales force and other employees of the named Defendants Warrick, Schering-
Plough and Schering herein entered into an agreement or combination among themselves as follows: 
(a) By reporting false drug prices to the TVDP. 
(b) By failing and purposefully refusing to timely update and report declining drug prices. 
(c) By purposefully omitting and refusing to provide truthful drug prices which were 
specifically requested by category. 
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(d) By reporting false drug prices to TVDP and to redognized industry price reporting 
services with the intent (and result) of creating an illegal "spread" which caused the payment of 
inflated and excessive reimbursement amounts for each company's relevant drugs named in this 
pleading, 
(e) By directly and indirectly causing their own sales and marketing force employees, as 
well as independent contractor telemarketers, to "market the spHead" by advertising and urging 
pharmaceutical vendors to purchase and dispense their particular! brand of drugs based upon the 
illegally inflated and excessive reimbursement amounts made possible by the combined actions of 
the Defendants and others in the industry. Some or all of these acts and omissions also constitute 
common law fraud as well as violations of TMFPA. 
4.6, (Amended in Response to Special Exception) The Defendants created, promoted and 
fostered a complex scheme using undisclosed chargebacks, rebates,idiscounts, instant rebates, price 
protection, stock adjustments and contract prices which had no trueiand bona fide business purpose 
other than to enable the use of arbitrary pricing on invoices and otl)ier ostensible purchase records 
and documents which concealed the true sales prices and acquisition costs, In fact, these false 
invoices only revealed "Dummy Prices" and other incorrect and misleading financial information 
which would hinder or prevent the discovery of true price/cost information by persons and 
organizations which might need to investigate, survey or audit invoices in search of true price/cost 
information. By causing their various customers to accept and acquiesce in these extraordinary 
invoicing practices, these Defendants created and maintained various combinations with other 
companies as identified in paragraph 4.4 who participated in the cor^bination(s) but who may have 
been completely unaware and unconcerned about the reasons for or and results of these extraordinary 
invoicing methods and procedures. 
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4.7 (Amended in Response to Special Exception) With regard to the Defendants 
Warrick, Schering-Plough and Schering and their efforts to deal with activities of Dey, Inc. and its 
affiliates (all parties who were originally Defendants in this case but who have now settled), it is 
alleged that the Defendants, acting through their authorized officers and employees, engaged in a 
game of one-upsmanship in that when one would report fraudulent prices to authorities so as to 
create a more attractive profit spread on Medicaid reimbursement prices, the other would compound 
its fraudulent actions by reporting an increasingly inflated price in order to "out-fraud" the other. 
These activities have been documented in documents and deposition testimony pertaining to both 
Dey and Warrick. 
4.8 Defendants Warrick, Schering and Roxane made conscientious efforts in their 
business operations avoid reporting truthful price/cost information. Furthermore, their legal 
obligations to truthfully and candidly report such information to Medicaid authorities in Texas and 
elsewhere and to price reporting services was intentionally subverted or ignored. Thus, the 
Defendants were able to further the combinations by limiting disclosure or deleting the publication 
or reporting of such information. Also, certain of Roxane's employees whose job it was to report 
price/cost information and to comply with all legal requirements, including those of the State of 
Texas, were intentionally instructed: (a) to provide incorrect or incomplete price/cost information 
or (b) to fail to supply all requested and required price/cost information and updates about changes 
in such data. 
V. JURISDICTION & VENUE 
5.1 Jurisdiction over the subject matter is founded in part upon the TMFPA, which 
prohibits, and provides exclusive remedies to redress, the conduct of the Defendants and which 
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provides for this action to be brought by the State of Texas and by private Person Plaintiff, Ven-A-
Care. 
5.2 Venue is proper in Travis County pursuant to Texas Human Resources Code 
§36.052(d) in that many of the unlawful acts committed by the Defendants were committed in Travis 
County including the making of false statements and misrepresentations of material fact to the State 
of Texas, its departments, agencies, instrumentalities, contractors and to the Texas Medicaid 
Program. 
5.3 A copy of pleadings and written disclosure of substantially all material evidence and 
information Ven-A-Care possesses were served on the State pursuant to §36.102 of the Act before 
the Original Petition was filed. 
5.4 The Private Person Plaintiff is the original source oflthe information and has direct 
and independent knowledge of the information on which these allegations are based within the 
meaning of §36.113(b) of the Act and has voluntarily provided the information to the State of Texas 
before filing pleadings which are based upon the information provided by the Private Person Plaintiff 
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to the State of Texas. 
5.5 Additionally, venue is proper against these Defendants in Travis County as all or a 
substantial portion of the events giving rise to the instant claims occurred in Travis County. TEX. 
CIV.PRAC. &REM. CODE §§ 15.001,15.002 (Vernon 2001). 
VI. BACKGROUND: HOW PHARMACEUTICAL CLAIMS ARE PAID UNDER 
THE MEDICAID PROGRAM IN TEXAS 
6.1 The Texas Medicaid Program pays for the use of approved pharmaceuticals 
provided to Medicaid recipients by eligible providers, including pharmacies. The Vendor Drug 
Program (TVDP) of the Texas Department of Health ("TDH")2 administers this program. Providers 
can only obtain reimbursement through the Vendor Drug Program for products listed on the Texas 
Drug Code Index. 25 TEX. ADMIN. CODE §35.201. To have its particular pharmaceutical products 
listed on the index, a drug company or manufacturer must file and have approved an application for 
its products with the Texas Department of Health. 25 TEX. ADMIN. CODE § 35.801. Section 2 of 
the application requires the manufacturer to report, for each drug submitted, the suggested 
wholesale price to pharmacies, the price at which the drug is sold to wholesalers and distributors, 
the direct price to pharmacies, the price to chain warehouses and the price at which the drug is sold 
to any other special purchasing groups. Additionally, the form contains a separate question in 
section 4 inquiring as to whether the drug company sells the drug to wholesalers or distributors. 
The application requires that a manufacturer certify that the information it has provided is correct 
The Vendor Drug Program has recently been transferred to the Texas Health and 
Human Services Commission. 
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and that it will provide correct information regarding subsequent changes in pricing of the product 
within 15 days of such changes occurring. Further, in approving] the application, TDH expressly 
requires that supplemental updated price information be provided timely. 
6.2 TDH bases its reimbursement schedule on the prices reported by the manufacturer 
on the application and subsequent price changes supplied by the mlanufacturer. Reimbursement to 
a pharmaceutical provider (i.e., a pharmacy or physician) is based on TDH's best estimate of 
acquisition cost, referred to as ("EAC"). 1 TEX. ADMIN. CODE § 3|55.8541 (1). 
6.3 When a manufacturer reports false pricing information to TVDP, the calculation of 
estimated acquisition cost ("EAC") is inflated and thus the reimbursement schedule is also inflated. 
These circumstances result in drug reimbursement overpayments t^> drug providers by the State. 
VII ACTIONABLE CONDUCT OF DEFENDANTS 
7.1 The Defendants knew that reporting false drug prices |and costs would cause the Texas 
Medicaid Program to be unable to reasonably estimate acquisition costs and it would thus pay 
excessive reimbursement to the Defendants' Medicaid provider customers. Notwithstanding this 
knowledge, the Defendants reported false or misleading price, cost, Or sales information to the Texas 
Medicaid program in order to cause it to pay claims for their specifibd pharmaceuticals in amounts 
that exceeded the prices at which the Defendants actually sold their products and exceeded a 
reasonable estimation of acquisition cost. This reporting of false Information created a "spread" 
between the amount reimbursed by Medicaid and a reasonable estimate of the acquisition cost of a 
drug. The "spread" financially benefitted their Texas Medicaid provider customers and thus induced 
them to order, prescribe, dispense, or administer the Defendants' specified pharmaceuticals. The 
specific allegations of Common Law Fraud contained in preceding paragraph 4.3 are incorporated 
by reference and are specifically asserted against the Defendant Ro^ane. 
7.2 The Defendants were each fully capable of making [truthful representations about 
prices and costs of the specified pharmaceuticals and did so when it \Vas economically beneficial to 
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them, such as when they reported Average Manufacturers' Prices and Best Prices to the federal 
government under the Medicaid rebate program mandated by the Omnibus Budget Reconciliation 
Actofl990("OBRA'90"). 
7.3 Notwithstanding the Defendants' knowledge that they were required to provide 
truthful price information vital to Texas Medicaid's ability to estimate the acquisition cost, the 
Defendants each knowingly or intentionally reported false price information about the specified 
pharmaceuticals. 
7.4 The Defendants acted knowingly or intentionally in making false statements and 
misrepresentations of material fact when reporting false prices or costs to the Texas Medicaid 
program in one or more of the following ways: 
A, Reporting false prices on initial applications to have specified pharmaceuticals 
covered by Texas Medicaid; 
B. Concealing or otherwise failing to disclose decreases in the prices or costs of 
the specified pharmaceuticals; 
C, Concealing or otherwise failing to disclose transactions that decrease the cost, 
and thereby the price, of the specified pharmaceuticals such as discounts, rebates, off-invoice pricing, 
free goods, cash payments, chargebacks, or other financial incentives; 
D. Reporting that the price or cost of a specified pharmaceutical was increasing 
when it in fact was increasing in a lesser proportion, or remained the same, or was decreasing; 
E. Reporting that the price or cost of a specified pharmaceutical was the 
same when in fact it was falling; and 
F, Reporting that specified pharmaceuticals were not sold to a specific 
sector or segment of the market (also known as a "class of trade") when in fact they were, regularly 
and in significant quantities concealing or failing to disclose such facts. 
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These acts and omissions were committed by the Inamed Defendants of their own 
volition and in combination with each other and with other segments of the pharmaceutical industry, 
knowing that Medicaid officials would rely upon such false information and thus constitute 
violations of Texas Medicaid Fraud Prevention laws as well as constituting common law fraud. 
7.5 Between 1990 and the present, Defendants Scherilng and/or Schering-Plough also 
directly marketed and sold "Warrick" products3 through Schering/Schering-Plough's "third party 
home healthcare solution business", "Production Planning" and/oil "Managed Care" divisions, and 
possibly through other divisions and/or personnel. Schering/Schering-Plough marketed and sold 
these "Warrick" drugs to customers at prices far below the false (prices of the drugs reported by 
Schering/Schering-Plough and/or Warrick for reimbursement purposes. As a result, customers 
purchasing these "Warrick" drugs from Schering/Schering-Plough knew they would receive, and did 
receive, windfall reimbursements as a direct result of the misrepresentations made by 
Schering/Schering-Plough and/or Warrick to reimbursers, including the Texas Medicaid Program. 
7.6 To accomplish this scheme, between 1990 and the present Schering/Schering-Plough 
sold identical products deriving from the exact same New Drug A^pplication(s), but marketed the 
drugs differently. Schering/Schering-Plough marketed its drug "Proventil" as a brand with few, if 
any, discounts and marketed the same Proventil drug under a "Warwick" label and NDC number as 
a "generic" upon which it offered deep discounts while reporting filse price information to Texas. 
In both instances the two differently labeled product types were made at the same location, and in 
all chemical and regulatory respects brand products approved by the FDA under a New Drug 
Application. The only difference between the two types of products was that the "Warrick" products 
(also referred to as the "brand, generic" in Schering/Schering-Plqugh/Warrick documents) were 
marketed and sold at significantly lower prices than the Scheribg/Schering Plough Proventil 
Some, if not all, of these drugs are at issue in this litigation ai^ d are listed in the attached 
Exhibit A, incorporated herein by reference. 
Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU. 
Machine-generated OCR, may contain errors.
products; thereby providing the purchasers of the "Warrick" drugs with large spreads and large 
windfall reimbursements as described herein. Schering/Schering Plough used the Warrick label and 
NDC number to implement a marketing program which induced customers to choose Warrick's 
albuterol, which was in fact Schering's Proventil, over competing products based upon the large 
windfall reimbursements the customers would receive. 
VIIL THE ACTIONS OF DEFENDANTS CONSTITUTE "UNLAWFUL ACTS" AND 
VIOLATE THE TEXAS MEDICAID FRAUD PREVENTION ACT 
8.1 At various times on or after September 1, 1995, and continuing through the present 
date, Defendants knowingly or intentionally reported to the State of Texas' Medicaid Program false 
prices for the pharmaceuticals described in the attached Exhibit "A." 
8.2 Defendants have repeatedly and continuously violated the TMFPA. The Act specifies 
10 separate acts which are declared to be unlawful. At least four of those unlawful acts were 
committed by the Defendants in this case on numerous occasions. The Act prohibits a person from 
knowingly or intentionally making or causing to be made a false statement or misrepresentation of 
material fact on an application for a contract, benefit, or payment under the Medicaid Program; or 
that is intended to be used to determine a person's eligibility for a payment under the Medicaid 
Program. TEX. HUM. RES. CODE § 36.002(1). The Act further prohibits a person from knowingly 
or intentionally concealing or failing to disclose an event that permits a person to receive a benefit 
or payment that is not authorized, or that permits a person to receive a benefit or payment that is 
greater than the benefit or payment that is authorized. TEX. HUM. RES. CODE §36.002(2). 
Additionally, the Act prohibits a person from knowingly or intentionally making or causing to be 
made a false statement or misrepresentation of fact concerning information required to be provided 
by a federal or state law, rule, regulation or provider agreement pertaining to the Medicaid Program. 
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TEX. HUM. RES. CODE §36.002(4). The act also prohibits a person from knowingly or intentionally 
entering into an agreement combination or conspiracy to defraudl the State by obtaining or aiding 
another to obtain unauthorized Medicaid payments or benefits §3^.002(9). 
8.3 The Defendants have knowingly or intentionally qommunicated false price or cost 
statements or other material misrepresentations or omissions on |the Application for Addition of 
Drugs to the Texas Drug Code Index for certain drugs manufactured by Defendants and subsequent 
price updates provided by the Defendants in violation of §36.002(4|) of the Act. Further, in violation 
of §36.002(1) of the Act, the Defendants failed to disclose the truthful prices paid by providers and 
concealed the existence of kickbacks, inducements, discounts, rebates, chargebacks, off invoice 
pricing, free goods, or grants which reduced the price paid by the Defendants5 customers for certain 
drugs. 
8.4 (Amended in Response to Special Exception) Alscj, in violation of § 36.002(9), the 
Defendants knowingly or intentionally entered into a combination with wholesalers or Group 
Purchasing Organizations ("GPO's") or Prescription Benefit Managers or Pharmaceutical/Pharmacy 
Benefit Managers ("PBM's") or pharmacies (including chain pharmacies) to defraud the State of 
Texas by obtaining or aiding another person in obtaining unauthorized payments or benefits from 
the Medicaid program by misrepresenting the prices paid to manufacturers by wholesalers and the 
prices paid by pharmacies (including chain pharmacies) to manufacturers, as well as by concealing 
the remunerations paid by manufacturers to GPO's or PBM's. The facts set forth in preceding 
paragraphs 4.4,4.5 and 4.6 are incorporated by reference to specify the allegations of a combination 
under § 36.002(a). 
8.5 (Amended in Response to Special Exception) Pleading more specifically, and in 
addition to the foregoing, the Plaintiff and Relator would allege and show as follows with respect 
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to other entities and sectors of the pharmaceutical industry who participated directly or indirectly in 
the combination mentioned previously: 
1. The named Defendants entered into a combination and course of dealings with the 
following as limited by paragraph 4.4: 
(a) National Full Line Wholesalers; McKesson, Bergen; Brunswig, Cardinal, 
AmeriSource, FoxMeyer, Bindley Western. 
(b) Regional Full Line Wholesalers (which conducted business and sold the Relevant 
Drugs of the named Defendants within the State of Texas); Walsh, Behrens, and 
Morris & Dickson. 
(c) Institutional Purchasers; Gerimed, RDI (Respiratory Distributors, Inc), Apria, 
Accurate Pharmacy, Caremark, Rx Med, MHA (Managed Healthcare Associates). 
These other identified companies are not named as Defendants in this suit and no relief or 
recovery is sought against them herein at this time. These companies were named in response to a 
demand made by Defendants herein in Special Exceptions. The named Defendants already knew 
the identity of these other companies because Defendants are the very ones who created the schemes 
resulting in the combinations which perpetuated the schemes to violate the TMFPA. As part of the 
combination created by the named Defendants, these wholesalers and institutional purchasers were 
doing what the Defendants asked them to do or what they obviously were required to do to keep the 
business of the drug manufacturers. The state of mind and actual knowledge of the wholesalers and 
institutional purchasers is irrelevant and immaterial to the liability and culpability of the Defendants 
and the proof relating to their actions only goes to show that they were cogs in the illicit wheel 
created by the named Defendants. With respect to each wholesaler with which any Defendant joined 
Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU. 
Machine-generated OCR, may contain errors.
in combination, such universe of companies is finite and limited Exclusively to those wholesalers 
with whom each respective Defendant sold its drugs or delivered cjrugs pursuant to contract. Thus, 
these wholesalers can be identified with certainty and limitation! by each Defendants' own sales 
history records. 
The foregoing wholesaler entities participated in informing and educating their respective 
pharmacy customers of each and every AWP for the Relevant Drugs. Furthermore, these 
wholesalers also published information which would reveal the difference between the stated AWP 
and/or reimbursement on the one hand and, the given pharmacyi customer's cost on each of the 
respective generic products on the other hand. This difference is known as "spread"; "MAC spread", 
"Gross Profit", "Gross Margin" (among other phrases and terms msed within the industry). This 
information enables virtually all pharmacies within the State pf Texas to quickly and easily 
understand which generic drug will be most profitable to dispense in consideration of the 
reimbursement level set given the false prices reported. 
Based upon documents obtained from the records of Sdhering/Warrick, it appears that 
Bindley Western, at one point in time asked to be released from contractual obligations to deal with 
invoices containing arbitrary, artificially inflated and false price information which served no 
legitimate business purpose and which caused unnecessary, costly ai^ d meaningless bookkeeping and 
accounting work to be done. Instead, Bindley Western asked to receive invoices in the future which 
more accurately represented the actual transactions reflected by the respective invoices. 
8.6 To the extent that any of the aforementioned full linf wholesalers, both regional and 
national, also offer what is known as "autosubstitution" and or "sellect", "source" programs which 
mandate the exclusive dispensing of a particular product within £ach therapeutic class by those 
wholesalers' pharmacy customers, these wholesalers choose the generic product which will have a 
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large "spread" and be most profitable to their customers pursuant to feedback and demand from such 
customers as a result of the tactics of the Defendants and others as described herein. 
These companies were required or invited to participate in the schemes and combinations 
involving; disseminating reimbursement information, the exclusive use within a therapeutic class 
of a single generic product (based in part on profitability), dummy pricing, false and fraudulent 
invoices, hidden discounts, chargebacks, rebates, free goods, price protection plans, or accounting 
gimmicks to conceal true and accurate price/cost information. 
8.7 With respect to Distributors (a/k/a "Generic Wholesalers") of generic drugs, it is 
alleged that such Distributors/wholesalers likewise participated in a course of dealings which enabled 
the combination with named Defendants and which facilitated and enabled the "marketing of the 
spread" to pharmacies by use of Distributors, agents, employees, or independent contractor 
telemarketing companies and through telemarketing, sales calls and advertising (both electronically 
and by print). 
Distributors/wholesalers which participated in these activities include Major, J. J. Balan, 
ANDA, Harvard, Genetco and others known collectively within the Warrick organization as the 
"Care Group" and "Premier Group". 
These distributors/wholesalers are not named as Defendants in this suit and no relief or 
recovery is sought at this time against them herein. They were named in response to a demand made 
by Defendants herein in Special Exceptions. The named Defendants already knew the identity of 
these other companies because Defendants are the very ones who created the schemes resulting in 
the combinations which perpetuated the schemes to violate the TMFPA. As part of the combination 
created by the named Defendants, these distributors were merely doing what the Defendants asked 
them to do or what they obviously were required to do to keep the business of the drug 
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manufacturers. The state of mind and actual knowledge of the distributors is irrelevant and 
immaterial to the liability and culpability of the Defendants and t)he proof relating to their actions 
only goes to show that they were cogs in the illicit wheel created by the named Defendants, 
8.8 The Defendants Warrick and Schering entered into specific agreements and contracts 
with one or more telemarketing companies, including TMS (a/k/a Access Worldwide) a company 
located in the State of Florida, but doing business by making telephonic contacts in the State of 
Texas and other states. As part of telephone sales pitches, telemarketers would advertise and 
promote Warrick and Schering products in part by marketing the| spread and urging purchases of 
these products based upon the large and profitable spread between the true net price the pharmacies 
would pay for the drugs and the high reimbursement amount; tlliose pharmacies would receive; 
known as the "profit message" and/or ROI; among other phrases. 
8.9 The Defendant Schering employed a group known as its Managed Care Sales Force 
and this group of marketers had as a part of their job responsibilities, the duty to call upon decision 
makers for Healthcare Management/Maintenance Organization, Pharmaceutical Benefits Manager, 
Hospitals and other Managed Care Organizations to explain tlie perspective of generic drug 
profitability on behalf of Schering and Warrick's. Thus, employees and agents of Schering 
combined with Warrick to market the spread on Warrick products and to "bundle" Warrick and 
Schering products in a manner which was fraudulent and illegal. 
8.10 In the TMFPA, The Texas Legislature has specified actions and omissions, conduct 
and combinations which are illegal and give rise to civil and criminal liability and penalties which 
can be imposed against drug manufacturers such as the named Defendants who themselves 
voluntarily chose to place their respective products into the Texas Medicaid Vendor Drug Program 
and thus submitted to and agreed to be bound by these rules and lalvs. This is a statute of absolute 
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strict liability. There are no stated and enumerated defenses and none are allowed. There are no 
references to common law defenses or allowances for mitigation. With a finding of any violation 
of the statute, liability is strictly imposed absolutely and the only remaining question is the amount 
of damages, penalties, fees and expenses to be assessed. This is precisely the same as the very 
similar Texas Deceptive Trade Practices Act as originally enacted in 1973. In its original form and 
before subsequent changes and amendments were added by later legislative enactment, there were 
no defenses to the liability strictly imposed by the DTPA and likewise there are no defenses to the 
strict liability imposed by the TMFPA. 
8.11 (Amended based upon Court instruction to list all drugs, in addition to "damages 
drugs'5 which will be used to offer proof at trial) 
The Primary drugs which evidence the differing motivations for sometimes, but not always 
reporting manipulated and misleading prices by Defendants are as follows: 
Warrick: Cimetidine, Perphenazine, Albuterol tablets and Albuterol syrup 
Schering: Proventil 
Roxane: Haloperidol tablets, Mehotrexate tablets, Roxicet tablets, Mexiletine HCL 
capsules; Dexamethasone tablets,Meperidine, Azathioprine, Cyclophosphamide, Combivent, 
Lorazepam Intensol, Hydromorphone, Prednisone, Propranolol, Torecan, Azathioprine, Diclofenac 
Sodium, Hydroxyurea and Lithium Carbonate. 
Evidence concerning other drugs is relevant, probative and admissible for at least three 
different reasons, Defendants were motivated to misrepresent price information when they could 
profit from such conduct by making one of their drugs more likely to be purchased due to the 
promise of higher reimbursement. This opportunity routinely and normally arose in the marketing 
of certain drugs such as those listed in this paragraph. This is the situation where creating the largest 
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"spread" worked its illegal magic. To the contrary, in the case of drugs where competitive pressures 
did not drive the misrepresentation of pricing, the tendency was Unreport prices which were correct 
and not misleading. An additional result of this situation was that|Medicaid programs and officials 
were lulled into a false sense of security because sometimes many prices reported by a manufacturer 
would be fair and reasonable. 
Therefore evidence that a drug manufacturer routinely reported non-misleading prices for 
certain drugs and misleading prices for other drugs is admissible: 
1. Under T.R.E. 404 (b) as proof of motive, opportunity, intent, plan, knowledge and 
absence of mistake or accident. 
2. Under T.R.E. 406 as proof of routine practice to consistently act illegally where profit 
resulted yet legally where the profit motive was l£ss compelling and to show that 
such company was able to comply with the law ar^ d did know how to report prices 
that were not misleading where the motive to act illegally was lessened or missing. 
3. Under T.M.R.P.A. § 36.052 (b)(1) through (5) for [assessment of a civil penalty. 
IX. THE COURT SHOULD DISREGARD THE CORPORATE FICTION FOR 
WARRICK, SCHERING, AND SCHERINfi-PLOUGH; 
9.1 The corporate fiction may be disregarded when the [corporate form has been used as 
part of a basically unfair device to achieve an inequitable result, (specifically when the corporate 
fiction is used to perpetrate a fraud, as a mere tool or business codduit of another corporation, as a 
means of evading existing legal obligations, to achieve or perpetrate a monopoly, to circumvent a 
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statue, or to protect crime or justify a wrong. Castleberry v. Branscum, 111 S.W.2d 270,271 (Tex. 
1986), superseded on other grounds by Tex. Bus. Corp. Act Ann. art. 2.21 A (Vernon 2002). 
9.2 (Amended in Response to Special Exception) In addition to its own acts for which 
it is liable, Schering/Schering-Plough Corporation as the parent, owner and primary, if not exclusive, 
shareholder of Warrick Pharmaceuticals, Inc., is liable for the conduct of any and all agents of 
Warrick Pharmaceuticals Inc. Schering/Schering-Plough is liable for Warrick's wrongful activities 
under the equitable doctrines of joint business enterprise, single business enterprise, and alter ego. 
Each of these theories is advanced in the alternative. The facts set forth in paragraphs 4.3,4.4,4.5, 
4.6,4.7,4.8,7.5,7.6,8.2,8.3,8.4 and 8.5 are herein incorporated by reference to identify allegations 
asserted against Defendant Schering Corporation. 
9.3 The following allegations support piercing the corporate veil for the "Schering" 
entities under any or all of these theories. Warrick could not exist without Schering/Schering-
Plough. Warrick has only a handful of employees, yet Warrick generates annual sales of over 
$150M. Warrick depends upon Schering/Schering-Plough's manufacturing, distribution, accounting 
and administrative departments for all of these internal functions. Warrick apparently does not even 
employ persons with those traditional business responsibilities. The only personnel Warrick 
allegedly employs are those who market and sell Schering/Schering-Plough's generic products. 
Warrick's business offices are within the offices of Schering/Schering-Plough. Warrick does not 
conduct its corporate business in Reno, Nevada as its letterhead represents. Instead, 
Schering/Schering-Plough and Warrick operate from the same office space in New Jersey, use the 
same computer systems, telephone systems, employees, and centralized departments, and apparently 
use each other's letterhead interchangeably. 
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9.4 The companies are so closely aligned that in deposition, even the founder of Warrick 
did not know whether his "Warrick" consulting contract is with Warrick or Schering/Schering-
Plough. These companies are not operated as separate entities, but rather integrate their resources 
to achieve a common business purpose to sell Schering/Schering-Plough's generic products. 
Whether express or implied, Warrick and Schering/Schering-Plough agreed that Warrick would act 
as Schering/Schering-Plough's marketing unit for generic products, with the common purpose of 
selling more of Schering/Schering-Plough's and Warrick's products and with Schering/Schering-
Plough's having at least an equal right to direct and control the operation of the enterprise. 
9.5 Also, Schering/Schering-Plough's brand version of Albuterol Sulfate, Proventil, was 
sold in conjunction with Warrick's generic Albuterol Sulfate. When Warrick's customers purchased 
enough Warrick generic Albuterol Sulfate, Warrick would then ghie that customer a credit to obtain 
Proventil. These companies acted as one rather than as two independent drug manufacturers, 
9.6 Furthermore, Schering/Schering-Plough may havd purposefully under capitalized 
Warrick in light of the nature and risk of its business in order to avoid financial responsibility and 
allow Schering/Schering-Plough to breakthe law without suffering|the consequences. Allowingthe 
corporate structure to protect Schering/Schering-Plough from these wrongful acts would lead to 
injustice. In light of the above allegations, Warrick and Schering/Schering-Plough should be treated 
as one entity for liability purposes in order to insure Plaintiff can Hilly and completely recover any 
judgment rendered in its favor in this matter. Also, Schering/Scheriiig-Plough sells Warrick products 
to large market segments with full knowledge of the false price (representations, and, therefore, 
benefits from them. 
X. DAMAGES 
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10.1 Pursuant to the terms of the Medicaid Fraud Prevention Act, each Defendant is liable 
to the State of Texas for the value of any payment. •. provided under the Medicaid program, directly 
or indirectly, as a result of the unlawful act. Tex. Hum. Res. Code Ann. §36.052 (1). Additionally, 
each Defendant is liable for interest on the value of the payment, civil penalties ranging from $1,000 
to $10,000 for each unlawful act, and two times the value of the payment. Id. at (2), (3), & (4). 
Therefore, the Defendants are liable for the following amounts:4 
1. Schering/Schering-Plough/Warrick Pharmaceuticals Corporation 
A. Value of Payments $ 32,147,022 
B. Statutory Double Damages $ 64,294,044 
C. Minimum Civil Penalties $ 9.125,000 
Total (not including interest) $105,566,066 
2. Roxane Laboratories, Inc. 
A. Value of Payments $ 3,277,513 
B. Statutory Double Damages $ 6,555,026 
C. Minimum Civil Penalties $ 5,475.000 
These calculations are based upon utilizations for periods ending at the end of 2002. 
These calculations will be updated and increased as additional information becomes available 
prior to trial consistent with the court's orders. The civil penalty figures are only minimum 
amounts available under TMFPA and at trial, the State may seek recovery of maximum 
penalties allowed by law under § 36.052. 
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Total (not including interest) $ 15J307,539 
Plaintiff and Relator invoke in the broadest sense all relief possible at law or in equity 
under § 36.052, whether specified in this pleading or not. By agreement of counsel on June 4, 
2003, Defendants withdrew their request to require Plaintiffs to specify a maximum amount 
being sought as civil penalties. Therefore, Plaintiffs will seek an amount as civil penalties 
which will be justified and appropriate under the facts relevant t0 this issue and under the laws 
as determined by the Court. 
(Amended to respond to Special Exception. Specific and maximum monetary damages 
pled in the alternative under T.R.C.P. 48 and to make specific those damage allegations alleged 
in general terms in paragraphs 10.1 and 10.2) 
10.2 Alternatively, the Defendants are liable to the State for common law fraud in an 
amount that exceeds the minimum jurisdictional limits of this Coprt, including, but not limited to 
actual damages, pre-judgment interest, attorney fees, and punitivei damages in an amount not to 
exceed the amounts set forth as follows: 
As monetary damages for the alternative claims based upoti common law fraud and as a 
T.R.C.P. Rule 48 alternative measure of damages under the TMFBA the Plaintiffs seek the 
following elements of monetary damages: 
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A. The difference between the reimbursement amount paid by TVDP for the relevant 
drugs, on the one hand and the amount that would have been paid but for false 
price/cost reporting on the other hand. 
B. Two times the amount found by the trier of fact in section A, as per TMFPA § 
36.052(a)(4). (To the Court Only) 
C. Prejudgment interest at 10% per annum, (To the Court Only) 
D. A civil penalty to be assessed by the trier of fact using the guidelines at § 36.052 
(b) (l)-(5) inclusive. 
By agreement of counsel on June 4, 2003, Defendants withdrew their request to require 
Plaintiffs to specify a maximum amount being sought as civil penalties. Therefore, Plaintiffs 
will seek an amount as civil penalties which will be justified and appropriate under the facts 
relevant to this issue and under the laws as determined by the Court. 
E. Reasonable and necessary attorney fees, costs and expenses of litigation of the State 
and Relator in an amount not to exceed $15,000,000.00. This amount includes fees 
to be set and awarded by the Court pursuant to TMFPA § 36.110(c). 
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10.3 The TMFPA is a statute of absolute strict liability aind there are no defenses available 
for any violation of its provisions and in particular any violation of any part of Section 36.002. 
Likewise, as a matter of law the defenses of laches and limitations are not available as against the 
State of Texas, as a Sovereign. 
10.4 In order for the trier of fact to be apprised of relevattt and probative information upon 
which to assess a finding of an appropriate civil penalty, the ju^y will need to receive and hear 
evidence relating to TMFPA § 36.052 (b) (l)-(4) inclusive. Specifilcally the trier of fact must receive 
evidence on the following topics: 
(1) previous and other violations of the law; 
(2) the seriousness of the unlawful act ".. .including the nature, circumstances, extent, 
and gravity of the unlawful act;" 
(3) health and safety of the public; and 
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(4) whether the person acted in bad faith when engaged in the conduct that formed the 
basis of the unlawful act. 
The trier of fact must have a complete and accurate understanding of the total conduct of 
Defendants in all dealings with TVDP to show that the Relevant Drugs were not an unusual or 
isolated error of judgment but rather a systematic and calculated plan to defraud the system at every 
opportunity. Therefore, other drugs placed by the Defendants into the formulary of the TVDP which 
had relatively small utilization in the State of Texas and which therefore are not the subject of large 
monetary damages are nonetheless probative evidence of other violations; the seriousness of 
conduct; the nature, circumstances, extent and gravity as well as evidence of bad faith of the 
Defendants. The trier of fact should be presented with complete and accurate=information of how 
the Defendants dealt with pricing and price reporting issues relating to government reimbursement 
programs to understand that the prices the Defendants reported to the TVDP for the Relevant Drugs 
were not the result of an unusual or isolated error in judgment or mistake, but were the result of a 
systematic and calculated plan to defraud the system at every opportunity. These are the other drugs 
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for which damages are not sought in this case, but aboutwhich evidence will be offered to show the 
jury the Defendants' plan or scheme. These are primarily those dlrugs listed in paragraph 8.11. 
XI. JURY DEMAND 
11.1 The State respectfully requests a trial by jury pursuant to Texas Rules of Civil 
Procedure 216. 
XII PRAYER 
12.1 The State asks that it recover from the Defendants Restitution of payments, statutory 
additional double damages, pre-judgment interest, attorneys fees, costs, and expenses and civil 
penalties as provided in TEX. HUM. RES. CODE ANN,, Chapter 36, or actual damages, pre-judgment 
interest, attorney fees and punitive damages under common law. Plaintiff and Relator invoke in the 
broadest sense all relief possible at law or equity under Texas Huntan Resources Code, Chapter 36 
without qualification or limitation. The State asks that citation andlnotice be issued immediately to 
the defendants identified herein who have not already answered andl appeared in this action and that 
they be served with process and that upon trial of this case that judgment be entered in favor of the 
State and against the named defendants in at the amounts set forth.. The Relator further asks that it 
be awarded its costs and expenses; a reasonable attorney fee; and the maximum Relator's share 
provided for under the TMFPA. The State prays for such other aijd further relief to which it may 
show itself entitled either at law or in equity. 
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MONTANA FIRST JUDICIAL DISTRICT COURT 
LEWIS AND CLARK COUNTY 
MIKE McGRATIL ATTORNEY 
GENERAL of the Slate of Montana, 
THE STATE OF MONTANA, 
Plaintiff, 
v. 
JANSSEN, LP, JANSSEN ORTHO LLC, 
JANSSEN PHARMACEUTICA, INC., 
ASTRAZENECA PHARMACEUTICALS, 
LP, 
Defendants. 
Cause No.: CDV-2008-164 
MEMORANDUM AND 
ORDER ON DEFENDANTS' 
MOTION TO DISMISS 
AND PARTIES* 
AGREEMENT TO SEVER 
BACKGROUND 
Before the Court is Defendants' motion toi dismiss the complaint. The 
named Defendants are Janssen, LP, Janssen Ortho LLC, Janssen Pharmaceutica, 
Inc. (collectively Janssen), and AstraZeneca Pharmaceiliticals, LP (AstraZeneca). 
Defendants have since clarified their identities and the Caption should be corrected 
as set forth above. Plaintiff is Mike McGrath, Attorney General of the State of 
Montana, on behalf of the State of Montana (Plaintiff). 
///// 
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On February 20, 2008, Plaintiff filed this action against Janssen and 
AsIraZenec-i alleging various causes of ncuoi: relating t . the marketing of two 
prescription I n dici.ies, kuspcida! an J Seroquel. Risperdal is produced and 
marketed by Janssen; Seroquel is produced and marketed by AstraZeneca. 
Plaintiffs complaint alleges seven causes of action. The causes of 
action are based on claims of strict liability, violation of the Montana Food, Drug 
and Cosmetic Act, willful deceit as provided in Section 27-1-712, MCA, unfair trade 
practices in violation of Section 30-14-103, MCA, violation of Montana's False 
Claims Act as provided in Section 17-8-403, MCA, unjust enrichment, and Montana 
common law fraud, 
Janssen and AstraZeneca filed a combined motion to dismiss on 
January 19, 2010. The Court heard argument on the motion July 14, 2010, and the 
matter was deemed submitted. The Court concludes that the motion should be 
denied, with the exception of Count 11, which should be granted. 
At the July 14,2010 hearing, the parties stipulated to severance of the 
cases involving Janssen and AstraZeneca. The parties indicated they would prefer 
to have both cases remain in Department 3. 
STANDARD OF REVIEW 
In reviewing a motion to dismiss pursuant to Rule 12(b)(6), 
M.R.Civ.P.5 the Court must consider the complaint in the light most favorable to the 
plaintiff and accept the allegations in the complaint as true. Goodman Realty, Inc. v. 
Momon, 267 Mont 228, 231, 883 P,2d 121, 123 (1994). A complaint should not be 
dismissed under Rule 12(b)(6), M.R.Civ.P., unless it appears that the plaintiff can 
prove no set of facts in support of his claim which would entitle him to relief. 
Wheeler v. Moe, 163 Mont. 154, 161,515 P.2d 679, 683 (1973). In other words, 
Memorandum and Ordci on Defendants* Motion to Dismiss and Parties' Agreement to Sevei - Page 2 
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dismissal ih justified only when the allegations of the complaint itself clearly 
j demolish rt v thai plaintiff d« es not have a claim, ]J, U;3 Mont, at 161, 515 l\2d i;t 
683. KeojUsii UuUrcll v. McBridc* Land & Lhr^ock (>., i70 Mont. 206, 298, 553 
P.2d 407, 408 (1976). For these reasons, a trial court rarely grants a motion to 
dismiss for failure to state a claim upon which relief can be granted. 
DISCUSSION 
Plaint iIT seeks damages and other monetary and injunctive relief based 
upon Janssen \s and AstraZcneca's allegedly wrongful a|nd illegal design, testing, 
marketing, sales, and promotion of the antipsychotics risperidone (known as 
Risperdal) and quetiapine (known as Scroquel). The cotaplaint alleges that these 
drugs were in defective condition and unreasonably dangerous. It further alleges 
that Janssen and AstraZeneca aggressively marketed and promoted Risperdal and 
Seroquei for \ises other than those for which the drugs hftd received FDA approval. 
Plaintiff asserts that because of a false and misleading marketing campaign by the 
companies, patients prescribed the drugs by uninformedjphysicians suffered serious 
medical consequences. According to Plaintiffs complaint, Janssen and AstraZeneca 
knew or should have known that many users were Montana Medicaid recipients and 
thus the state would be expending state funds through thfc Montana Department of 
Health and Human Services (DPHHS) to purchase the dtfugs for non-medically 
accepted applications. 
Based on these allegations, Plaintiff seeks, inter alia, recovery of 
damages, civil penalties, punitive and exemplary damages, and "restitution which 
would restore the State of Montana and the citizens of the State of Montana to the 
financial position that they would have enjoyed absent Defendants' false 
representations and promotion of Risperdal and SeroquelL" (Compl. at 38, \ 8.) 
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Defendants' motion to dismiss is picmised on several grounds First, 
they claim ihol Rv^c 9(b), M.R.Ci /.P., requires a degree ( f speeifieiiy locking in 
PiaujtifTt. com]»laijii. Rule 9(b) states that "[i]n ai! averments of fraud or mistake, 
the circumstances constituting fraud or mistake shall be stated with particularity." 
Defendants maintain that the conehisory assertions running throughout Plaintiffs 
claims are fraud-related but fail to satisfy the mandate of Rule 9(b), Defendants' 
second argument asserts that Plaintiffs claims fail to plead facts necessary to 
establish the element of causation and therefore all fail as a matter of law. 
Defendants next argue that the strici liability claim (Count 1) fails as a mattei of law 
because this Court should follow comment k to the Restatement Second of'forts 
§ 402A. Defendants also argue that Plaintiff does not have standing to bring a claim 
under the Montana Food, Drug, and Cosmetic Act (FDCA) (Count 11). Finally, 
Defendants argue that Plaintiffs unjust enrichment claim (Count VI) fails because 
any benefit conferred on Defendants cannot be characterized as unjust, and the 
unjust enrichment count simply restates Plaintiffs deficient tort claims. 
1. Rule 9(b) Specificity 
Plaintiff disagrees with Defendants' contention about lack of Rule 9(b) 
specificity, citing Swierkiewicz v. SoremaN.A,, 534 U.S. 506 (2002), for the 
proposition that Rule 8(a)'s simplified pleading standard applies to all civil actions.1 
Plaintiff also relies on dicta from Lawson v. Affirmative Equities Co., L.P., 341 F. 
Supp. 2d 51 (D. Mass. 2004), to the effect that fraud-related counts (consumer 
protection - related in Lawson) need not rely on Rule 9(b)'s heightened standard of 
particularity. The Lawson court stated: "Defendants' remaining argument that a 
In Swierkiewicz, the United Stales Supreme Court was addressing Rule 8(a)(2) of the Federal Rules of Civil 
Procedure, which is the same as Rule 8(a)(1), M.R.Civ.P. 
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Consumer Protection Act count must conform to Rule 9l(h;!r> heightened pleading 
shndard, while it has some support in okW case law, isiforec!o*.ed by 
Srt'lerkiewiez" Id, at 67. 
Defendants, however, correctly note that S^ierkicwicz and Lawson do 
not supply the support assigned to them by Plaintiff. In \Swierkiewicz, the United 
Stales Supreme Court actually observed, "Rule 8(a)ls simplified pleading standard 
applies to all civil actions, with limited exceptions. Rule 9(b), for example, provides 
for greater particularity in all averments of fraud or mistake." Id., 534 U.S. at 513. 
Likewise, the decision in Uiwstm appears td> have been subsequently 
"foreclosed" in other decisions in the 1 irst Circuit. Seejfor example, SJC.C. v 
Tarnbom, 597 F.3d 436, 442 (2010), wherein the First Circuit Court of Appeals 
stated: 
As a general proposition, a complaint must contain no more 
than "a short and plain statement of the claim showing that the 
pleader is entitled to relief." Fed. R. Civ. P. 8(a)(2). But even 
though a complaint need not plead "detailed factual allegations," it 
must nonetheless "contain sufficient factual matter, accepted as true, 
to state a claim to relief that is plausible on its face." In other words, 
the complaint must include "factual content that allows the court to 
draw the reasonable inference that the defendant is liable for the 
misconduct alleged." If the factual allegations in the complaint are 
too meager, vague, or conclusory to remove the possibility of relief 
from the realm of mere conjecture, the complaint i|s open to 
dismissal 
Because the complaint in this case contains allegations of 
fraud, an additional hurdle must be surmounted: the pleader 
(herc% the SEC) must "state with particularity the circumstances 
constituting the fraud." Fed. R. Civ. P. 9(b). To satisfy this 
particularity requirement the pleader must set out the time, place, 
and content of the alleged misrepresentation with specificity. 
See also the Seventh Circuit decision in Lantz v. Am. Hotitda Motor Co., 2007 U.S. 
Dist, LEXIS 34948, which is critical of the Rule 9(b) construction in Lawson. 
IIIH 
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The Montana Supreme Couit decision in Slate ex rel. Stale Comp. 
Mutual Ins. Fund v. Ben:> 279 i^ont. 161, 927 )\2d 975 (1996), is instructive. In 
Berg, the supreme court addressed the interplay between Rule 8(a) ixm) Rule (9j(b): 
Of primary importance in understanding (he particularity 
requirement of Rule 9(b) is the recognition that it does not render 
the general principles set forth in Rule 8 entirely inapplicable to 
pleadings alleging fraud; rather, the two rules must be read in 
conjunction with each other. Jl should be kept in mind that Rule 
8(a) requests "a short and plain statement ofthe claim" for relief.... 
Thus, it is inappropriate to focus exclusively on the fact that Rule 
9(b) requires particularity in pleading fraud. This is too narrow an 
approach and fails to take account ox the general simplicity and 
flexibility contemplated by the rules. . . . 
THe sufficiency of a particular pleading under Rule 9(b) 
depends upon a number of variables. For example, the degree of 
detail required often turns on the context in which the fraud is 
alleged to have occurred.., . Perhaps the most basic consideration 
in making a judgment as to the sufficiency of a pleading is the 
determination oi how much detail is necessary to give adequate 
notice to an adverse party and enable him to prepare a responsive 
pleading. 
Id, 279 Mont, at 176-77, 927 P.2d at 984 (citations omitted). 
Similarly, in United States ex rel Franklin v. Parke-Davis, 147 F. 
Supp. 2d 39, 46-47 (D. Mass. 2001), a qui lam action against a drug company 
brought under the federal False Claims Act, the federal district court stated, 'To pass 
Rule 9(b) muster, the complaint must plead with particularity the time, place and 
contents or the false representations as well as the identity ofthe person making the 
false representations and what he obtained with them.5' The court recognized, 
however, that Rule 9(b) must be read in conjunction with Rule 8(a), Fed.R.CivJP., 
which requires "a short and plain statement ofthe claim" for relief. Id. The court 
noted that the relator must allege the circumstances ofthe fraud, but is not required 
to plead all ofthe evidence or facts supporting it, adding: "In addition, strict 
application of requirements of Rule 9(b) may be relaxed in certain circumstances. 
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For instance, \vi en* facts undcrlyii.g the fraud am 'peculiarly wiihin the defendants'' 
control,* a plaintiff moy b^ ex used from plcadlri; the c]ircunutanr,Oo of the fraud 
witn a high degree of predion." Id 
This Couri agrees that the degree of specificity contemplated by most 
decisions involving fraud allegations is lacking here. Nonetheless, Plaintiff has 
given Defendants notice of the specific types of wrongful conduct being alleged, 
including wrongfully marketed drugs, company-funded Research studies and 
publications, CME presentations, misleading advertisements in medical journals, 
and financial incentives to physicians. If the Court accents Defendants' contentions 
that the requirements of Rule 9(b) are not met by Plaintiffs complaint, such finding 
would necessarily assume that Defendants have not been|provided adequate notice 
of the allegations against them to formulate a proper respbnsive pleading. Given the 
arguments advanced by Defendants in their motion to dismiss, such does not appear 
to be the case. Thus, while the Court is mindful of the Defendants' concern about 
lack of specifics, considering the complaint in the light mbst favorable to the 
Plaintiff, it concludes that complete dismissal at this junctlure pursuant to Rule 12(b) 
would be premature. 
2. Cassation 
Defendants also maintain that Plaintiffs complaint should be dismissed 
in its entirety because Plaintiff fails to establish the requisite element of causation. 
Defendants assert that the causal link between Defendants* alleged misconduct and 
each beneficiary's alleged injury is loo remote, Defendants claim that Plaintiff has 
not - and cannot - plead sufficiently individualized facts m> establish causation. 
Defendants cite myiiad federal case authority for the proposition that 
Plaintiffs allegations are simply too attenuated and indefinite to satisfy a causal 
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nextiK between the acts complained of and the damages alleged to have been 
suffered. 1 bimiff disagrees and cites the Court lo the concluding p w igraphs of 
each oi'its causes of action, all of which stale essentially the same thLg- thai as a 
result or consequence of Defendants' actions "the Stale, its citizens, corporations 
and business entities have been injured and suffered damages and are entitled to all 
the remedies and damages provided by law." 
Representative of the cases cited by Defendants is Ironworkers Local 
Union No. 68 v. AslraZeneca Pharm. LP, 585 F. Supp. 2d 1339 (D. Fla. 2008). JJI 
this case, the federal court considered various claims by plaintiffs against 
AslraZeneca and its marketing practices of the drug Seroqucl. The claims were 
based on federal and slate causes of action, some of which are the same as those 
invoked by Plaintiff in this case, such as state consumer protection laws, unjust 
enrichment and common law fraud. Many of the factual allegations of misconduct 
are the same as or similar to those alleged in this case. 
The court in Ironworkers took up each of the causes of action, and after 
addressing the proof elements of each, concluded that the defendants' motion to 
dismiss all claims was well taken. In addressing the state and common law claims, 
the court held: 
As the Court earlier concluded with respect to the civil 
RICO claims, Plaintiffs have not established that their injuries 
were proximately caused by Defendants' alleged scheme to 
defraud. Therefore, their state consumer protection claims must 
also fail. 
Ironworkers was filed as a class action lawsuit, but class action certification had not been determined at the time of 
the court's decision. The court addressed the state-related claims only for the three slates in which representative 
plaintiffs resided. The federal cause of action was based on the Racketeer Influenced and Corrupt Organizations Act 
(RICO), which requires a specific showing of proximate cause grounded in the United States Supreme Court decision 
in Holmes v. Sec Investor ProL Corp., 503 U.S. 258 (1992). 
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The common law .fraud am' neglige, t mi ^ presentation 
ciaims alleged by Plaintiffs in Counts VI rnH V)J \\ cewise lad for 
2 I! lack ofcausaiiori. 
/«., 585 J\ Supp. 2u at 13^ 56. Tne court then dismissed rfcaiainin civil conspiracy 
and unjust enrichment counts, citing case law to the effect that there was no basis 
to proceed on these theories once the tort claims had beep dismissed. 
Other federal courts have followed the reasoning of the Ironworkers 
court as noted in Defendants5 briefs. However, most of the decisions involve 
dismissal based on a failure to plead causation under the til CO statutes, as required 
by Holmes v. Sec, Investor Prof. Corp., 503 U.S. 25S (19^2). State law related 
claims were then dismissed on a Rule 9(b) basis. See, e.g., In re Actimmune Mktg. 
Ling., 614 F. Supp. 2d 1037 (N.D. Cal. 2009). Other case decisions turn on 
interpretation of state laws that require a specific proximate cause allegation found 
lacking, See PCL Employees Benefit Trust Fitnctv, Asiralmeca Phanru, 2009 U.S. 
Dist. LEXIS 76555; N.I Citizen Action v. Schering-Ploug\h Corp., 842 A.2d 174 
(N.J. 2003), 
While the need to prove causation cannot be disputed, /; onworkers and 
like cases discuss the issue in terms of "establishing" or "proving'5 causation, and 
contemplate the trial-related proof problems plaintiffs woujd have in meeting the 
causation element. For example, in Pa. Employees Benefit Trust Fund, the court 
relied on Ironworkers stating: 
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Thus, in the context of this case, establishing that Plaintiffs' 
injuries were caused by Defendants' misconduct would require 
an inquiry into the specifics of each doctor-patient relationship 
implicated by the lawsuit In other words, each physician who 
prescribed Seroquel to an individual consumer or health and 
welfare fund member would have to be questioned as to 
whether his or her independent medical judgment was 
influenced by Defendants5 misrepresentations, and tojwhat 
extent Furthermore,.., this individualized inquiry would 
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likely have to be conducted with repaid to each consumer 
purchase traiISPC ion or third-parly reimbursement pa)men! 
maae over the last api >ro>s imaidy'ten years. 
W. atlS. 
The problem this Court has with that approach is that it assumes a 
prospective view that is premature when considering causation in the context of a 
motion to dismiss. Although Plaintiffs causation allegations are general, there is 
no requirement of proof at this juncture when considering a Rule 12(b) motion. As 
noted above in Wheeler v. Moe dismissal is appropriate only when the allegations of 
the complaint clearly demonstrate no claim. Given the complexity of this litigation 
and the conflicting representations of the parties about marketing practices, the 
Court cannot conclude that Plaintiff has failed to allege causation. 
3. Strict Liability 
Defendants argue that Count I, the strict liability claim, fails as a matter 
of law because Montana is likely to join other states in adopting comment k to the 
Restatement Second of Torts § 402 A. Montana has not yet adopted comment k5 and 
this Court will not grant dismissal based upon this ground. 
4. FDCA Claim 
Defendants also argue that Plaintiff does not have standing to bring a 
claim under the Montana Food, Drug, and Cosmetic Act (FDCA) (Count II). 
No reference to a report from DPHHS is referenced. Sections 
50-31-505 and -506, MCA, clearly contemplate a misdemeanor criminal 
prosecution by the Attorney General or a county attorney following a report from 
the department. Section 50-31-508, MCA, further authorizes DPHHS to apply to 
district court for an injunction. The Court finds the statutes do not contemplate a 
///// 
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tori action by the Attorney General for a violation c." Ihtt MX A. The in Viion to 
dismiss Count U should uc (iranled. 
5. Unjust tun rebmen? 
Defendants argue that Plaintiffs unjust enrichment claim (Count VI) 
fails because any benefit conferred on Defendants cannot be characterized as unjust, 
and the unjust enrichment count simply restates Plaintiffs tort claims. The Court 
has declined to dismiss the majority of the complaint and therefore declines to 
dismiss the unjust enrichment count. 
Based on the foregoing, IT IS ORDERED: 
(1) Defendants' motion to dismiss is DEFIED as to Counts I and 111 
through VII. The motion to dismiss Count 11 is GRANTED. 
(2) Based upon the stipulation of the parses, Defendants' joint 
motion to sever is GRANTED. The ease against Defendants Janssen, LP, 
lanssen Ortho LLC, and Janssen Pharmaceulica, Inc., slifrll remain in Cause No. 
CDV-2008-164. The case against AstraZencca Pharmaceuticals, LP, shall be 
assigned a new cause number, but shall remain in Department 3. 
DATED this 3 '""day of November 2010. 
^iKgpL^/ <P^AJL 
KATIftY SEELEY 
District CourtJudgfe 
c: William A. Rossbach/Joscph H. Meltzor/Sean Handler/lBradley E. Beckworth 
/Keith Langston 
William Evan Jones/A. Craig Eddy/Elena J. Zlalnik 
Randy J. Cox 
d/fCCS/McCiraili v Jansscii CDV-2008-1 M 
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